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ABSTRACT 
Skeletal muscle growth is important for animal agriculture, particularly for 
meat-producing animals, and for human health as well. A better understanding of the 
mechanisms regulating skeletal muscle growth is expected to contribute to improving 
the efficiency of meat animal production and alleviating human suffereings caused by 
muscle atrorphic conditions. Currently, two molecules have been shown to have 
dramatic effects on skeletal muscle mass: myostatin and β-adrenergic agonists. 
Myostatin (Mstn), a member of the TGF-β superfamily proteins, acts as a potent 
negative regulator of skeletal muscle growth. Suppression of Mstn by varying means 
has shown to increase skeletal muscle mass of animals. Administration of β-adrenergic 
agonist (BAA) such as clenbuterol (CL) induces dramatic increase in skeletal muscle 
mass or inhibits muscle atrophy. 
Although there have been numerous demonstrations of the muscle growth–
promoting effect of BAA administration or Mstn suppression, the effect of a 
combination of BAA administration and Mstn inhibition on skeletal muscle growth has 
not been investigated. Similarly, very little is known about the molecular signaling 
pathways leading to muscle hypertrophy induced by the two stimuli and the genes that 
are commonly regulated by both Mstn and BAA administration. Therefore, the 
objectives of this study were 1) to investigate the combined effect of Mstn-suppression 
and BAA administration on skeletal muscle growth, 2) to examine the role of the 
Akt/mTOR pathway in the two muscle hypertrophic models, 3) to examine global 
changes in gene expression in skeletal muscle undergoing hypertrophy induced by 
chronic suppression of Mstn or BAA administration , and 4) to compare the changes in 
gene expression between these two muscle hypertrophic models. 
We used a transgenic mouse strain that overexpresses the Mstn-prodomain 
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(Mstn-pro) and exhibits a significant increase in skeletal muscle mass regardless of age 
and sex. Clenbuterol (CL) was used as a BAA compound. Heterozygous Mstn-pro and 
wild-type littermates were produced and were given 0 or 20 ppm of CL in their drinking 
water. Phosphorylation of molecules involved in the Akt/mTOR pathway was examined 
by using the Western blot analysis. RNA samples of the gastrocnemius muscle in each 
group were subjected to microarray analysis using the Affymetrix GeneChip Mouse 
430-2.0 platform.  
CL increased body and muscle mass of male and female mice in both genotypes, 
indincating that the muscle-hypertrophic effect of CL is additive to the effect of Mstn 
suppression. Levels of phosphorylated muscle 4E-BP1 and p70S6k, two downstream 
effectors of the mTOR pathway, were higher in Mstn-pro mice than in wild type mice. 
Levels of phosphorylated muscle Akt, an upstream effector of the mTOR pathway, were 
also higher in Mstn-pro mice than in wild type mice, indicating that the Akt/mTOR 
anabolic pathway is involved in the regulation of muscle mass by Mstn. CL increased 
the phosphorylation of Akt, 4E-BP1 and p70S6k in both genotypes, resulting in the 
highest phosphorylation levels of Akt, 4E-BP1 and p70S6k in CL-fed Mstn-pro mice. 
This result suggests that like Mstn, BAA also regulates muscle hypertrophy through the 
Akt/mTOR pathway, and the pathways of Mstn and CL signaling converge to the 
Akt/mTOR anabolic pathway to regulate skeletal muscle hypertrophy.  
 Microarray analysis of global gene expression showed that Mstn suppression 
and CL administration induced significant changes in the mRNA abundance of various 
genes associated with muscle contraction, initiation of translation, transcription, and 
muscle hypertrophic signal pathway, suggesting that increased protein synthesis is 
partly responsible for the hypetrophy induced by Mstn and CL. Additionally, the 
alteration of Igf2 obsderved in Mstn suppressed mice, and the alterations of eIF4e, 
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Acvr2b, FoxO and PTEN observed in mice treated with CL indicate that the pathways 
of Mstn and CL signaling converge to the Akt/mTOR anabolic pathway to regulate 
skeletal muscle hypertrophy.  
 v
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1.1 SKELETAL MUSCLE GROWTH AND DEVELOPMENT 
1.1.1 Embryonic development of skeletal muscle  
During vertebrate embryogenesis, skeletal muscle forming cells arise from the 
somites, which are formed sequentially as epithelial spheres from the rostral part of the 
unsegmented paraxial mesoderm (reviewed by Stockdale et al., 2000). The somites 
mature according to a rostro-caudal gradient of differentiation and become subsequently 
subdivided into the ventrolateral sclerotome that gives rise to axial skeleton and ribs, 
and the dorsomedial dermomyotome that contributes to the formation of dermis and 
skeletal muscles (reviewed by Stockdale et al., 2000). Two distinctive compartments 
present in the dermomyotome give rise to separate lineage of skeletal muscles during 
embryogeneis: the dorsomedial epaxial domain gives rise to the deep back and 
intercostal muscles, and the lateral hypaxial domain gives rise to the rest of the 
musculature of the body and limbs. The hypaxial dermomyotome gives rise to muscles 
in two distinct ways: ventrolateral extension of the dermomyotome forms the body wall 
muscles and some migratory precursor cells leaving the dermomyotome form more 
distant muscle masses of the wing and limb (Ordahl and Ledouarin, 1992; Miller et al., 
1999).  
The myotomal compartments of somites eventually give rise to myoblasts, 
mono-nucleated muscle precursor cells. During embryonic muscle development, the 
mono-nucleated myoblasts fuse together to form multi-nucleated myotubes. Later, 
myotubes mature into highly specialized skeletal muscle fibers that show cross striation. 
The determination of myogenic cell lineage (myoblast) and control of terminal 
differentiation is regulated by the expression of myogenic regulatory transcription 
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factors (reviewed by Perry and Rudnicki, 2000). In addition, the presence of some 
particular growth factors such as insulin, insulin like growth factor-1 (IGF-1), fibroblast 
growth factor (FGF) and transforming growth factor (TGF)-β, regulates sustained 
proliferation of myoblasts and subsequent withdrawal from the cell cycle as part of 
differentiation process (reviewed by Florini et al., 1996). The timing of entry of 
myoblasts into differentiation is likely to play a significant role in determining the 
number of muscle fibers, and subsequent postnatal muscle mass. 
1.1.2 Myogenic regulatory factors (MRFs) 
 The myogenic regulatory factors (MRFs) form a family of basic helix-loop-
helix (bHLH) transcription factors consisting of Myf5, MyoD, myogenin, and MRF4. 
The MRFs are expressed exclusively in the skeletal muscle lineage, and forcing their 
expression in a wide range of cultured cells induces the skeletal muscle differentiation 
program. They activate muscle specific gene expression by binding to the E-boxes 
(CANNTG) in the promoter region of target genes after dimmer formation with the E2A 
proteins, ubiquitously expressed bHLH proteins. Gene targeting studies that induced 
null mutations in Myf5, MyoD, myogenin and MRF4 into the germ line of mice 
revealed a hierarchical relationship among the MRFs and established that functional 
redundancy is a feature of the MRF regulatory network (reviewed by Rudnicki and 
Jaenisch, 1995). The MRF family can be divided two-tiered subclassification through 
sequence homology, expression patterns, and gene targeting expressions: Myf5 and 
MyoD are homologous genes, and are expressed in myoblasts before differentiation, 
and are required for the determination or survival of muscle progenitor cells. Myogenin 
and MRF4 are homologous genes, and are expressed upon differentiation. Myf5 and 
MyoD are classified as primary MRFs because they are required for the determination 
of skeletal myoblasts in proliferation and early differentiation stages, and myogenin and 
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MRF4 are classified as secondary MRFs because they are required in the later stages of 
myognic program for the terminal differentiation of myoblasts and myofibril synthesis 
(reviewed by Rudnicki and Jaenisch, 1995).  
The MyoD null mice show no obvious abnormalities in skeletal muscle but 
express four-fold higher level of Myf5, suggesting the presence of functional 
redundancy between MyoD and Myf5 (Rudnicki et al., 1992). Newborn mice lacking 
Myf5 also have normal skeletal muscle but die prenatally because of severe rib 
abnormalities, indicating the requirement of Myf5 for normal rib development in 
addition to the role in myoblast determination and proliferation (Braun et al., 1992). 
Newborn mice lacking both MyoD and Myf5 have a complete absence of skeletal 
muscle (Rudnicki et al., 1993), indicating the requirement of either MyoD or Myf5 for 
myoblast proliferation. The myogenin gene null mice die at birth due to a lack of 
myofibers, suggesting that myogenin plays an important role in the differentiation of 
myoblast into myotube and myofibers (Hasty et al., 1993). The MRF4 gene null mice 
displayed normal Myf5 expression and a four-fold induction in myogenin, and is viable 
with seemingly normal skeletal muscle, suggesting that MRF4 may function late in the 
myogenic pathway, and its function may be substituted by the presence of myogenin 
(Zhang et al., 1995). 
The expression of MRFs appears to be regulated by pax3, a paired-domain 
containing transcription factor, since forced expression of pax3 using retroviral 
expression systems in chick tissue explants revealed that pax3 activates the expression 
of MyoD, Myf5, and myogenin (Maroto et al., 1997). Another paired-domain 
containing transcription factor pax7 have shown to play an important role in the biology 
of satellites cells (reviewed by Hawke and Garry, 2001). 
1.1.3 Postnatal development of skeletal muscle 
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 The increase in skeletal muscle mass during postnatal growth is mainly due to 
an increase in muscle fiber size (hypertrophy). This process is accompanied by the 
proliferative activity of satellite cells, which are the source of new nuclei incorporated 
into the muscle fibers (reviewed by Rehfeldt et al., 2000). After birth, the number of 
skeletal muscle fiber in most mammals and avian species does not increase due to the 
completion of embryonic proliferation of skeletal muscle cells (Rowe and Goldspink, 
1969). For example, no significant changes in postnatal fiber number have been found 
in mice (Rowe and Goldspink, 1969), rat (Rosenblatt and Woods, 1992), pig (Fiedler et 
al., 1983), cattle (Wegner et al., 2000) and chicken (Smith and Fletcher, 1988). However, 
some studies indicated that in some species, limited extent of muscle cell proliferation 
occurs after birth. For example, the increase in muscle fiber number was observed 
shortly after birth in rodents (Summers and Medrano, 1994) and pigs (Swatland, 1975). 
Others argued that the increase in fiber number during the first days of postnatal life 
was a result of maturation and elongation of the existing myotubes rather than due to a 
production of new fibers (Ontell and Kozeka, 1984). In this regard, the postnatal 
increase in skeletal muscle mass appears to be achieved mostly by an increase in fiber 
size and not much by an increase in fiber number. Since fiber size cannot be increased 
beyond a certain limit, the growth potential for skeletal muscle is virtually determined 
by the number of fibers established at around the time of birth. This relationship of 
muscle number and growth potential has been demonstrated in the enlarged muscles of 
double-muscled cattle (Swatland and Kieffer, 1974), in genetically different size of 
animals (Hanrahan et al., 1973), and in runts as compared with normal pigs (Powell and 
Aberle, 1981). Interestingly, some studies indicate that muscle hypertrophy is inversely 
correlated with muscle fiber number at the end of the intensive growth period. For 
example, the postnatal growth rate of the individual muscle fiber is lower when there 
 5
are high numbers of fibers and higher when there are low numbers of fibers (reviewed 
by Rehfeldt et al., 2000). 
1.1.4 Muscle hypertrophy and satellite cell 
Muscle mass increases more than 10 fold from birth to mature body size with a 
slight decrease in DNA: protein ratio during this period, indicating that there is an 
increase in the number of myonuclei during the postnatal hypertrophy of skeletal 
muscle fibers. The increase in the number of myonuclei is solely contributed to satellite 
cells that are located between the basal lamina and sarcolemma of myofibers (Moss and 
Leblond, 1971). Satellite cells have one nucleus that occupies most of the cell volume 
and unlike the nuclei inside muscle fibers, the satellites cells retain the capacity to 
proliferate in response to stimuli, thus provide most of the myonuclei to adult muscles 
during growth to balance the cytoplasm/nuclei ratio. Satellites cells have long been 
considered monopotential only giving rise to cells of myogenic lineage (Bischoff and 
Heintz, 1994). However, recent evidence demonstrates that satellite cells are capable of 
forming osteocytes and adipocytes in response to different growth factors in vitro, 
indicating that satellites possess multipotential mesenchymal stem cell activity (Asakura 
et al., 2001). 
The remarkable adaptability of skeletal muscle to physiological stimuli such as 
exercise training, stress and injury is attributable to the function of satellite cells. 
Usually, satellite cells are dormant, but they become activated when the muscle fiber 
receives any forms of trauma, damage or injury. The satellite cells then proliferate or 
multiply, and the daughter cells are drawn to the damaged muscle site to form new 
muscle fibers during the regeneration period (reviewed by Hawke and Garry, 2001).  
While it is well established that satellite cells play a role in maintaining the 
relatively constant myonuclear domain size during growth and are source of new muscle 
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fibers during regeneration, there has been a debate regarding whether satellite cell 
activation is prerequisite for muscle hypertrophy occurring in response to various 
hypertrophic stimuli or during growth. Recent studies suggest that muscle hypertrophy 
can occur without the activation of satellite cells. Blaauw et al., (2009) showed that the 
increase in skeletal muscle mass induced by overexpression of Akt occurred without 
satellite cell activcation. Postnatal blockade of myostatin, a negative regulator of muscle 
growth, induced massive skeletal muscle hypertrophy without satellite cell activation 
(Amthor et al., 2009). Some β2-adrenergic agonists induced skeletal muscle hypertrophy 
by increased protein synthesis and decreased protein degradation without satellite cell 
activation in rats (Rehfeldt et al., 1994) and chickens (Rehfeldt et al., 1997). 
Furthermore, stretch-overload could induce hypertrophy in skeletal muscle whose 
satellite cells were inactivated by irradiation (Lowe and Always, 1999), supporting that 
satellite cell activation is not prerequisite for muscle hypertrophy. In contrast, Kawano 
et al. (2008) reported that satellite cell activation in response to mechanical load/or 
neural activity plays an essential role in muscle hypertrophy. While the debate on the 
role of satellite cells on muscle hypertrophy is not settled, it is generally agreed that 
experimental models (type of hypertrophic stimuli) and situations (magnitude of growth 
response and the age of animal, timing of measurement) influence the relationship 
between muscle hypertrophy and satellite cell activation (O'Connor et al., 2007). 
1.2 SIGNALING PATHWAYS IN SKELETAL MUSCLE HYPERTROPHY AND 
ATROPHY  
Changes in skeletal muscle mass are dictated through the process of 
myofibrillar protein turnover, which is the balance between protein synthesis and 
protein breakdown. Higher rate of protein synthesis relative to protein degradation must 
be maintained in order to achieve hypertrophy, whereas elevated protein breakdown will 
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induce a loss in muscle mass (atrophy). Overall, these processes continuously operate 
and are controlled by the intimate relationship between the mitogen, growth factors, and 
hormone-responsive signaling pathways (reviewed by Richardson et al., 2004; Glass, 
2005, Sandri, 2008). Figure 1.1 illustrates the major signaling pathways that control 
muscle fiber size.   
1.2.1 Akt/mTOR signaling pathway 
The mammalian target of rapamycin (mTOR) pathway has emerged as a key 
regulator of cell growth that integrates signals from growth factors, nutrients, and 
energy status to control protein synthesis and other cell functions (reviwed by Asnaghi 
et al., 2004). The serine/threonine kinase mTOR interacts with multiple protein partners, 
forming two distinctive multi-protein complexes, mTORC1 consisting of GβL, and 
raptor, and mTORC2 consisting of GβL, mSin, and rictor. The mTORC1 complex is 
selectively inhibited by rapamycin, a drug used as an immunosuppressant in organ 
transplantation: rapamycin binds to members of the FK binding protein (FKBP) family 
and the complex rapamycin/FKBP binds to mTORC1 and blocks its activity. The 
mTORC1 complex mediates functions that are sensitive to rapamycin such as protein 
translation, whereas mTORC2 mediates functions not sensitive to rapamycin. The major 
upstream regulator of mTOR is Akt, a serine/threonine kinase also known as protein 
kinase B. Akt activation of mTOR is indirect through the phosphorylation of tuberous 
sclerosis 2 (TSC2), a GTPase activating protein (GAP) that functions together with 
TSC1 to inactivate the small G protein Rheb. The phosphorylation of TSC2 activtes 
Rheb, leading to the activation of the mTOR signal transduction pathway.  
The role of the mTOR pathway in muscle growth was demonstrated by in vivo 
studies, in which the hypertrophic responses induced by overload or regenerating 
muscle growth are blocked by rapamysin (Bodine et al., 2001; Pallafacchina et al., 
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2002). In addition, transgenic mice overexpressing TSC1 specifically in skeletal muscle 
showed a defect in muscle growth through the downregualtion of mTOR activation 
(Wan et al., 2006). It was also reported that muscle-specific ablation of mTORC1 (by 
ablating raptor) results in a dystrophic phenotype (Bentzinger et al., 2008).  
One of the major upstream regulators of Akt is phosphatidylinositol-3-OH 
kinase (PI3K), a lipid kinase mediating the action of IGF-1. It is well established that 
IGF-1 is a potent stimulator of skeletal muscle hypertrophy as demonstrated by an 
increase in muscle mass and strength by forced expression of IGF-1 in mice (Coleman 
et al., 1995; Musaro et al., 2001). Studies have shown that the PI3K/Akt pathway plays 
an important role in mediating the hypertrophic action of IGF-1, as well as other 
anabolic stimuli, such as overloading, mechanical stimuli and insulin (reviewed by 
Nader, 2005; Glass, 2005). Expression of constructs encoding constitutively active 
forms of either PI3k or Akt induced muscle hypertrophy both in vitro (Rommel et al., 
1999; Rommel et al., 2001) and in vivo (Bodine et al., 2001; Pallafacchina et al., 2002). 
Furthemore, activation of the Akt/mTOR pathway could oppose muscle atrophy induced 
by disuse (Bodine et al., 2001).   
mTOR activation by Akt induces the phosphorylation of two downstream 
effectors, ribosomal protein p70S6k and 4E-BP1, a suppressor of the cap binding 
protein eIF4E, resulting in increased protein translation (reviewed by Sarbassov et al., 
2005). Supporting the role of p70S6k as a downstream mediator for the mTOR anabolic 
pathway, p70S6k null mice has a smaller muscle fiber size and the hypertrophic 
response to IGF-1 and activated Akt is blocked in p70S6k null mice (Ohanna et al., 
2005). Anabolic stimuli, such as overloading, resistance exercise, and essential amino 
acid ingestion, have been shown to increase the phosphorylation of p70S6k and 4E-BP1 
along with a corresponding increase in protein synthesis (reviewed by Sarbassov et al., 
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2005). Conversely, atrophying muscles have decreased levels of phosphorylation of the 
downstream targets of mTOR (Bodine et al., 2001; Hornberger et al., 2001). 
1.2.2 FoxO transcription factors 
A major contributor for skeletal muscle atrophy (decrease in skeletal muscle 
mass) is the degradation of myofibrillar proteins via ubiquitin-proteasome system. 
Recent studies have shown that two muscle-specific ubiquitin ligases, atrogin-1/MAFbx 
and MurF1 are responsible for the increased protein breakdown via ubiquitin-
proteasome system observed in various models of muscle atrophy including 
immobilization, denervation, hindlimb suspension, administration of IL-1, and 
administration of the glucocorticoid hormone (reviewed by Sandri, 2008). Studies have 
shown that muscle atrophy in various models could be blocked by IGF-1 treatment, and 
this was accompanied by a complete suppression of the induction of these two genes 
(Lee et al., 2004). Genetic activation of Akt, a downstream mediator of IGF-1 signaling, 
was shown to be sufficient to block the atrophy-associated increases in MAFbx and 
MuRF1 transcription (Stitt et al., 2004). These findings together demonstrated that Akt 
stimulation could dominantly inhibit the induction of atrophy signaling. The mechanism 
by which Akt inhibits MAFbx and MuRF1 upregulation involves the Forkhead box O 
(FoxO) family of transcription factors (Lee et al., 2004; Sandri et al., 2004; Stitt et al., 
2004). FoxO transcription factors are excluded from the nucleus when phosphorylated 
by Akt, and translocate to the nucleus upon dephosphorylation. The nuclear 
translocation of FoxO transcription factors was required for upregulation of MuRF1 and 
MAFbx, and FoxO was found to be sufficient to induce atrophy when trasfected in 
skeletal muscles in vivo (Sandri et al., 2004). Moreover, the knockdown of FoxO 
expression by RNAi suppressed the upregulation of atrogin-1/MAFbx expression during 
atrophy and muscle loss (Liu et al., 2007). It should be noted that FoxO is not only 
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regulated by Akt, but also many other Akt-independent regulatory pathways (Huang and 
Tindall, 2007), suggesting a presence of Akt/Foxo-independent atrophic pathways.  
According to a study by Southgate et al. (2007), FoxO can also induce atrophy by 
suppressing the anabolic mTOR pathway since activation of FoxO1 in skeletal muscle 
induced the expression of 4E-BP1 along with a reduction in the abundance of Raptor 
and mTOR protein. 
1.2.3 NF-kB signaling pathway 
The NF-κB transcription factors (p65/p50) belong to the Rel family of 
transcription factors, which play a major role as mediators of immunity and 
inflammation. The NF-κB transcription factors are also expressed in skeletal muscle and 
appear to play a role in regulating muscle differentiation and mediate the effect of 
inflammatory cytokines, in particular TNF-α, on muscle wasting and cachexia 
(reviewed by Glass, 2005). This NF-κB pathway is activated by phosphorylation, 
ubiquitination, and proteolysis of the inhibitory protein IκB, which in non-activated 
state binds to NF-κB in the cytosol to prevent nuclear translocation of NF-κB and 
suppress NF-κB-mediated gene trascriptions. The inactivation of IκB is through 
phosphorylation of the molecule on serine residue mediated by IK kinase complex 
(IKK). TNF-α-induced NF-κB activation leads to muscle protein loss and inhibition of 
NF-κB protects against TNF-α-induced protein degradation in cultured muscle cells 
(reviewed by Glass, 2005; Sandri, 2008). The activation of NF-κB through muscle-
specific overexpression of IKKβ in transgenic mice led to severe muscle wasting (Cai et 
al., 2004). On the other hand, muscle atrophy induced by hindlimb unloading is reduced 
in mice with a knockout of the p105/p50 NF-κB1 gene (Hunter and Kandarian, 2004). 
Moreover, the electrotransfer of constitutively active IκB in soleus muscles inhibited 
unloading-induced fiber atrophy by 40% (Judge et al., 2007). 
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It appears that muscle atrophy mediated by NF-κB activation involves the 
activation of proteasome system. Inhibiting NF-κB activity attenuated the induction of 
proteasome expression in skeletal muscle (Wyke et al., 2004). In contrast, elevation in 
the expression of the ubiquitin-ligase MuRF1 was observed in wasting muscles of 
transgenic mice in which the NF-κB pathway was constitutively active through muscle-
specific overexpression of IKKβ (Cai et al., 2004). Interestingly, the above study did not 
observe any changes in the expression of another muscle-speicif ubiquitin ligase 
MAFbx.  
1.2.4 MAPK/ERK signaling pathway  
The mitogen-activated protein kinase (MAPK) is a family of serine/threonine 
kinases that exists in all eukaryotes, and controls such fundamental cellular processes as 
proliferation, differentiation, survival and apoptosis (reviewed by Pearson et al., 2001). 
In mammals, three major MAPK cascades are known, the extracellular signal-regulated 
protein kinase (ERK) cascade, c-Jun amino-terminal protein kinase/stress-activated 
protein kinase (JNK/SAPK) cascade and p38MAPK cascade. Among those three 
MAPK cascades, the Ras/Raf/MEK (mitogen-activated protein kinase)/ERK pathway 
controls such fundamental cellular processes as cell proliferation, differentiation and 
survival. A wide variety of hormones, growth factors and differentiation factors activate 
Ras proteins by inducing the exchange GDP to GTP. The activated Ras functions as an 
adapter that binds to Raf kinases with high affinity and causes their translocation to the 
cell membrane, where Raf activation takes place. The activated Raf can activate MEK, 
and then MEK can activate the downstream ERK kinases. One effect of ERK activation 
is to alter the translation of mRNA to proteins, and phosphorylation of 40S ribosomal 
protein S6 kinase. Also, MAPK/ERK signaling pathway regulates the actvitiy of several 
transcription factors, such as C-myc, MNK, CREB, C-fos (reviewed by Moodie and 
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Wolfman, 1994; Kolch, 2000; Avruch et al., 2001). The MAPK/ERK signaling pathway 
appears to have a role in cardiac muscle growth and protein synthesis by stimulating 
initiation and elongation of protein translation. For example, Babu et al. (2000) 
demonstrated that in vitro phosphorylation of Elk-1 by the ERK kinase pathway is 
important for early gene activation during phenylephrine-induced cardiac myocyte 
hypertrophy. Huang et al. (2005) also demonstrated that the activation of ERK induced 
myocardial hypertrophy in rats (Huang et al., 2005). Moreover, Kim et al. (2006) 
demonstrated that the administration of isoproterenol induced cardiac hypertrophy by 
increased phosphorylation of ERK. In human skeletal muscles, phosphorylation of 
ERK1/2 and MEK1/2 increased in an exercise intensity-dependent manner, suggesting a 
potential role of the MAPK/ERK signaling pathway in skeletal muscle growth 
(Widegren et al., 2000). 
1.3 REGULATION OF MUSCLE GROWTH BY MYOSTATIN  
Myostatin (Mstn), also known as a growth differentiation factor-8 (GDF-8), 
was first identified by McPherron et al. (1997) in a study seeking novel mammalian 
members of the transforming growth factor-β (TGF-β) superfamily. The study reported 
that knock-out of the myostatin gene increased muscle mass up to three-fold in mice 
(McPherron et al., 1997). Subsequently, studies have demonstrated that nonfunctional 
mutations of Mstn are associated with dramatic muscularity in cattle (Grobet et al., 
1997; Kambadur et al., 1997; McPherron and Lee, 1997), dogs (Mosher et al., 2007), 
sheep (Clop et al., 2006) and humans (Schuelke et al., 2004), collectively demonstrating 
that Mstn is a negative regulator of skeletal muscle growth. Studies have demonstrated 
that Mstn suppresses muscle growth in two ways: one way to limit muscle growth is by 
regulating the number of muscle fiber during development, and the other way is by 
regulating postnatal hypertrophy of skeletal muscle fibers. Because of its unique role on 
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muscle growth and development, extensive investigations have been performed with 
related to myostatin, resulting in almost 1,000 publications in the last 13 years since its 
first identification in 1997. Many reviews on myostatin are available (Sharma et al., 
2001; Kocamis and Killefer, 2002; Gonzalez-Cadavid and Bhasin, 2004; Lee, 2004; 
Patel and Amthor, 2005; Joulia-Ekaza and Cabello, 2007; McFarlane et al., 2008; 
Rodgers and Garikipati, 2008). 
1.3.1 Role of myostatin in the control of myoblast proliferation and differentiation 
Mstn is expressed in cells in the myotome during embryogenesis (McPherron et 
al., 1997). In pigs, Mstn mRNA was detectable in whole fetuses at 21 and 35 days of 
gestation and was markedly increased by 49 days (Ji et al., 1998). At birth, mRNA 
abundance in longissimus muscle had declined significantly from the level at day 105 of 
gestation and continued to decrease to its lowest level at 2 weeks postnatally (Ji et al., 
1998). The reduction in Mstn mRNA abundance at birth and postnatal period coincides 
also with the period of reduction in myoblast mitogenic activity and differentiation. In 
skeletal muscle cell cultures, addition of recombinant Mstn or over-expression of Mstn 
inhibited the proliferation of mouse myoblasts (Thomas et al., 2000; Taylor et al., 2001), 
turkey embryonic myoblasts and satellite cells (McFarland et al., 2006), and chicken 
embryonic myoblasts (McFarland et al., 2007). Levels of Mstn mRNA expression 
during chicken embryonic development and in muscle cell culture support the inhibitory 
role of Mstn on myoblast proliferation because the lower level of Mstn mRNA 
coincides generally with the period of myoblast proliferation before myotube formation 
(Kocamis et al., 1999; Kocamis et al., 2001). The inhibitory role of Mstn on myoblast 
proliferation explains the hyperplasia of muscle fibers observed in mice, cattle, sheep 
and dogs carrying a non-functional myostatin gene. 
The inhibition of the proliferation of myoblasts by Mstn appears to be through 
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the prevention of the progression of myoblasts from the G1- to S- phase of the cell cycle 
regulated by retinoblastoma (Rb) protein hypophosphorylation (Thomas et al., 2000; 
Joulia et al., 2003). The maintenance of the proliferative capacity of myoblasts after 
removing Mstn from the cell culture indicates that the inhibitory effect of Mstn is 
reversible (Taylor et al., 2001). In addition, the Mstn-added muscle cell cultures showed 
the upregulation of p21, a cyclin-dependent kinase inhibitor, and down regulation of 
cyclin dependent kinase-2 (Cdk-2) with higher levels of hypophosphorylated Rb 
(Thomas et al., 2000). The upregulation of p21 was also observed in C2C12 muscle cell 
cultures over-expressing Mstn (Rios et al., 2001). Because Cdks are the key regulatory 
molecules for cell proliferation, these results indicate that Mstn inhibit myoblast 
proliferation through the Cdk system. Since Rb protein phosphorylation by Cdk 
physically releases E2F-DP1, a component that is needed for the transcription of S-
phase-specific genes, by inhibiting the phosphorylation of Rb and its dissociation of 
E2F-DP1, Mstn ceases the cells in G0/G1 phase of cell cycle (Thomas et al., 2000; 
Joulia et al., 2003). These results suggest that myostatin probably arrests the myoblast at 
G0/G1 phase of the cell cycle in a phosphorylation of Rb-dependent pathway. Results 
from Langley et al. (2004) showed that myostatin inhibited myoblast proliferation by 
down regulating Cdk2 and Cyclin E, without altering phosphorylation status of Rb in 
rhabdosarcoma cell cultures, indicating a presence of Rb-independent pathway to inhibit 
myoblast proliferation. Yang et al. (2007) also demonstrated that Mstn treatment 
inhibited C2C12 cells proliferation by down regulating Cdk4 and Cyclin D1 through the 
Akt/GSK-3β pathway independent of Rb phosphorylation. In addition, a recent study 
indicated that inhibition of myoblast proliferation by Mstn is associated with 
upregulation of ubiquitin ligase RING finger protein 13 (RNF 13) at both the 
transcriptional and translational levels (Zhang et al., 2010). 
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Besides inhibiting myoblast proliferation, myostatin also appears to have a 
negative regulatory role in myoblast differentiation. Mstn inhibited myoblast 
differentiation in a dose-dependent manner in C2C12 myoblast culture, where down-
regulation of MyoD, Myf5, and myogenin were observed in C2C12 cells by Mstn 
treatment (Langley et al., 2002; Rios et al., 2002; Joulia et al., 2003). Increased 
phosphorylation of Smad 2/3, a down-stream mediator of Mstn signaling, and Smad2/3-
MyoD association were observed by Mstn treatment during myoblast differentiation 
(Bogdanovich et al., 2002; Langley et al., 2002). Conversely, when cultured C2C12 
cells were treated with blocking antibodies generated against Mstn, cells treated with 
anti-myostatin antibody had decreased concentrations of phosphorylated Smad2 and 3 
as compared to controls (Bogdanovich et al., 2002). Using siRNA to block Smad2/3, 
Trendelenburg et al., (2009) demonstrated that the Mstn’s anti-differentiation effect 
requires both of the Smads. These studies together indicate that Mstn requires Smad 2/3 
activation in order to inhibit myoblast differentiation. Recent evidences indicate that 
Mstn inhibition of myoblast differentiation requires the activation of the 
Akt/mammalian target of rapamycin (mTOR) pathway. For example, Trendelenburg et 
al., (2009) demonstrated that the Mstn’s anti-differentiation effects can be blocked by 
blockade of the Akt/mTOR pathway by using small interfering RNA.  
1.3.2 Role of myostatin in the control of post-natal muscle growth 
In addition to the inhibitory role of Mstn in myoblast proliferation and 
differentiation during development, numerous studies indicate that Mstn has a role in 
skeletal muscle growth and maintenance in postnatal animals. Whittemore et al. (2003) 
produced monoclonal anti-Mstn antibody, and when they administered the antibody to 
mice, they observed that the antibody-treated mice gained approximately 10 % more 
weight than the control. The administration of monoclonal anti-Mstn antibodies to mdx 
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mice (an animal model for Dunchenne muscular dystrophy) increased body weight, 
whole muscle cross sectional area and muscle fiber area after 3 months of treatment as 
compared to control animals (Bogdanovich et al., 2002). Mstn suppression by anti-Mstn 
antibody generated via DNA vaccine method in mice increased skeletal muscle mass up 
to 31%, as well as muscle function (Tang et al., 2007). Conversely, systemic 
administration of Mstn by injection of Mstn–producing CHO cells into the thigh muscle 
or ectopic expression of Mstn through the electrotransfer of Mstn-containing plasmid 
significantly decreased skeletal muscle mass in adult mice (Zimmers et al., 2002). 
Studies in which genectic manipulation was used to modify postnatal Mstn 
concentration also provide evidence supporting the role of Mstn in postnatal skeletal 
muscles. Grobet et al. (2003) generated conditional Mstn knockout mice that 
demonstrated postnatal inactivation of Mstn. They reported that the conditional Mstn 
knockout mice had significantly increased muscle mass, as was demonstrated in the 
constitutive Mstn knockout mice generated by McPherron et al. (1997). However, 
unlike the constitutive myostatin knockout mice, they reported that the increase in 
skeletal muscle mass in the conditional myostatin knockout mice was primarily due to 
the hypertrophy of skeletal muscle fibers. Injection of plasmid expressing short-
interfereing RNA (siRNA) targeting Mstn in adult mice increased tibialis muscle mass 
(10%) and fiber size (24%), along with a two-fold increase in satellite cell number 
(Magee et al., 2006). Direct injection of antisense RNA against Mstn also improved the 
muscle growth in adult normal and cachexia mice (Liu et al., 2008). Systemic 
overexpression of dominant negative form of Mstn in liver via aneno-associated virous 
method led to an increase in skeletal muscle mass in normal and dystrophic mice 
(Morine et al., 2010). Overexpression of dominant-negative latency-associated Mstn 
propeptide under the control of myosin light chain 1F promoter and 1/3 enhancer from 
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the TSPY locus on the Y chromosome in transgenic mice induced a 5-20% increase in 
skeletal muscle mass (Pirottin et al., 2005).  
In support of the negative regulation of Mstn on postnatal muscle hypertrophy, 
various studies reported a negative relationship between the level of Mstn and muscle 
mass under various physiological or pathological conditions that induced muscle loss or 
gain in many vertebrate species. Carlson et al. (1999) examined Mstn mRNA abundance 
in mice gatrocnemius and plantaris muscles undergoing hindlimb unloading at 1, 3 and 
7 days. Significant muscle atrophy was observed at 3 day after unloading. Mstn mRNA 
increased significantly in mice gatrocnemius and plantaris muscles at 1 day after 
hindlimb unloading but not at 3 or 7 days of hindlimb unloading, suggesting that Mstn 
upregulation was associated with the atrophy of skeletal muscles. Wehling et al. (2000) 
also reported that 10 days of unloading caused a 16 % decrease in plantaris mass and a 
110 % increase in Mstn mRNA. Consistent with the above results, the expression of 
Mstn mRNA level increased 30-fold in both chronic and acute disuse-induced muscle 
atrophy (Reardon et al., 2001). Mstn mRNA concentrations were significantly higher in 
skeletal muscles from the spaceflight rat than those in the ground-based controls, 
resulting in negative relationship between the myostatin mRNA expression and muscle 
mass (Lalani et al., 2000). 
Some studies indicate that regulation of satellite cell proliferation by Mstn is 
associated with the negative role of Mstn on postnatal skeletal muscle growth. 
McCroskery et al. (2003) demonstrated that satellitce cell activation was inhibited by 
the addition of Mstn to myofiber explant cultures. The Mstn-deficient mice had higher 
number of satellite cells as compared with wild type mice. In contrast, addition of Mstn 
to myofiber explant cultures inhibited satellite cell activation. Cell cycle analysis 
showed that Mstn up-regulated p21 and decreased the levels and activity of Cdk2 
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protein in satellite cells. Hence, Mstn negatively regulates the G1 to S progression of 
statellite cells and thus maintains the quiescent status of satellite cells. McFarland et al. 
(2006) also demonstrated that Mstn inhibts the proliferation and differentiation of 
myogenic satellite cells, indicating that Mstn is a potential negative regulator of the 
activation of satellite cells. Furthermore, McFarlane et al. (2008) demonstrated that 
exogenous addition of Mstn dramatically reduced Pax7 expression, which is required 
for satellite cell specification (self-renewal process) in C2C12 cells. In contrast, either 
functional blockade or complete genetic inactivation of Mstn resulted in an increase in 
Pax7 expression. These results suggest that Mstn signals via a Pax7-dependent 
mechanism to regulate satellite cell self-renewal. 
Other studies indicate that Mstn regulates postnatal skeletal muscle hypertrophy 
through regulation of protein synthesis mediated by the Akt/mTOR signaling pathway. 
Amirouche et al. (2009) demonstrated that the overexpressed-Mstn in mice skeletal 
muscle by electrotransfer of Mstn expression vector attenuated the phosphorylation of 
Akt and 4E-BP1, indicating an mTOR-dependent downregulation of protein synthesis 
by myostatin. Welle et al. (2009) also demonstrated that the administration of anti-Mstn 
antibody suppressed Mstn activity through an increased phosphorylation of p70S6k, but 
not by an increased phosphorylation of Akt and 4E-BP1. Furthermore, genetic loss of 
Mstn in mice led to enhanced muscle expression of Akt and elevated activity of the 
components of the Akt/mTOR pathway (Lipina et al., 2010), and adenoviral-mediated 
overexpression of Mstn attenuated the IGF-1-induced myotube diameter through the 
down-regulation of Akt (Morissette et al., 2009). 
1.3.3 Role of myostatin on muscle fiber type 
In addition to the regulation of muscle mass, Mstn also appears to be involved 
in the determination of muscle fiber type composition and to regulate the hypertrophy of 
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muscle fiber differentially dependent upon muscle fiber types. The expression of Mstn 
was higher in fast type muscle than in slow type muscle (Mendler et al., 2000). In 
agreement with this finding, the greatest amount of Mstn mRNA was also found in the 
white portion of mouse quadriceps muscle that was composed of 100 % type IIB 
(Carlson et al., 1999). Thus, Mstn appears to be more involved in the regulation of fast-
twitch fibers rather than slow-twitch fibers. In support of the above hypothesis, mice 
overexpressing Mstn prodomain exhibited preferential hypertrophy of type II muscle 
fiber (Yang et al. 2001). Moreover, Mstn gene knockout mice and cattle with non-
functional Mstn mutation showed an increased percentage of fast-twitch glycolytic (type 
IIB) muscle fibers (Carlson et al., 1999; Salerno et al., 2004; Hayashi et al., 2008).  
While molecular mechanisms determining muscle fiber type differentiation is 
largely unknown, recent studies suggest that MyoD, calcineurin (a calcium dependent 
phosphatase), and MEF (a MADS box transcription factor) are involved in the 
regulation of muscle fiber type differentiation. It was demonstrated that MEF2 as a 
downstream effector of calcineurin-dependent signaling pathway is necessary for the 
formation of slow fibers since overexpression of MEF2 isoforms and calcineurin results 
in an increased number of type IIA and type I fibers (Wu et al., 2000). Similarly, in 
myotonic mice, in which an increased number of slow fibers are seen, there was an 
increased activity of MEF2 proteins (Wu et al., 2001). A study by Hughes et al. (1993) 
demonstrated that MyoD mRNA specifically accumulated in fast type IIB/IIX fiber of 
hindlimb muscles in mice, leading to a hypothesis that MyoD is required for the fast-
fiber formation. Recently, Hennebry et al. (2009) examined the expression levels of 
MEF2, calcineurin, and MyoD in myostatin null mice to investigate whether Mstn 
regulates muscle fiber type differentiation via regulation of these molecules. They 
observed reduced MEF2 protein in nuclear extracts of Mstn null mice muscle and 
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myoblast along with reduced MEF2-DNA complex in electrophoretic mobility-shift 
assay. Calcineurin mRNA expression depressed, but MyoD protein level increased in 
Mstn null mice. These results, thus, suggest that the fiber type differentiation regulated 
by Mstn is probably via the pathways involving MyoD, calcineurin, and MEF2 
regulation.  
1.3.4 Myostatin synthesis, processing, activation and inhibition 
Mstn is mainly synthesized as a precursor protein composed of a signal 
sequence (24 amino acid (AA)), an N-terminal propeptide domain (prodomain, 240-243 
AA) and a C-terminal active domain (mature myostatin, 109 AA) in skeletal muscles 
(Zimmers et al., 2002). Mstn undergoes two proteolytic processing events in order to 
generate the biologically active molecule. The first cleavage event removes the signal 
peptide, which plays a role in the transport of Mstn precursor protein from the 
cytoplasm into endoplasmic reticulum. The second cleavage event generating N-
terminal propeptide and C-terminal active-form of myostatin occur at the tetrabasic 
(RSRR) site, which is mediated by a calcium-dependent serine protease called furin 
(Lee and McPherron, 2001; Thies et al., 2001). After the proteolytic processing of the 
precursor, Mstn is secreted as an inactive latent complex of a mature dimmer bound by 
two propeptides, thus the propeptide is functioning to suppress Mstn activity. In support 
of the role of propeptide to inhibit Mstn biological activity, the overexpression of Mstn 
propeptide in mice resulted in a dramatic increase in skeletal muscle mass (Lee and 
McPherron, 2001; Yang et al., 2001). In addition, the administration of recombinant 
Mstn propeptide (Li et al., 2010) or plasmid- or adeno-associated virus-mediated 
delivary of Mstn propeptide induced an increase in muscle mass (Matsakas et al., 2009; 
Hu et al., 2010). 
Binding of mature Mstn to its receptor (activin type IIB receptor) for induction 
 21
of intracellular signaling cascade, thus, requires dissociation of the propeptide from the 
latent complex. The propeptide binding to the mature region can be physically or 
biochemically destabilized after it is cleaved by protease, such as bone morphogenetic 
protein-1/tolloid (BMP-1/TLD) family of metalloproteinases (Wolfman et al., 2003; Lee, 
2008). The importance of BMP-1/TLD metalloproteinase in regulating Mstn latency in 
vivo is supported by studies using a mutant form of the propeptide in which aspartate 76 
was mutated to alanine (Wolfman et al., 2003). The mutant form of propeptide resistant 
to cleavage by BMP-1/TLD metalloproteinases caused a significant increase in muscle 
mass when injected into adult mice (Wolfman et al., 2003). Mice engineered to carry a 
germline point mutation of propeptide rendered to be resistant to the BMP-1/TLD 
metalloproteinases exhibited an increase in skeletal muscle mass (Lee, 2008), 
suggesting that the BMP-1/TLD metalloproteinases is involved in activating latent Mstn 
in vivo and that molecules capable of inhibiting these proteinases may be an effective 
therapeutic strategy for enhancing muscle growth in clinical settings of muscle loss and 
degeneration. 
In addition to the propeptide, several other proteins have also been shown to be 
capable of binding and inhibitng the activity of mature Mstn. Several studies suggested 
that follistatin can function as a potent myostatin antagonist and plays an important role 
in modulating Mstn activity. Follistatin was capable of blocking Mstn activity in both 
receptor binding and reporter gene assays in CHO cells (Zimmers et al., 2002). 
Overexpression of follistatin in muscle induced dramatic increases in skeletal muscle 
growth in mice (Lee and McPherron, 2001). Amother et al. (2004) also demonstrated 
that follistatin and Mstn interact directly with high affinity during chick development, 
and Mstn inhibits terminal differential of muscle cells in high-density cell cultures of 
limb mesenchyme and that follistatin rescues muscle differentiation in a concentration-
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dependent manner. The results suggest that follistatin antagonizes Mstn by direct 
interaction, resulting in prevention of Mstn from executing its inhibitory effect on 
muscle development. Recently, gene-targeted approach of follistatin overexpression, 
such as adenoviral vector-mediated gene theraphy and cell-mediated theraphy using 
myogenic stem cells, showed that the over-expression of follistatin enhanced skeletal 
muscle growth in dystrophic mice (Nakatani et al., 2008; Tsuchida, 2008; Rodino-
Klapac et al., 2009).  
Follistatin related gene (FLRG) and growth and differentiation factor (GDF)-
associated serum protein-1 (GASP-1) also appear to be involved in regulating the 
activity of mature Mstn (Hill et al., 2002; Hill et al., 2003; Takehara-Kasamatsu et al., 
2007; Saremi et al., 2010). For example, Hill et al. (2002, 2003) demomstrated that both 
FLRG and GASP-1 is complexed to myostatin in the blood of mice and human, and 
studies with recombinant proteins have shown that both proteins can bind with high 
affinitiy to the Mstn and inhibit its acitivity as assessed by reporter gene assays. 
Moreover, Takehara-Kasamatsu et al. (2007) demonostrated that the overexpression of 
FLRG mRNA suppressed the Mstn activity as a negative regulator during fetal and 
adult mouse heart development. In addition, Saremi et al. (2010) demonstrated that 
resistance training caused a significant decrease in serum levels of Mstn and increase in 
GASP-1. The effect of resistance training on serum levels of Mstn and GASP-1, may 
explain the increased muscle mass. 
In addition to FLRG and GASP-1, titin-cap (T-cap), decorin and perlecan also 
appear to be involved in regulating the activity of Mstn (Nicholas et al., 2002; Miura et 
al., 2006; Nishimura et al., 2007; Kishioka et al., 2008; Xu et al., 2010). For example, 
the overexpression of titin-cap, a sarcomeric protein, in C2C12 myoblasts induced an 
increase in the rate of cell proliferation through suppression of Mstn expression, 
 23
indicating that titin-cap controls Mstn secretion in myogenic precursor cells without 
affecting the processing step of precursor Mstn (Nicholas et al., 2002). Decorin, which 
is a small leucine-rich proteoglycan, binds to myostatin and blocks the inhibitory effect 
of Mstn on muscle cell growth in vitro (Miura et al., 2006). Moreover, the 
overexpression of decorin enhances the proliferation and differentiation of C2C12 
myoblasts through suppressing myostatin acitivty (Kishioka et al., 2008). In addtion, 
skeletal muscle-specific knock-out of perlecan, a component of the basement membrane 
that surrounds skeletal muscle, induced a decrease in Mstn expression and increased 
fiber cross-sectional area as compared with control mice, suggesting that perlecan is 
critical for maintaining skeletal muscle mass and fiber composition, and for regulating 
Mstn signaling (Xu et al., 2010). 
1.3.5 Myostatin signal transduction  
Most members of the TGF-β superfamily are believed to signal through Smad 
complex activated by heteromeric complexes of type I and type II serine/threonine 
kinase receptors (reviewed by Kawabata and Miyazono, 1999; Mehra and Wrana, 2002). 
Most ligands binding to type II receptor activates type I receptor, resulting in the 
initiation of signal transduction pathways by phosphorylation of intracellular mediators, 
such as Smad proteins. Eight different Smad proteins are divided into three functional 
groups: Smad 1, 2, 3, 5 and 8 belongs to the receptor regulated R-Smads, and Smad 4 
belongs to the common partner Co-Smad, and Smad 6 and 7 belongs to the inhibitory I-
Smads. R-Smads are phosphorylated by type I receptor serine kinase in response to the 
binding of TGF-β superfamily to type II receptors. The Co-Smad positively regulates 
the phosphorylated R-Smads by hetero-oligomer formation with the R-Smads. The 
entire complex of R-Smads and Co-Smad translocates into the nucleus. Inside nucleus, 
they interact with different cellular partners, bind to DNA, and regulate transcription of 
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various downstream response genes. In contrast to R-Smads and Co-Smads, I-Smads 
inhibits the signaling of TGF-β superfamily proteins. The I-Smads interact with type I 
receptors, thus compete with R-Smads for activation by the type I receptors. In addition, 
I-Smads also recruit Smurf ubiquitin ligases to catalyze degradation of the receptor 
complex. The transcription of I-Smads is known to be initiated by TGF-β superfamily 
proteins, thus providing a negative feedback regulation.  
Similar to many other TGF-β superfamily proteins, Mstn was shown to bind to 
the activin type IIB receptor (ActRIIB) in a specific and saturable manner (Lee and 
McPherron, 2001), suggesting that Mstn initiates its signaling cascade by binding to 
ActRIIB and subsequent activation of Smads pathway. Lee and McPherron (2001) have 
demonstrated that transgenic mice over-expressing a dominant negative form of 
ActRIIB had increased muscle growth similar to the Mstn null mice, suggesting that 
Mstn binds to ActRIIB receptor for signaling cascade. Recently, it was shown that 
lentiviral-mediated delivery of dominant negative mutated ActRIIB increased myobalst 
proliferation and fusion and changed the expression of myogenic regulatory factors 
(Fakhfakh et al., 2010). In support of the activation of Smad pathway by Mstn, Langly 
et al. (2002) demonstrated that the addition of Mstn in muscle cell culture up-regulated 
the level of phosphorylated Smad3 during the myoblast differentiation, and the addition 
of anti-Mstn antibodies down-regulated the level of phosphorylated Smad3 in C2C12 
cells (Bogdanovich et al., 2002). Moreover, Zhu et al. (2004) investigated the Mstn 
signaling pathway using a myostain-responsive p(CAGA)12-MLP luciferase reporter 
assay system in which plasmids containing various Smads were co-transfected. Their 
results showed that the myostatin-induced transcription required the participation of R-
Smads (Smad 2/3) and Co-Smad (Smad 4), and inhibitory Smad7 dramatically reduced 
the Mstn-induced transcription.  
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The activation of Smad signaling by mysotatin has been well characterized, but 
very little has been known about the molecular mechanisms connecting Smads 
activation to muscle protein metabolism. Recently, however, several studies indicate an 
existence of a cross-talk between the Smads signaling and the Akt/mammalian target of 
rapamycin (mTOR) pathway. For example, Sartori et al. (2009) observed an atrophy in 
muscle fibers that were transfected with constitutively active (c.a.) ALK4/5, a type I 
Mstn receptor, in mice, conforming the muscle atrophic effect of Mstn stimulation. To 
examine the involvement of Smad phosphorylation in the atrophic effect of ALK4/5 
activation, they suppressed the Smad2 and 3 activities through siRNA method in the c.a. 
ALK transfected muscle fiber. They observed that inhibition of Smad 2 and 3 could 
completely block ALK4/5-mediated atrophy. Furthermore, induction of Akt could 
completely block the atrophic action of c.a. ALK4/5, indicating that Mstn signaling 
involves the Akt downstream of Smad regulation. It was also reported that Akt 
phosphorylation was inhibited by Mstn in human myotube, and the effect was 
dependent upon the presence of Smad2 and 3 (Trendelenburg et al., 2009). Blockade of 
the Akt/mTOR pathway, using small interfering RNA to regulatory-associated protein 
of mTOR (RAPTOR), a component of TOR signaling complex 1 (TORC1), increased 
Mstn-induced Smad phosphorylation, establishing a feed-forward mechanism: Mstn 
activates Smad2, which inhibits Akt, inhibiting TORC1, which in turn potentiates Mstn 
's activation of Smad2 (Trendelenburg et al., 2009). Addition of IGF-1 dominantly 
blocked the effects of myostatin, when applied to either myoblasts or myotubes 
(Trendelenburg et al., 2009). The results combinded together indicate that Akt is a 
particular crossing point between the IGF-1 and Mstn signaling and that IGF-1 can 
rescue the activation of the PI3k/Akt pathway that is blunted by Mstn. 
1.4 REGULATION OF MUSCLE GROWTH BY β-ADRENERGIC AGONISTS 
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1.4.1 Function of β-adrenergic agonists 
The β-adrenergic agonists (β-gonists) regulate a variety of physiological 
functions in almost all organ systems, including cardiovascular, respiratory, 
gastrointestinal, urogenital, ocular, hormonal secretion, and central nervous systems 
through binding to β-adrenergic receptors (β-adrenoceptors) (reviewed by Hieble and 
Ruffolo Jr., 1991). Naturally occurring endogenous β-agonists in mammals are 
adrenaline (epinephrine) and noradrenaline (norepinephrine). Multiple metabolic 
responses are also controlled by β-adrenoceptor activation, including stimulation of 
lipolysis and glycogenolysis. Furthermore, anabolic effects of β-agonists have been 
widely studied for potential applications in the prevention of muscle atrophy, and 
improvement of the efficiency of muscle growth, feed efficiency, and carcass 
composition in production livestock (reviewed by Kim and Sainz, 1992). Although the 
degree of responses varies depending on the dose and type of β-agonists, animal breed, 
age, sex, nutritional support and experinmental period, muscle gain and feed efficiency 
were significantly increased by the treatment of β-agonists (Buttery, 1993). Moreover, 
β-agonists increase carcass protein content and decrease carcass fat deposition. The 
increase in protein content by β-agonists is 10-17% in ruminants (Allen et al., 1987), 
7% in swine (Buttery, 1993), and 2-3% in poultry (Duquette et al., 1987). The decrease 
in carcass fat by β-agonists is up to 30% in ruminants (Hanrahan et al., 1987), 6-27% in 
swine (Bekaert et al., 1987), and 8-10% in poultry (Scholtyssek, 1987). 
1.4.2 Skeletal muscle hypertrophic effect of β-adrenergic agonists  
Several studies demonstrated that β-agonists have a specific anabolic effect on 
skeletal muscle in animals. In rats, for instance, fenoterol or clenbuterol increased 
skeletal muscle mass by 20-30% after 2-4 weeks (Ryall et al., 2002). In lambs, 
administration of cimaterol for 7-8 weeks increased muscle weight by 30-40% (Kim et 
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al., 1987). In pigs, salbutamol significantly increased the weight of longissimus dorsi 
muscle by 17% after 44 days of administration (Oksbjerg et al., 1990). Lean muscle 
mass was increased up to 20% by clenbuterol administration in mice (Hayes and 
Williams, 1994). Moreover, the hypertrophic effect of β-agonists is selective to skeletal 
muscle fibers types. The cross-sectional area of fast muscle fiber type (type II) was 
increased by the hypertrophic effect of β-agonists in muscles of various animals. 
However, the effects of β-agonists on slow muscle fiber type (type I) are not consistent 
among studies (reviewed by Yang and McElligott, 1989; Kim and Sainz, 1992), 
indicating that the growth effects induced by β-agonists are more pronounced in 
predominantly fast-twitch muscle than slow-twitch muscle.  
In addition to skeletal muscle hypertrophic effect in normally growing animals, 
β-agonists have been shown to prevent or inhibit weight loss or decrease in growth of 
animals induced by physiological or pharmacological disturbance. For example, 
clenbuterol increased the weight of the gastrocnemius and soleus muscles in dystrophic 
mice by 29% (Rothwell and Stock, 1985). Moreover, clenbuterol retarded atrophy in 
denervated muscles in rats (Zeman et al., 1987), and cimaterol delayed chicken muscle 
atrophy induced by stretch-release (Lee et al., 1994). In addition, administration of 
clenbuterol prevented glucocorticoid-induced muscle atrophy (Agbenyega and 
Wareham, 1992), and reduced the muscle loss caused by phytohaemaglutinin injection 
(Bardocz et al., 1992). Furthermore, clenbuterol enhanced the recovery of body weight 
gain from weight loss caused by endotoxemia in rats (Choo et al., 1989), and 
pretreatment of cimaterol significantly reduced the catabolic effect of corticosterone on 
carcass and muscle protein (Brown et al., 1992). 
1.4.3 β-adrenergic receptors 
β-adrenoceptors are G-protein-coupled receptors, which comprise a large 
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protein family of transmembrane receptors that sense molecules outside the cell and 
activate inside signal transduction pathways, cellular responses, and specifically 
mediate physiological responses to epinephrine and norepinephrine. There are three 
different receptor subtypes: β1-, β2-, and β3-adrenoceptors, each with a 65-70% 
homology in their amino acid composition. β1-adrenoceptor is located at highest levels 
in the heart and brain (Frielle et al., 1987), β2-adrenoceptor is widely expressed (Dixon 
et al., 1986), and β3-adrenoceptor is located at highest levels in the adipose tissue 
(Emorine et al., 1989). These three receptors have two principal signal transduction 
pathways involving the adenyl cyclase pathway and the phophatidylinositol signal 
pathway (reviewed by Yang and McElligott, 1989; Hinkle et al., 2002; Hall, 2004; 
Lynch and Ryall, 2008). 
1.4.4. Signaling pathways of β2-adrenergic receptor leading to muscle hypertrophy 
The activated β2-adrenoceptor stimulates the adenylyl cyclase (AC) pathway 
via the activation of guanine nucleotide binding protein Gαs, which stimulated G protein 
complex exchange GDP and GTP and is released from the complex, resulting in 
increased cyclic adenosine monophosphate (cAMP) levels. The production of cAMP 
results in the activation of numerous downstream signaling pathways, including the 
well-described protein kinase A (PKA) signaling pathways. The cAMP- PKA signaling 
pathway is one of the most common and versatile signaling pathway in eukaryotic cells 
and is involved in regulation of cellular functions in almost all tissues in mammals. 
Thus, the classic signaling pathway of β2-adrenoceptor involves activation of adenyl 
cyclase (AC) and subsequent formation of cAMP (reviwed by Bos, 2003; Tasken and 
Aandahl, 2004; Hall, 2004). Nevertheless, the link between the classic β2-adrenergic 
receptor/Gα/AC/cAMP signaling pathway and the change in protein metabolism 
induced by the administration of β-adrenergic agonists has remained elusive. Recent 
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results, however, indicate that like MSTN, β-adrenergic agonists may induce muscle 
hypertrophy via the Akt/mTOR signaling pathway. For example, clenbuterol treatment 
induced protein accretion in mice via stimulation of protein translation through the 
phosphorylation of p70S6k and 4E-BP1, which are downstream effectors of the 
Akt/mTOR signaling pathway (Sneddon et al., 2001). Kline et al. (2007) also 
demonstrated that clenbuterol administration induced dramatic increase in skeletal 
muscle mass through the Akt phosphorylation and subsequent activation of the mTOR. 
In addition, Sable et al. (1997) demonstrated that in vivo the cAMP elevating agents led 
to a significant increase in the activity of Akt through a mechanism which is 
independent of PI3k, suggesting that cAMP can lead to the activation of Akt.  
1.4.5 Adaptation of animals to growth promoting effects of β-adrenergic agonists 
Some studies demonstrated that the growth-promoting effect of β-agonists is 
effective for a limited time period. The response is attenuated or disappears with 
prolonged treatment (reviewed by Yang and McElligott, 1989; Kim and Sainz, 1992). 
For example, the onset of the anabolic effect is rapidly observed within 2 days after 
administration of clenbuterol and reached a maximum within 8 days in rats. However, 
the response was attenuated after 14 days of treatment with the same daily gain as 
control (Mcelligott et al., 1989). Chronic treatment with clenbuterol for 18 days reduced 
β-adrenoceptor density by 50% in rat skeletal muscles (Rothwell et al., 1987). Chronic 
treatment with cimaterol also reduced β-adrenoceptor density in mice skeletal muscle 
after 3 days and remained lower thereafter (Kim et al., 1992). Ryall et al. (2002) also 
demonstrated that β-adrenoceptor density was decreased by fenoterol and clenbuterol 
treatment for 4 weeks in EDL muscles (51 and 34%, respectively) and in soleus muscles 
(42 and 44%, respectively). Taken together, the decrease in growth-promoting effect of 
β-agonists is probably due to the desensitization process operated by down-regulation of 
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β-aerenoceptors (reviewed by Ferguson, 2001). 
1.5 DNA MICROARRAY TECHNOLOGY 
DNA microarray technology has provided researchers with the ability to 
measure the expression levels of thousands of genes simultaneously in a single 
experiment. The ability to probe a sample for hundred to million different genes 
simultaneously is very powerful in evaluating cellular functions and genetic variations 
in a systemic way. For this reason, DNA microarray assay has become an important tool 
in many genomics research laboratories, as well as other various fields of life science 
laboratories (reviewed by Barrett and Kawasaki, 2003). 
1.5.1 Principles of DNA microarray  
DNA microarray is a multiplex technology used in molecular biology. It 
consists of an arrayed series of thousands of microscopic spots of DNA oligonucleotides, 
known as probes (or reporters). These can be a short section of a gene or other DNA 
element that are used to hybridize a cDNA or cRNA sample (called target) under high-
stringency conditions. The probes are attached via surface engineering to a solid surface 
by a covalent bond to a chemical matrix (via epoxy-silane, amino-silane, lysine, 
polyacrylamide or others). Surface engineering includes printing with fine-pointed pins 
onto glass slides, photolithography using pre-made masks, dynamic micromirror 
devices, ink-jet printing, or electrochemistry on microelectrode arrays (reviewed by 
Schena et al., 1998; Lausted et al., 2004).  
The main advantage of DNA microarray is that it obviates the need for 
expensive sequencing of entire genomes since it allows the evaluation of gene 
expression in an organism for which little sequence data is available. The next 
microarray technology to emerge involved in situ-synthesized oligonucleotide arrays 
using photolithographic technology (Affymetrix). Each gene target is proved by a 
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number of distinct probes collectively termed a probe set, while some probes within a 
set are known to overlap in sequence. Each probe with the same 25 bp segment of a 
target gene consists of millions of single strands of DNA of exact length and sequence, 
and is confined to a small square area. Some of the probes on the surface have 
sequences that are perfectly complementary to particular target sequences and are 
referred to as perfect match (PM) probes. Also, present on the chip are probes whose 
sequence is deliberately selected not to be perfectly complementary to a target sequence. 
Such probes are referred to as mismatched (MM) control probes. Thus, the biological 
sample such as an mRNA sample can be analyzed for gene expression for hybridization 
to above-described microarray chip (reviewed by Naef et al., 2002; Sasik et al., 2004). 
The presence of RNA sequences that bind to the oligonucleotide probes on the chips are 
then detected by methods such as tagging with a fluorescence material and then 
detecting the fluorescence (Pease et al., 1994). Since sequences that are different from 
the target sequences may also bind to the PM probes that correspond to such target 
sequences, the fluorescence signals from such sequences would appear as noise. Signal 
to noise ratio is improved by calculating the difference from signals from the sequences 
that bind to the PM probes and the signals form sequences that bind to the MM probes 
(Pease et al., 1994). 
1.5.2 Two-channel and one-channel microarray detection 
Two-channel microarray detection is typically hybridized with cDNA prepared 
from two samples to be compared and that are labeled with two different fluorophores 
(Shalon et al., 1996). Fluorescent dyes commonly used for cDNA labeling include Cy3, 
which has a fluorescence emission wavelength of 570 nm (corresponding to the green 
part of the light spectrum), and Cy5 with a fluorescence emission wavelength of 670 nm 
(corresponding to the red part of the light spectrum). The two Cy-labelled cDNA 
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samples are mixed and hybridized to a single microarray that is then scanned in a 
microarray scanner to visualize fluorescence of the two fluorophores after excitation 
with a laser beam of a defined wavelength. Relative intensities of each fluorophore may 
then be used in ratio-based analysis to identify up-regulated and down-regulated genes 
(Tang et al., 2007).  
The single-channel microarray detection provides intensity data for each probe 
or probe set indicating a relative level of hybridization with the labeled target. However, 
they do not truly indicate abundance levels of a gene but rather relative abundance when 
compared to other samples or conditions when processed in the same experiment 
(Patterson et al., 2006). The advantage of single-channel microarray system is that an 
aberrant sample cannot affect the raw data derived from other samples, because each 
array chip is exposed to only one sample. Another benefit is that data are more easily 
compared to arrays from different experiments, and the absolute values of gene 
expression may be compared between studies conducted months or years apart. 
However, disadvantage of the one-color system is that, when compared to the two-color 
system, twice as many microarrays are needed to compare samples within an 
experiment (reviewed by Barrett and Kawasaki, 2003). 
1.5.3 Use of microarray analysis to examine global gene expression during skeletal 
muscle growth 
Bey et al. (2003) analyzed the patterns of global gene expression in rat 
skeletal muscle during unloading and low-intensity ambulatory activaity using 
microarray. They identified 121 (≥1.5 fold) genes being differentially expressed, and 
analyis of these genes indicated that key signaling proteins and transcription factors 
involved in protein synthesis/degradation and energy metabolism were regulated in rat 
soleus muscle during unloading and low-intensity amululatory activaity. They also 
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identified potential new targets that may initiate muscle alterations during inactivity. 
Carson et al. (2002) analyzed the differential gene expression in the rat soleus muscle 
during early work overload-induced hypertrophy. They identified 112 genes being 
differentially expressed, and these genes were classified into cell proliferation, 
autocrine/paracrine, extracellular matrix, immune response, intracellular signaling, 
metabolism, neural, protein synthesis/degradation, structural, and transcription. Jagoe et 
al. (2002) analyzed the patterns of gene expression in atrophying skeletal muscles 
response to food deprivation. The results indicated that the about 200 genes (≥1.8 fold) 
were differentially expressed. Functional analysis of those genes showed increased 
patterns of polyubiquitin, ubiquitin extension proteins and ligase, atrogin-1 and many 
proteasome subunits, and decreased patterns of myosin binding protein H, IGF binding 
protein 5, glycolytic enzymes and phosphorylase kinase subunits. Lecker et al. (2004) 
compared changes in gene expression between normal and atrophying muscle casued by 
fasting, cancer cachexia, streptozotocin-induced diabetes and uremia. They found that 
genes encoding myofibrillar proteins were not affected by the catabolic conditions, but 
they observed an upregulation of genes involved in protein degradation genes, including 
polyubiquitions, ubiquitin fusion proteins, atrogin-1/MAFbx, MuRF-1, proteasome 
subunits and cathepsin L in muscles of the catabolic states. Many genes required for 
ATP production and late steps in glycolysis, and extracellular matrix proteins were 
down-regulated. Campbell et al. (2001) analyzed the differential global gene expression 
in red and white skeletal muscle. They identified 49 genes that were differentially 
expressed between white and red skeletal muscles. The list of genes included genes 
reflecting the metabolic and contractile difference between the fast and slow muscle 
fiber type, as well as newly identified transcription factors that may be involved in the 
determination of the phenotypic differences between muscle fiber types.  
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Microarray anlaysis also have used to examine the changes in global gene 
expression induced by Mstn or β-adrenergic agonists. Steelman et al. (2006) analyzed 
the patterns of gene expression in pectoral muscles of wild type and Mstn-null mice, 
and identified 717 genes (p < 0.05, 1.5 fold change) being differentially expressed. They 
observed a downregulation of genes encoding slow isoforms of myofibrillar contractile 
proteins, and fucntional analysis of the differentially expressed genes indicated that 
Mstn may act upstream of Wnt pathway. Wnt4 is known to stimulate satellite cell 
proliferation, indicating a role of Mstn in the growth and maintenance of postnatal 
skeletal mucle through Wnt/calcium signaling. Welle et al. (2009) reported that 124 
genes (p < 0.01, 1.5 fold change) were differentially expressed in gastrocnemius 
muscles between wild type and Mstn null mice. Unlike the results of Steelman et al. 
(2006), they did not observe downregulation of genes encoding slow isoforms of 
myofibrillar contractile proteins or genes encoding proteins involved in energy 
metabolism. Most of the other genes affected by Mstn depletion have not been 
previously linked to Mstn signaling, thus the results indicated that Smads are not the 
only transcription factors with reduced activity after Mstn depletion. Spurlock et al. 
(2006) reported that over 50 genes were differentially expressed (FDR < 10%) in mouse 
skeletal muscle 24 hours and 10 days after administration of CL. Functional 
characterization of differentially expressed genes revealed several categories that 
participate in biological processes important to skeletal muscle growth, including 
regulators of transcription and translation, mediators of cell-signaling pathways, and 
genes involved in polyamine metabolism. Pearson et al. (2009) analyzed the skeletal 
muscle gene expression following systemic administration of formoterol at both 1 and 4 
hours. They identified 23 genes at one hour and 112 genes at four hours, and these 
genes were classified into skeletal muscle hypertrophy, myoblast differentiation, 
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metabolism, circadian rhythm, transcription, histones, and oxidative stress, providing 
new insights into many of the underlying changes in gene expression that mediated β- 
agonists-induced skeletal muscle hypertrophy and altered metabolism. 
1.6 POTENTIALS OF MYOSTATIN AND BETA-ADRENERGIC AGONISTS IN  
ANIMAL PRODUCTION AND HUMAN HEALTH 
An increase in skeletal muscle growth and decrease in fat deposition are important 
aspects in increasing animal productivity efficiency for animal agriculture, particularly 
for meat-producing animals (reviewed by Beitz, 1985). Moreover, normal development 
of skeletal muscle growth is important for human health, because abnormal 
development of the skeletal muscle growth results in appearance defects and function of 
the body, causing serious health problems to humans, such as sarcopenia, cachexia, and 
muscular dystrophy (reviewed by Gelfi et al., 2011; Whittemore et al., 2003). Therefore, 
expanding our understanding of the mechanisms regulating skeletal muscle growth is 
expected to contribute to developing novel means to improve the efficiency of meat 
production and to alleviate human suffering caused by muscle atrophic conditions.  
 Because of the potent role of Mstn on skeletal muscle growth, there have been 
many interests in Mstn-based technologies to improve skeletal muscle growth of 
agriculturally-important species and to treat muscle atrophic conditions in humans. The 
strategies have mostly focused on utilizing Mstn-inhibiting molecules, such as anti-
Mstn antibody, soluble activin typeIIB receptor, follistatin, and Mstn prodomain. Kim et 
al. (2006) have shown that broilers from eggs that had anti-Mstn antibody injected into 
the yolk had significantly heavier body (4.2%) and muscle (5.5%) mass than the 
controls in both male and female birds, demonstrating for the first time that skeletal 
muscle growth of meat-producing animals can be improved by blocking Mstn activity. 
Medeiros et al. (2009) produced transgenic rainbow trout overexpressing follistatin, to 
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investigate the effect of this protein on muscle development and growth. The study 
demonstrated that transgenic overexpression of follistatin in trout muscle tissue 
increased epaxial and hypaxial muscling similar to that observed in double-muscled 
cattle and Mstn null mice. Carpio et al. (2008) examined the growth effect of 
administering a soluble form of goldfish activin typeIIB receptor to juvenile and larval 
goldfish, and found that the recombinant protein improved body weight and muscle 
mass in teleost fish in a dose-dependent manner. Lee et al. (2010) produced Mstn 
prodomain in soluble forms in E. coli, to examine its capacity to suppress Mstn activity 
in vitro, and to investigate the effect of treating fish with the Mstn prodomain on fish 
growth. This study indicates that Mstn prodomain suppresses Mstn activity and improve 
rainbow trout growth. These studies together indicate that inhibition of Mstn might help 
to promote skeletal muscle growth and improve the production efficiency of 
agriculturally important animal species.  
 Mstn blockade has been considered as a mean to treat muscular dystrophy. 
Bogdanovich et al. (2002) administered monoclonal anti-Mstn antibody to mdx mice, 
and found a significant alleviation of dystrophic pathophysiology by 3 months of 
treatment with an increased whole muscle cross sectional area and muscle fiber area. 
Wagner et al. (2002) also demonstrated that Mstn null mutation in the mdx mice showed 
the improving muscle regeneration. It has been shown that Mstn-null mice undergo 
reduced atrophy during aging along with improved muscle regenerative capacity (Siriett 
et al., 2006), illustrating the therapeutic potential of Mstn inhibition to treat sarcopenia. 
Indeed, inhibiting Mstn via the administration of an aniti-Mstn antibody in aged mice 
significantly attenuated the decline of skeletal muscle mass and function (LeBrasseur et 
al., 2009; Murphy et al., 2010). In human trials, Wagner et al. (2008) conducted a safety 
trial of a neutralizing antibody to Mstn, MYO-029, in adult muscular dystrophy patients. 
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This study showed that the MYO-029 had good safety and tolerability with the 
exception of cutaneous hypersensitivity at the 10 and 30 mg/kg doses without 
improving muscular dystrophic conditions, indicating that the systemic administration 
of Mstn inhibitors provides an adequate safety margin for clinical studies. As discussed 
before, many Mstn-suppressing molecules are known including anti-Mstn antibody, 
soluble activin typeIIB receptor, follistatin, and Mstn prodomain. Therefore, further 
studies needs to explore the potentials of these molecules in improving muscle growth 
in meat-producing animals and treating muscle-wasting conditions in humans.  
 The anabolic effects of β-adrenergic agonists have been widely studied for 
potential applications in the improvement of animal growth rate, feed efficiency, and 
carcass composition in production livestock animals (reviewed by Yang and McElligott, 
1989; Kim and Sainz, 1992). Currently, ractopamine, a beta-adrenergic compound, is 
commercialized and approved by the FDA to be used in pig and cattle to improve 
growth rate and carcass composition. Moreover, β-adrenergic agonists have been shown 
to prevent or inhibit weight loss or retardation of animal growth induced by 
physiological or pharmacological disturbances. For example, clenbuterol increased the 
weight of the gastrocnemius and soleus muscles in dystrophic mice by 29% (Rothwell 
and Stock, 1985). Moreover, clenbuterol retarded atrophy in denervated muscles in rats 
(Zeman et al., 1987), and cimaterol delayed chicken muscle atrophy induced by stretch-
release (Lee et al., 1994). Besides, administration of clenbuterol prevented 
glucocorticoid-induced muscle atrophy (Agbenyega and Wareham, 1992), and reduced 
the muscle loss caused by phytohaemaglutinin injection (Bardocz et al., 1992). In 
addition, clenbuterol enhanced the recovery of body weight gain from weight loss 
caused by endotoxemia in rats (Choo et al., 1989), and pretreatment of cimaterol 
significantly reduced the catabolic effect of corticosterone on carcass and muscle 
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protein (Brown et al., 1992). Furthermore, Hayes and Williams (1998) examined the 
effects of clenbuterol on dystrophic skeletal muscle in mice. This study indicates that 
clenbuterol significantly reduced the natural death rate of dystrophic mice, and 
significantly increased the relative mass (P<0.001) and relative tetanic force production 
(P<0.01) of the soleus of dystrophic animals, suggesting that clenbuterol could be a 
valuable adjunct to treatments of muscle wasting diseases such as muscular dystrophy. 
In humans, trials with salbutamol, a β-adrenergic agonist approved for humans, have 
shown limited positive effect in muscular dystrophy patients (Kissel et al., 2001; Fowler 
et al., 2004; van der Kooi et al., 2004). New generation of adrenergic agonists, such as 
formoterol and salmeterol, have shown more powerful skeletal muscle anabolic effects 
with less side effects (Busquets et al., 2004; Ryall et al., 2006; Harcourt et al., 2007). 
 Given that both Mstn and β-adrenergic agonists have a strong effect of on 
skeletal muscle growth, future studies probably need to consider investigating the 
potentials of the combination of the two agents in improving skeletal muscle growth in 














 THE MUSCLE-HYPERTROPHIC EFFECT OF CLENBUTEROL IS 
ADDITIVE TO THE HYPERTROPHIC EFFECT OF MYOSTATIN 
SUPPRESSION 
2.1 ABSTRACT  
In this study, we investigated the combined effect of myostatin (Mstn) 
suppression and β-agonist (clenbuterol) administration on muscle hypertrophy and the 
phosphorylation of muscle 4E-BP1 and p70S6k, two downstream effectors of the 
Akt/mTOR anabolic pathway. Female heterozygous Mstn-prodomain transgenic mice 
(Mstn-pro) and wild-type littermates were given 0 or 20 ppm of clenbuterol (CL) in 
their drinking water, and muscle samples were collected at 1 and 2 weeks after 
treatment. CL increased body and muscle mass in both genotypes. Levels of 
phosphorylated muscle 4E-BP1 and p70S6k were higher in Mstn-pro mice than in wild 
type mice. CL increased the phosphorylation of 4E-BP1 and p70S6k in both genotypes. 
The muscle-hypertrophic effect of CL is additive to the effect of Mstn suppression. The 
combination of Mstn suppression and treatment with β-agonists may be an effective 
therapeutic approach to combat muscle-wasting conditions. 
2.2 INTRODUCTION 
Loss of muscle mass can adversely affect human health and viability, and 
molecules involved in the regulation of skeletal muscle growth are valuable targets in 
developing therapeutic strategies for muscle-wasting conditions. Myostatin (Mstn) and 
some β-adrenergic agonists, such as clenbuterol (CL), have emerged as powerful 
regulators of skeletal muscle growth and mass (Lee et al., 2004; Lynch and Ryall, 2008). 
Both CL administration and Mstn inhibition have individually demonstrated their 
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therapeutic potential for preventing or reversing muscle loss in various conditions that 
lead to muscle atrophy or wasting (Carter et al., 1991; Kissel et al., 2001; Lynch et al., 
2001; Wagner et al., 2002; Fowler et al., 2004; van der Kooi et al., 2004; Bogdanovich 
et al., 2005; Li et al., 2005; Wagner, 2005; Jespersen et al., 2006).  
Mstn, a member of the transforming growth factor-beta (TGF- β) superfamily 
of growth and differentiation factors, is a potent negative regulator of myogenesis 
during development, and it also inhibits postnatal skeletal muscle growth (Lee et al., 
2004). Mstn is synthesized mainly in skeletal muscle as a precursor form that is 
proteolytically cleaved into an N-terminal prodomain (Mstn-pro) and a C-terminal 
active form. The cleaved Mstn-pro remains noncovalently associated with the active 
Mstn and inhibits its biological activity by preventing binding to its receptor (Thies et 
al., 2001; Hill et al., 2002; Lee et al., 2004). The important role of Mstn-pro in 
regulating Mstn activity was demonstrated by a dramatic increase in skeletal muscle 
mass in transgenic mice that overexpress Mstn-pro (Lee and McPherron, 2001; Yang et 
al., 2001).  
Mstn binds to activin receptor type IIB (ActRIIB) to exert its biological activity 
(Thies et al., 2001; Rebbapragada et al., 2003; Lee et al., 2005). The binding of Mstn to 
its receptor leads to phosphorylation of transcription factors Smad2 and Smad3 and 
complex formation with Smad4, resulting in nuclear translocation of the Smad complex 
and consequent regulation of transcription of downstream target genes (Bogdanovich et 
al., 2002; Langley et al., 2002; Zhu et al., 2004). Although the activation of Smad 
signaling by Mstn has been well characterized, very little is known about the molecular 
mechanisms that connect Smads activation to muscle protein metabolism. Recent 
studies, however, indicate there is cross-talk between Smads signaling and the 
Akt/mammalian target-of-rapamycin (mTOR) anabolic pathway. For example, muscle 
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fiber atrophy induced by Smad2/3 activation was prevented by the presence of 
constitutively active Akt (Sartori et al., 2009). It was also reported that Akt 
phosphorylation was inhibited by Mstn in human myotubes, and the effect was 
dependent upon the presence of Smad2 and 3 (Trendelenburg et al., 2009). The mTOR, 
a downstream target of Akt, is an integral control point for various signals involved in 
muscle hypertrophy and atrophy (Bodine et al., 2001; Proud, 2007; Drummond et al., 
2009). Activation of mTOR promotes the phosphorylation of two key downstream 
effectors that are closely associated with translational regulation of protein synthesis: 
p70S6 kinase (p70S6k) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) 
(Wang and Proud, 2006). Recent results have indicated that myostatin inhibits muscle 
hypertrophy in part through inhibition of protein synthesis mediated by the Akt/mTOR 
pathway (Welle et al., 2006; Amirouche et al., 2009; Welle et al., 2009a).  
It is well documented that administration of β-adrenergic agonists such as CL 
induces a dramatic increase in skeletal muscle growth in various mammalian species 
(Kim and Sainz, 1992; Mersmann, 1998; Kissel et al., 2001) . The growth- and muscle-
promoting action of β-adrenergic agonists is short-lived, as the effect disappears during 
prolonged treatment (McElligott et al., 1989; Kim and Sainz, 1992; Maltin et al., 1992; 
Kissel et al., 2001). The temporal nature of the growth-promoting responsiveness to β-
adrenergic agonists is caused by receptor desensitization operating at both the receptor 
level and downstream from receptors (Pierce et al., 2002). Studies with transgenic mice 
lacking the β1-, β2-, or both β1- and β2-adrenergic receptors have indicated that β-
adrenergic agonists mediate the hypertrophic effect through binding to the β2-
adrenergic receptor (Hinkle et al., 2002). The β2-adrenergic receptor is a member of the 
G-protein–coupled receptor superfamily, and ligand binding induces GDP-to-GTP 
exchange on the Gα subunit and subsequent activation of Gα. Thus, the classic signaling 
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pathway of β2-adrenergic receptor involves activation of adenyl cyclase (AC) and 
subsequent formation of cAMP (Pierce et al., 2002). The link between the classic β2-
adrenergic receptor/Gα/AC/cAMP signaling pathway and the change in protein 
metabolism induced by the administration of β-adrenergic agonists has remained elusive, 
but recent results indicate that, like Mstn, β-adrenergic agonists may induce muscle 
hypertrophy via the Akt/mTOR signaling pathway (Sneddon et al., 2001; Kline et al., 
2007).  
Although there have been numerous demonstrations of the muscle growth–
promoting effect of CL administration or Mstn suppression, the effect of a combination 
of CL administration and Mstn inhibition on skeletal muscle growth has not been 
investigated. Therefore, we designed an experiment in which CL was fed to wild-type 
and Mstn suppressed mice to assess the combined effect of CL administration and Mstn 
suppression on body and muscle growth. At the same time, we examined the 
phosphorylation of 4E-BP1 and p70S6k, two key downstream effectors of the mTOR 
pathway, during treatment. 
2.3 MATERIALS AND METHODS 
2.3.1 Animals and sample collection 
All procedures using experimental animals were approved by the Institutional 
Animal Care and Use Committee at the University of Hawaii. All mice were maintained 
in temperature- and humidity-controlled conditions with a 12 h light/dark cycle and had 
free access to food (10% kcal fat, ME3.85 kcal/g) and water. For Mstn suppression, we 
used a transgenic mouse strain that overexpress the Mstn-prodomain (Mstn-pro) and 
exhibits a significant increase in skeletal muscle mass, regardless of age and gender 
(Yang et al., 2001). To produce the heterozygous Mstn-pro transgenic and wild-type 
littermate genotypes used in this study, female B6SJL F1 mice were mated to 
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heterozygous Mstn-pro transgenic male mice. Pups were weaned at 28 days of age, and 
tail tissue samples were collected for genotyping at the time of weaning (Appendix 2.1). 
At 35 days of age, female mice were separated by their genotypes, and randomly 
assigned to one of the two groups: 0 or 20 ppm CL. CL was administered in the 
drinking water for 14 days, and body weights were monitored periodically. Previous 
studies have demonstrated the effectiveness of the 20-ppm dose (about 5 mg/kg body 
weight/day) of CL via drinking water on promoting body and muscle growth (Lynch et 
al., 1996). At 7 and 14 days after the administration, animals were sacrificed (about half 
in each killing) by CO2 asphyxiation, and gastrocnemius, plantaris, soleus, and extensor 
digitorum longus muscles of the hind leg were rapidly dissected out, weighed, snap-
frozen in liquid nitrogen and stored at -80°С until analysis.  
2.3.2 Genotyping 
DNA was extracted from tail samples by phenol/chloroform extraction after 
solubilization of the tissue in a Tris buffer (50 mM, pH 8.0) containing 0.5% sodium 
dodecylsulfate (SDS), 0.1 M ethylene-diamine tetraacetic acid (EDTA), and proteinase 
K (0.7 mg/ml). The extracted DNA was subjected to polymerase chain reaction (PCR) 
amplification with a primer set unique to transgenic mice. The forward and reverse 
primers were 5’ GACAGCAGTGATGGCTCT 3’ and 5’ 
CTTGTCATCGTCGTCCTTGTAATCGGTAC 3’, respectively. PCR condition was the 
same as described previously (Yang et al., 2001). The PCR products were subjected to 
electrophoresis in a 1.2 % agarose gel and stained with ethidium bromide to examine for 
the presence of a transgenic PCR product (Appendix 2.1). 
2.3.3 Measurement of skeletal muscle DNA and RNA concentration 
 Plantaris muscle samples were homogenized in 20 volumes of ice-cold distilled 
water, then duplicate aliquots of the homogenates were drawn and added to 0.5 volume 
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of 0.6 N ice-cold perchloric acid. The aforementioned mixtures were used to separate 
DNA and RNA following the procedure of Munro and Fleck (1966). RNA concentration 
was measured by absorption at 260 nm, and DNA concentration was measured by 
fluorescence spectrophotometry method using Hoechst H33258 dye as described by 
previously (Brunk et al., 1979). Protein concentrations in muscle homogenates were 
determined using the modified Lowry protein assay kit (Pierce, Rockford, IL) to 
estimate muscle protein content.  
2.3.4 Western blot analysis of the phosphorylation of 4E-BP1 and p70s6k 
The procedure described by Dreyer et al. (2006) was used for Western blot 
analysis. Briefly, extensor digitorum longus muscle samples were homogenized at 4°С 
in 9 volumes of ice-cold lysis buffer [50 mM Tris-HCl (pH 7.4), 250 mM mannitol, 50 
mM NaF, 5 mM Na pyrophosphate, 1 mM EDTA, 1 mM ethylene-glycol teraacetic acid 
(EGTA), 1% Triton X-100, 1 mM dithiothreitol (DTT), 1 mM benxamidine, 0.1 mM 
phenylmethylsulfonylfluoride (PMSF), and 5 µg/ml soybean trypsin inhibitor]. The 
homogenates were centrifuged at 6,000 g for 10 min at 4°С, and aliquots of the 
supernatants were saved for Western blot detection of p70S6k. For Western blot 
detection of 4E-BP1, 50 µl of the above supernatants were heated at 100oC for 10 min, 
centrifuged for 30 min at 10,000 g at 4oC, and the supernatants were saved. Protein 
concentrations in supernatants were determined using the modified Lowry protein assay 
kit (Pierce, Rockford, IL) to estimate protein content. The protein concentration of 
supernatants was not significantly (P < 0.01) affected by the genotype and CL 
administration, and thus equal volumes of supernatants were loaded per lane with 
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  
Twenty µl of the protein extract for p70S6k and 4E-BP1were subjected to 7.5% 
and 15% SDS-PAGE, respectively, and then proteins were transferred to polyvinylidene 
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difluoride (PVDF) membranes. The blots were blocked for 3 hrs at room temperature in 
Tris-buttered saline (20 mM Tris-HCI, 150 mM NaCI at pH 7.5) containing 3 % bovine 
serum albumin (BSA), followed by incubation with primary antibody in Tris-buffered 
saline plus 0.01% Tween-20 (TBST, 20 mM Tris-HCL, 150 mM NaCl at pH 7.5) at 4°С 
overnight. The primary antibodies were rabbit anti-phospho-p70S6k (Thr389; 1:1,000; 
Cell signaling, Beverly, MA), and rabbit anti-phospho-4E-BP1 (Thr37/46; 1:1,000; Cell 
signaling). The blots were washed twice with TBST and incubated with horseradish 
peroxidase-conjugated anti-rabbit antibody (1:2,500, Invitrogen, Carlsbad, CA) in 
TBST for 2 hrs at room temperature. After washing, the membrane was developed with 
the enhanced chemiluminescent reagent (ECL plus Western Detection System; GE 
Healthcare Biosciences; Pittsburg, PA), followed by apposition of the membrane to 
auto-radiographic films (Hyperfilm ECL; Kodak, CA). After obtaining an appropriate 
image, band intensity was quantitatively analyzed using Quantity One analysis software 
(Bio-Rad, Hercules, CA). 
2.3.5 Statistical analysis 
All values are expressed as mean ± SEM. Two-way analysis of variance 
(ANOVA) was performed using Prism5 software (GraphPad, San Diego, CA) to 
examine the effects of genotype, CL, and interaction on body and muscle weights; 
muscle DNA and RNA concentrations; and the levels of phosphorylation of 4E-BP1 and 
p70S6k.  
2.4 RESULTS 
2.4.1 Effects of CL on body and muscle weights of wild type and Mstn-pro mice 
Consistent with our previous report (Yang et al., 2001), Mstn-pro mice were 
heavier than wild-type mice at the time of CL administration (P < 0.001; Fig. 2.1), and 
they grew significantly faster than wild-type mice over the 14-day period (P < 0.001, 
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Fig. 2.1). The growth-promoting effect of CL was evident in both wild-type and Mstn-
pro mice (Fig. 2.1), demonstrating that the growth-promoting effect of CL is additive to 
the growth-promoting effect of Mstn suppression. The temporal effect of CL on body 
weight gain was evident in both genotypes (Fig. 2.1): the increase in body weight gain 
occurred at up to 7–10 days of CL administration, and no further increase was observed 
thereafter.  
Skeletal muscle weights of wild-type and Mstn-pro mice as affected by CL 
administration for 7 and 14 days are summarized in Table 2.1 and 2.2. As expected, 
gastrocnemius, plantaris, extensor digitorum longus (EDL), and soleus muscles of 
Mstn-pro mice were significantly (P < 0.001) heavier than those of wild-type mice 
during the experimental period. The protein concentration of plantaris muscle of Mstn-
pro mice was greater than that of wild-type mice (P < 0.001). CL administration 
significantly increased the four muscle weights of both Mstn-pro and wild-type mice 
after both the 7- and 14-day administration periods. CL administration also increased 
the protein concentration of plantaris muscle in both Mstn mice and wild-type mice (P < 
0.001), leading to the highest muscle protein concentration in CL-fed Mstn-pro mice. 
When concentrations of soluble proteins in lysis buffer were measured from EDL 
muscle during Western blot analysis, genotype and CL administration had no effect on 
soluble protein concentration. Thus, it is postulated that the increase in total muscle 
protein concentration in Mstn-pro mice or by CL administration is probably due to an 
increase in insoluble myofibrillar proteins. The increases in weight gain of the 
gastrocnemius (23%) and plantaris (27%) at 7 day CL administration in Mstn-pro mice 
were significantly (P < 0.05) greater than those in wild-type mice (8.5% for 
gastrocnemius and 6.4% for plantaris). However, at 14 days after CL administration, the 
increases in weight gain of the gastrocnemius (26.9%) and plantaris (34.9%) by CL in 
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Mstn-pro mice were not different from those in the wild-type mice (25.6% for 
gastrocnemius and 38.9% for plantaris), suggesting that a synergistic effect of Mstn 
suppression and CL administration on the growth of these muscles may occur only 
during the early period of CL administration.  
2.4.2 Effects of CL on muscle DNA and RNA concentrations of wild type and Mstn-
pro mice 
DNA and RNA concentrations in plantaris muscle were measured to determine 
indirectly the myonuclei domain size and protein synthetic capacity, respectively (Table 
2.3). No significant difference in muscle RNA concentration was observed between 
wild type and Mstn-pro mice during the experimental period. Muscle DNA 
concentration of Mstn-pro mice was significantly (P < 0.001) lower than that of wild 
type mice during the experimental period (5.9% at day 7 and 7.6% at day 14), As a 
result of the lower muscle DNA concentration, the muscle RNA/DNA ratio of Mstn-pro 
mice was significantly (P < 0.05) greater than that of wild-type mice.  
CL administration significantly (P < 0.05) increased muscle RNA concentrations 
of both the wild-type and Mstn-pro mice at 7 days, but the effect disappeared at 14 days 
after administration. Likewise, CL administration significantly (P < 0.001) decreased 
muscle DNA concentrations of both wild-type and Mstn-pro mice, leading to a lowest 
DNA concentration in Mstn-pro mice treated with CL. The extent of decrease in muscle 
DNA concentration was greater at 14 days after CL administration (13.9% in wild-type 
and 9.5% in Mstn-pro) than at 7 days of CL administration (5.3% in wild-type and 5.9% 
in Mstn-pro). Because CL administration lowered DNA concentration, it significantly (P 
< 0.05) increased the muscle RNA/DNA ratio in both wild-type and Mstn-pro mice, 
resulting in the highest RNA/DNA ratio in the Mstn-pro mice treated with CL. 
2.4.3 Effect of CL administration on the phosphorylation of muscle 4E-BP1 and 
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p70S6k in wild type and Mstn-pro mice. 
The phosphorylations of 4E-BP1 and p70S6k have been shown to play an 
important role in regulating protein synthesis, and thus the levels of phosphorylations of 
these proteins in EDL muscles were examined using Western blot analysis (Fig. 2.2 and 
2.3). In our Western blot analysis of the phosphorylation of 4E-BP1 and p70S6k, we did 
not perform immunoblot against the total amount of these proteins. Accordingly, the 
levels of phosphorylation expressed in this study represent the phosphorylated amount 
of those proteins per unit tissue volume, not the phosphorylated proportion of these 
proteins. Thus, these results cannot reveal whether the changes in phosphorylated 4E-
BP1 or p70S6k observed in this study occurred in the absence of changes in the total 
amount of these proteins. However, a recent study showed that myostatin blockage did 
not significantly affect muscle concentrations of p70S6k or 4E-BP1 (Welle et al., 2006), 
indicating that modulation of Mstn activity does not affect the muscle concentration of 
these proteins.  
The levels of both phosphorylated 4E-BP1 and p70S6k were significantly (P < 
0.001) greater in Mstn-pro mice than in wild-type mice during the experimental period. 
CL administration significantly (P < 0.001) increased the levels of phosphorylated 4E-
BP1 and p70S6k regardless of genotype, leading to the highest levels of 
phosphorylation of these proteins in Mstn-pro mice treated with CL. This result 
suggests that both Mstn suppression and CL administration stimulate the 
phosphorylation of 4E-BP1 and p70S6k, two downstream effectors of the mTOR 
pathway, and the phosphorylations of 4E-BP1 and p70S6k are summed when the Mstn 
suppression and CL administration are combined.  
The increase in phosphorylated 4E-BP1 by CL administration was greater at 7 
days of CL administration (38.2% for wild-type and 69.2% for Mstn-pro) than at 14 
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days of CL administration (24.0% for wild-type and 13.9% for Mstn-pro). Likewise, the 
increase in phosphorylated p70S6k by CL administration was greater at 7 days of CL 
administration (70.1% for wild-type and 41.7% for Mstn-pro) than at 14 days of CL 
administration (22.2% for wild-type and 18.5% for Mstn-pro). This result suggests that, 
like other cellular responses, the effect of CL on phosphorylation of 4E-BP1 and 
p70S6k is diminished during long-term administration of CL. 
2.5 DISCUSSION 
The results from this study show that the muscle hypertrophic effects of CL is 
additive to the muscle hypertrophic effect of Mstn suppression, an important implication 
for future therapeutic approaches aimed to reverse muscle-wasting conditions. Our 
study, however, did not examine the change in muscle function such as grip strength and 
endurance during the hypertrophy induced by the combination of CL administration and 
Mstn-suppression, and therefore future studies will need to investigate muscle 
functionality as affected by the combination of β-agonist treatment and Mstn 
suppression.  
The temporal nature of the growth-promoting effect of CL was observed in both 
wild-type and Mstn-pro mice, suggesting that the desensitization process of muscle β-
adrenoceptors appears not be influenced by chronic suppression of Mstn activity. It also 
appears that, during the early period of CL administration, CL may act synergistically 
with the hypertrophic effect of Mstn suppression, because the increase in body and 
muscle weight gains of Mstn-pro mice by CL was significantly greater than that of wild-
type mice at 7 days after CL administration, whereas the increase at 14 days of 
administration was similar between the two genotypes.  
Some studies have indicated that Mstn regulates postnatal muscle growth and 
repair via satellite cell activation because lack of Mstn increased satellite activation and 
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resulted in improved muscle repair in mice (McCrosky et al., 2003 and 2005). In 
contrast, recent results by Sartori et al. (2009) and Amthor et al. (2009) suggest that 
muscle hypertrophy induced by Mstn suppression is not due to the activation of satellite 
cells and addition of new nuclei into the adult fibers. When new myonuclei formation 
was measured by BrdU incorporation method, no new myonuclei addition occurred in 
muscles expressing dominant negative ActRIIB (Sartori et al., 2009). Myonuclei 
number per muscle fiber was significantly lower in hypertrophic muscles induced by 
Mstn blockade than in non-hypertrophic muscles, along with no difference in the 
number of Pax7 expressing satellite cells in muscles or satellite cell proliferation and 
differentiation between those two muscles (Amthor et al., 2009; Matsakas et al., 2009). 
Our current results show that the muscle DNA concentration in Mstn-pro mice was 
lower than that of wild-type mice but without a difference in RNA concentration, 
resulting in higher RNA/DNA ratios in Mstn-pro mice. These results are consistent with 
a previous study that showed muscle DNA concentration and RNA/DNA ratio of Mstn-
deficient transgenic mice are lower and higher, respectively, than those of wild-type 
mice, without differences in muscle RNA concentration between the two groups (Welle 
et al., 2006). The total fiber number in gastrocnemius muscle of Mstn-pro mice was not 
different from that of wild-type mice (Yang et al., 2001), indicating that the increase in 
muscle mass in the Mstn-pro group was mostly due to an increase in fiber size 
(hypertrophy) and not an increase in fiber number (hyperplasia). Taken together, these 
results indicate that the myonuclear domain size of Mstn-pro mice probably was not 
maintained during the enhanced muscle hypertrophy of the Mstn-pro mice, thus suggest 
that satellite cell activation is probably not a primary factor for muscle hypertrophy 
induced by Mstn-suppression. β-Adrenergic agonists have been shown to increase 
muscle RNA concentration during the early period of administration and decrease 
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muscle DNA concentration (Kim and Sainz, 1992). This is consistent with our results 
that show CL administration for 7 days increased muscle RNA concentrations and 
decreased muscle DNA concentrations of both the wild-type and Mstn-pro mice, 
resulting in an increased RNA/DNA ratio by CL administration. This suggests that, like 
the Mstn suppression, satellite cell activation in not involved in the muscle hypertrophy 
induced by CL administration. 
The mTOR pathway has emerged as a critical mediator of cell growth and 
proliferation by integrating signals from growth factors, nutrients, and the energy status 
of cells (Sarbassov et al., 2005). The serine/threonine kinase mTOR interacts with 
multiple protein partners, forming two distinctive multiprotein complexes, mTORC1 
and mTORC2. The mTORC1 complex mediates functions that are sensitive to 
rapamycin, such as protein translation, whereas mTORC2 mediates functions not 
sensitive to rapamycin. mTORC1 activation by Akt induces the phosphorylation of two 
downstream effectors, ribosomal protein p70S6k and 4E-BP1, a suppressor of the cap 
binding protein eIF4E, resulting in increased protein translation (Sarbassov et al., 2005). 
Muscle growth also appears to be regulated by the mTOR pathway, as demonstrated by 
studies showing that the hypertrophic response induced by overload or regenerating 
muscle growth was blocked by rapamycin, an inhibitor of mTOR (Bodine et al., 2001; 
Pallafacchina et al., 2002). Anabolic stimuli, such as overloading, resistance exercise, 
and essential amino acid ingestion, have been shown to increase the phosphorylation of 
p70S6k and 4E-BP1 along with a corresponding increase in protein synthesis (Bodine et 
al., 2001; Dreyer et al., 2006; Fujita et al., 2007; Dreyer et al., 2008; Drummond et al., 
2008). Conversely, atrophying muscles have decreased levels of phosphorylation of the 
downstream targets of mTOR (Bodine et al., 2001; Hornberger et al., 2001).  
In our study, we observed that levels of phosphorylated 4E-BP1 (Thr37/46) and 
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p70S6k (Thr389) were greater in Mstn-pro transgenic mice compared with wild-type 
mice, suggesting that Mstn also regulates muscle mass probably through the mTOR 
pathway. This result is in agreement with a recent report that showed Mstn 
overexpression in mice skeletal muscle by electrotransfer of Mstn-expression vector 
attenuated the phosphorylation of 4E-BP1 (Thr37/46) (Wang and Proud, 2006). In 
addition to the decrease in 4E-BP1 phosphorylation, the study also observed a decrease 
in the phosphorylation of TSC2 (Thr1462), ribosomal protein S6 (Ser235/236), and Akt 
(Thr308) in response to Mstn overexpression, supporting the role of the Akt/mTOR 
signaling pathway in Mstn regulation of skeletal muscle mass. Interestingly, in another 
study using a different model, where Mstn activity was suppressed by the administration 
of anti-Mstn antibody in mice (Welle et al., 2009a), Mstn suppression did not affect the 
phosphorylation of Akt (Thr308 and Ser473) and 4E-BP1 (Thr36/45, Ser64, and Thr69), but it 
increased the phosphorylation of p70S6k (Thr389) as well as rpS6, a substrate for 
p70S6k. In that study it was also noted that rapamycin, a pharmacological blocker of 
mTOR, eliminated the phosphorylation of p70S6k and rpS6, but it did not block the 
increase in muscle protein synthetic rate induced by Mstn suppression (Welle et al., 
2009a). These results suggest that Mstn regulation of muscle protein synthesis can be 
independent of Akt/mTOR signaling even though we cannot rule out the possibility that 
the discrepancy resulted from differences in Mstn modulation in conjunction with 
sampling factors. The mTOR pathway is known to take diverse signals and produce a 
myriad of responses (Sarbassov et al., 2005), and thus further studies are needed to 
clearly define the details of the involvement of the Akt/mTOR pathway in Mstn 
signaling.  
Like Mstn, β-adrenergic agonists also induce muscle hypertrophy through the 
Akt/mTOR signaling pathway (Sneddon et al., 2001; Kline et al., 2007). For example, 
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CL treatment in mice promoted phosphorylation of 4E-BP1 (Thr70) and p70S6k (Thr412) 
(Sneddon et al., 2001). In addition to 4E-BP1 and p70S6k phosphorylation, CL 
treatment also promoted the phosphorylation of Akt (Kline et al., 2007). Furthermore, 
the CL effect was suppressed by rapamycin (Kline et al., 2007). In agreement with the 
results of previous studies, increased levels of phosphorylated 4E-BP1 and p70S6k were 
observed by CL administration in our study, supporting the role of the Akt/mTOR 
pathway in β-adrenergic agonist–induced skeletal muscle hypertrophy. Notably, our 
result demonstrated that CL administration increased the phosphorylation of 4E-BP1 
and p70S6k not only in wild-type mice but also in Mstn-pro mice, resulting in a 
summation of the levels of phosphorylation of the two molecules. The findings further 
show that skeletal muscle masses of treatment groups were closely related to the levels 
of phosphorylation of 4E-BP1 and p70S6k and the RNA/DNA ratio of treatment groups. 
It is thus suggested that the post-receptor signaling of both Mstn suppression and β-
receptor activation by CL induces the phosphorylation of 4E-BP1 and p70S6k to 
enhance protein translation, and the combination of Mstn suppression and β-receptor 
activation induces the summation of 4E-BP1 and p70S6k phosphorylation and 
subsequent protein translation. In this study we did not extensively examine signaling 
intermediates of the Akt/mTOR pathway, and more studies are needed to understand the 
role of the Akt/mTOR pathway in the convergence of Mstn and β-adrenergic agonist 
signaling to 4E-BP1 and p70S6k phosphorylation.  
In conclusion, the results of this study demonstrate that the skeletal muscle 
hypertrophic effect of CL is additive to the hypertrophic effect of Mstn suppression. 
Although CL is not approved for use in humans, a few trials with salbutamol, a β-
adrenergic agonist approved for human use, have shown a limited positive effect in 
muscular dystrophy patients (Kissel et al., 2001; Fowler et al., 2004; van der Kooi et al., 
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2004). A new generation of adrenergic agonists, including formoterol and salmeterol, 
appear to have more powerful skeletal muscle anabolic effects, with fewer side effects 
(Busquets et al., 2004; Ryall et al., 2006; Harcourt et al., 2007). Our findings thus 
indicate the potential of the combination of Mstn suppression and treatment with β-
agonists in the prevention or reversal of muscle-wasting conditions. The results on 4E-
BP1 and p70S6k phosphorylation also show that the pathways of Mstn and CL signaling 
converge to the phosphorylation of 4E-BP1 and p70S6k, two downstream effectors of 
the Akt/mTOR anabolic pathway, to regulate skeletal muscle hypertrophy.  
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 Wild type  Mstn-pro Significance 
Days 0 ppm 20 ppm 0 ppm 20 ppm GT CL GTxCL 
0-3 0.4 (0.16) 0.7 (0.16) 0.6 (0.16) 0.9 (0.15) NS * NS 
3-7 0.4 (0.15) 1.1 (0.15) 0.8 (0.15) 2.1 (0.14) *** *** * 
7-10 0.3 (0.15) 0.8 (0.15) 0.7 (0.17) 1.0 (0.15) + ** NS 
10-14 0.3 (0.14) 0.2 (0.14) 0.5 (0.15) 0.5 (0.14) * NS NS 
 
 
Figure 2.1 Effect of CL administration on body weights of wild type and Mstn-pro 
mice. Solid and dotted lines indicate 20 and 0 ppm CL administration, respectively, to 
wild type (open circle) and Mstn-pro mice (closed circle). Values are means (SEM). 
(A): Growth curve of female mice during 14 days (a, difference between wild type and 
Mstn-pro; b, difference between 0 ppm and 20 ppm CL administration (***, P < 0.001, 
**, P < 0.01)). (B): Body weight gain of female mice during 14 days (***, P < 0.001, **, 


























Figure 2.2 Effect of CL administration on 4E-BP1 at Thr37/46 phosphoryalation in 
extensor digitorum longus muscles of wild type and Mstn-pro mice. Representative 
immunoblot images are shown above the bar graph. Each lane sequentially represents 
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Figure 2.3 Effect of CL administration on p70S6k phosphoryalation at Thr389 in 
extensor digitorum longus muscles of wild type and Mstn-pro mice. Representative 
immunoblot images are shown above the bar graph. Each lane sequentially represents 
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Table 2.1 Muscle weights of wild type and Mstn-pro mice as affected by CL administration for 7 days. 
 
 Wild type Mstn-pro Significance 
 
 0 ppm  20 ppm 0 ppm 20 ppm     GT      CL GT x CL 
 
7 days after administration 
Number of animals         12           10           15           15 
Initial body Wt, g 17.7 (0.47)  17.7 (0.37) 18.5 (0.49) 18.7 (0.37) * NS NS 
Final body Wt, g 18.5 (0.44) 19.3 (0.40) 19.7 (0.47) 21.8 (0.40) *** ** NS 
Gastrocnemius Wt, mg 87.6 (3.73) 95.0 (3.41) 110.8 (4.30) 136.6 (3.51) *** *** * 
Plantaris Wt, mg 9.8 (0.52) 10.4 (0.68) 12.6 (0.45) 15.9 (0.55) *** *** * 
EDL Wt, mg 6.9 (0.51) 7.5 (0.37) 9.4 (0.40) 11.2 (0.23) *** ** NS 
Soleus Wt, mg 4.2 (0.38) 5.9 (0.38) 4.85 (0.295) 6.1 (0.36) NS *** NS 
Muscle protein, %1 21.1 (0.14) 25.9 (0.20) 24.7 (0.17) 28.5 (0.20) *** *** NS 
 
Values are means (SEM). CL, clenbuterol; GT, genotype; Wt, weight; EDL, extensor digitorum longus; NS, not significant; *, P<0.05; **, 
P<0.01; ***, P<0.001. 1Muscle protein concentration was measured in plantaris muscle using the modified Lowry method. 
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Table 2.2 Muscle weights of wild type and Mstn-pro mice as affected by CL administration for 14 days. 
 
 Wild type Mstn-pro Significance 
 
 0 ppm  20 ppm 0 ppm 20 ppm     GT      CL GT x CL 
 
14 days after administration 
Number of animals         12        14           11           14 
Initial body Wt, g 17.7 (0.36)  17.6 (0.30) 18.8 (0.56) 18.6 (0.37) ** NS NS 
Final body Wt, g 19.1 (0.34) 20.6 (0.24) 21.6 (0.60) 22.8 (0.37) *** ** NS 
Gastrocnemius Wt, mg 84.9 (2.75) 106.6 (2.49) 119.1 (4.10) 151.1 (3.99) *** *** NS 
Plantaris Wt, mg 9.5 (0.34) 13.2 (0.50) 13.9 (0.43) 18.7 (0.72) *** *** NS 
EDL Wt, mg 6.3 (0.34) 9.1 (0.31) 8.6 (0.61) 11.2 (0.34) *** *** NS 
Soleus Wt, mg 4.46 (0.287) 5.97 (0.229) 5.13 (0.192) 6.96 (0.311) ** *** NS 
Muscle protein, %1 20.1 (0.12) 25.2 (0.17) 24.1 (0.14) 27.4 (0.15) *** *** NS 
 
Values are means (SEM). CL, clenbuterol; GT, genotype; Wt, weight; EDL, extensor digitorum longus; NS, not significant; *, P<0.05; **, 
P<0.01; ***, P<0.001. 1Muscle protein concentration was measured in plantaris muscle using the modified Lowry method. 
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Table 2.3 Muscle DNA and RNA concentrations in wild-type and MSTN-pro mice as affected by CL administration. 
 
 Wild type Mstn-pro Significance 
 
 0 ppm  20 ppm 0 ppm 20 ppm GT CL       GT x CL 
  
7 day after administration  
Number of animals              12            10               15            15  
DNA (mg/g wet muscle) 1.22 (0.010)  1.15 (0.015) 1.14 (0.030) 1.08 (0.012) *** *** NS 
RNA (mg/g wet muscle) 1.13 (0.044)  1.27 (0.030) 1.24 (0.031) 1.36 (0.031) NS * NS 
RNA/DNA ratio 1.01 (0.035)  1.11 (0.032) 1.09 (0.037) 1.27 (0.036) ** *** NS 
 
14 day after administration  
Number of animals              12            14               11            14  
DNA (mg/g wet muscle) 0.95 (0.031)  0.87 (0.026) 0.88 (0.030) 0.79 (0.012) ** * NS 
RNA (mg/g wet muscle) 1.13 (0.032)  1.15 (0.027) 1.15 (0.022) 1.15 (0.019) NS NS NS 
RNA/DNA ratio  1.22 (0.072)  1.35 (0.055) 1.32 (0.035) 1.45 (0.034) * * NS 
 










INVESTIGATION OF DIFFERENTIAL GENE EXPRESSION IN 
HYPERTROPHIC MUSCLES INDUCED BY MYOSTATIN SUPPRESSION OR 
CLENBUTEROL, A BETA-ADRENERGIC AGONIST  
3.1 ABSTRACT 
 In this study, we employed microarray analysis to acquire a comprehensive 
picture of gene expression occurring in hypertrophic muscles induced by Mstn 
suppression (Mstn-prodomain overexpression) and/or clenbuterol (CL). Involvement of 
the Akt/mTOR pathway was also investigated in the regulation of muscle hypertrophy 
occurring in the two models. Male heterozygous Mstn-pro and wild-type littermates 
were given 0 or 20 ppm of CL in their drinking water, and muscle samples were 
collected at 3 and 14 days after treatment. Phosphorylation levels of Akt, 4E-BP1 and 
p70S6k in EDL muscle were analyzed using the Western blot analysis. Four or five 
pooled RNA samples of the gastrocnemius muscle in each group were subjected to 
microarray analysis using the Affymetrix GeneChip Mouse 430-2.0 platform, and data 
were analyzed by t-test and fold changes. The skeletal muscle hypertrophic effect of CL 
was additive to the hypertrophic effect of Mstn suppression, and the results on Akt, 4E-
BP1 and p70S6k phosphorylation indicate that muscle hypertrophy induced by Mstn 
suppression or CL administration is through the activation of the Akt/mTOR anabolic 
pathway, and Mstn and CL signaling converge to the Akt/mTOR pathway to regulate 
skeletal muscle hypertrophy. Microarray analysis showed that genes differentially 
expressed by Mstn-suppression (108 at 1.5 fold cutoff) is far less than those 
differentially expressed by CL administration (1241 at 1.5 fold cutoff), reflecting the 
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diverse physiological role of CL. Functional anlysis of those differentially expressed 
gene showed that Mstn suppression and CL administration induced significant changes 
in the mRNA abundance of various genes associated with muscle contraction, initiation 
of translation, transcription, and muscle hypertrophic signal pathway, suggesting that 
increased protein synthesis is partly responsible for the hypetrophy induced by Mstn 
and CL.. Additionally, the alteration of Igf2 obsderved in Mstn suppressed mice, and the 
alterations of eIF4e, Acvr2b, FoxO and PTEN observed in mice treated with CL indicate 
that the pathways of Mstn and CL signaling converge to the Akt/mTOR anabolic 
pathway to regulate skeletal muscle hypertrophy.  
3.2 INTRODUCTION 
 The ability to increase skeletal muscle mass is highly desirable for both human 
health and agriculture applications. Of major interest in this study is the growth factor 
myostatin (Mstn) and β-adrenergic agonist (BAA) such as clenbuterol (CL). Mstn is a 
member of the TGF-β superfamily that acts as a potent negative regulator of skeletal 
muscle growth. Mice with constitutive knockout of the Mstn gene have a remarkable 
double-muscled phenotype caused by both muscle cell hypertrophy and hyperplasia 
(McPherron et al., 1997). Mstn also regulates muscle development in other mammals, 
including human (Mosher et al., 2007; Grobet et al., 1997; Kambadur et al., 1997; 
McPherron and Lee, 1997; Clop et al., 2006; Schuelke et al., 2004). Mstn binds to 
activin type IIb receptor to exert its biological activity (Lee and McPherron, 2001; Thies 
et al., 2001; Rebbapragada et al., 2003) and initiate a signaling cascade through the 
Smad pathway (Lee and McPherron, 2001; Zhu et al., 2004; Tsuchida et al., 2008). The 
activation of Smad signaling by Mstn has been well characterized. Recent studies, 
however, indicated that there is a cross-talk between Smads signaling and the 
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Akt/mammalian target-of-rapamycin (mTOR) anabolic pathway, which plays an 
important role in mediating the muscle hypertrophy (Sartori et al., 2009; Trendelenburg 
et al., 2009; Welle et al., 2006; Amirouche et al., 2009; Morissette et al., 2009; Welle et 
al., 2009a). 
Anabolic effects of BAA have been widely studied for potential applications in 
the prevention of muscle atrophy in humans and improvement of the efficiency of 
muscle growth in livestock (Kim and Sainz, 1992; Mersmann, 1998; Kissel et al., 2001). 
The muscle hypertrophic effect of BAA is mediated through the binding of ligands to 
β2-adrenergic receptor (β2AR), and subsequent activation of the adenylyl cyclase 
(AC)/cyclic adenosine monophosphate (cAMP) signaling pathway (Hinkle et al., 2002). 
Although the β2AR /AC/cAMP pathway is responsible for the β2AR -mediated 
hypertrophy in skeletal muscle (Navegantes et al., 2000; Hinkle et al., 2002), the link 
between the classic β2AR /AC/cAMP signaling pathway and the change in protein 
metabolism induced by the administration of BAAs has remained elusive. Recent 
results, however, indicate that like Mstn, BAAs may induce muscle hypertrophy via the 
Akt/mTOR anabolic pathway (Sneddon et al., 2001; Kline et al., 2007). 
Microarray technology enables a broad overview of the impact of treatments on 
expression of all known genes, and this technology has already been used to examine 
the effects of constitutive Mstn deficiency or the effects of acute BAA stimulation in 
mice (Steelman et al., 2006; Welle et al., 2009; Spurlock et al., 2006; Pearson et al., 
2009). For example, Steelman et al. (2006) reported that 717 genes (p < 0.05, 1.5 fold 
change) were differentially expressed in pectoral muscles of wild type and Mstn null 
mice, and Welle et al. (2009) reported that 124 genes (p < 0.01, 1.5 fold change) were 
differentially expressed in gastrocnemius muscles between wild type and Mstn null 
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mice. Moreover, Spurlock et al. (2006) reported that over 50 genes were differentially 
expressed (FDR < 10%) in mouse skeletal muscle 24 hours and 10 days after 
administration of CL, and Pearson et al. (2009) reported that 23 and 112 genes were 
differentially expressed by systemic administration of the formoterol at both 1 and 4 
hours in mice.  
Even though Mstn and CL bind to different receptors, their receptor activations 
have a dramatic effect on skeletal muscle growth. Thus, it was hypothesized that 
comparing global gene expression between the two different models of muscle 
hypertrophy (Mstn-suppression and CL administration) would allows us to acquire a 
comprehensive picture of transcriptional changes in skeletal muscles undergoing 
hypertrophy, which may lead to the identification of key transcriptional adaptations and 
signaling pathways involved in muscle hypertrophy. Therefore, the objective of this 
study was 1) to examine global changes in gene expressions of skeletal muscle 
undergoing hypertrophy induced by genetic suppression of Mstn or administration of 
BAA, 2) to compare the gene expression changes between the two muscle hypertrophic 
models, and 3) to examine the role of the Akt/mTOR pathway in the two muscle 
hypertrophic models. 
3.3 MATERIALS AND METHODS 
3.3.1 Animals and sample collection 
All procedures using experimental animals were approved by the Institutional 
Animal Care and Use Committee, University of Hawaii. All mice were maintained in 
temperature- and humidity-controlled conditions with a 12 h light/dark cycle and had 
free access to food (10% kcal fat, ME3.85 kcal/g) and water ad libitum. For Mstn 
suppression, we used transgenic mice overexpressing Mstn prodomain (Mstn-pro). The 
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generation and phenotype of the Mstn-pro transgenic mice was previously reported 
(Yang et al., 2001). To produce heterozygous Mstn-pro transgenic mice and wild-type 
littermate, female B6SJL F1 mice were mated to heterozygous Mstn-pro transgenic 
male mice. Pups were weaned at 28 days, then males and females were housed 
separately. Tail tissue samples were collected at weaning for genotyping (Appendix 3.1). 
At 35 days of age, male mice were separated by their genotypes, and mice in each 
genotype were randomly assigned to one of the two groups: 0 or 20 ppm clenbuterol 
(CL). Mice were administered with CL in the drinking water (20 ppm) during the 
experimental period, and body weights were monitored periodically. Previous studies 
have demonstrated the effectiveness of the 20-ppm dose (about 5 mg/kg body 
weight/day) of CL via drinking water on promoting body and muscle growth (Lynch et 
al., 1996). At 3 and 14 days after the CL administration, animals were sacrificed (about 
half in each sacrifice) by CO2 asphyxiation, and gastrocnemius, plantaris, soleus, and 
extensor digitorum longus (EDL) muscles of the lower hind leg were rapidly dissected 
out, weighed, snap-frozen in liquid nitrogen and stored at -80°С until analysis.  
3.3.2 Genotyping 
Genotyping was determined by the same PCR procedure described in the Chapter 
2. The PCR products were subjected to electrophoresis in a 1.2 % agarose gel and 
stained with ethidium bromide to examine the presence of a transgenic PCR product 
(Appendix 3.1). 
3.3.3 Measurement of skeletal muscle DNA and RNA concentration 
 DNA and RNA concentrations of plantaris muscle samples were estimated by 
the same procedure described in Chapter 2.  
3.3.4 Western blot analysis of Akt, 4E-BP1 and p70S6k phosphoryalation 
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The procedure described by Dreyer et al. (2006) was used for Western blot 
analysis. Briefly, EDL muscle samples were homogenized at 4°С in 9 volumes of ice-
cold lysis buffer [50 mM Tris-HCl (pH 7.4), 250 mM mannitol, 50 mM NaF, 5 mM Na 
pyrophosphate, 1 mM EDTA, 1 mM ethylene-glycol teraacetic acid (EGTA), 1% Triton 
X-100, 1 mM dithiothreitol (DTT), 1 mM benxamidine, 0.1 mM 
phenylmethylsulfonylfluoride (PMSF), and 5 µg/ml soybean trypsin inhibitor]. The 
homogenates were centrifuged at 6,000 g for 10 min at 4°С, and aliquots of the 
supernatants were saved for Western blot detection of Akt and p70S6k phosphorylation. 
For Western blot detection of 4E-BP1, 100 µl of the above supernatants were heated at 
100 oC for 10 min, centrifuged for 30 min at 10,000 g at 4 oC, and the supernatants were 
saved. Protein concentrations in supernatants were determined using the modified 
Lowry protein assay kit (Pierce, Rockford, IL) to estimate protein content. The protein 
concentration of supernatants was not significantly (P < 0.01) affected by the genotype 
and CL administration, and thus equal volumes of supernatants were loaded per lane 
with sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  
Twenty µl of the protein extract for Akt, p70S6k and 4E-BP1were subjected to 
7.5%, 7.5% and 15% SDS-PAGE, respectively, and then proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes. The blots were blocked for 3 hrs at room 
temperature in Tris-buttered saline (20 mM Tris-HCI, 150 mM NaCI at pH 7.5) 
containing 3 % bovine serum albumin (BSA), followed by incubation with primary 
antibody in Tris-buffered saline plus 0.01% Tween-20 (TBST, 20 mM Tris-HCL, 150 
mM NaCl at pH 7.5) at 4°С overnight. The primary antibodies were rabbit anti-
phospho-Akt (Thr308; 1:1,000; Cell signaling, Beverly, MA), rabbit anti-phospho-
p70S6k (Thr389; 1:1,000; Cell signaling), rabbit anti-phospho-4E-BP1 (Thr37/46; 1:1,000; 
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Cell signaling), rabbit anti-Akt (1:1,000; Santa Cruz Biotechnology, Delaware, CA), 
rabbit anti-p70S6k (1:1,000; Santa Cruz Biotechnology), and rabbit anti-4E-BP1 
(1:1,000; Santa Cruz Biotechnology). The blots were washed twice with TBST and 
incubated with horseradish peroxidase-conjugated anti-rabbit antibody (1:2,500, 
Invitrogen, Carlsbad, CA) in TBST for 2 hrs at room temperature. After washing, the 
membrane was developed with the enhanced chemiluminescent reagent (ECL plus 
Western Detection System; GE Healthcare Biosciences; Pittsburg, PA), followed by 
apposition of the membrane to auto-radiographic films (Hyperfilm ECL; Kodak, CA). 
After obtaining an appropriate image, band intensity was quantitatively analyzed using 
Quantity One analysis software (Bio-Rad, Hercules, CA). 
3.3.5 RNA Extraction, Gene Chip Hybridization, and Data Acquisition 
Total RNA was extracted from the gastrocnemius muscle using Trizol reagent 
(Invitrogen, Carlsbad, CA) following the manufacture’s instructions. RNA integrity was 
confirmed using the Agilent Bionalyzer 2100 (Agilent Technologies, Palo Alto, CA). 
Total RNA samples from three or four individual mice were pooled together for 
microarray analysis to minimize the effect of individual variability in gene expression. 
Four or five pooled samples for each group were subjected to microarray analysis. The 
sample labeling, gene chip hybridization and data acquisition were preformed using the 
standard Affymetrix protocol at the University of Hawaii Biotech/Molecular Biology 
Core facility. Briefly, about 18 micrograms of pooled total RNA were converted into 
double-stranded cDNAs using the SuperScript Choice system (Invitrogen, Carlsbad, 
CA) with an oligo-dT24 primer containing the T7 polymerase promoter attached to a 
poly-dT sequence. In vitro transcription was performed using a commercially available 
RNA transcript biotin labeling kit (Affymetrix, Santa Clara, CA). Biotin-labeled cRNA 
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were purified using a commercially available kit (Affymetrix, Santa Clara, CA), then 
fragmented. Labeled cRNAs were hybridized first to Tester arrays (Affymetrix, Santa 
Clara, CA), then to Mouse 430-2 arrays after examination of the results of Tester array 
hybridization. Briefly, ten micrograms of fragmented cRNAs were hybridized for 16 
hours on the Affymetrix Mouse 430-2 microarray chips. After incubation, Affymetrix 
Fluidics Station 450 was used for washing and staining according to the manufacturer’s 
instructions with its reagents. Briefly, non-hybridized materials were removed, then the 
hybridized chips were incubated with streptavidin-phycoerythrin (SAPE) to detect 
hybridized cRNA. The signal intensity was amplified by a second staining with biotin-
labeled anti-streptavidin antibody followed by SAPE staining. Fluorescent images were 
scanned before and after amplification using the Affymetrix Gene Chip Scanner 3000.  
3.3.6 Microarray Data Processing and Analysis 
 The Affymetrix Mouse 430-2 microarray contains probe spots for over 45,000 
genes. The microarray images were processed with the GenChip® Operating Software v. 
1.4 (GCOS, Affymetrix, Santa Clara, CA). Gene expression signals were scaled to a 
target intensity of 500, and detection values were determined with the default settings of 
the GCOS. The probes sets having at least an absent call in microarrays of each group 
were eliminated from the GCOS-generated raw data. To examine differential gene 
expression during muscle hypertrophy induced by chornic myostatin suppression, signal 
intensities of wild type and Mstn-pro mice were subjected to t-test (p<0.01), then 
various fold change cutoffs were applied to select genes that were differentially 
expressed between the two groups. To examine differential gene expression during 
muscle hypertrophy induced by the administration of CL, signal intensities of wild type 
and wild type-CL mice were subjected to the same approach. To determine the 
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biological significance of the differentially expressed genes, genes were categorized 
based on Gene Ontology (GO) biological process categories and over-represented 
categories were identified using the DAVID software (Dennis, Jr. et al. 2003). 
3.3.7 Validation of Microarray Results with Real-time PCR 
 Ten genes were selected among the differentially expressed genes, and primers 
were synthesized (Table 3.4) for a validation of microarray expression results using the 
real-time PCR method. Total RNAs isolated for microarray hybridization were used for 
PCR. Five µg of total RNAs were reverse transcribed using Superscript II reverse 
transcriptase (Invitrogen, Carlsbad, CA) with oligo-dT primers in a 50 µL total volume. 
Five µL of the resulting cDNA was used for real-time PCR in a 50 µL total volume at 
the University of Hawaii Biotech/Molecular Biology Core facility using the iCycler iQ 
Real-Time PCR Detection System (Bio-Rad, Hercules, CA) following the 
manufacturer’s instruction. Threshold cycle (Ct) of each sample was obtained and 
analyzed by Prism5 software for statistical significance (Grapad, San Diego, CA). 
3.3.8 Statistical analysis 
All values are expressed as mean ± SEM. Two-way analysis of variance 
(ANOVA) was performed using Prism5 software (GraphPad, San Diego, California) to 
examine the effects of genotype, CL, and interaction on body and muscle weights; 
muscle DNA and RNA concentrations; and the levels of phosphorylation of Akt, 4E-
BP1 and p70S6k. Statistical significance was determined to be P < 0.05 unless 
otherwise indicated.  
3.4 RESULTS 
3.4.1 Effects of CL on body and muscle weights of wild type and Mstn-pro mice 
The effect of CL administration on body weights of wild type and Mstn-pro 
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mice is summarized in Fig. 3.1. As expected from a previous report (Yang et al., 2001), 
Mstn-pro mice were heavier than wild type mice at the time of CL administration (P < 
0.001), and they grew significantly faster than wild type mice over the 14 day period (P 
< 0.001). The growth-promoting effect of CL was evident in both genotypes (Fig. 3.1), 
indicating that the growth-promoting effect of CL is additive to the growth-promoting 
effect of Mstn-pro. The temporal effect of CL on body weight gain was evident in both 
genotypes: the increase in body weight gain of Mstn-pro mice occurred at up to 7 days 
of CL administration in both genotypes and no further increase was observed afterward. 
Skeletal muscle weights of wild type and Mstn-pro mice as affected by CL 
administration for 3 and 14 days are summarized in Table 3.1 and 3.2. As expected, the 
skeletal muscle weights of Mstn-pro mice were significantly (P < 0.001) heavier than 
those of wild type mice over the experimental period. The protein concentration of 
plantaris muscle of Mstn-pro mice was greater than that of wild type mice (P < 0.001). 
CL administration significantly (P < 0.001) increased the skeletal muscle weights of 
both Mstn-pro and wild type mice over the experimental period. CL administration also 
increased the protein concentrations of plantaris muscle in both Mstn-pro and wild type 
mice (P < 0.001), leading to the highest muscle protein concentration in CL-fed Mstn-
pro mice. When concentrations of soluble proteins in lysis buffer were measured from 
the EDL muscle during Western blot analysis, genotype and CL administration had no 
effect on soluble protein concentration. Thus, it is postulated that the increase in total 
muscle protein concentration in Mstn-pro mice or by CL administration is probably due 
to an increase in insoluble myofibrilar proteins.  
3.4.2 Effects of CL on muscle RNA and DNA concentrations of wild type and Mstn-
pro mice 
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RNA and DNA concentrations in plantaris muscle were measured to examine 
indirectly the myonuclei domain size and protein synthetic capacity (Table 3.3). Muscle 
RNA concentration of Mstn-pro was not significantly different from those in the wild 
type mice at 3 and 14 days. However, muscle RNA concentrations of the wild type and 
Mstn-pro mice were significantly (P <0.05) increased at 3 days after CL administration 
(6.4% for wild type and 15.9% for Mstn-pro), but the effect disappeared at 14 days after 
CL administration. Muscle DNA concentration of Mstn-pro mice was significantly (P 
<0.001) lower than that of wild type mice during the experimental period (10.2% at 3 
days and 9.3 % at 14 days), and CL administration also significantly (P <0.05) 
decreased the muscle DNA concentrations of both wild type and Mstn-pro mice. As a 
result of lower DNA concentration of Mstn-pro mice, the muscle RNA/DNA ratio of 
Mstn-pro mice was significantly (P <0.001) higher than that of wild type mice. Similarly, 
CL administration significantly (P <0.05) increased the muscle RNA/DNA ratio of both 
wild type and Mstn-pro mice, leading to the highest RNA/DNA ratio in CL-fed Mstn-
pro mice. The increased RNA/DNA ratio by both Mstn-pro and CL administration 
suggests that overall capacity of protein synthesis was enhanced by both Mstn-pro 
and/or CL administration. 
3.4.3 Effect of CL administration on the phosphorylation of muscle Akt, 4E-BP1 
and p70S6k in wild type and Mstn-pro mice 
The phosphorylation of Akt, 4E-BP1 and p70S6k have been shown to play an 
important role in regulating protein synthesis, thus the phosphorylation levels of Akt, 
4E-BP1 and p70S6k in EDL muscles were examined using Western blot analysis (Fig. 
3.2-3.4). The levels of phosphorylated Akt, 4E-BP1 and p70S6k were significantly (P 
<0.001) higher in Mstn-pro mice than in wild-type mice, but no difference was observed 
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in the levels of total Akt, 4E-BP1 and p70S6k between the groups during the 
experimental period. Regardless of genotype, CL administration also significantly (P 
<0.001) increased the phosphorylation levels of Akt, 4E-BP1 and p70S6k without 
affecting the total levels of Akt, 4E-BP1 and p70S6k, leading to the highest levels of 
phosphorylation of these proteins in CL-fed Mstn-pro mice.  
Notably, at 3day of CL administration, significant effects of genotype and CL 
interaction on levels of phosphorylated Akt, 4E-BP1 and p70S6k were observed. The 
increase in the levels of phosphorylated Akt, 4E-BP1 and p70S6k induced by CL 
administration was greater in Mstn-pro mice than in wild type mice. However, the 
interaction effects disappeared at 14 days of CL administration. These results suggest 
that the effect of CL on phosphorylation of Akt, 4E-BP1 and p70S6k diminished during 
the 14 day administration of CL.  
3.4.4 Identification of differential gene expression 
We analyzed gene expression profiles to gain a better understanding of the 
genetic basis of the muscle hypertrophic effects of either Mstn-pro or CL administration 
by using the Affymetrix 430-2.0 microarray containing ~45,000 probe sets. The probe 
sets not expressed in skeletal muscles were removed from analysis by eliminating 
probes sets having at least an absent call in microarrays of each group.  
Differential gene expression profile as affected by the effect of genotype (Wild type vs 
Mstn-pro mice) 
 We identified that 108 genes (92 overexpressed genes and 16 underexpressed 
genes), represented by 134 probe sets, were differentially expressed between the Mstn-
pro and wild type mice at 1.5 fold change cutoff. Among the 108 different genes, 11 
genes were ESTs, resulting identification of 97 known genes (87 overexpressed genes 
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and 10 underexpressed genes, Appendix 3.5). With a fold change cutoff of 3.0 being 
applied, the list of genes showing differential expression was reduced to 8 
overexpressed genes (Table 3.5). To examine the validity of the microarray results, five 
genes that showed significantly differential expression in microarray analysis were 
selected for real-time PCR assay. Those genes included Mt3 (5.7 fold), Tnnt2 (3.5 fold), 
S100a4 (2.9 fold), Ctss (2.3 fold) and Cgref1 (1.6 fold). Equal amount of total RNA 
samples of individual animal used in the microarray analysis were subjected to the real-
time PCR analysis. The real time PCR results confirmed the microarray results (Table 
3.10). 
Differential gene expression profile as affected by the effect of genotype under CL 
administration (CL treated wild type mice vs CL treated Mstn-pro mice) 
 We identified that 96 genes (43 overexpressed genes and 53 underexpressed 
genes), represented by 121 probe sets, were differentially expressed between the CL-
treated wild type and CL-treated Mstn-pro mice. Among the 96 different genes, 3 genes 
were ESTs, resulting in the identification of 93 known genes (40 overexpressed genes 
and 53 underexpressed genes, Appendix 3.6). With a fold change cutoff of 3 being 
applied, the list of gene showing differential expression was reduced to 3 overexpressed 
genes (Table 3.6). To examine the validity of the microarray results, five genes that 
showed significantly differential expression in microarray analysis were selected for 
real-time PCR assay. Those genes included Tubb2a (4.4 fold), Myof (2.2 fold), Atf3 (2.1 
fold), Palm2 (1.7 fold) and Cgref1 (1.5 fold). Equal amount of total RNA samples of 
individual animal used in the microarray analysis were subjected to the real-time PCR 
analysis. The real time PCR results confirmed the microarray results (Table 3.10). 
To examine whether the differential gene expression induced by Mstn-pro 
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overexpression is affected by CL administration, the 108 genes differentially expressed 
between the wild type and Mstn-pro groups were compared to the 96 differentially 
expressed genes between CL-treated wild type and CL-treated Mstn-pro groups (Fig. 
3.5c). Only two genes were shown to be overlapping between the two lists of 
differentially expressed genes, indicating that differential gene expression caused by 
Mstn-pro is dramatically altered by CL administration. 
Differential gene expression profile as affected by the effect of CL in wild type mice 
(Wild type mice vs CL treated wild type mice) 
 We identified that 1241 genes (650 overexpressed genes and 591 
underexpressed genes), represented by 1652 probe sets, were differentially expressed 
between the wild type and CL-treated wild type mice. Among the 1241 different genes, 
90 genes were ESTs, resulting in the identification of 1151 known genes (616 
overexpressed genes and 535 underexpressed genes, Appendix 3.7). With a fold change 
cutoff of 3.0 being applied, the list of genes showing differential expression was 
reduced to 104 overexpressed genes (Table 3.7). To examine the validity of the 
microarray results, five genes that showed significantly differential expression in 
microarray analysis were selected for real-time PCR assay. Those genes included Krt8 
(390.3 fold), Rrad (54.8 fold), Gdf5 (50.83 fold), Myog (8.6 fold) and Myo10 (3.3 fold). 
Equal amount of total RNA samples of individual animal used in the microarray 
analysis were subjected to the real-time PCR analysis. The real time PCR results 
confirmed the microarray results (Table 3.10). 
Differential gene expression profile as affected by the effect of CL in Mstn-pro (Mstn-pro 
mice vs CL treated Mstn-pro mice)  
 We identified that 1522 genes (682 overexpressed genes and 840 
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underexpressed genes), represented by 1907 probe sets, were differentially expressed 
between Mstn-pro and CL-treated Mstn-pro mice. Among the 1522 different genes, 115 
genes were ESTs, resulting in the identification of 1407 known genes (618 
overexpressed genes and 789 underexpressed genes, Appendix 3.8). With a fold change 
cutoff of 3.0 being applied, the list of genes showing differential expression was 
reduced to 99 overexpressed genes (Table 3.8). To examine the validity of the 
microarray results, five genes that showed significantly differential expression in 
microarray analysis were selected for real-time PCR assay. Those genes included Krt8 
(413.4 fold), Runx1 (41 fold), Orm2 (20.6 fold), Myog (8.4 fold) and Tubb2a (4.7 fold). 
Equal amount of total RNA samples of individual animal used in the microarray 
analysis were subjected to the real-time PCR analysis. The real time PCR results 
confirmed the microarray results (Table 3.10).  
To examine whether the differential gene expression induced by CL 
administration is affected by chronic Mstn-pro overexpression, we compared 1241 
genes differentially expressed between wild type and CL-treated wild type groups to the 
1522 genes differentially expressed between Mstn-pro and CL-treated Mstn-pro mice 
groups. Six hundred sixty genes were shown to be overlapping between the two lists of 
differentially expressed genes (Fig. 3.5b). The result indicates about half of the genes 
differentially expressed by CL administration is altered by the chronic overexpression of 
Mstn-pro.  
Differentially expressed gene profile as affected by both Mstn-pro overexpression and 
CL administration  
To examine the genes that are differentially expressed during muscle 
hypertrophy induced by both chronic Mstn suppression and CL administration, the 
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profile of differentially expressed genes induced by Mstn-pro overexpression was 
compared to the profile of differentially expressed genes induced by CL administration. 
Forty genes (36 overexpressed genes and 4 underexpressed genes) were identified to be 
overlapping between the two models of muscle hypertophy (Fig. 3.5a). The 40 genes 
represent 37% of the differentially expressed genes induced by Mstn-pro overexpression 
and 3.2% of the differentially expressed genes induced by CL administration (Table 3.9). 
3.4.5 Functional clustering of differentially expressed genes 
 To gain insight into the physiological relevance of the differential gene 
expression caused by Mstn-pro overexpression and/or CL administration, we 
functionally classified the differentially expressed genes with more than 1.5 fold change 
using the DAVID software that categorizes genes based on Gene Ontology (GO) 
biological process and identifies over-represented clusters.  
Functional clustering of genes differentially expressed by the effect of Mstn-pro 
overexpression (Wild type mice vs Mstn-pro mice) 
 The 108 genes were categorized into overexpression of 27 clusters, and 
underexpresssion of 2 clusters (Table 3.11). Among these clusters, cell differentiation 
(24 genes), organ development (20 genes), transport (19 genes), system development 
(18 genes), neuron development (14 genes), immune response (14 genes) and cell cycle 
(12 genes) contained large number of overexpression genes. Underexpression functional 
clusters include lipid metabolic process (3 genes) and cell redox homeostasis (2 genes).  
Functional clustering of genes differentially expressed by the effect of genotype under 
CL (CL treated wild type mice vs CL treated Mstn-pro mice) 
The 96 genes were categorized into overexpression of 8 clusters and 
underexpression of 8 clusters (Table 3.11). Among these clusters, regulation of cellular 
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process (24 genes), nucleic acid metabolic process (21 genes), transcription, DNA-
dependent (18 genes), regulation of transcription (18 genes), regulation of gene 
expression (18 genes), regulation of cellular metabolic process (18 genes) and 
regulation of metabolic process (18 genes) contain large number of overexpression 
genes. Transport (23 genes) and protein localization (12 genes) contain large number of 
underexpression genes. The result indicates that functional clusters of differentially 
expressed genes caused by Mstn-pro overexpression are dramatically altered under CL 
administration.  
Functional clustering of genes differentially expressed by the effect of CL (Wild type 
mice vs CL treated wild type mice) 
 The 1241 genes were categorized into overexpression of 36 clusters and 
underexpression of 5 clusters (Table 3.12). Among these clusters, cellular metabolic 
process (403 genes), metabolic process (275 genes), transport (222 genes), protein 
metabolic process (182 genes), organ development (156 genes), cellular component 
organization and biogenesis (110 genes), developmental process (107 genes), cellular 
localization (106 genes) and protein localization (87 genes) contain large number of 
overexpression genes. Underexpression functional clusters include electron transport 
(19 genes), reproductive structure development (5 genes), regulation of heart 
contraction (5 genes), menstrual cycle phase (4 genes) and menstrual cycle process (4 
genes).   
Functional clustering of genes differentially expressed by the effect of CL in Mstn-pro 
mice (Mstn-pro mice vs CL treated Mstn-pro mice) 
 The 1522 genes were categorized into overexpression of 26 clusters and 
underexpression of 9 clusters (Table 3.12). Among these clusters, cellular metabolic 
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process (427 genes), metabolic process (258 genes), transport (188 genes), protein 
metabolic process (181 genes), organ development (119 genes), developmental process 
(103 genes), biological process (99 genes), cellular localization (87 genes), cell 
differentiation (84 genes) and protein localization (75 genes) contain large number of 
overexpression genes. Underexpression functional clusters include negative regulation 
of biological process (53 genes), negative regulation of cellular process (51 genes), 
electron transport (32 genes), regulation of catalytic activity (22 genes), hemopoietic or 
lymphoid organ development (17 genes), lipid transport (13), negative regulation of 
growth (6 genes), regulation of binding (5 genes) and opsonization (2 genes). The result 
indicates that the functional clusters of differentially expressed genes induced by CL 
administration were much greater than those induced by Mstn-suppression, reflecting 
the divese physiological functions regulated by β-adrenergic agonists.  
Functional clustering of genes differentially expressed by both Mstn-pro overexpression 
and CL administration 
 The 40 genes were categorized into overexpression of 17 clusters (Table 3.13). 
Among these clusters, system development (11 genes), organ development (9 genes) 
and cell differentiation (8 genes) contain large number of overexpression genes. 
3.4.6 Functional clustering of differentially expressed genes based on skeletal 
muscle growth 
To gain insight into the relevance of the differential gene expression occurred 
during muscle hypertrophy in the two models to skeletal muscle growth, we 
functionally classified the differentially expressed gene based on carboxylic acid and 
amino acid metabolism, protein metabolic process, transcription, translation, muscle 
contraction, cell proliferation and cell cycle, cell differentiation, skeletal muscle 
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development and signal transduction pathway using DAVID software. We assumed 
those functional clusters are key regulators involved in skeletal muscle growth. 
Functional clustering of genes differentially expressed by the effect of Mstn-
overexpression (Wild type mice vs Mstn-pro mice) 
 The 108 genes were categorized into carboxylic acid and amino acid 
metabolism (6 genes), protein metabolic process (12 genes), transcription (3 genes), cell 
proliferation and cell cycle (7 genes), cell differentiation (16 genes), skeletal muscle 
development (3 genes) and signal transduction (10 genes) (Table 3.14).  
Functional clustering of genes differentially expressed by the effect of Mstn-
overexpression under CL (CL treated wild type mice vs CL treated Mstn-pro mice) 
 The 96 genes were categorized into carboxylic acid and amino acid metabolism 
(6 genes), protein metabolic process (16 genes), transcription (12 genes), cell 
proliferation and cell cycle (19 genes), cell differentiation (5 genes) and signal 
transduction (15 genes) (Table 3.15).  
Functional clustering of genes differentially expressed by the effect of CL (Wild type 
mice vs CL treated wild type mice) 
 The 1241 genes were categorized into carboxylic acid and amino acid 
metabolism (6 genes), protein metabolic process (50 genes), translation (22 genes), 
transcription (49 genes), cell proliferation and cell cycle (32 genes), cell differentiation 
(37 genes), skeletal muscle development (11 genes) and signal transduction (59 genes) 
(Table 3.16).  
Functional clustering of genes differentially expressed by the effect of CL (Mstn-pro 
mice vs CL treated Mstn-pro mice) 
 The 1522 genes were categorized into muscle contraction (6 genes), carboxylic 
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acid and amino acid metabolism (12 genes), protein metabolic process (53 genes), 
translation (20 genes), transcription (22 genes), cell proliferation and cell cycle (43 
genes), cell differentiation (32 genes), skeletal muscle development (8 genes) and signal 
transduction (41 genes) (Table 3.17).  
Functional clustering of genes differentially expressed by both Mstn-pro overexpression 
and CL administration  
The 40 genes were categorized into carboxylic acid and amino acid metabolism 
(5 genes), protein metabolic process (3 genes), cell differentiation (3 genes) and skeletal 
muscle development (3 genes) (Table 3.18). 
3.5 DISCUSSION  
3.5.1 Effect of CL administration on skeletal muscle growth of Mstn-pro 
overexpression mice 
 The results of this study show that the muscle hypertrophic effects of CL is 
additive to the muscle hypertrophic effect of Mstn suppression in male mice. In our 
previous experiment (chapter 2) with female mice, we also observed that muscle 
hypertrophic effects of CL is additive to the muscle hypertrophic effect of Mstn 
suppression, indicating that the additive hypertrophic effect of CL administration is not 
affected by gender. Furthermore, the results suggest that during the early period of CL 
administration, CL may act synergistically to the hypertrophic effect of Mstn 
suppression since the increase in body and muscle weight gains of Mstn-pro mice by CL 
was significantly greater than that of wild type mice at 3-day CL administration, 
whereas the increase of body and muscle weight gains at 14-day CL administration was 
similar between the two genotypes. This result is in agreement with our previous female 
experiment (chapter 2), indicating that there is no gender influence on this synergistic 
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effect. 
In agreement with our previous female study (chapter 2), the current results also 
show that muscle DNA concentration of Mstn-pro mice is lower than that of wild-type 
mice, without a difference in RNA concentration, indicating that the increase in muscle 
mass in the Mstn-pro group was probably due to an increase in fiber size (hypertrophy) 
not by an increase in fiber number (hyperplasia). Welle et al. (2006) also reported that 
muscle DNA concentration was reduced in Mstn-deficient mice, whereas RNA 
concentration was not affected, and as a result, the ratio of RNA to DNA of Mstn-
deficient mice was 30% greater than that of wild-type mice.   
CL administration increased muscle RNA concentration of both genotypes at 
3day, but the muscle RNA concentration was not affected by the CL administration at 
14 days. The muscle DNA concentration of both genotypes was decreased by the CL 
administration during experimental period, leading to the higher RNA/DNA ratio in CL-
treated mice. This result is consistent with our previous female experiment (chapter 2 ) 
and others, which showed that BAAs increases muscle RNA concentration and decrease 
muscle DNA concentration during the early period of administration (Kim and Sainz, 
1992). The decrease in muscle DNA concentration by CL administration indicated that 
the increase in muscle mass in the CL administration was probably due to an increase in 
fiber size (hypertrophy) not by an increase in fiber number (hyperplasia). Taken together, 
the current results indicate that the myonuclear domain size was not maintained during 
the enhanced muscle hypertrophy induced by Mstn suppression or CL administration, 
thus suggest that satellite cell activation is probably not a primary factor for muscle 
hypertrophy induced by Mstn-suppression and CL administration.  
3.5.2 Changes in the mTOR signaling pathway as affected by Mstn-pro 
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overexpression and CL administration 
 The mammalian target of rapamycin (mTOR) pathway is considered as a 
central regulator of ribosome biogenesis, protein synthesis, cell growth and proliferation 
by integrating signals from growth factors, nutrients, and energy status of cells (Asnaghi 
et al., 2004; Sarbassov et al., 2005). The mTOR activation by Akt induces the 
phosphorylation of two downstream effectors, ribosomal protein p70S6k and 4E-BP1, a 
suppressor of cap binding protein eIF4E, resulting in increased protein translation 
(Sarbassov et al., 2005). Studies have shown that the mTOR pathway plays an important 
role in regulating skeletal muscle growth. Anabolic stimuli, such as overloading, 
resistance exercise, and essential amino acid ingestion, have been shown to increase the 
phosphorylation of p70S6k and 4E-BP1 along with a corresponding increase in protein 
synthesis (Bodine et al., 2001; Dreyer et al., 2006; Fujita et al., 2007; Dreyer et al., 
2008; Drummond et al., 2008). Conversely, atrophying muscles have decreased levels 
of the phosphorylation of the downstream targets of mTOR (Bodine et al., 2001; 
Hornberger et al., 2001). Supporting the role of the mTOR pathway on skeletal muscle 
growth, p70S6k null mice have a smaller muscle fiber size and the hypertrophic 
response to IGF-1 was blocked in p70S6k null mice (Ohanna et al., 2005). Recent 
results have indicated that the mTOR pathway is also involved in the regulation of 
muscle mass induced by Mstn (Amirouche et al., 2009; Sartori et al., 2009) or BAAs 
(Sneddon et al., 2001; Kline et al., 2007).  
 As was observed in our previous experiment with female mice (chapter 2), we 
also observed that the levels of phosphorylated 4E-BP1 at Thr37/46 and p70S6k at Thr389 
were greater in Mstn-pro male mice compared with wild type male mice. In addition, 
we also observed that the levels of phosphorylated Akt at Thr308 were greater in Mstn-
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pro mice compared with wild type mice, suggesting that the increased phosphorylations 
of 4E-BP1 and p70S6k observed in Mstn-pro mice were probably through the 
Akt/mTOR pathway. This result is consistent with a previous study, which showed that 
a decrease in the phosphorylation of both 4E-BP1 at Thr37/46 and p70S6k at Ser235/236 
along with a decrease in the phosphorylation of Akt at Thr308 in Mstn overexpression 
mice (Amirouche et al., 2009), and supports that Akt/mTOR pathway is involved in the 
regulation of muscle mass by Mstn. Interestingly, Welle et al. (2009) observed an 
increase in the phosphorylation of p70S6k at Thr389, but not of 4E-BP1 at Thr36/45, Ser64, 
orThr69, nor Akt at Thr308 or Ser473 in anti-Mstn antibody administration mice. At the 
same time, it was also noted that rapamycin did not suppress the effect of Mstn 
suppression on increasing myofiber size or the rate of muscle protein synthesis (Sartori 
et al., 2009; Welle et al., 2009), suggesting that Mstn regulation of muscle protein 
synthesis can be independent of Akt/mTOR pathway signaling or other yet unidentified 
components are involved in mTOR phosphorylation of 4E-BP1 and p70S6k.  
Like in our previous female study (chapter 2), we also observed that the levels 
of phosphorylated 4E-BP1 at Thr37/46 and p70S6k at Thr389 were also significantly 
increased by CL administration regardless of genotype. In addition, we also observed 
that the levels of phosphorylated Akt at Thr308 were significantly increased by CL 
administration regardless of genotype, suggesting that like Mstn, BAA is also regulate 
muscle hypertrophy probably through the Akt/mTOR pathway. In support of our results, 
Senddon et al. (2001) demonstrated that CL treatment induced protein accretion in mice 
via stimulation of protein translation through the phosphorylation of p70S6k at Thr412 
and 4E-BP1 at Thr70. It is also noted that CL administration induced dramatic increase 
in skeletal muscle mass through the Akt phosphorylation and subsequent activation of 
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the mTOR, supporting the role of the Akt/mTOR pathway in BAA-induced skeletal 
muscle hypertrophy (Kline et al., 2007). Notably, the increase in levels of 
phosphorylated Akt, 4E-BP1 and p70S6k induced by CL administration was less at 14 
days CL administration (Akt, 26.1% for wild type and 26% for Mstn-pro; 4E-BP1, 
22.1% for wild type and 16.3% for Mstn-pro; p70S6k, 23.9% for wild type and 15.4% 
for Mstn-pro) than at 3 days CL administration (Akt, 29.7% for wild type and 31.1% for 
Mstn-pro; 4E-BP1, 24.2% for wild type and 39.8% for Mstn-pro; p70S6k, 33% for wild 
type and 37% for Mstn-pro) in both genotypes, reflecting the temporal responsiveness 
of muscle hypertrophy to BAAs. 
3.5.3 Differential gene expression during muscle hypertrophy induced by Mstn 
suppression or clenbuterol administration 
Differential gene expression induced by chronic Mstn-pro suppression 
 There have been studies using microarray to investigate the global gene 
expression in skeletal muscle hypertrophy induced by Mstn inhibition (Steelman et al., 
2006; Sadkowski et al., 2008; Welle et al., 2009b). Steelman et al. (2006) reported that 
717 genes were differentially expressed (p < 0.05, 1.5 fold change) in pectoral muscles 
between wild type and Mstn null mice. Welle et al. (2009) reported that 124 genes (p < 
0.01, 1.5 fold change) were differentially expressed in gastrocnemius muscles between 
wild type and Mstn null mice. Our current results showed that 108 genes (p < 0.01, 1.5 
fold change) were differentially expressed in gastrocnemius muscle by chronic 
suppression of Mstn.  
 Functional analysis revealed that the differentially expressed genes represent a 
wide variety of biological processes, including cell differentiation, organ development, 
transport, system development, neuron development, immune response, cell cycle, lipid 
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metabolic process, and cell redox homeostasis, indicating that a wide variety of 
biological processes are altered during muscle hypertohphy induced by Mstn-pro 
overexpresseion. However, the limitation of microarray analysis is that it is not possible 
to tell whether the alteration of the biological process was due to a direct effect of the 
modification of Mstn signaling or due to indirect consequences of muscle hypertrophy 
induced by Mstn-pro overexpression. Therefore, we further focused on gene clusters 
which we assume to be involved in skeletal muscle development, and these include 
carboxylic acid and amino acid metabolism, protein metabolic process, transcription, 
cell proliferation and cell cycle, cell differentiation, skeletal muscle development and 
signal transduction.  
We have also included a more detaile table (Table 3.19 and 3.20), which 
compares the microarray information in this study to previously published studies on 
chronic Mstn-suppression-induced hypertrophy. 
Genes encoding muscle contractile proteins  
 Steelman et al. (2006) have reported a decreased expression of genes for slow 
isoforms of myosin (Myh7 [slowest myosin heavy chain isoform, type I], Myl2, Myl3) 
and troponin (Tnnc1, Tnni1, Tnnt1, Tpm3) in constitutive Mstn null mice as compared 
to wild type mice. In bovine late fetus, Cassar-Malek et al. (2007) reported that 
constitutive non-functional mutation of Mstn decreased the expression of slow forms of 
contractile proteins (Myh7, Myl2, Tpm3). Sadkowski et al. (2008) also observed that 
there was increased expression of genes for fast isoforms of myosin (Myh3) in skeletal 
muscle carrying a SNP in the 5’flanking region of the Mstn gene in bulls, while slow 
isoforms of myosin (Myh8 [myosin heavy chain neonatial isoform 2], Myo5a, Myl6) 
were decreased. However, in this study, we could not observe any alteration in gene 
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expression ecoding myofibrillar in Mstn-pro mice except the differential expression of 
troponin T2 (Tnnt2, 3.5 fold), which is mostly expressed during embryonic 
development. Similar to our results, Welle et al. (2009) reported that the expression of 
myofibrillar genes was not significantly altered in mice with post-developmental Mstn 
knockout. The above inconsistency appears to be related to differences in the 
developmental stages of Mstn-suppression. While Steelman et al. (2006) and Cassar-
Malek et al. (2007) used constitutive Mstn-null animal models, the current study and 
Welle et al. (2009) used postnatal Mstn-suppression models. The suppression of Mstn 
from embryonic development (constitutive Mstn knockout models) induces greater 
development of fast, glycolytic fiber types at the expense of slow, oxidative fibers 
(Girgenrath et al. 2005), explaining the decreased expression of slow isoforms of 
myofibrillar contractile proteins in constitutive Mstn-null animal modles. Unlike the 
constitutive Mstn-knockout nodels, the muscle hypertrophy induce by postnatal Mstn-
suppression is much less slective on muscle fiber types, thus less effect on the 
expression of genes encoding isoforms of myofibrillar proteins. 
Genes encoding proteins involved in transcription  
 In this study, we observed that the 3 transcription factor genes were 
differentially expressed by Mstn-pro overexpression, including runt related transcription 
factor 1 (Runx1, 2.2 fold), DNA methyltransferase (Dnmt1, 1.6 fold) and sterol 
regulatory element binding transcription factor 1 (Sreb1, -1.5 fold). However, studies by 
other groups did not observe that these genes were differentially regulated by Mstn 
modulation (Steelman et al., 2006; Welle et al., 2009). Zhu et al. (1994) reported that a 
50-100 fold upregulation in runx1 expression was observed after 5 days of denervation 
in vivo. Similarly, Wang et al. (2005) also reported that a 73 fold upregulation in runx1 
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expression was observed after 7 days of denervation using micrarray analysis in mice 
muscle. It has been shown that this up-regulation is an attempt to prevent the autophagy 
and to minimize muscle wasting. The Sreb1 gene is a transcription factor involved in 
adipocyte differentiation (Briggs et al., 1993) as well as in the biosynthesis of 
cholesterol and fatty acids (Brown and Goldstein, 1997). Shimano et al. (1999) reported 
that the Sreb1 gene knockout mice showed the low levels of all lipogenic enzymes and 
severely impaired the marked induction of hepatic mRNAs of fatty acid synthetic genes, 
such as acetyl-CoA carboxylase, fatty acid synthase, and stearoyl-CoA desaturase, 
indicating that Sreb1 plays a crucial role in the induction of lipogenesis. Taken together, 
it is postulated that the muscle hypertrophy induced by Mstn-suppression is through the 
alteration of Runx1 and Sreb1.  
Genes encoding proteins involved in immune response 
 In the present study, we observed that metallothionein 3 (Mt3) was 
differentially overexpressed, and many genes involved in immune response were 
overrepresented. The expression of Mt3 is enhanced by heavy metals, cytokines, 
glucocorticoids, oxidative stress, and other stresses, and under some conditions, Mt3 
may protect cells against DNA damage from apoptosis (Davis and Cousins, 2000; Coyle 
et al., 2002). It is not clear how the overexpression of Mt3 and genes involved in 
immune response are related to muscle hypertrophy induced by Mstn-pro 
overexpression. Mendias et al. (2008) and Eliasson et al. (2009) recently demonstrated 
that Mstn-deficient rodents have abnormally large muscles, but also small, stiff and 
brittle tendons with a higher peak stress and a lower peak strain during stretch, 
indicating a potential for high-strain muscle damage during excessive muscle 
contraction. If Mstn suppression indeed cuases stiff and brittle tendons, it is speculated 
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that Mstn-pro mice is highly susceptible to muscle damage due to a weakness in muscle 
tendons, leading to enhanced immune responses during repair of the damaged skeletal 
muscles. 
Genes encoding proteins involved in muscle hypertrophic signal pathway 
 In this study, we observed that insulin-like growth factor 2 (Igf2, 2.1 fold) was 
differentially expressed in the skeletal muscle of Mstn-pro mice even though previous 
studies (Steelman et al., 2006; Cassar-Malek et al., 2007; Welle et al., 2009) have not 
observed that Igf2 is regulated by Mstn. Like Igf1, Igf2 is known to regulate muscle 
hypertrophy. For example, Miyake et al. (2010) demonstrated that IGF-2 mRNA 
expression was higher in the regenerating muscle of double-muscled cattle than those of 
normal cattle. An addition of recombinant mouse Mstn to myoblast cultures attenuated 
IGF-2 mRNA expression and decreased myotube formation, but not IGF-1 mRNA 
expression, indicating that Mstn may negatively regulate myoblast differentiation by 
suppressing IGF-2 expression. Recently, several studies indicated that Mstn inhibits 
muscle hypertrophy in part through inhibition of protein synthesis mediated by the 
Akt/mTOR pathway (Welle et al., 2006; Amirouche et al., 2009; Morissette et al., 2009; 
Welle et al., 2009a). Igf2 appears to activate the Akt/mTOR pathway since 
administration of Igf2 to human chondrocytes increased the phosphorylation levels of 
Akt and GSK3β (Hamamura et al., 2008). Taken together, it is postulated that Igf2 is a 
target for Mstn signaling, and the muscle hypertrophy induced by Mstn-suppression is 
through the Igf2-induced activation of the Akt/mTOR anabolic pathway.  
Differential gene expression induced by CL administration 
 Several studies have previously used microarray technology to examine skeletal 
muscle gene expression following chronic BAAs administration (Spurlock et al., 2006; 
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Pearen et al., 2009). For example, Spurlock et al. (2006) reported that 52 genes were 
differentially expressed (FDR < 10%) in mouse skeletal muscle 24 hours and 10 days 
after administration of CL. Pearson et al. (2009) reported that 23 genes at one hour and 
112 genes at four hours were significantly (p < 0.05, 1.85 fold change) altered in mice 
after systemic administration of formoterol. Our current results showed that 1241 genes 
(p < 0.01, 1.5 fold change) were differentially expressed in gastrocnemius muscle by 
chronic administration of CL.  
 Functional analysis revealed that the differentially expressed genes represent a 
wide variety of biological processes, including cellular metabolic process, metabolic 
process, transport, protein metabolic process, organ development, cellular component 
organization and biogenesis, developmental process, cellular localization, protein 
localization, electron transport, reproductive structure development, regulation of heart 
contraction, menstrual cycle phase, and menstrual cycle process, indicating that a wide 
variety of biological processes are altered during muscle hypertrophy induced by CL 
administration. However, the limitation of microarray analysis is that it is not possible to 
tell whether the alteration of the biological process was due to a direct effect of the 
modification of CL signaling or due to indirect consequences of muscle hypertrophy 
induced by CL administration. Therefore, we further focused on gene clusters which we 
assume to be involved in skeletal muscle development, and these include carboxylic 
acid and amino acid metabolism, protein metabolic process, transcription, translation, 
cell proliferation and cell cycle, cell differentiation, skeletal muscle development and 
signal transduction.  
We have also included a more detaile table (Table 3.21 and 3.22), which 
compares the microarray information in this study to previously published studies on 
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BAA-induced hypertrophy. 
Genes encoding muscle contractile proteins  
 Previous studies have demonstrated that BAAs increase the expression of 
several contractile proteins (Oishi et al., 2002; Spurlock et al., 2006). For example, 
Oishi et al. (2002) have reported that CL administration resulted in muscle fiber 
hypertrophy, stimulated a de novo expression of type IIx MHC and increased the 
percentage of fibers containing multiple MHC isoforms in the rat soleus muscle. 
Spurlock et al. (2006) have reported that muscle contractile proteins, including myosin 
isoforms (Myo1b, Myo18a) and actin isoform (Actn4), were altered in mouse skeletal 
muscle at 24 hours and 10 days after administration of CL. In contrast, Pearen et al. 
(2009) demonstrated that no significant changes were observed in muscle contractile 
proteins at 1 and 4 hours after administration formoterol in mice muscle. However, they 
found that alterations in Stat3, Smad 3, and Acvr2b three genes directly associated with 
the regulation of muscle hypertophy at molecular level. In this study, we showed that 
myosin heavy polypeptide 8 (Myh8, 5 fold), troponin T2 (Tnnt2, 1.9 fold), myosin light 
polypeptide 2 (Myl2, -1.8 fold) and myosin light polypeptide kinase 2 (Mylk2, -1.7 
fold) were altered by CL administration, which are myofibrillar proteins mostly 
expressed during embryonic development. Thus, it is reasonable to hypothesize that in 
the current study the altered expression of Myh8, Tmnt2, Myl2, and Mylk2 lead to an 
increase in structural proteins which are associated with muscular hypertrophy. Similar 
to Pearen et al. (2009) study, we also found the differentially expressed activin receptor 
IIB (Acvr2b, -2.4 fold) gene, which is a well-characterized negative mediator of 
downstream of Mstn on muscle growth. The dominant-negative form of Acvr2b by 
using a skeletal muscle-specific promoter exhibited dramatic increase skeletal muscle 
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mass in mice (Lee and McPherron, 2001). Given that this result could provide a partial 
mechanistic basis for muscle hypertrophy and the underexpression of Acvr2b would be 
another target for CL signaling. 
Genes encoding proteins involved in translation and transcription 
 Previous studies have used microarray technology to examine skeletal muscle 
gene expression associated with translation and transcription following CL 
administration. For example, Spurlock et al. (2006) reported that the increase 
expressions of 13 genes including eukaryotic initiation factors (Eif2, Eif2b, Eif2b4, 
Eif2b2, Eif5, Eif4g3), and 18 genes including protein transcription factors (Hod, Yy1, 
Mef2c, and Myog) were observed mainly at 24 h after CL administration. Pearen et al. 
(2009) reported that the increase expressions of 11 genes including transcriptional 
regulators (Fos, Klf2/4, Crem, Cebpb, Nurr1, Fosl2, Maff, Aft3, Tbx3, and Litaf) were 
observed at 1 and 4 hours by CL administration in mice muscle, but no significant 
changes were observed in translation proteins. In this study, we observed a regulation of 
translational and transcriptional factors responsible for increased protein synthesis. The 
22 translation genes, including 40S ribosomal protein S20 pseudogene (Gm6607, 2.5 
fold), ribosomal protein L3 (Rpl3, 2.4 fold), ribosomal protein L13A (Rpl13a, 2.2 fold), 
ribosomal protein L23 (Rpl23, 1.8 fold), eukaryotic translation initiation factor 2b 
(Eif2b, 1.5 fold), eukaryotic translation initiation factor 1 (Eif1, 2.0 fold), eukaryotic 
translation initiation factor 4a1 (Eif4a1, 1.9 fold), eukaryotic translation initiation factor 
4e (Eif4e, 1.9 fold), and 48 transcription genes, including three genes with known 
functions in muscle growth and development: myogenin (Myog, 8.6 fold), myogenic 
differentiation 1 (Myod1, 2.7 fold), myocyte enhancer factor 2A (Mef2a, 2.0 fold), were 
differentially expressed by CL administration. Although, the four ribosomal proteins 
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(Rpl3, Rpl13a, Rpl23, and Gm6607) are differentially expressed by CL administration, 
the functions of ribosomal proteins are largely unknown. Similar to Spurlock et al. 
(2006) study, we also observed the differentially expressed Eif2b gene by CL 
administration. The function of Eif2b is that a new cycle of initiation of translation 
requires Eif2b to catalyze the exchange of eukaryotic initiation factor 2 (Eif2)-bound 
GDP for GTP, which is an important step in the regulation of translation initiation 
(Hershey, 1991; Proud, 2004). Therefore, the increased abundance of Eif2b by CL 
administration may contiribute to increased activity of Eif2 and the global upregulation 
of protein synthesis in skeletal muscle. In addition, eukaryotic translation initiation 
factor Eif1, Eif4a1, and Eif4e also increased after CL administration. These genes are 
the most abundant in translation initiation factors, involved in the initation of eukaryotic 
translation (Fletcher et al., 1999; Rogers et al., 2002). Furthermore, we also observed 
differentially expressed transcription factors (Myog, Myod1, Mef2a) by CL 
administration. The Myogenin, Myod1, and Mef2a are well characterized transcription 
factors known to be essential for myoblast differentiation (Ridgeway et al., 2000; Ma et 
al., 2005). Although significant alteration of satellite cell differentiation and recruitment 
into muscle fibers in the effect of CL administration has not been described, the 
observed increase in mRNA of transcription factors that contribute to muscle cell 
differentiation suggest the recruitment and differentiation of pre-myogenic cells may be 
involved in the physiological response of skeletal muscle to CL administration. Taken 
together, these current results could provide a general upregulation of translational and 
transcriptional machinery occurring after the administration of CL.  
Genes encoding proteins involved in muscle hypertrophic signal pathway 
  Spurlock et al. (2006) have reported that insulin-like growth factor1 (Igf1) and 
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TSC22 domain family member1 (Tss22d1) were altered in mouse skeletal muscle 24 
hours after administration of CL. Pearen et al. (2009) have reported that forkhead box 
O1 (FoxO1) was altered in mice after systemic administration of formorterol. In this 
study, we observed that eukaryotic translation initiation factor 4E (eIF4E, 1.9 fold), 
forkhead box (FoxO, -2.0 fold) and PTEN (-1.5 fold) were differentially expressed in 
the muscle hypertrophy induced by CL administration even though previous studies 
(Spurlock et al., 2006; Pearen et al., 2009) have not observed that the alteration of 
eIF4E and PTEN are regulated by BAA administration. The eIF4E is the interacting 
protein of the eukaryotic initiation factor (eIF) 4E binding proteins (4E-BPs), indicating 
that the overexpressed gene induced the increase of protein translation. In other words, 
the eIF4E binds to eIF4G, a scaffolding protein required for formation of the eIF4F 
complex and the form of eIF4F complex involved in a critical protein synthesis 
(Lawrence and Abraham, 1997). The differentially underexpressed PTEN and FoxO 
genes also might be related to the skeletal muscle hypertrophy. For example, the PI3k 
dependent Akt activation can be regulated through the tumor suppressor PTEN. The 
PTEN acts as a tumor suppressor gene through the action of its phosphatase protein 
product (Chu and Tarnawski, 2004). The PTEN negatively regulates intracellular levels 
of PIP3 in cells and functions as a tumor suppressor by negatively regulating PI3k/Akt 
signaling pathway (Sun et al., 1999). Also, the activation of Akt inhibits FoxO 
expression, which acts on the atrogin-1 promoter to cause atrogin-1 transcription and 
dramatic atrophy of myotubes and muscle fibers. Thus, FoxO play a critical role in the 
development of muscle atrophy, and inhibition of FoxO factors is an attractive approach 
to prevent muscle atrophy (Sandri et al., 2004). Taken together, it is postulated that 
eIF4E, FoxO and PTEN are targets for CL signaling, and the muscle hypertrophy 
 95
incuded by CL administration is through the alteration of eIF4E, FoxO and PTEN-
induced activation of the Akt/mTOR anabolic pathway.  
Differential expression overelapping genes induced by both chronic Mstn-pro 
suppression and CL administration 
 Between the differential genes expressed by Mstn-pro and CL administration, 
we found forty genes which overlapped. We believe these forty genes, including 
Ahnak2, Anxa4, Blnk, Cgref1, Chrna1, Col19a1, Cyb5r3, D11Wsu99e, Ddc, Gatm, 
Hmox1, Hn1, Ift122, Kif5c, Lgals3, Lgmn, Obfc2a, Pak1, Pdia3, Psat1, Rab27b, Rnh1, 
Rtn4, Runx1, Slc25a24, Sln, Snx5, Stbd1, Tnnt2, Tspo, Ttll1, Tubb2a, Tubb6, Vash2, 
Txnl1, Rps6ka5 and Acot6, might be common targets in the skeletal muscle 
hypertrophy induced by Mstn-pro and CL administration. However, the full mechanisms 
of forty genes are not previously reported to be elated to skeletal muscle hypertrophy, 
suggesting that further studies will be needed to examine these genes expression change 
for their biological relevance in skeletal muscle hypertrophy. 
3.6 CONCLUSIONS 
 The results of this study demonstrate that the muscle hypertrophic effect of 
Mstn suppression and CL administration led to significant increase in body and muscle 
weight gain. The skeletal muscle hypertrophic effect of CL was additive to the 
hypertrophic effect of Mstn suppression. The pathways of Mstn and CL signaling 
appears to converge to the Akt/mTOR anabolic pathway to regulate skeletal muscle 
hypertrophy. Global evaluation of gene expression after CL administration and Mstn 
suppression by microarray analysis showed that genes involved in many biological 
processes are differentially expressed by the Mstn supperession and CL administration.  
Muscle contraction, initiation of translation, transcription, and muscle hypertrophic 
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signal pathway were represnted among those biological processes, suggesting that 
increased porotein syntheis is partly responsible for the hypertophy induced by Mstn 
suppression and CL administration. Alterations of the mRNA level of Igf2 observed in 
Mstn suppressed mice and the mRNA levels of eIF4e, Acvr2b, FoxO and PTEN 
observed in mice treated with CL indicate that the pathways of Mstn and CL signaling 
converge to the Akt/mTOR anabolic pathway to regulate skeletal muscle hypertrophy.  
Future study 
 Microarray analysis in this study revealed that numerous genes involved in 
various biological processes were differentially expressed by Mstn suppression and CL 
administration, providing a comprehensive picture of changes in gene expression during 
muscle hypertophy induced by the two stimuli. However, it is not possible to tell what 
genes are directly regulated by the stimuli or what genes are indirectly regulated as the 
consequence of the muscle hypertrophy. At the same time, muscle tissue contains 
various cell types from blood vessels, nerve fibers and cellular matrix in addition to 
muscle fiber, thus it is expected that some changes in gene expression observed in this 
study were contributed from other cell types. Therefore, further studies need to sort out 
among those differentially expressed genes, which genes are directly involved in the 
mechanisms regulating muscle hypertrophy.  
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 Wild type  Mstn-pro Significance 
Days 0 ppm 20 ppm 0 ppm 20 ppm GT CL GTxCL 
0-3 0.6 (0.13) 1.4 (0.13) 1.3 (0.19) 2.1 (0.16) *** *** NS 
3-7 0.7 (0.14) 1.8 (0.06) 1.2 (0.21) 2.5 (0.29) *** *** NS 
7-10 1.2 (0.17) 1.5 (0.13) 1.5 (0.11) 1.5 (0.26) NS NS NS 
10-14 0.4 (0.18) 0.7 (0.15) 0.7 (0.13) 0.3 (0.21) NS NS NS 
 
Figure 3.1 Effect of CL administration on body weights of wild type and Mstn-pro 
mice. Solid and dotted lines indicate 20 and 0 ppm CL administration, respectively, to 
wild type (open circle) and Mstn-pro mice (closed circle). Values are means (SEM). 
(A): Growth curve of male mice during 14 days (a, difference between wild type and 
Mstn-pro; b, difference between 0 ppm and 20 ppm CL administration (***, P < 0.001, 
**, P < 0.01)). (B): Body weight gain of male mice during 14 days (***, P < 0.001, NS, 




Figure 3.2 Effect of CL administration on AKT at Thr308 phosphoryalation in 
extensor digitorum longus muscles of wild type and Mstn-pro mice. Representative 
immunoblot images are shown above the bar graph. Each lane sequentially represents 
the group in the bar graph. A): 3day phosphorylation levels of Akt. B): 14day 
phosphorylation levels of Akt. C): 3day non-phosphorylation levels of Akt. D): 14day 
non-phosphorylation levels of Akt. Values are expressed as mean ±SEM. ***, P<0.001; 




Figure 3.3 Effect of CL administration on 4E-BP1 at Thr37/46 phosphoryalation in 
extensor digitorum longus muscles of wild type and Mstn-pro mice. Representative 
immunoblot images are shown above the bar graph. Each lane sequentially represents 
the group in the bar graph. A): 3day phosphorylation levels of 4E-BP1. B): 14day 
phosphorylation levels of 4E-BP1. C): 3day non-phosphorylation levels of 4E-BP1. D): 
14day non-phosphorylation levels of 4E-BP1. Values are expressed as mean ±SEM. ***, 




Figure 3.4 Effect of CL administration on p70S6k phosphoryalation at Thr389 in 
extensor digitorum longus muscles of wild type and Mstn-pro mice. Representative 
immunoblot images are shown above the bar graph. Each lane sequentially represents 
the group in the bar graph. A): 3day phosphorylation levels of p70S6k. B): 14day 
phosphorylation levels of p70S6k. C): 3day non-phosphorylation levels of p70S6k. D): 
14day non-phosphorylation levels of p70S6k. Values are expressed as mean ±SEM. ***, 







Figure 3.5 Comparison of genes that were differentially expressed by Mstn-pro 
overexpression and/or CL administration. A) Comparison of differentially expressed 
genes induced by Mstn-pro overexpression with those induced by CL administration B) 
comparison of differentially expressed genes induced by CL administration under the 
influence of Mstn-pro overexpression, C) comparison of differentially expressed genes 
induced by Mstn-pro overexpression under the influence of CL treatment. W, wild type 






Table 3.1 Muscle weights of wild type and Mstn-pro mice as affected by CL administration for 3 days. 
 
 Wild type Mstn-pro Significance 
 
 0 ppm  20 ppm 0 ppm 20 ppm GT CL      GT x CL  
 
Number of animals          11            25              15           19  
Initial body Wt, g 19.9 (0.63)  20.6 (0.31) 21.6 (0.56) 21.8 (0.37) ** NS NS 
Final body Wt, g 20.2 (0.58) 22.0 (0.31) 22.5 (0.50) 23.5 (0.39) *** ** NS 
 
Gastrocnemius Wt, mg 99.0 (6.08) 115.55 (3.45) 131.4 (5.55) 158.8 (5.09) *** *** NS 
% Gastrocnemius1 0.49 (0.018) 0.52 (0.011) 0.58 (0.018) 0.67 (0.014) *** *** NS 
Plantaris Wt, mg 11.5 (0.76) 14.9 (0.55) 15.1 (0.65) 20.2 (0.96) *** *** NS 
% Plantaris1 0.056 (0.0026) 0.067 (0.0020) 0.067 (0.0024) 0.085 (0.0031) *** *** NS 
EDL2 Wt, mg 7.4 (0.35) 9.7 (0.33) 10.3 (0.23) 12.9 (0.35) *** *** NS 
%EDL1 0.037 (0.0011) 0.044 (0.0011) 0.046 (0.0010) 0.055 (0.0011) *** *** NS 
Soleus Wt, mg 5.4 (0.37) 6.1 (0.24) 5.3 (0.36) 6.4 (0.37) NS * NS 
% Soleus1 0.026 (0.0013) 0.028 (0.0010) 0.023 (0.0014) 0.027 (0.0014) NS NS NS 
Muscle protein, %# 23.1 (0.77) 26.9 (0.28) 27.4 (0.99) 29.2 (0.43) *** *** NS 
Soluble muscle protein, %+  2.2 (0.02)  2.2 (0.02)  2.2 (0.01)  2.2 (0.01) NS NS NS 
Values are means (SEM). CL, clenbuterol; GT, genotype; EDL, extensor digitorum longus; NS, not significant; *, P<0.05; **, P<0.01; ***, 
P<0.001. 1% weight of muscle to body weight. 2EDL: extensor digitorum longus muscle. #Total muscle protein concentration was measured in 
plantaris muscle using the modified Lowry method. + The EDL muscle was homogenized in 9 volumes of ice-cold lysis buffer, centrifuged at 
6,000 g for 10 min at 4oC, and supernatant protein concentration was measured using the modified Lowry method. 
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Table 3.2 Muscle weights of wild type and Mstn-pro mice as affected by CL administration for 14 days. 
 
 Wild type Mstn-pro Significance 
 
 0 ppm  20 ppm 0 ppm 20 ppm GT CL      GT x CL  
 
Number of animals         13        18           13           14 
Initial body Wt, g 20.1 (0.47)  20.1 (0.34) 21.8 (0.60) 21.9 (0.62) *** NS NS 
Final body Wt, g 23.2 (0.50) 25.5 (0.45) 26.8 (0.55) 28.7 (0.80) *** *** NS 
 
Gastrocnemius Wt, mg 121.4 (5.28) 138.1 (2.30) 175.7 (5.40) 199.8 (6.10) *** *** NS 
% Gastrocnemius1 0.52 (0.014) 0.54 (0.005) 0.66 (0.015) 0.70 (0.010) *** ** NS 
Plantaris Wt, mg 13.5 (0.68) 17.1 (0.64) 20.3 (0.91) 25.7 (1.22) *** *** NS 
% Plantaris1 0.058 (0.0020) 0.067 (0.0024) 0.076 (0.0026) 0.089 (0.0021) *** *** NS 
EDL2 Wt, mg 8.7 (0.51) 10.8 (0.43) 12.8 (0.43) 15.1 (0.49) *** *** NS 
%EDL1 0.037 (0.0017) 0.042 (0.0013) 0.048 (0.0014) 0.053 (0.0010) *** *** NS 
Soleus Wt, mg 5.3 (0.32) 8.1 (0.28) 6.6 (0.21) 8.4 (0.46) * *** NS 
% Soleus1 0.023 (0.0012) 0.031 (0.0009) 0.025 (0.0008) 0.029 (0.0015) NS *** * 
Muscle protein, %# 21.5 (0.32) 25.4 (0.39) 25.5 (0.39) 28.0 (0.34) *** *** NS 
Soluble muscle protein, %+  2.0 (0.01)  2.0 (0.01)  2.0 (0.01)  2.0 (0.01) NS NS NS 
Values are means (SEM). CL, clenbuterol; GT, genotype; EDL, extensor digitorum longus; NS, not significant; *, P<0.05; **, P<0.01; ***, 
P<0.001. 1% weight of muscle to body weight. 2EDL: extensor digitorum longus muscle. # Total muscle protein concentration was measured in 
plantaris muscle using the modified Lowry method. + The EDL muscle was homogenized in 9 volumes of ice-cold lysis buffer, centrifuged at 6,000 g 
for 10 min at 4oC, and supernatant protein concentration was measured using the modified Lowry method. 
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Table 3.3 Muscle DNA and RNA concentrations in wild-type and MSTN-pro mice as affected by CL administration. 
 
 Wild type Mstn-pro Significance 
 
 0 ppm  20 ppm 0 ppm 20 ppm GT CL      GT x CL
  
3 day after administration  
Number of animals              8             25               11            17  
DNA (mg/g wet muscle) 1.25 (0.042)  1.07 (0.022) 1.12 (0.021) 0.95 (0.011) *** *** NS 
RNA (mg/g wet muscle) 1.08 (0.046)  1.15 (0.049) 1.13 (0.040) 1.31 (0.034) NS * NS 
RNA/DNA ratio 0.87 (0.041)  1.08 (0.043) 1.01 (0.047) 1.37 (0.035) *** *** NS 
 
14 day after administration  
Number of animals              13            18               11            10  
DNA (mg/g wet muscle) 0.99 (0.028)  0.95 (0.011) 0.90 (0.028) 0.83 (0.013) *** * NS 
RNA (mg/g wet muscle) 1.21 (0.041)  1.24 (0.017) 1.22 (0.023) 1.22 (0.030) NS NS NS 
RNA/DNA ratio  1.24 (0.048)  1.31 (0.020) 1.38 (0.048) 1.47 (0.028) *** * NS 
 
Values are means (SEM). CL, clenbuterol; GT, genotype; NS, not significant; *, P<0.05; ***, P<0.001. 
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Table 3.4 Sequence of PCR primers used for real-time PCR. 
Probe set ID (Gene symbol) Forward Primers (5’-3’) Reverse Primers (5’-3’) 
1420575_at (Mt3) GGACTGGATATGGACCCTGAGACCTG CACACACAGTCCTTGGCACACTT- 
1418726_a_at (Tnnt2) TCACAACCTGGAGGCTGAGAACTT              TCATCTATTTCCAACGCCCGGTGA 
1424542_at (S100a4) CATGGCAAGACCCTTGGAGGAGGCCCTGGA  AGCTTCATCTGTCCTTTTCCCCAGGAAGCT 
1448591_at (Ctss) TGGATGCTTCTGTGACAAGCTCCGATTTC CAGAGATCCCAATGGTAGTCCAGGGTAGGG 
1424529_s_at (Cgref1) GCCAAAGAACTGCTGGTGGAAACA              TTCAACACCATGCTTCTGCTCTGC 
1423691_x_at (Krt8) TATGAGGAATTGCAGACCCTGGCT  TCTGGCCTTTGAGGGCTTCAATCT 
1419139_at (Gdf5) TGAATATTTGTTCAGCCAGCGGCG  ACTCAAGAGGTGCGATGATCCAGT 
1422562_at (Rrad) TATGCAGCACACACCCTTGTCTCA  AGAAAGGCAGAGTCCTGTCCACAA 
1419391_at (Myog) ACAATCTGCACTCCCTTACGTCCA  TCTCAGTTGGGCATGGTTTCGTCT 
1450650_at (Myo10) ATTGGCCATGGCACTTTATGCTCG ATCCGAAGATGTCAAGGATGCCGA 
1418625_s_at (Gapdh) TCAACAGCAACTCCCACTCTTCCA  ACCCTGTTGCTGTAGCCGTATTCA 
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Table 3.5 Differential gene expression profiles as affected by the effect of genotype at 3-fold change 
(W vs M). 
Probe Set ID 
Fold 
change 
Gene Title Gene Symbol 
1420575_at 5.75 metallothionein 3 Mt3 
1420884_at 4.37 sarcolipin Sln 
1426808_at 4.36 lectin, galactose binding, soluble 3 Lgals3 
1427076_at 3.94 macrophage expressed gene 1 Mpeg1 
1418726_a_at 3.54 troponin T2, cardiaca Tnnt2 
1416431_at 3.49 tubulin, beta 6a Tubb6 
1459860_x_at 3.18 tripartite motif-containing 2 Trim2 
1427201_at 3.13 musculoskeletal, embryonic nuclear protein 1 Mustn1 












Table 3.6 Differential gene expression profiles as affected by the effect of genotype under CL 
administration at 3-fold change (CLW vs CLM).  
Probe Set ID 
Fold 
change 
Gene Title Gene Symbol 
1427838_at 4.38 tubulin, beta 2A Tubb2a 
1451054_at 3.75 orosomucoid 1 Orm1 
1449700_at 3.01 Immunoglobulin (CD79A) binding protein 1 Igbp1 
1437915_at 3.35 target of myb1-like 2 (chicken) Tom1l2 
1426340_at 3.23 solute carrier family 1, member 3 Slc1a3 
CLW, clenbuterol treated wild type mice; CLM, clenbuterol treated Mstn-pro mice. 
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Table 3.7 Differential gene expression profiles as affected by the effect of CL at 3-fold change (W vs 
CLW). 
Probe Set ID 
Fold 
change 
Gene Title Gene Symbol 
1423691_x_at 390.33 keratin 8b Krt8 
1448169_at 187.70 keratin 18 Krt18 
1440878_at 65.37 runt related transcription factor 1b Runx1 
1422562_at 54.82 Ras-related associated with diabetes Rrad 
1435053_s_at 52.42 Pleckstrin homology domain b Plekh 
1419139_at 50.83 growth differentiation factor 5 Gdf5 
1434709_at 30.46 neuron-glia-CAM-related cell adhesion moleculea Nrcam 
1420991_at 23.76 ankyrin repeat domain 1 (cardiac muscle) a Ankrd1 
1424831_at 23.02 copine II Cpne2 
1448975_s_at 21.68 renin 1 structural Ren1 
1426808_at 16.80 lectin, galactose binding, soluble 3 Lgals3 
1424245_at 16.56 carboxylesterase 2 Ces2 
1458813_at 16.54 sodium channel, voltage-gated, type V, alpha Scn5a 
1418852_at 15.79 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) Chrna1 
1428640_at 14.23 heat shock transcription factor 2 binding protein Hsf2bp 
1430086_at 13.92 cholinergic receptor, nicotinic, alpha polypeptide 9 Chrna9 
1449519_at 13.70 growth arrest and DNA-damage-inducible 45 alpha Gadd45a 
1421698_a_at 9.43 collagen, type XIX, alpha 1a Col19a1 
1418460_at 9.23 SH3 domain protein b Sh3 
1440085_at 9.14 ectodysplasin A2 isoform receptor Eda2r 
1435176_a_at 8.97 inhibitor of DNA binding 2 a Id2 
1451287_s_at 8.93 allograft inflammatory factor 1-like a Aif1l 
1419391_at 8.63 myogenin Myog 
1420884_at 8.55 sarcolipin Sln 
1422580_at 8.43 myosin, light polypeptide 4 Myl4 
1455649_at 7.72 tetratricopeptide repeat domain 9 Ttc9 
1421852_at 7.71 potassium channel, subfamily K, member 5 Kcnk5 
1419394_s_at 7.71 S100 calcium binding protein A8 (calgranulin A) S100a8 
1455342_at 7.59 prune homolog 2 (Drosophila)a Prune2 
1421269_at 7.41 UDP-glucose ceramide glucosyltransferase b Ugcg 
1453125_at 7.12 SRY-box containing gene 11b Sox11 
1423186_at 6.99 T-cell lymphoma invasion and metastasis 2a Tiam2 
1427910_at 6.94 cystatin E/M Cst6 
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1418571_at 6.86 tumor necrosis factor receptor superfamily, member 12aa Tnfrsf12a 
1438988_x_at 6.59 hematological and neurological expressed sequence 1b Hn1 
1420444_at 6.56 solute carrier family 22 (organic cation transporter), member 3 Slc22a3 
1416431_at 6.53 tubulin, beta 6 Tubb6 
1422629_s_at 6.38 shroom family member 3 Shroom3 
1423719_at 6.28 similar to long palate LOC632073 
1434513_at 5.92 ATPase type 13A3a Atp13a3 
1460290_at 5.82 lipin 2b Lpin2 
1420938_at 5.80 heparan sulfate 6-O-sulfotransferase 2a Hs6st2 
1455771_at 5.47 benzodiazapine receptor associated protein 1 Bzrap1 
1448660_at 5.38 Rho GDP dissociation inhibitor (GDI) gamma Arhgdig 
1421679_a_at 5.19 Cyclin-dependent kinase inhibitor 1A(P21)a Cdkn1a 
1426650_at 5.02 myosin, heavy polypeptide 8, skeletal muscle, perinatal Myh8 
1451036_at 4.80 spastic paraplegia 21 homolog (human) Spg21 
1420438_at 4.72 orosomucoid 2 Orm2 
1418158_at 4.50 transformation related protein 63a  Trp63 
1442590_at 4.49 tumor necrosis factor receptor superfamily, member 22 a Tnfrsf22 
1437224_at 4.36 reticulon 4 Rtn4 
1449533_at 4.36 transmembrane protein 100 Tmem100 
1425543_s_at 4.34 pleckstrin homology domain containing, family A member 5 Plekha5 
1422573_at 4.33 adenosine monophosphate deaminase 3 Ampd3 
1434754_at 4.30 GTPase activating RANGAP domain-like 4 Garnl4 
1452232_at 4.23 UDP-N-acetyl-alpha-D-galactosamine Galnt7 
1428834_at 4.15 dual specificity phosphatase 4 Dusp4 
1421499_a_at 4.10 protein tyrosine phosphatase, non-receptor type 14 Ptpn14 
1448605_at 4.06 ras homolog gene family, member Ca Rhoc 
1426337_a_at 3.99 TEA domain family member 4 Tead4 
1454674_at 3.96 fasciculation and elongation protein zeta 1 (zygin I) Fez1 
1422929_s_at 3.91 atonal homolog 7 (Drosophila) Atoh7 
1430062_at 3.89 hedgehog interacting protein-like 1 Hhipl1 
1451160_s_at 3.88 poliovirus receptorc Pvr 
1449852_a_at 3.86 EH-domain containing 4 Ehd4 
1424613_at 3.83 G protein-coupled receptor, family C, group 5, member B a Gprc5b 
1442827_at 3.83 Toll-like receptor 4 b Tlr4 
1421175_at 3.78 myelin transcription factor 1-like Myt1l 
1420682_at 3.70 cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) Chrnb1 
1422286_a_at 3.60 TGFB-induced factor homeobox 1 Tgif1 
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1451105_at 3.59 vasohibin 2 Vash2 
1427347_s_at 3.57 tubulin, beta 2A Tubb2a 
1452799_at 3.55 FGGY carbohydrate kinase domain containing Fggy 
1429786_a_at 3.52 ZW10 interactorc Zwint 
1460521_a_at 3.51 oligonucleotide/oligosaccharide-binding fold containing 2Ad Obfc2a 
1416401_at 3.51 CD82 antigen Cd82 
1417014_at 3.49 heat shock protein 8 a Hspb8 
1421042_at 3.46 rho/rac guanine nucleotide exchange factor (GEF) 2a Arhgef2 
1436507_at 3.35 interleukin-1 receptor-associated kinase 2 Irak2 
1450650_at 3.34 myosin X b Myo10 
1428803_at 3.32 acyl-CoA thioesterase 6 Acot6 
1427005_at 3.29 polo-like kinase 2 (Drosophila) Plk2 
1424354_at 3.25 transmembrane protein 140 Tmem140 
1451680_at 3.24 sulfiredoxin 1 homolog (S. cerevisiae) b Srxn1 
1435184_at 3.21 natriuretic peptide receptor 3a Npr3 
1426471_at 3.15 zinc finger protein 52 a Zfp52 
1450241_a_at 3.13 ecotropic viral integration site 2a Evi2a 
1432075_a_at 3.12 tektin 1 Tekt1 
1424507_at 3.12 Ras and Rab interactor 1 Rin1 
1418649_at 3.11 EGL nine homolog 3 (C. elegans)a Egln3 
1433571_at 3.10 serine incorporator 5 Serinc5 
1427483_at 3.10 solute carrier family 25, member 24a Slc25a24 
1435948_at 3.09 transmembrane protein 181A Tmem181a 
1434526_at 3.09 epoxide hydrolase 4 Ephx4 
1416231_at 3.09 Vac14 homolog (S. cerevisiae) Vac14 
1423596_at 3.06 NIMA (never in mitosis gene a)-related expressed kinase 6a Nek6 
1420895_at 3.02 transforming growth factor, beta receptor I Tgfbr1 
1417481_at 6.03 receptor (calcitonin) activity modifying protein 1 Ramp1 
1451382_at 4.67 ChaC, cation transport regulator-like 1 (E. coli) Chac1 
1437250_at 4.23 melanoregulin Mreg 
1449876_at 3.92 protein kinase, cGMP-dependent, type I  Prkg1 
1428025_s_at 3.68 phosphatidylinositol transfer protein, cytoplasmic 1 Pitpnc1 
1434499_a_at 3.65 lactate dehydrogenase B Ldhb 
1449422_at 3.55 cadherin 4 Cdh4 
1458635_at 3.54 RIKEN cDNA 4832428D23 gene 4832428D23Rik 
1439143_at 3.42 RIKEN cDNA A930018M24 gene A930018M24Rik
1422798_at 3.40 contactin associated protein-like 2 Cntnap2 
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1427329_a_at 3.35 immunoglobulin heavy chain 6 (heavy chain of IgM) Igh-6 
1450048_a_at 3.33 isocitrate dehydrogenase 2 (NADP+), mitochondrial Idh2 
1424393_s_at 3.28 alcohol dehydrogenase, iron containing, 1 Adhfe1 
1435370_a_at 3.18 carboxylesterase 3 Ces3 
1434645_at 3.17 RIKEN cDNA C530008M17 gene C530008M17Rik
1416023_at 3.12 fatty acid binding protein 3, muscle and heart Fabp3 
1448300_at 3.12 microsomal glutathione S-transferase 3 Mgst3 
1440335_at 3.11 hypothetical protein LOC100046468 LOC100046468 
1423454_a_at 3.10 sema domain, transmembrane domain (TM) Sema6c 
1444504_at 3.02 dehydrogenase/reductase (SDR family) member 7C Dhrs7c 
a This gene appears two times; b This gene appears three times; c This gene appears four times; d This gene appears 
five times; W, wild type mice; CLW, clenbuterol treated wild type mice. Gray box is underexrpessed genes. 
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Table 3.8 Differential gene expression profiles as affected by the effect of CL under Mstn-pro at 3 
fold change (M vs CLM). 
Probe Set ID 
Fold 
change 
Gene Title Gene Symbol 
1423691_x_at 413.40 keratin 8b Krt8 
1448169_at 144.41 keratin 18 Krt18 
1419139_at 77.47 growth differentiation factor 5 Gdf5 
1440878_at 41.09 runt related transcription factor 1c Runx1 
1422562_at 38.79 Ras-related associated with diabetes Rrad 
1424245_at 32.27 carboxylesterase 2 Ces2 
1458813_at 31.87 sodium channel, voltage-gated, type V, alpha Scn5a 
1420992_at 21.26 ankyrin repeat domain 1 (cardiac muscle)a Ankrd1 
1420438_at 20.69 orosomucoid 2 Orm2 
1434709_at 18.91 neuron-glia-CAM-related cell adhesion moleculea Nrcam 
1435053_s_at 16.27 pleckstrin homology domaina Plekh 
1419394_s_at 12.54 S100 calcium binding protein A8 (calgranulin A) S100a8 
1435176_a_at 12.29 inhibitor of DNA binding 2 Id2 
1421852_at 12.14 potassium channel, subfamily K, member 5 Kcnk5 
1451054_at 11.27 orosomucoid 1 Orm1 
1449519_at 10.97 growth arrest and DNA-damage-inducible 45 alpha Gadd45a 
1448975_s_at 10.72 renin 1 structural Ren1 
1418852_at 9.72 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) Chrna1 
1420444_at 9.18 solute carrier family 22 (organic cation transporter), member 3 Slc22a3 
1451287_s_at 9.15 allograft inflammatory factor 1-likea Aif1l 
1421269_at 9.04 UDP-glucose ceramide glucosyltransferase b Ugcg 
1419391_at 8.47 myogenin Myog 
1428640_at 7.96 heat shock transcription factor 2 binding protein Hsf2bp 
1456953_at 6.78 collagen, type XIX, alpha 1a Col19a1 
1430062_at 6.74 hedgehog interacting protein-like 1 Hhipl1 
1424638_at 6.72 Cyclin-dependent kinase inhibitor 1A(P21)a Cdkn1a 
1442145_at 6.72 ATPase type 13A3a Atp13a3 
1449084_s_at 6.72 SH3 domain proteinb  Sh3 
1440085_at 6.65 ectodysplasin A2 isoform receptor Eda2r 
1426808_at 6.63 lectin, galactose binding, soluble 3 Lgals3 
1427910_at 6.58 cystatin E/M Cst6 
1437669_x_at 6.52 Chemokine (C-C motif) receptor-like 1a Ccrl1 
1423186_at 6.50 T-cell lymphoma invasion and metastasis 2 Tiam2 
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1424831_at 6.29 copine II Cpne2 
1436790_a_at 6.17 SRY-box containing gene 11c Sox11 
1437460_x_at 5.99 Ras and Rab interactor 1a Rin1 
1434754_at 5.84 GTPase activating RANGAP domain-like 4 Garnl4 
1455649_at 5.70 tetratricopeptide repeat domain 9 Ttc9 
1455771_at 5.58 benzodiazapine receptor associated protein 1 Bzrap1 
1422629_s_at 5.58 shroom family member 3 Shroom3 
1421499_a_at 5.14 protein tyrosine phosphatase, non-receptor type 14a Ptpn14 
1423719_at 5.02 similar to long palate LOC632073 
1422573_at 4.95 adenosine monophosphate deaminase 3 Ampd3 
1427838_at 4.77 tubulin, beta 2Aa Tubb2a 
1418572_x_at 4.77 tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 
1455342_at 4.76 prune homolog 2 (Drosophila)a Prune2 
1454674_at 4.69 fasciculation and elongation protein zeta 1 (zygin I) Fez1 
1442827_at 4.54 Toll-like receptor 4 b Tlr4 
1424354_at 4.46 transmembrane protein 140 Tmem140 
1428834_at 4.46 dual specificity phosphatase 4 Dusp4 
1440999_at 4.34 zinc finger protein 697 Zfp697 
1452836_at 4.33 lipin 2a Lpin2 
1426337_a_at 4.24 TEA domain family member 4 Tead4 
1437062_s_at 4.15 phytanoyl-CoA hydroxylase interacting protein-like Phyhipl 
1430086_at 4.14 cholinergic receptor, nicotinic, alpha polypeptide 9 Chrna9 
1416028_a_at 4.06 hematological and neurological expressed sequence 1b Hn1 
1424517_at 3.97 coiled-coil domain containing 12a Ccdc12 
1435184_at 3.95 natriuretic peptide receptor 3 Npr3 
1451006_at 3.95 xanthine dehydrogenase Xdh 
1457157_at 3.94 phospholipase C, eta 1 Plch1 
1419621_at 3.92 ankyrin repeat domain 2 (stretch responsive muscle) Ankrd2 
1428803_at 3.91 acyl-CoA thioesterase 6a Acot6 
1451411_at 3.89 G protein-coupled receptor, family C, group 5, member Ba Gprc5b 
1441055_at 3.89 paralemmin 2 Palm2 
1449852_a_at 3.89 EH-domain containing 4 Ehd4 
1452799_at 3.80 FGGY carbohydrate kinase domain containing Fggy 
1419184_a_at 3.77 four and a half LIM domains Fhl 
1433731_at 3.70 insulin-like growth factor 2 mRNA binding protein 3 Igf2bp3 
1450047_at 3.70 heparan sulfate 6-O-sulfotransferase 2 Hs6st2 
1455149_at 3.64 SH3 domain containing ring finger 1a Sh3rf1 
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1437224_at 3.55 reticulon 4a Rtn4 
1429086_at 3.45 grainyhead-like 2 (Drosophila) Grhl2 
1418840_at 3.43 programmed cell death 4 Pdcd4 
1438795_x_at 3.38 FK506 binding protein 1 Fkbp1 
1460392_a_at 3.38 enhancer of yellow 2 homolog (Drosophila)a Eny2 
1417103_at 3.37 D-dopachrome tautomerase Ddt 
1431281_at 3.37 dysferlin interacting protein 1 Dysfip1 
1416065_a_at 3.36 ankyrin repeat domain 10 b Ankrd10 
1436362_x_at 3.34 CCR4 carbon catabolite repression 4-like (S. cerevisiae) Ccrn4l 
1418158_at 3.32 transformation related protein 63a Trp63 
1420884_at 3.32 sarcolipin Sln 
1452232_at 3.29 UDP-N-acetyl-alpha-D-galactosamine Galnt7 
1456291_x_at 3.29 scleraxisa Scx 
1451757_at 3.27 cDNA sequence BC003883 BC003883 
1448660_at 3.25 Rho GDP dissociation inhibitor (GDI) gamma Arhgdig 
1418853_at 3.22 apolipoprotein N Apon 
1425964_x_at 3.21 heat shock protein 1a Hspb1 
1425543_s_at 3.14 pleckstrin homology domain containing, family A member 5 Plekha5 
1420895_at 3.13 transforming growth factor, beta receptor Ia Tgfbr1 
1448793_a_at 3.10 syndecan 4 a Sdc4 
1435394_s_at 3.10 ras homolog gene family, member C Rhoc 
1426329_s_at 3.09 brain and acute leukemia, cytoplasmic Baalc 
1418648_at 3.08 EGL nine homolog 3 (C. elegans)a Egln3 
1443667_at 3.07 expressed sequence C79407 C79407 
1458067_at 3.06 Family with sequence similarity 179, member B Fam179b 
1433972_at 3.02 calmodulin binding transcription activator 1a Camta1 
1422286_a_at 3.02 TGFB-induced factor homeobox 1 Tgif1 
1421479_at 3.02 zinc finger protein 318c Zfp318 
1416401_at 3.01 CD82 antigen Cd82 
1425546_a_at 5.88 transferrin Trf 
1458635_at 5.71 RIKEN cDNA 4832428D23 gene 4832428D23Rik 
1444504_at 5.42 dehydrogenase/reductase (SDR family) member 7C Dhrs7c 
1425089_at 5.42 potassium voltage gated channel member 4 Kcnc4 
1420575_at 5.36 metallothionein 3 Mt3 
1436644_x_at 5.27 transmembrane protein 25 Tmem25 
1421979_at 5.03 phosphate regulating gene with homologies to endopeptidases on the X chromosome Phex 
1437273_at 4.95 HtrA serine peptidase 4 Htra4 
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1436986_at 4.89 syntrophin, basic 2 Sntb2 
1417481_at 4.68 receptor (calcitonin) activity modifying protein 1 Ramp1 
1439821_at 4.57 Lrp2 binding protein Lrp2bp 
1453904_at 4.52 coiled-coil domain containing 146 Ccdc146 
1439491_at 4.41 leucine rich repeat containing 38 Lrrc38 
1427919_at 4.34 sushi-repeat-containing protein, X-linked 2 Srpx2 
1439426_x_at 4.33 lysozyme 1 Lyz1 
1442251_at 4.19 valosin containing protein (p97) Vcpip1 
1451715_at 4.18 v-maf musculoaponeurotic fibrosarcoma oncogene family Mafb 
1432107_at 4.18 RIKEN cDNA 2310010M20 gene 2310010M20Rik 
1427329_a_at 4.12 immunoglobulin heavy chain 6 (heavy chain of IgM) Igh-6 
1435370_a_at 4.10 carboxylesterase 3 Ces3 
1436359_at 4.10 ret proto-oncogene Ret 
1434911_s_at 4.07 Rho GTPase activating protein 19 Arhgap19 
1416863_at 4.04 abhydrolase domain containing 8 Abhd8 
1439311_at 3.97 RIKEN cDNA B830012L14 gene B830012L14Rik 
1427076_at 3.95 macrophage expressed gene 1 Mpeg1 
1451305_at 3.92 chibby homolog 1 (Drosophila) Cby1 
1442739_at 3.92 cDNA sequence BC031441 BC031441 
1440435_at 3.92 kyphoscoliosis peptidase Ky 
1434210_s_at 3.90 leucine-rich repeats and immunoglobulin-like domains 1 Lrig1 
1450243_a_at 3.81 regulator of calcineurin 2 Rcan2 
1419456_at 3.78 dicarbonyl L-xylulose reductase Dcxr 
1429012_at 3.77 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 Arhgef6 
1450048_a_at 3.76 isocitrate dehydrogenase 2 (NADP+), mitochondrial Idh2 
1448300_at 3.75 microsomal glutathione S-transferase 3 Mgst3 
1418589_a_at 3.74 myeloid leukemia factor 1 Mlf1 
1455224_at 3.68 angiopoietin-like 1 Angptl1 
1438431_at 3.63 ATP-binding cassette, sub-family D (ALD), member 2 Abcd2 
1453851_a_at 3.63 growth arrest and DNA-damage-inducible 45 gamma Gadd45g 
1424393_s_at 3.49 alcohol dehydrogenase, iron containing, 1 Adhfe1 
1455220_at 3.45 frequently rearranged in advanced T-cell lymphomas 2 Frat2 
1420346_at 3.42 ankyrin repeat and SOCS box-containing 12 Asb12 
1416318_at 3.42 serine (or cysteine) peptidase inhibitor, clade B, member 1a Serpinb1a 
1456397_at 3.38 cadherin 4 Cdh4 
1437915_at 3.36 target of myb1-like 2 (chicken) Tom1l2 
1438396_at 3.35 oculocerebrorenal syndrome of Lowe Ocrl 
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1451989_a_at 3.35 microtubule-associated protein, RP/EB family, member 2 Mapre2 
1451322_at 3.35 carboxymethylenebutenolidase-like (Pseudomonas) Cmbl 
1451500_at 3.34 Usher syndrome 1C binding protein 1 Ushbp1 
1426981_at 3.29 proprotein convertase subtilisin/kexin type 6 Pcsk6 
1428025_s_at 3.26 phosphatidylinositol transfer protein, cytoplasmic 1 Pitpnc1 
1429474_at 3.23 prostaglandin reductase 2 Ptgr2 
1421878_at 3.21 mitogen-activated protein kinase 9 Mapk9 
1452766_at 3.17 tubulin polymerization promoting protein Tppp 
1452474_a_at 3.16 ADP-ribosyltransferase 3 Art3 
1436763_a_at 3.16 Kruppel-like factor 9 Klf9 
1422605_at 3.14 protein phosphatase 1, regulatory (inhibitor) subunit 1A Ppp1r1a 
1439836_at 3.13 ankyrin repeat and SOCS box-containing 15 Asb15 
1427053_at 3.11 ABI gene family, member 3 (NESH) binding protein Abi3bp 
1449547_at 3.09 ankyrin repeat and SOCS box-containing 14 Asb14 
1449078_at 3.08 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 St3gal6 
1422798_at 3.06 contactin associated protein-like 2 Cntnap2 
1426208_x_at 3.06 pleiomorphic adenoma gene-like 1 Plagl1 
1451991_at 3.00 Eph receptor A7 Epha7 
a This gene appears two times; b This gene appears three times; c This gene appears four times; M, Mstn-pro mice; CLM, clenbuterol treated 
Mstn-pro mice. 
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Table 3.9 The expression of overlapping genes between the effect of genotype and CL (W vs M VS 
W vs CLW) at 1.5 fold change. 
Probe Set ID Gene Symbol Gene Title 
1436520_at Ahnak2 AHNAK nucleoprotein 2 
1424176_a_at Anxa4 annexin A4 
1451780_at Blnk B-cell linker 
1424529_s_at Cgref1 cell growth regulator with EF hand domain 1 
1418852_at Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 
1421698_a_at Col19a1 collagen, type XIX, alpha 1 
1422186_s_at Cyb5r3 cytochrome b5 reductase 3 
1449258_at D11Wsu99e DNA segment, Chr 11, Wayne State University 99, expressed 
1426215_at Ddc dopa decarboxylase 
1423569_at Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
1448239_at Hmox1 heme oxygenase (decycling) 1 
1438988_x_at Hn1 hematological and neurological expressed sequence 1 
1441259_s_at Ift122 intraflagellar transport 122 homolog (Chlamydomonas) 
1455266_at Kif5c kinesin family member 5C 
1426808_at Lgals3 lectin, galactose binding, soluble 3 
1448883_at Lgmn Legumain 
1455679_at Obfc2a oligonucleotide/oligosaccharide-binding fold containing 2A 
1450070_s_at Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 
1423423_at Pdia3 protein disulfide isomerase associated 3 
1451064_a_at Psat1 phosphoserine aminotransferase 1 
1439610_at Rab27b RAB27b, member RAS oncogene family 
1451201_s_at Rnh1 ribonuclease/angiogenin inhibitor 1 
1437224_at Rtn4 reticulon 4 
1422864_at Runx1 runt related transcription factor 1 
1452717_at Slc25a24 solute carrier family 25, member 24 
1420884_at Sln Sarcolipin 
1417647_at Snx5 sorting nexin 5 
1434442_at Stbd1 starch binding domain 1 
1418726_a_at Tnnt2 troponin T2, cardiac 
1438948_x_at Tspo translocator protein 
1436833_x_at Ttll1 tubulin tyrosine ligase-like 1 
1427347_s_at Tubb2a tubulin, beta 2A 
1416431_at Tubb6 tubulin, beta 6 
1451105_at Vash2 vasohibin 2 
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1437906_x_at Txnl1 thioredoxin-like 1 
1440343_at Rps6ka5 ribosomal protein S6 kinase, polypeptide 5 
1460388_at Acot6 acyl-CoA thioesterase 6 
A total 40 genes was identified between the effects of genotype and CL (36 overexpressed genes and 4 
underexpressed genes). Among the 40 genes, 3 genes were ESTs resulting in 37 known gene identified (34 
overexpressed genes and 3 underexpressed genes). W, wild type mice; M, Mstn-pro mice; CLM, clenbuterol treated 
Mstn-pro mice. Gray box is underexpressed genes. 
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Table 3.10 Comparison of gene expression changes measured by microarray analysis and RT-PCR. 
Threshold cycle of real-time PCR1 Probe set ID 
(Gene symbol) 
Ratio CT/CLT 
by array analysis Control group Comparison group 
Group 
1420575_at (Mt3) 5.75 28.3 ± 1.24 18.9 ± 0.17*** I 
1418726_a_at (Tnnt2) 3.54 23.4 ± 0.61 16.9 ± 0.26*** I 
1424542_at (S100a4) 2.9 23.5 ± 0.87 17.9 ± 0.36*** I 
1448591_at (Ctss) 2.3 23.6 ± 0.80 15.6 ± 0.36*** I 
1424529_s_at (Cgref1) 1.69 23.2 ± 0.63 18.9 ± 0.16*** I 
1418625_s_at (Gapdh) - 9.9 ± 0.28 9.7 ± 0.16 I 
1423691_x_at (Krt8) 390.33 27.4 ± 0.46 14.9 ± 0.22*** II 
1422562_at (Rrad) 54.82 21.4 ± 0.55 14.0 ± 0.34*** II 
1419139_at (Gdf5) 50.83 25.0 ± 0.55 17.8 ± 0.21*** II 
1419391_at (Myog) 8.63 24.1 ± 0.58 17.2 ± 0.39*** II 
1450650_at (Myo10) 3.34 23.5 ± 0.54 19.7 ± 0.12*** II 
1418625_s_at (Gapdh) - 10.7 ± 0.37 10.4 ± 0.38 II 
1423691_x_at (Krt8) 413.4 27.4 ± 0.43 14.0 ± 0.42*** III 
1440878_at (Runx1) 41.29 24.0 ± 0.43 16.9 ± 0.40*** III 
1420438_at (Orm2) 20.69 19.4 ± 0.26 12.4 ± 0.40*** III 
1419391_at (Myog) 8.47 21.4 ± 0.15 15.4 ± 0.46*** III 
1427838_at (Tubb2a) 4.77 22.1 ± 0.22 19.5 ± 0.24*** III 
1418625_s_at (Gapdh) - 9.1 ± 0.06 9.6 ± 0.11 III 
1427838_at (Tubb2a) 4.38 22.4 ± 0.17 19.5 ± 0.24*** IV 
1452455_at (Myof) 2.15 21.4 ± 0.15 16.7 ± 0.24*** IV 
1449363_at (Atf3) 2.13 20.1 ± 0.18 17.1 ± 0.19*** IV 
1441055_at (Palm2) 1.66 23.5 ± 0.87 18.0 ± 0.16*** IV 
1424529_s_at (Cgref1) 1.5 25.5 ± 0.32 22.2 ± 0.21*** IV 
1418625_s_at (Gapdh) - 9.6 ± 0.06 9.5 ± 0.16 IV 
1 Threshold cycle (Ct) of each sample of the wild type mice (W, n=18), Mstn-pro mice (M, n=18), CL treated wild 
type mice (CLW, n=18) and CL treated Mstn-pro mice (CLM, n=12) was obtained and analyzed by Prism5 
software (Grapad, San Diego, CA). ***, P<0.001. I, W vs M; II, W vs CLW; III, M vs CLM; IV, CLW vs CLM. 
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Table 3.11 Differentially expressed gene clusters by the effect of genotype based on Gene Ontology 
(GO) biological process terms. 
W vs M 
GO Biological Process Terms Number of Genes p-Value 
Overexpression  
Antigen processing and presentation of exogenous antigen or peptide 12 0.00037 
Neuron development 14 0.00076 
Cell differentiation 24 0.0011 
Regulation of cell activation 5 0.0012 
System development 18 0.0016 
Lymphocyte activation 6 0.0029 
Organ development 20 0.0039 
Leukocyte activation 6 0.0041 
Immune response 14 0.01 
Regulation of multicellular organismal process 6 0.013 
Extracellular structure organization and biogenesis 4 0.014 
Dendrite development 3 0.014 
Transport 19 0.04 
Muscle fiber development 3 0.041 
Cell death 8 0.045 
Cell cycle  12 0.053 
Mononuclear cell proliferation 3 0.056 
Organic acid metabolic process 6 0.08 
Other categories2 41 - 
Underexpression  
Cell redox homeostasis 2 0.03 
Lipid metabolic process 3 0.049 
CLW vs CLM 
GO Biological Process Terms Number of Genes p-Value 
Overexpression  
transcription, DNA-dependent 18 0.0026 
regulation of transcription 18 0.004 
regulation of gene expression 18 0.0078 
regulation of cellular process 24 0.0081 
regulation of cellular metabolic process 18 0.011 
regulation of metabolic process 18 0.016 
nucleic acid metabolic process 21 0.027 
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one-carbon compound metabolic process 3 0.05 
Underexpression  
protein localization 12 0.0091 
post-embryonic hemopoiesis 2 0.012 
cellular component assembly 8 0.017 
Transport 23 0.057 
organic acid metabolic process 7 0.084 
cell-substrate adhesion 3 0.084 
cell maturation 3 0.094 
lipid metabolic process 8 0.099 
W vs M: A total 108 genes identified as differentially over and underexpressed genes by DAVID bioinformatics 
software (Dennis et al., 2003) to functionally classify the genes based on Gene Ontology biological process terms. 
Count and EASE thresholds were set at 2 and 0.1, respectively. For overexpressed 48 genes were unclassified. For 
underexpressed 14 genes were unclassified. 2The other categories include negative T cell selection, inflammatory 
response to antigenic stimulus, regulation of programmed cell death, thymic T cell selection, cell wall metabolic 
process, external encapsulating structure organization and biogenesis, anatomical structure morphogenesis, 
negative regulation of biological process and cellular structure morphogenesis. CLW vs CLM: A total 96 genes 
identified as differentially over and underexpressed genes by DAVID bioinformatics software (Dennis et al., 2003) 
to functionally classify the genes based on Gene Ontology biological process terms. Count and EASE thresholds 
were set at 2 and 0.1, respectively. For overexpressed 65 genes were unclassified. For underexpressed 94 genes 
were unclassified. W, wild type mice; M, Mstn-pro mice; CLW, clenbuterol treated wild type mice; CLM, 
clenbuterol treated Mstn-pro mice. 
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Table 3.12 Differentially expressed gene clusters by the effect of CL based on Gene Ontology (GO) 
biological process terms.  
W vs CLW 
GO Biological Process Terms Number of Genes p-Value 
Overexpression  
Transport 222 0.0000036 
Cellular localization 106 0.000024 
Cellular metabolic process 403 0.000043 
Protein metabolic process 182 0.000058 
Regulation of biological process 104 0.00012 
Cell proliferation 26 0.00048 
Protein localization 87 0.00049 
Developmental process 107 0.0017 
Muscle fiber development 9 0.002 
Metabolic process 275 0.0023 
Cell cycle 88 0.005 
Cell death 37 0.0064 
Cell differentiation 91 0.0069 
Cell redox homeostasis 7 0.0083 
Cellular component organization and biogenesis  110 0.011 
Signal transduction 25 0.011 
Ribonucleoprotein complex biogenesis and assembly 15 0.012 
Embryonic development  38 0.014 
Cell growth 11 0.014 
Organ development 156 0.017 
Phosphorus metabolic process 42 0.019 
Cell maturation 8 0.021 
Anatomical structure development and formation  63 0.034 
Neurogenesis 29 0.034 
Homeostatic process 20 0.035 
Translational initiation 6 0.041 
Cell migration  6 0.082 
Regulation of locomotion 6 0.098 
Other categories1 103 - 
Underexpression  
Regulation of heart contraction 5 0.027 
Menstrual cycle phase 4 0.078 
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Menstrual cycle process 4 0.083 
Reproductive structure development 5 0.098 
Electron transport 19 0.096 
M vs CLM 
GO Biological Process Terms Number of Genes p-Value 
Overexpressed  
Cellular metabolic process 427 0.0000096 
Protein metabolic process 181 0.000033 
Transport 188 0.00024 
Cell differentiation 84 0.00086 
Metabolic process 258 0.0011 
Developmental process 103 0.0019 
Signal transduction 27 0.0028 
Biological process 99 0.0035 
Cellular localization 87 0.0076 
Protein localization 75 0.0078 
Cell cycle 50 0.0096 
Ribonucleoprotein complex biogenesis and assembly 15 0.011 
Cell death 57 0.017 
Muscle fiber development 7 0.026 
Neurogenesis 40 0.027 
Anatomical structure development and formation 63 0.031 
Organ development 119 0.044 
Angiogenesis 10 0.057 
Cell maturation 7 0.058 
Cellular component organization and biogenesis 62 0.082 
Phosphorus metabolic process 38 0.085 
Homeostatic process 18 0.099 
Other categories2 185 - 
Underexpressed  
lipid transport 13 0.00045 
electron transport 32 0.007 
negative regulation of growth 6 0.025 
regulation of binding 5 0.035 
negative regulation of cellular process 51 0.069 
regulation of catalytic activity 22 0.08 
Opsonization 2 0.082 
 124
negative regulation of biological process 53 0.09 
hemopoietic or lymphoid organ development 17 0.09 
W vs CLW: A total 1241 genes identified as differentially over and uncerexpressed genes by DAVID bioinformatics 
software (Dennis et al., 2003) to functionally classify the genes based on Gene Ontology biological process terms. 
Count and EASE thresholds were set at 2 and 0.1, respectively. 280 overexpressed genes were unclassified. 309 
underexpressed genes were unclassified. 1other categories include regulation of catalytic activity, macromolecule 
catabolic process, response to tumor cell, lymphocyte homeostasis, macromolecule biosynthetic process, 
extracellular structure organization and biogenesis, formation of primary germ layer and cytokinesis. M vs CLM: A 
total 1522 genes identified as differentially over and underexpressed genes by DAVID bioinformatics software 
(Dennis et al., 2003) to functionally classify the genes based on Gene Ontology biological process terms. Count 
and EASE thresholds were set at 2 and 0.1, respectively. 383 overexpressed genes were unclassified. 384 
underexpressed genes were unclassified. 2 other categories include macromolecule biosynthetic process, tissue 
development, rRNA processing and nucleic acid metabolic process. W, wild type mice; M, Mstn-pro mice; CLW, 
clenbuterol treated wild type mice; CLM, clenbuterol treated Mstn-pro mice. 
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Table 3.13 Differentially expressed gene clusters by the effect of genotype and CL (W vs M VS W vs 
CLW) based on Gene Ontology (GO) biological process terms. 
GO Biological Process Terms Number of Genes p-Value 
Overexpression  
system development 11 0.0043 
response to nutrient 3 0.01 
organ development 9 0.014 
microtubule-based movement 3 0.017 
regulation of multicellular organismal process 6 0.018 
regulation of anti-apoptosis 2 0.026 
response to extracellular stimulus 3 0.029 
cell differentiation 8 0.032 
cell development 5 0.032 
positive regulation of angiogenesis 2 0.034 
tissue development 5 0.037 
regulation of anatomical structure morphogenesis 3 0.054 
cellular macromolecular complex assembly 3 0.07 
protein complex assembly 3 0.076 
cellular macromolecular complex subunit organization 3 0.086 
regulation of angiogenesis 2 0.087 
synapse organization 2 0.094 
A total 40 genes identified as differentially over and underexpressed genes by DAVID bioinformatics software 
(Dennis et al., 2003) to functionally classify the genes based on Gene Ontology biological process terms. Count 
and EASE thresholds were set at 2 and 0.1, respectively.  19 overexpressed genes were unclassified. W, wild type 
mice; M, Mstn-pro mice; CLW, clenbuterol treated wild type mice. 
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Table 3.14 Differentially expressed gene clusters by the effect of genotype (W vs M) based on 
skeletal muscle growth at 1.5 fold change.  
Ontology/Gene symbol Gene name Fold change 
Carboxylic acid and amino acid metabolism 
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 2.58 
Cd74 CD74 antigen  2.34 
Arrb2 arrestin, beta 2 2.06 
Alox5ap arachidonate 5-lipoxygenase activating protein 1.92 
Psat1 phosphoserine aminotransferase 1 1.66 
Ddc dopa decarboxylase 1.60 
Protein metabolic process 
Tubb6 Tubulin, beta 6 3.54 
Serpinb1a serine (or cysteine) peptidase inhibitor, clade B, member 1a 2.94 
Cd74 CD74 antigen  2.34 
Ctss cathepsin S 2.30 
Lgmn legumain 2.15 
Arrb2 arrestin, beta 2 2.06 
Tubb2a tubulin, beta 2A 1.87 
Ptprc protein tyrosine phosphatase, receptor type, C 1.79 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1.63 
Rab40b Rab40b, member RAS oncogene family 1.60 
Ttll1 tubulin tyrosine ligase-like 1 1.54 
Ctsz cathepsin Z 1.51 
Transcription 
Runx1 runt related transcription factor 1 2.17 
Dnmt1 DNA methyltransferase (cytosine-5) 1 1.62 
Srebf1 sterol regulatory element binding transcription factor 1 -1.51 
Cell proliferation and cell cycle 
Tubb6 Tubulin, beta 6 3.54 
S100a4 S100 calcium binding protein A4 2.90 
Igf2 insulin-like growth factor 2 2.05 
Fcgr2b Fc receptor, IgG, low affinity IIb 1.93 
Ptprc protein tyrosine phosphatase, receptor type, C 1.79 
Cgref1 cell growth regulator with EF hand domain 1 1.69 
Smc4 structural maintenance of chromosomes 4 1.61 
Grn granulin 1.59 
Cell differentiation 
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Mt3 metallothionein 3 5.75 
Tnnt2 troponin T2, cardiac 3.54 
Lyz1 lysozyme 1 2.92 
H2-Aa histocompatibility 2, class II antigen A, alpha 2.83 
Lyz2 lysozyme 2 2.47 
Kif5c kinesin family member 5C 2.19 
Runx1 runt related transcription factor 1 2.17 
Rtn4 reticulon 4 2.00 
Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 1.90 
Ptprc protein tyrosine phosphatase, receptor type, C 1.79 
Col19a1 collagen, type XIX, alpha 1 1.78 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1.77 
Naip5 NLR family, apoptosis inhibitory protein 5 1.76 
Pdia3 protein disulfide isomerase associated 3 1.60 
Ndrg4 N-myc downstream regulated gene 4 1.55 
Mal myelin and lymphocyte protein, T-cell differentiation protein -1.54 
Skeletal muscle development 
Tnnt2 troponin T2, cardiac 3.54 
Col19a1 collagen, type XIX, alpha 1 1.78 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1.77 
Signal transduction 
Arrb2 arrestin, beta 2 2.06 
Igf2 insulin-like growth factor 2 2.05 
Dclk1 doublecortin-like kinase 1 1.91 
Ptprc protein tyrosine phosphatase, receptor type, C 1.79 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1.77 
Emr1 EGF-like module containing, hormone receptor-like sequence 1 1.73 
Hmox1 heme oxygenase 1 1.73 
Rab40b Rab40b, member RAS oncogene family 1.60 
Csf1r colony stimulating factor 1 receptor 1.59 
Rab27b RAB27b, member RAS oncogene family 1.53 
A total 108 genes identified as differentially expressed genes were uploaded to DAVID bioinformatics software 
(Dennis et al., 2003) to functionally classify the genes based on skeletal muscle growth. W, wild type mice; M, 
Mstn-pro mice. 
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Table 3.15 Differentially expressed gene clusters by the effect of genotype in CL (CLW vs CLM) 
based on skeletal muscle growth.  
Ontology/Gene symbol Gene name Fold change 
Carboxylic acid metabolic process  
Atf3 activating transcription factor 3 2.13 
Shmt2 serine hydroxymethyltransferase 2 (mitochondrial) 1.91 
Ddt D-dopachrome tautomerase 1.85 
Acaa2 acetyl-Coenzyme A acyltransferase 2  -1.75 
Plp1 proteolipid protein (myelin) 1 -1.64 
Slc37a4 solute carrier family 37 (glucose-6-phosphate transporter), member 4 -1.60 
Protein metabolic process 
Tubb2a tubulin, beta 2A 4.38 
Tubb2b tubulin, beta 2B 2.21 
Hspa4l heat shock protein 4 like 2.01 
Rpl41 ribosomal protein L41 1.73 
Dyn3 dynamin 3 1.70 
Itga2b integrin alpha 2b 1.61 
Ttll5 tubulin tyrosine ligase-like family, member 5 1.55 
Prkg2 protein kinase, cGMP-dependent, type II 1.54 
Erf Ets2 repressor factor 1.50 
Ret ret proto-oncogene -2.58 
Gsn gelsolin -2.03 
Lamc1 laminin, gamma 1 -1.70 
Colec12 collectin sub-family member 12 -1.69 
Prcp prolylcarboxypeptidase (angiotensinase C) -1.62 
Mme membrane metallo endopeptidase -1.59 
Phkg1 phosphorylase kinase gamma 1 -1.57 
Transcription 
Atf3 activating transcription factor 3 2.13 
Fubp1 far upstream element (FUSE) binding protein 1 2.07 
Zfp697 zinc finger protein 697 1.90 
Elk3 ELK3, member of ETS oncogene family 1.72 
Meox1 mesenchyme homeobox 1 1.59 
Sbcg11 sry-box containing gene 11 1.59 
Erf Ets2 repressor factor 1.50 
Gtf2a1 general transcription factor II A, 1 -1.84 
Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog -1.70 
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Txnip thioredoxin interacting protein -1.65 
Ikzf2 IKAROS family zinc finger 2 -1.58 
Lrrfip1 leucine rich repeat (in FLII) interacting protein 1 -1.55 
Cell proliferation and cell cycle Cell cycle 
Igbp1 Immunoglobulin (CD79A) binding protein 1 3.01 
Wnt5a wingless-related MMTV integration site 5A 1.89 
Gng3 guanine nucleotide binding protein (G protein), gamma 3 1.75 
Snx4 sorting nexin 4 1.75 
Rap2b RAP2B, member of RAS oncogene family 1.74 
Mras muscle and microspikes RAS 1.64 
Itga2b integrin alpha 2b 1.61 
Cgref1 cell growth regulator with EF hand domain 1 1.50 
Ret ret proto-oncogene -2.58 
Calm2 calmodulin 2 -2.06 
Cxcr7 chemokine (C-X-C motif) receptor 7 -1.75 
Grb14 growth factor receptor bound protein 14 -1.73 
Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog -1.70 
Colec12 collectin sub-family member 12 -1.69 
Cd47 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) -1.65 
Txnip thioredoxin interacting protein -1.65 
Plp1 proteolipid protein (myelin) 1 -1.64 
Atrnl1 attractin like 1 -1.56 
Stac3 SH3 and cysteine rich domain 3 -1.56 
Cell differentiation 
Cbf core-binding factor, runt domain, alpha subunit 2 1.94 
Ret ret proto-oncogene -2.58 
Plp1 proteolipid protein (myelin) 1 -1.64 
Txnip thioredoxin interacting protein -1.65 
Slc37a4 solute carrier family 37 (glucose-6-phosphate transporter), member 4 -1.60 
Signal transduction 
Igbp1 Immunoglobulin (CD79A) binding protein 1 3.01 
Wnt5a wingless-related MMTV integration site 5A 1.89 
Gng3 guanine nucleotide binding protein (G protein), gamma 3 1.75 
Snx4 sorting nexin 4 1.75 
Rap2b RAP2B, member of RAS oncogene family 1.74 
Mras muscle and microspikes RAS 1.64 
Itga2b integrin alpha 2b 1.61 
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Ret ret proto-oncogene -2.58 
Calm2 calmodulin 2 -2.06 
Cxcr7 chemokine (C-X-C motif) receptor 7 -1.75 
Grb14 growth factor receptor bound protein 14 -1.73 
Colec12 collectin sub-family member 12 -1.69 
Cd47 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) -1.65 
Atrnl1 attractin like 1 -1.56 
Stac3 SH3 and cysteine rich domain 3 -1.56 
A total 96 genes identified as differentially expressed genes were uploaded to DAVID bioinformatics software 
(Dennis et al., 2003) to functionally classify the genes based on skeletal muscle growth. CLW, clenbuterol treated 
wild type mice; CLM, clenbuterol treated Mstn-pro mice. 
 131
Table 3.16 Differentially expressed gene clusters by the effect of CL (W vs CLW) based on skeletal 
muscle growth at 1.5 fold change. 
Ontology/Gene symbol Gene name Fold change 
Carboxylic acid and amino acid metabolism 
Acot10 acyl-CoA thioesterase 10 2.20 
Egf epidermal growth factor 1.69 
Prkce protein kinase C, epsilon 1.64 
Gars glycyl-tRNA synthetase 1.59 
Vars valyl-tRNA synthetase 1.57 
Pdzd2 PDZ domain containing 2 -1.74 
Protein metabolic process 
Krt8 keratin 8 390.33 
Tubb tubulin 6.53 
Ptpn14 protein tyrosine phosphatase, non-receptor type 14 4.10 
Tlr4 toll-like receptor 4 3.48 
Tgfbr1 transforming growth factor, beta receptor I 3.02 
Musk muscle, skeletal, receptor tyrosine kinase 2.46 
Map3k14 mitogen-activated protein kinase kinase kinase 14 2.41 
Ppap2a phosphatidic acid phosphatase type 2A 2.17 
Rbm3 RNA binding motif protein 3 2.13 
Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 2.00 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1.97 
Prkar1a protein kinase, cAMP dependent regulatory, type I, alpha 1.85 
Mapk1 mitogen-activated protein kinase 1 1.84 
Map1lc3a microtubule-associated protein 1 light chain 3 alpha 1.79 
Egf epidermal growth factor 1.69 
Cdk7 cyclin-dependent kinase 7 (homolog of Xenopus MO15 cdk-activating kinase) 1.67 
Prkce protein kinase C, epsilon 1.64 
Mknk2 MAP kinase-interacting serine/threonine kinase 2 1.63 
Mapk6 mitogen-activated protein kinase 6 1.62 
Atf6 activating transcription factor 6 1.58 
Gtpbp4 GTP binding protein 4 1.54 
Arf6 ADP-ribosylation factor 6 1.53 
Ptprd protein tyrosine phosphatase, receptor type, D 1.50 
Gadd45g growth arrest and DNA-damage-inducible 45 gamma -2.68 
Acvr2b activin receptor IIB -2.38 
Pparr peroxisome proliferative activated receptor-γ -2.38
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Cdc2l6 cell division cycle 2-like 6 (CDK8-like) -2.19 
Camk2a calcium/calmodulin-dependent protein kinase II alpha -2.18 
Socs2 suppressor of cytokine signaling 2 -2.15 
Cabc1 chaperone, ABC1 activity of bc1 complex like (S. pombe) -2.15 
Ppm1k protein phosphatase 1K (PP2C domain containing) -1.94 
Cul3 cullin 3 -1.76 
Capn3 calpain 3 -1.74 
Inhbb inhibin beta-B -1.72 
Ppm1l protein phosphatase 1 (formerly 2C)-like -1.72 
Apba3 amyloid beta (A4) precursor protein-binding, family A, member 3 -1.70 
Ppp1cb protein phosphatase 1, catalytic subunit, beta isoform -1.70 
Mylk2 myosin, light polypeptide kinase 2, skeletal muscle -1.68 
Acvr1b activin A receptor, type 1B -1.66 
Smad6 MAD homolog 6 (Drosophila) -1.63 
Fkbp FK506 binding protein -1.63 
Crebbp CREB binding protein -1.61 
Map3k5 mitogen-activated protein kinase kinase kinase 5 -1.61 
Ctsc cathepsin C -1.59 
Ube2n ubiquitin-conjugating enzyme E2N -1.59 
Prss23 protease, serine, 23 -1.57 
Kcmf1 potassium channel modulatory factor 1 -1.56 
Smad1 MAD homolog 1 (Drosophila) -1.55 
Pten PTEN  -1.54 
Ubr2 ubiquitin protein ligase E3 component n-recognin 2 -1.53 
Ribosome biogenesis and assembly (Translation) 
Runx1 runt related transcription factor 1 23.76 
Trp63 transformation related protein 63 4.50 
Myt1l myelin transcription factor 1-like 3.78 
Gm6607 40S ribosomal protein S20 pseudogene 2.47 
Rb1 retinoblastoma 1 2.47 
Rpl3 ribosomal protein L3 2.39 
Rpl13a ribosomal protein L13A 2.19 
Scx Scleraxis 2.07 
E2f4 E2F transcription factor 4 1.97 
Etf1 eukaryotic translation termination factor 1 1.95 
Eif4e eukaryotic translation initiation factor 4E 1.86 
Eif4a1 eukaryotic translation initiation factor 4A1 1.86 
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Rpl23 ribosomal protein L23 1.81 
Eif6 eukaryotic translation initiation factor 6 1.77 
Cdk7 cyclin-dependent kinase 7 (homolog of Xenopus MO15 cdk-activating kinase) 1.67 
Eif1a eukaryotic translation initiation factor 1A 1.64 
Eef1a1 eukaryotic translation elongation factor 1 alpha 1 1.63 
Eif2b2 eukaryotic translation initiation factor 2B, subunit 2 beta 1.54 
Trp53 transformation related protein 53 1.54 
Esr1 estrogen receptor 1 (alpha) -1.73 
Crebbp CREB binding protein -1.61 
Bcor BCL6 interacting corepressor -1.58 
Transcription 
Myog myogenin 8.63 
Sox11 SRY-box containing gene 11   7.12 
Trp63 transformation related protein 63    4.50 
Tead4 TEA domain family member 4 3.99 
Myt1l myelin transcription factor 1-like 3.78 
Myod1 myogenic differentiation 1 2.73 
Rb1 retinoblastoma 1 2.47 
Hdac4 histone deacetylase 4 2.44 
Junb Jun-B oncogene 2.26 
Scx scleraxis 2.08 
Eaf1 ELL associated factor 1 1.97 
E2f4 E2F transcription factor 4 1.97 
Mef2a myocyte enhancer factor 2A 1.95 
Baz1a bromodomain adjacent to zinc finger domain 1A 1.93 
Bzw1 basic leucine zipper and W2 domains 1 1.92 
Myc myelocytomatosis oncogene 1.90 
Crem cAMP responsive element modulator 1.79 
Lbh limb-bud and heart 1.73 
Xbp1 X-box binding protein 1 1.73 
Ndn necdin 1.72 
Gtf2f2 general transcription factor IIF, polypeptide 2 1.71 
Jun Jun oncogene 1.69 
Cdk7 cyclin-dependent kinase 7 (homolog of Xenopus MO15 cdk-activating kinase) 1.67 
Pcgf6 polycomb group ring finger 6 1.64 
Fubp1 far upstream element (FUSE) binding protein 1 1.64 
Atf6 activating transcription factor 6 1.58 
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Runx2 runt related transcription factor 2 1.55 
Trp53 transformation related protein 53 1.54 
Trp53bp1 transformation related protein 53 binding protein 1 1.53 
Tceal1 transcription elongation factor A (SII)-like 1 1.52 
Foxo forkhead box -1.99
Lbx1 ladybird homeobox homolog 1 (Drosophila) -1.82 
Hdac5 histone deacetylase 5 -1.80 
Esr1 estrogen receptor 1 (alpha) -1.73 
Trim24 tripartite motif-containing 24 -1.65 
Dnmt3a DNA methyltransferase 3A -1.65 
Nfia nuclear factor I/A -1.64 
Mxi1 Max interacting protein 1 -1.64 
Smad6 MAD homolog 6 (Drosophila) -1.63 
Jarid2 jumonji, AT rich interactive domain 2 -1.59 
Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 -1.58 
Bcor BCL6 interacting corepressor -1.58 
Smad1 MAD homolog 1 (Drosophila) -1.55 
Rcor3 REST corepressor 3 -1.55 
Rere arginine glutamic acid dipeptide (RE) repeats -1.54 
Ncor1 nuclear receptor co-repressor 1 -1.54 
Gatad2b GATA zinc finger domain containing 2B -1.53 
Rxra retinoid X receptor alpha -1.51 
Mitf microphthalmia-associated transcription factor -1.50 
Cell proliferation and cell cycle 
Tubb6 tubulin, beta 6 6.53 
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 5.19
Trp63 transformation related protein 63 4.50 
Plekh pleckstrin homology domain  2.64 
Rb1 retinoblastoma 1 2.47 
Prc1 protein regulator of cytokinesis 1 2.33 
Ppap2a phosphatidic acid phosphatase type 2A 2.17 
Ckap2 cytoskeleton associated protein 2 2.09 
Cgref1 cell growth regulator with EF hand domain 1 2.06 
E2f4 E2F transcription factor 4 1.97 
Col8a1 collagen, type VIII, alpha 1 1.90 
Prkar1a protein kinase, cAMP dependent regulatory, type I, alpha 1.85 
Mapk1 mitogen-activated protein kinase 1 1.84 
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Egf epidermal growth factor 1.69 
Cdk7 cyclin-dependent kinase 7 (homolog of Xenopus MO15 cdk-activating kinase) 1.67 
Mapk6 mitogen-activated protein kinase 6 1.62 
Runx2 runt related transcription factor 2 1.55 
Il6st interleukin 6 signal transducer 1.55 
Trp53 transformation related protein 53 1.54 
Gtpbp4 GTP binding protein 4 1.54 
Shb src homology 2 domain-containing transforming protein B 1.51 
Mlf1 myeloid leukemia factor 1 -2.76 
Pttg1 pituitary tumor-transforming gene 1 -2.70 
Gadd45g growth arrest and DNA-damage-inducible 45 gamma -2.68 
Camk2a calcium/calmodulin-dependent protein kinase II alpha -2.18 
Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog -2.11 
Foxo forkhead box -1.99
Cul3 cullin 3 -1.76 
Acvr1b activin A receptor, type 1B -1.66 
Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 -1.58 
Smad1 MAD homolog 1 (Drosophila) -1.55 
Ubr2 ubiquitin protein ligase E3 component n-recognin 2 -1.53 
Cell differentiation 
Krt8 keratin 8 390.33 
Krt18 keratin 18 187.70 
Gdf5 growth differentiation factor 5 50.83 
Runx1 runt related transcription factor 1 23.76 
Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 15.79 
Col19a1 collagen, type XIX, alpha 1 9.43 
Myog myogenin 8.63 
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 5.19
Trp63 transformation related protein 63 4.50 
Tgfbr1 transforming growth factor, beta receptor I 3.02 
Myod1 myogenic differentiation 1 2.73 
Casp3 Caspase 3 2.49 
Rb1 retinoblastoma 1 2.47 
Musk muscle, skeletal, receptor tyrosine kinase 2.46 
Myf6 myogenic factor 6 2.29 
Ckap2 cytoskeleton associated protein 2 2.09 
Mapt microtubule-associated protein tau 2.04 
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Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1.97 
Mef2a myocyte enhancer factor 2A 1.95 
Tnnt2 troponin T2, cardiac 1.92 
Mapk1 mitogen-activated protein kinase 1 1.84 
Stk17b serine/threonine kinase 17b (apoptosis-inducing) 1.74 
Akt1 thymoma viral proto-oncogene 1 1.59 
Runx2 runt related transcription factor 2 1.55 
Trp53 transformation related protein 53 1.54 
Eif2b2 eukaryotic translation initiation factor 2B, subunit 2 beta 1.54 
Mlf1 myeloid leukemia factor 1 -2.76 
Tiam1 T-cell lymphoma invasion and metastasis 1 -2.70 
Gadd45g growth arrest and DNA-damage-inducible 45 -2.68 
Cdh4 cadherin 4 -2.67 
Prkg1 protein kinase, cGMP-dependent, type I -2.47 
Pparr peroxisome proliferative activated receptor-γ -2.38
Socs2 suppressor of cytokine signaling 2 -2.15 
Foxo forkhead box  -1.99
Myl2 Myosin, light polypeptide 2, regulatory, cardiac, slow -1.78 
Capn3 Calpain 3 -1.74 
Plp1 proteolipid protein (myelin) 1 -1.69 
Skeletal muscle development 
Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 15.79 
Col19a1 collagen, type XIX, alpha 1 9.43 
Myog myogenin 8.63 
Myod1 myogenic differentiation 1 2.73 
Musk muscle, skeletal, receptor tyrosine kinase 2.46 
Myf6 myogenic factor 6 2.29 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1.97 
Tnnt2 troponin T2, cardiac 1.92 
Mubl1 muscleblind-like 1 (drosophila) -1.83 
Myl2 myosin, light polypeptide 2, regulatory, cardiac, slow -1.78 
Capn3 calpain 3 -1.74 
Signal transduction 
Krt8 keratin 8 390.33 
Krt18 keratin 18 187.70 
Rrad Ras-related associated with diabetes 54.82 
Gdf5 growth differentiation factor 5 50.83 
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Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 5.19
Trp63 transformation related protein 63 4.50 
Tlr4 toll-like receptor 4 3.48 
Myo10 myosin X 3.34 
Rin1 Ras and Rab interactor 1 3.12 
Tgfbr1 transforming growth factor, beta receptor I 3.02 
Pde10a phosphodiesterase 10A 2.99 
Casp3 caspase 3 2.49 
Musk muscle, skeletal, receptor tyrosine kinase 2.46 
Ppap2a phosphatidic acid phosphatase type 2A 2.17 
Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 2.00 
Fgf13 fibroblast growth factor 13 1.99 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 1.97 
Tgfb3 transforming growth factor, beta 3 1.95 
Eif4a1 eukaryotic translation initiation factor 4A1 1.86 
Eif4e eukaryotic translation initiation factor 4E 1.86
Prkar1a protein kinase, cAMP dependent regulatory, type I, alpha 1.85 
Mapk1 mitogen-activated protein kinase 1 1.84 
Adcy7 adenylate cyclase  1.84 
Stam Signal transducing adaptor molecule (SH3 domain and ITAM motif)  1.83 
Eif6 eukaryotic translation initiation factor 6 1.77 
Gprc5b G protein-coupled receptor, family C, group 5, member B 1.70 
Egf epidermal growth factor 1.69 
Prkce protein kinase C, epsilon 1.64 
Mknk2 MAP kinase-interacting serine/threonine kinase 2 1.63 
Akt1 thymoma viral proto-oncogene 1 1.59 
Atf6 activating transcription factor 6 1.58 
Grb2 growth factor receptor bound protein 2 1.57 
Il6st interleukin 6 signal transducer 1.55 
Trp53 transformation related protein 53 1.54 
Gtpbp4 GTP binding protein 4 1.54 
Rgs12 regulator of G-protein signaling 12 1.52 
Tiam1 T-cell lymphoma invasion and metastasis 1 -2.70 
Gadd45 growth arrest and DNA-damage-inducible 45 -2.68 
Acvr2b activin receptor IIB -2.38 
Plcl2 phospholipase C-like 2 -2.38 
Pparr peroxisome proliferative activated receptor-γ -2.38
 138
Timp3 tissue inhibitor of metalloproteinase 3 -2.15 
Rcan2 regulator of calcineurin 2 -2.13 
Foxo forkhead box -1.99
Iigp1 interferon inducible GTPase 1 -1.96 
Atp2a2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 -1.95 
Tns1 Tensin 1 -1.88 
Wif1 Wnt inhibitory factor 1 -1.85 
Itga6 integrin alpha 6 -1.75 
Ppm1l protein phosphatase 1 (formerly 2C)-like -1.72 
Inhbb inhibin beta-B -1.72 
Acvr1b activin A receptor, type 1B -1.66 
Smad6 MAD homolog 6 (Drosophila) -1.63 
Pkia protein kinase inhibitor, alpha -1.62 
Crebbp CREB binding protein -1.61 
Ube2n ubiquitin-conjugating enzyme E2N -1.59 
Cited2 Cbp/p300-interacting transactivator, Glu/Asp-rich carboxy-terminal domain, 2 -1.58 
Smad1 MAD homolog 1 (Drosophila) -1.55 
Pten PTEN  -1.54 
A total 1242 genes identified as differentially expressed genes were uploaded to DAVID bioinformatics software 
(Dennis et al., 2003) to functionally classify the genes based on skeletal muscle growth. W, wild type mice; CLW, 
clenbuterol treated wild type mice. 
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Table 3.17 Differentially expressed gene clusters in the effect of CL in Mstn-pro (M vs CLM) based 
on skeletal muscle growth. 
Ontology/Gene symbol Gene name Fold change
Muscle contraction 
Cnn3 Calponin 3, acidic 2.49 
Utrn utrophin 1.90 
Trim63 tripartite motif-containing 63 1.81 
Gaa glucosidase, alpha, acid 1.59 
Tnnc1 troponin C, cardiac/slow skeletal -2.19 
Tpm3 tropomyosin 3, gamma -2.10 
Carboxylic acid and amino acid metabolism  
Atf3 activating transcription factor 3 2.45 
Tyrp1 tyrosinase-related protein 1 2.27 
Gars glycyl-trna synthetase 1.59 
Asns asparagine synthetase 1.56 
Igh-6 immunoglobulin heavy chain 6 (heavy chain of igm) -4.12 
Ces3 carboxylesterase 3 -4.10 
Pparr peroxisome proliferative activated receptor-γ -1.99 
Mlycd malonyl-coa decarboxylase -1.84 
Pdzd2 pdz domain containing 2 -1.79 
Mdh1 malate dehydrogenase 1, nad (soluble) -1.55 
Polr3h polymerase (rna) iii (dna directed) polypeptide h -1.53 
Idh1 isocitrate dehydrogenase 1 (nadp+), soluble -1.53 
Protein metabolic process  
Krt8 keratin complex 2, basic, gene 8 34.06 
Ren1 renin 1 structural 10.72 
Ptpn14 protein tyrosine phosphatase, non-receptor type 14 5.14 
Tubb tubulin, beta  4.77 
Fkbp1 fk506 binding protein 12-rapamycin associated protein 1 3.38 
Gm6607 40s ribosomal protein s20 pseudogene 2.98 
Tgfbr1 transforming growth factor, beta receptor i 2.91 
Arhgef2 rho/rac guanine nucleotide exchange factor (gef) 2 2.72 
Eif4a1 eukaryotic translation initiation factor 4a, pseudogene 4 2.64 
Musk muscle, skeletal, receptor tyrosine kinase 2.50 
Tlr4 toll-like receptor 4 2.30 
Tubb6 tubulin, beta 6 2.28 
Ppme1 protein phosphatase methylesterase 1 2.12 
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Ptprd protein tyrosine phosphatase, receptor type, d 2.04 
Rpl3 ribosomal protein l3 1.99 
Eif1a eukaryotic translation initiation factor 1a 1.94 
Arpc5l actin related protein 2/3 complex, subunit 5-like 1.93 
Mapt microtubule-associated protein tau 1.90 
Prkg2 protein kinase, cgmp-dependent, type ii 1.86 
Gprk5 G protein-coupled receptor kinase 5 1.79 
Atf6 activating transcription factor 6 1.74 
Map2k2 mitogen activated protein kinase kinase 2 1.73 
Rpl37a ribosomal protein l37a 1.73 
Eif4g2 eukaryotic translation initiation factor 4, gamma 2 1.70 
Ttf2 transcription termination factor, rna polymerase ii 1.68 
Pa2g4 proliferation-associated 2g4 1.68 
Eif4e eukaryotic translation initiation factor 4e  1.65 
Eif2b3 eukaryotic translation initiation factor 2b, subunit 3 1.59 
Cdk7 cyclin-dependent kinase 7 (homolog of xenopus mo15 cdk-activating kinase) 1.57 
Vcpip1 valosin containing protein (p97)/p47 complex interacting protein 1 -4.19 
Gadd45g growth arrest and dna-damage-inducible 45 gamma -3.63 
Capn3 calpain 3 -2.78 
Serpinb1a serine (or cysteine) peptidase inhibitor, clade b, member 1a -2.62 
Acvr2b activin receptor iib -2.35 
Pten PTEN -2.27 
Ube2d1 ubiquitin-conjugating enzyme e2d 1, ubc4/5 homolog (yeast) -2.23 
Mylk2 myosin, light polypeptide kinase 2, skeletal muscle -2.22 
Ppp2 protein phosphatase 2 -2.19 
Acvr1b activin a receptor, type 1b -2.12 
Acvr1 activin a receptor, type 1 -2.12 
Usp15 ubiquitin specific peptidase 15 -2.07 
Ppargc1a caspase 7 -1.93 
Ctsc cathepsin c -1.92 
Gpx3 glutathione peroxidase 3 -1.90 
Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2 -1.89 
Ctsb cathepsin b -1.88 
Pias2 protein inhibitor of activated stat 2 -1.85 
Ppm1j protein phosphatase 1j -1.66 
Cebpg ccaat/enhancer binding protein (c/ebp), gamma -1.60 
Prkrir protein-kinase, interferon-inducible double stranded rna dependent inhibitor -1.59 
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Gm15361 ubiquitin-conjugating enzyme e2d 3 (ubc4/5 homolog, yeast) -1.59 
Dstn destrin -1.50 
Ribosome biogenesis and assembly (translation)  
Gm6607 40s ribosomal protein s20 pseudogene 2.98 
Eif4a1 eukaryotic translation initiation factor 4a, pseudogene 4 2.64 
Tlr4 toll-like receptor 4 2.30 
Rpl3 ribosomal protein l3 1.99 
Nhp2 nucleolar protein family a, member 2 1.97 
Eif1a eukaryotic translation initiation factor 1a 1.94 
Gart phosphoribosylglycinamide formyltransferase 1.84 
Rpl37a ribosomal protein l37a 1.73 
Gfm2 G elongation factor, mitochondrial 2 1.72 
Eif4g2 eukaryotic translation initiation factor 4, gamma 2 1.70 
Pa2g4 proliferation-associated 2g4 1.68 
Eif4e eukaryotic translation initiation factor 4e 1.65 
Rpl13a ribosomal protein l13a 1.61 
Gm2614 ribosomal protein s17 1.61 
Wdr46 wd repeat domain 46 1.60 
Eif2b3 eukaryotic translation initiation factor 2b, subunit 3 1.59 
Gars glycyl-trna synthetase 1.59 
Rpl3l ribosomal protein l3-like -2.28 
Eif1ay eukaryotic translation initiation factor 1a, y-linked -2.07 
Cebp ccaat/enhancer binding protein (c/ebp) -1.60 
Transcription 
Runx1 runt related transcription factor 1 15.90 
Sox11 sry-box containing gene 11 6.17 
Trp63 transformation related protein 63 3.32 
Scx scleraxis 3.29 
Atf3 activating transcription factor 3 2.45 
Nfat5 nuclear factor of activated t-cells 5 2.29 
Runx2 runt related transcription factor 2 2.17 
Rb1 retinoblastoma 1 1.92 
Mef2a myocyte enhancer factor 2a 1.88 
Med15 positive cofactor 2, multiprotein complex, glutamine/q-rich-associated protein 1.80 
Edf1 endothelial differentiation-related factor 1 1.75 
Ttf2 transcription termination factor, rna polymerase ii 1.68 
Pa2g4 proliferation-associated 2g4 1.68 
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Cdk7 cyclin-dependent kinase 7 (homolog of xenopus mo15 cdk-activating kinase) 1.57 
Tcea3 transcription elongation factor a (sii), 3 -2.46 
Ppp2 protein phosphatase 2 -2.19 
Tsc TSC domain  -2.12 
Pparr peroxisome proliferative activated receptor-γ -1.99 
Pias2 protein inhibitor of activated stat 2 -1.85 
Foxn3 checkpoint suppressor 1 -1.81 
Ctcf ccctc-binding factor -1.62 
Cebp ccaat/enhancer binding protein (c/ebp) -1.60 
Cell proliferation and cell cycle 
Krt18 keratin complex 1, acidic, gene 18 144.41 
Gdf5 growth differentiation factor 5 77.47 
Krt8 keratin complex 2, basic, gene 8 34.06 
Runx1 runt related transcription factor 1 15.90 
Myog myogenin 8.47 
Cdkn1a cyclin-dependent kinase inhibitor 1a (p21) 6.72 
Fkbp1 fk506 binding protein 12-rapamycin associated protein 1 3.38 
Trp63 transformation related protein 63 3.32 
Tgfbr1 transforming growth factor, beta receptor i 2.91 
Tgfa transforming growth factor alpha 2.91 
Notch2 notch gene homolog 2 (drosophila) 2.71 
Musk muscle, skeletal, receptor tyrosine kinase 2.50 
Sgms1 transmembrane protein 23 2.40 
Tubb6 tubulin, beta 6 2.28 
Plekh pleckstrin homology domain  2.26 
Runx2 runt related transcription factor 2 2.17 
Shb src homology 2 domain-containing transforming protein b 2.14 
Neb nebulin 2.10 
Rb1 retinoblastoma 1 1.92 
Cgref1 cell growth regulator with ef hand domain 1 1.82 
Rhou ras homolog gene family, member u 1.77 
Eif4g2 eukaryotic translation initiation factor 4, gamma 2 1.70 
Eif2b3 eukaryotic translation initiation factor 2b, subunit 3 1.59 
Cdk7 cyclin-dependent kinase 7 (homolog of xenopus mo15 cdk-activating kinase) 1.57 
Mlf1 myeloid leukemia factor 1 -3.74 
Gadd45g growth arrest and dna-damage-inducible 45 gamma -3.63 
Cdh4 cadherin 4 -3.38 
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Mapre2 microtubule-associated protein, rp/eb family, member 2 -3.35 
Capn3 calpain 3 -2.78 
Gadd45b growth arrest and dna-damage-inducible 45 beta -2.69 
Calm2 calmodulin 1 -2.28 
Sesn1 sestrin 1 -2.21 
Acvr1b activin a receptor, type 1b -2.12 
Acvr1 activin a receptor, type 1 -2.12 
Ppargc1a caspase 7 -1.93 
Socs2 suppressor of cytokine signaling 2 -1.82 
Foxo forkhead box  -1.81 
Mtus1 mitochondrial tumor suppressor 1 -1.72 
Bnip3l bcl2/adenovirus e1b interacting protein 3-like -1.67 
Pds5b androgen-induced proliferation inhibitor -1.67 
Cdkn2d cyclin-dependent kinase inhibitor 2d (p19, inhibits cdk4) -1.66 
Ctcf ccctc-binding factor -1.62 
Cebpg ccaat/enhancer binding protein (c/ebp), gamma -1.60 
Cell differentiation  
Krt18 keratin complex 1, acidic, gene 18 144.41 
Gdf5 growth differentiation factor 5 77.47 
Krt8 keratin complex 2, basic, gene 8 34.06 
Runx1 runt related transcription factor 1 15.90 
Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 9.72 
Myog myogenin 8.47 
Cdkn1a cyclin-dependent kinase inhibitor 1a (p21) 6.72 
Col19a1 procollagen, type xix, alpha 1 5.13 
Fkbp1 fk506 binding protein 12-rapamycin associated protein 1 3.38 
Trp63 transformation related protein 63 3.32 
Tgfbr1 transforming growth factor, beta receptor i 2.91 
Notch2 notch gene homolog 2 (drosophila) 2.71 
Musk muscle, skeletal, receptor tyrosine kinase 2.50 
Sgms1 transmembrane protein 23 2.40 
Runx2 runt related transcription factor 2 2.17 
Shb src homology 2 domain-containing transforming protein b 2.14 
Neb nebulin 2.10 
Rb1 retinoblastoma 1 1.92 
Mef2a myocyte enhancer factor 2a 1.88 
Myf6 myogenic factor 6 1.86 
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Acsl6 acyl-coa synthetase long-chain family member 6 1.83 
Edf1 endothelial differentiation-related factor 1 1.75 
Eif4g2 eukaryotic translation initiation factor 4, gamma 2 1.70 
Eif2b3 eukaryotic translation initiation factor 2b, subunit 3 1.59 
Rtn4 reticulon 4 1.57 
Gadd45g growth arrest and dna-damage-inducible 45 gamma -3.63 
Cdh4 cadherin 4 -3.38 
Capn3 calpain 3 -2.78 
Acvr1 activin a receptor, type 1 -2.12 
Tirap toll-interleukin 1 receptor (tir) domain-containing adaptor protein -2.09 
Pparr peroxisome proliferative activated receptor-γ -1.99 
Bnip3l bcl2/adenovirus e1b interacting protein 3-like -1.67 
Skeletal muscle development  
Myog myogenin 8.47 
Col19a1 procollagen, type xix, alpha 1 5.13 
Musk muscle, skeletal, receptor tyrosine kinase 2.50 
Neb nebulin 2.10 
Fkbp12 fk506 binding protein 12-rapamycin associated protein 1 1.89 
Myf6 myogenic factor 6 1.86 
Capn3 calpain 3 -2.78 
Dmd dystrophin, muscular dystrophy -2.08 
Signal transduction  
Gdf5 growth differentiation factor 5 77.47 
Rrad ras-related associated with diabetes 38.79 
Cdkn1a cyclin-dependent kinase inhibitor 1a (p21) 6.72 
Plch1 phospholipase c-like 3 3.94 
Fkbp1 fk506 binding protein 12-rapamycin associated protein 1 3.38 
Trp63 transformation related protein 63 3.32 
Rhoc ras homolog gene family, member c 3.10 
Tgfbr1 transforming growth factor, beta receptor i 2.91 
Tgfa transforming growth factor alpha 2.91 
Gprc5b G protein-coupled receptor, family c, group 5, member b 2.89 
Myo10 myosin x 2.82 
Notch2 notch gene homolog 2 (drosophila) 2.71 
Musk muscle, skeletal, receptor tyrosine kinase 2.50 
Sh3 sh3 domain  2.30 
Tlr4 toll-like receptor 4 2.30 
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Runx2 runt related transcription factor 2 2.17 
Shb src homology 2 domain-containing transforming protein b 2.14 
Itsn1 intersectin 1 (sh3 domain protein 1a) 2.13 
Fgf13 fibroblast growth factor 13 2.08 
Ptprd protein tyrosine phosphatase, receptor type, d 2.04 
Rgs12 regulator of g-protein signaling 12 1.88 
Gprk5 G protein-coupled receptor kinase 5 1.79 
Rhou ras homolog gene family, member u 1.77 
Stam2 signal transducing adaptor molecule (sh3 domain and itam motif) 2 1.77 
Adcy2 adenylate cyclase 2 1.63 
Ltbp3 latent transforming growth factor beta binding protein 3 1.55 
Pik3r3 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) 1.54 
Gadd45g growth arrest and dna-damage-inducible 45 gamma -3.63 
Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1a -3.14 
Acvr2b activin receptor iib -2.35 
Calm2 calmodulin 1 -2.28 
Pten PTEN  -2.27 
Ppp2 protein phosphatase 2 -2.19 
Acvr1b activin a receptor, type 1b -2.12 
Acvr1 activin a receptor, type 1 -2.12 
Timp3 tissue inhibitor of metalloproteinase 3 -2.02 
Pkia protein kinase inhibitor, alpha -2.01 
Socs2 suppressor of cytokine signaling 2 -1.82 
Hipk3 homeodomain interacting protein kinase 3 -1.76 
Rsu1 ras suppressor protein 1 -1.59 
Raf1 v-raf-leukemia viral oncogene 1 -1.56 
A total 1521 genes identified as differentially expressed genes were uploaded to DAVID bioinformatics software 
(Dennis et al., 2003) to functionally classify the genes based on skeletal muscle growth. M, Mstn-pro mice; CLM, 
clenbuterol treated Mstn-pro mice. 
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Table 3.18 Differentially expressed gene clusters by the effect of genotype and CL (W vs M VS W vs 
CLW) based on skeletal muscle growth.  
Ontology/Gene symbol Gene name 
Carboxylic acid and amino acid metabolism 
Ddc dopa decarboxylase 
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 
Tubb2a tubulin, beta 2A 
Tubb6 tubulin, beta 6 
Protein metabolic process 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 
Tubb2a tubulin, beta 2A 
Tubb6 tubulin, beta 6 
Cell differentiation 
Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)  
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 
Tnnt2 troponin T2, cardiac 
Skeletal muscle development 
Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 
Col19a1 collagen, type XIX, alpha 1 
Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 
A total 40 genes identified as differentially expressed genes were uploaded to DAVID bioinformatics software 
(Dennis et al., 2003) to functionally classify the genes based on skeletal muscle growth. W, wild type mice; M, 
Mstn-pro mice; CLW, clenbuterol treated wild type mice. 
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 Table 3.19 Summary of previous reports describing the known molecular effect of Mstn-
suppresion-induced hypertrophy in skeletal muscle.  




Steelman et al. (2006): There was a decreased expression of 
genes for slow isoforms of myosin (Myh7, Myl2, and Myl3) 
and troponin (Tnnc1, Tnni1, Tnnt1, and Tpm3) In muscle 
from myostatin null mice. 
Cassar-Malek et al. (2007): Constitutive non-functional 
mutation of Mstn decreased the expression of slow forms of 
contractile proteins (Myh7, Myl2, and Tpm3). 
Sadkowski et al. (2008): There was increased expression of 
genes for fast isoforms of myosin (Myh3) In skeletal muscle 
carrying a SNP in the 5’flanking region of the Mstn gene in 
bulls, while slow isoforms of myosin (Myh8, Myo5a, Myl6) 
were decreased.  
Welle et al. (2009): Gene encoding slow isoforms of several 
contractile proteins (Myh7, Myl2, Myl3, Tnnc1, Tnni1, 
Tnnt1 and Tpm3) are downregulated 4- to 10-fold in mice 
muscle with constitutive Mstn deficiency, none of the effects 
was statistically significant. 
In this study, we could not observe any alteration 
in gene expression encoding myofibrillar 
proteins in Mstn-pro mice similar to previous 
studies, except the differential expression of 
Tnnt2, which is mostly expressed during 
embryonic development. 
Genes encoding 
proteins involved in 
transcription 
Steelman et al. (2006): In muscle from myostatin null mice, 
there was an increased expression of Wnt4 gene, which is 
known to play a role in embryonic myogensis.  
Welle et al. (2009): They did not observe any genes 
encoding transcription. 
In this study, we observed that the 3 transcription 
factor genes were differentially expressed by 
Mstn-pro overexpression, including Runx1, 
Dnmt1, and Sreb1. However, studies by other 
groups did not observe that these genes were 
differentially regulated by Mstn modulation 
Genes encoding 
proteins involved in 
immune response 
Welle et al. (2009) and Steelman et al. (2006): They did 
not observe any genes encoding immune response. 
 
In this study study, we observed that immune 
response genes were differentially expressed by 
Msnt-pro overexpression, including Mt3. 
However, studies by other groups did not 
observe that this gene was differentially 
regulated by Mstn modulation 
Genes encoding 
proteins involved in 
muscle hypertrophic 
signal pathway 
Steelman et al. (2006) and Welle et al. (2009): They did 
not observe any genes encoding muscle hypertriphic signal 
pathway. 
 
In this study, we observed that Igf2 was 
differentially expressed in the skeletal muscle of 
Mstn-pro mice even though previous studies 
have not observed that Igf2 is regulated by Mstn.
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Table 3.20 Comparison of the genes describing the effect of Mstn-suppression-induced hypertrophy 
in skeletal muscle between previous studies and current study.  
Gene 
Steelman et al. 
(2006) 




Myosin heavy polypeptide 7 Down NS - 
Myosin light polypeptide 2 Down NS - 
Myosin light polypeptide 3 Down NS - 
Troponin C, cardiac/slow skeletal Down NS - 
Troponin I, skeletal, slow 1 Down NS - 
Troponin T1, skeletal, slow Down NS - 
Tropomyosin 3, gamma Down NS - 
Troponin T2, cardiac - - Down 
Wnt4 - Up - 
Runt related trasncription factor 1 - - Up 
sterol regulatory element binding transcription factor 1 - - Down 
metallothionein 3 - - Up 
insulin-like growth factor 2 - - Up 
nitric oxide synthase 1 - Down - 
dimethylarginine dimethylaminohydrolase 1 - Down - 
dynein light chain LC8-type 1 - Down - 
prosaposin - Down - 
HtrA serine peptidase 2 - Down - 
3-hydroxyisobutyryl-coenzyme A hydrolase - Up - 
glutamate-ammonia ligase (glutamine synthetase) - Up - 
cytochrome b5 type B - Up - 
acyl-coenzyme A dehydrogenase, short/branched chain - Up - 
cimilar to UDP glycosyltransferase family - Up - 
peroxisome proliferator-activated receptor gamma, coactivator 1 α - Down - 
protein phosphatase 1, regulatory (inhibitor) subunit 3C - Up - 
acyl-CoA synthetase long-chain family member 1 - Up - 
elastin - Down - 
procollagen C-endopeptidase enhancer protein - Down - 
zinc finger, MYND-type containing 17 - Down - 
family with sequence similarity 19, member A5 - Down - 
cerebral endothelial cell adhesion molecule - Down - 
BTB (POZ) domain containing 1 - Down - 
Ras-related associated with diabetes - Down - 
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myosin, light chain 4, alkali - Down - 
prostate transmembrane protein, androgen induced 1 - Down - 
sulfotransferase family 5A, member 1 - Down - 
keratin 18 - Down - 
deoxynucleotidyltransferase, terminal - Up - 
zinc finger protein 318 - Up - 
chemokine (C-C motif) ligand 25 - Up - 
receptor accessory protein 6 - Up - 
rhophilin, Rho GTPase binding protein 2 - Up - 
nephronectin - Up - 
cadherin 4 - Up - 
Collagen I,α1 Down - - 
Collagen I,α2 Down - - 
Collagen III,α1 Down - - 
Collagen IV,α1 Down - - 
Collagen IV,α4 Down - - 
Collagen V,α1 Down - - 
Collagen V,α2 Down - - 
Collagen VI,α1 Down - - 
Collagen VI,α2 Down - - 
Collagen VI,α3 Down - - 
Collagen XVI,α1 Down - - 
Up, upregulated gene; Down, downregulated gene, NS, not significant. 
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Table 3.21 Summary of previous reports describing the known molecular effect of CL 
administration-induced hypertrophy in skeletal muscle.  




Oishi et al. (2002): CL administration resulted in muscle 
fiber hypertrophy, stimulated a de novo expression of type 
IIx MHC and increased the percentage of fibers containing 
multiple MHC isoforms in the rat soleus muscle.  
Spurlock et al. ( 2006): The differentially expressed genes 
by CL administration increase the expression of several 
contractile proteins, including fast isoforms of myosin 
(Myo1b, Myo18a), actin (Actn4) in male mice  
Pearen et al. (2009): No significant changes were 
observed in contractile proteins at 1 and 4 hours by beta-
agonists in mice muscle. However, they found that 
alterations in Stat3, Smad 3, and Acvr2b three genes 
directly associated with the regulation of muscle 
hypertophy. 
In this study, we observed that Myh8, Tnnt2, Myl2, 
and Mylk2 were altered by CL administration even 
though previous studies have not observed that the 
genes are regulated by CL administration. 
At molecular levels, we found the differentially 
expressed Acvr2b gene by CL administration 
similar to Pearen et al. (2009) study. 
 
Genes encoding 
proteins involved in 
translation and 
transcription 
Spurlock et al. (2006): The increase expressions of 13 
genes encoding initiator of protein translation factors (Eif2, 
Eif2b, Eif2b4, Eif2b2, Eif5, and Eif4g3) and 18 genes 
encoding protein transcription factors (Hod, Yy1, Mef2c, 
and Myog) were observed mainly at 24h after CL 
administration. 
Pearen et al. (2009): The increase expressions of 11 genes 
encoding transcriptional regulators (Fos, Klf2/4, Crem, 
Cebpb, Nurr1, Fosl2, Maff, Aft3, Tbx3, and Litaf), but no 
significant changes were observed in translation proteins at 
1 and 4 hours by CL administration in mice muscle. 
In this study, we observed a regulation of 
translational and transcriptional factors responsible 
for increasing protein synthesis. The 22 translation 
genes, including Gm6607, Rpl3, Rpl13a, Rpl23, 
Eif1, Eif4a1, Eif4e, and the 48 transcription genes, 
including Myod1, Mef2a, were differentially 
expressed by CL administration even though 
previous studies have not observed that the genes 
are regulated by CL administration. However, we 
found the differentially expressed Eif2b and Myog 
gene similar to Spurlock et al. (2006) study.  
 
Genes encoding 




Spurlock et al. (2006): They reported that Igf1 and 
Tss22d1 genes were altered in mouse skeletal muscle 24 
hours after administration of CL.  
Pearen et al. (2009): They are reported that FoxO1 gene 
was altered in mice after systemic administration of 
formorterol. 
In this study, we observed that eIF4E and PTEN 
were differentially expressed in the skeletal muscle 
of CL administration even though previous studies 
have not observed that eIF4E and PTEN are 
regulated by CL administration. However, we 
found the differentially expressed FoxO gene by 
CL administration similar to Pearen et al. (2009) 
study. 
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Table 3.22 Comparison of the genes describing the effect of BAA administration-induced 
hypertrophy in skeletal muscle between previous studies and current study.  
Spurlock et al. (2006) 
Gene Name 
Pearen et al. 
(2009) Change 24h Change10D 
In current 
sutdy 
40S ribosomal protein S20 pseudogene - - - Up 
activin receptor IIB - - - Down 
ADP-ribosyltransferase 1 - Down NS Down 
Alkaline phosphatase 2 Up - - - 
Alpha Tubulin 6 Up - - - 
Alpha-kinase 2 Up - - - 
Angiotensinogen - Up Up - 
ankyrin repeat and BTB (POZ) domain containing 2 - - - Down 
ankyrin repeat and SOCS box-containing 10 - Down NS Down 
ankyrin repeat and SOCS box-containing 14 - Down NS Down 
Ankyrin repeat and SOCS box-containing protein 15 - Down NS - 
Aryl hydrocarbon receptor nuclear translocator-like - Up NS - 
ATPase, H+ transporting, V0 subunit E - Up Up - 
ATPase, H+ transporting, V1 subunit B, isoform 2 Up - - - 
Avian musculoaponeurotic fibrosarcoma (v-maf)  Up - - Down 
Bromodomain containing 4 - Down Down - 
cAMP responsive element modulator Up - - Up 
CCAAT/enhancer binding protein beta Up - - - 
CCR4 carbon catabolite repression 4-like  Up - - - 
cell growth regulator with EF hand domain 1 - - - Up 
Chemokine (C-C motif) ligand 9 Up - - - 
Chemokine ligand 12 - Up NS - 
Contactin associated protein-like 2 - Down Down Down 
Cryptochrome 2 Up - - - 
Cyclin-dependent kinase inhibitor 1A Up Up Up Up 
Cyclin-dependent kinase inhibitor 1C Down - - - 
Cytokine induced apoptosis inhibitor 1 Up - - - 
D site albumin promoter binding protein Down - - - 
Dehydrogenase/reductase (SDR family) member 7 - Down Down Down 
DNA segment, Chr 19, Wayne State University 162 Up - - - 
DNA-damage-inducible transcript 4-like Down Up Up - 
Down syndrome critical region gene 1-like 1 - Down Down - 
Downstream of Stk11 Up - - - 
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EGL nine homolog 3  Up - - Up 
Emerin Up Up NS - 
Endothelin 1 - Up Up - 
Enhancer of yellow 2 homolog - Up NS Up 
eukaryotic translation elongation factor 1 - - - Up 
eukaryotic translation initiation factor 1A - - - Up 
Eukaryotic translation initiation factor 2B, subunit 2 beta - Up NS Up 
Eukaryotic translation initiation factor 2B, subunit 4 delta - Up NS - 
Eukaryotic translation initiation factor 4 gamma, 3 - Down NS - 
Eukaryotic translation initiation factor 4A1 - Up Up Up 
eukaryotic translation initiation factor 4E - - - Up 
eukaryotic translation initiation factor 4E member 2 - - - Up 
Eukaryotic translation initiation factor 5 - Up NS - 
Excision repair cross-complementing rodent repair deficiency Up - - - 
F-box only protein 34 Up - - - 
Fibroblast growth factor 1 Up - - - 
forkhead box - - - Down 
Forkhead box O1 Up - - - 
Fos-like antigen 2 Up - - - 
Fructose bisphosphatase 2 - Up Up - 
Glutamic pyruvate transaminase 2  Up - - - 
Growth arrest and DNA-damage-inducible 45 alpha  Up - - Up 
Growth arrest and DNA-damage-inducible 45 gamma - Down NS Down 
Growth hormone receptor - Down Down - 
heat shock protein 1  - - - Up 
heat shock protein 4 - - - Up 
heat shock protein 8  - - - Up 
heat shock protein 90, alpha (cytosolic), class A member 1 - - - Up 
heat shock protein family, member 7  - - - Up 
heat shock transcription factor 2 binding protein - - - Up 
Hexokinase 2 (Hk2) Up - - - 
Histidyl-tRNA synthetase - Up NS - 
Histone 1, H2ai  Down - - - 
Histone 1, H2ao  Down - - - 
Homebox only domain - Up NS - 
Imprinted and ancient  Up - - Up 
Inhibitor of DNA binding 1  Up - - - 
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Insulin-like growth factor 1 - Up NS - 
Insulin-like growth factor 2 receptor - Down Down - 
Insulin-like growth factor binding protein 5 - Down Down - 
Integrin beta 1 binding protein 3  Up - - - 
Interferon gamma inducible protein 30  Up - - - 
Interleukin 6 signal transducer - Up Up Up 
Kelch repeat and BTB (POZ) domain containing 5 - Up NS - 
Kinesin family member 1B (Kif1b), transcript variant 1 Down - - Down 
Kruppel-like factor 4 (gut)  Up - - - 
Lady bird-like homeobox 1 homolog  - Down Down Down 
Lectin, galactose binding, soluble 3  Up - - Up 
Lipin 1 (Lpin1) Up - - Down 
LPS-induced TN factor (Litaf) Up - - - 
Lymphocyte antigen 6 complex, locus A  Up - - - 
MAP kinase-interacting serine/threonine kinase 2  Up - - - 
Metallothionein (Mt1) Up Up Up - 
Metallothionein 2 (Mt2) Up - - - 
Microfibrilar-associated protein 3-like - NS Up - 
Microtubule-associated protein 1 light chain 3 alpha  Up - - Up 
Midnolin (Midn) Up - - - 
Mitogen activated protein kinase kinase 4 - Up NS - 
Mitogen activated protein kinase kinase 6 - Down NS Down 
Mitogen-activated protein kinase kinase kinase 6  Up - - - 
Myeloid/lymphoid or mixed-lineage leukaemia - Down NS - 
myocyte enhancer factor 2A - - - Up 
Myocyte enhancer factor 2C - Down NS - 
myogenic differentiation 1 - - - Up 
Myogenin - Up NS Up 
Myosin IB - Down NS - 
myosin IC - - - Up 
myosin X - - - Up 
Myosin XVIIIa - Up Up - 
myosin, heavy polypeptide 8, skeletal muscle, perinatal - - - Up 
myosin, light polypeptide 2, regulatory, cardiac, slow - - - Down 
myosin, light polypeptide 4 - - - Up 
Myosin, light polypeptide kinase 2, skeletal muscle - Down NS - 
myosin, light polypeptide kinase 2, skeletal muscle - - - Down 
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Neuraminidase 1 - Up NS - 
Nuclear factor, interleukin 3, regulated  Up - - - 
Nuclear receptor subfamily 4, group A, member 1 - Down Down Down 
Nuclear receptor subfamily 4, group A, member 2  Up - - - 
Optineurin  Up - - - 
Ornithine decarboxylase, structural - Up Up Up 
pleckstrin homolog domains 1 - Up Up - 
Pannexin 1 - Up Up Up 
Peroxisome proliferator activator receptor delta (Pparδ) Up - - - 
Phosphodiesterase 4D (Pde4d) Up - - - 
Phosphomevalonate kinase (Pmvk) Up - - - 
Plasma membrane associated protein  Up - - - 
Platelet derived growth factor alpha  Down - - - 
Polo-like kinase 3 (Plk3) Up - - - 
PPARγ coactivator 1 alpha (Pgc-1α) Up - - - 
Protein kinase, cGMP-dependent, type 1 - Down NS Down 
Protein phosphatase 1 (formerly 2C)-like - Down NS Down 
Protein phosphatase 1 regulatory subunit 3C  Up - - - 
PTEN - - - Down 
Pyruvate dehydrogenase kinase 4  Up - - - 
retinoblastoma 1 - - - Up 
ribosomal protein L13A - - - Up 
ribosomal protein L23 - - - Up 
ribosomal protein L3 - - - Up 
ribosomal protein L3-like - - - Down 
ribosomal protein S25 - - - Up 
ribosomal protein S6 kinase, polypeptide 2 - - - Down 
ribosomal protein S6 kinase, polypeptide 5 - - - Down 
Ring finger protein 128 - Up Up Up 
S100 calcium binding protein A8  Up - - Up 
S-adenosylmethionine decarboxylase 1 - Down Down Down 
Scavenger receptor class B member 1  Down - - - 
Serine (or cysteine) preptidase inhibitor, clade A, member 1b - Up Up - 
Seven in absentia 2 - Up Up - 
SH3 domain protein - - - Up 
Signal transducer and activator of transcription 3  Up - - - 
Small chemokine (C-C motif) ligand 11  Up - - - 
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Small mothers against decapentaplegic homolog 1  Down - - - 
Small mothers against decapentaplegic homolog 3  Up - - - 
Sodium-dependent vitamin C transporter 2 (Slc23a2) Up - - - 
solute carrier family 10, member 3 Up - - Up 
Solute carrier family 7, member 2 - Down NS Down 
Solute carrier family 7, member 5 - Up Up - 
Sorbin and SH3-domains containing 1  Up - - - 
Spermine oxidase - Down NS - 
Ssemaphorin 3F  Up - - - 
Sulfiredoxin 1 homolog  Up - - - 
Synaptopodin 2-like  Down - - Down 
Syndecan 4  Up - - Up 
T-box 3 (Tbx3), transcript variant 2 Up - - - 
TG interacting factor  Up - - - 
Thimet oligopeptidase 1 - Up NS - 
TSC22 domain family, member 1 - Down NS - 
TSR 1, 20S rRNA accumulation, homolog - Up NS Up 
Tubulin, alpha 1A - - - Up 
Tubulin, alpha 1B -- - - Up 
Tubulin, alpha 4A - - - Up 
Tubulin, beta 2A - - - Up 
Tubulin, beta 2B - - - Up 
Tubulin, beta 2C - - - Up 
Tubulin, beta 5 - Up Up - 
Tubulin, beta 6 - Up Up Up 
Tubulointerstitial nephritis antigen-like - Up Up - 
Tumor necrosis factor receptor superfamily, member 12a Up Up NS Up 
Tweety homolog 1 (Drosophila)  Up - - - 
Ubiquitin C  Up - - - 
Ubiquitin G  Up - - - 
Ubiquitin protein ligase E3 component n-recognin 1 - n/s Up - 
Ubiquitin specific protease 2 (Usp2), transcript variant 2 Up - - - 
Uncoupling protein 3  Up - - - 
Vasodilator-stimulated phosphoprotein  Down - - - 
Vinculin - Up Up - 
v-maf musculoaponeurotic fibrosarcoma oncogene, protein B Up - - Down 
Y box protein 3 (Ybx3) Up - - - 
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YY1 transcription factor - Up Up - 
Zinc finger protein 46 (Zfp46) Down - - - 
Up, upregulated gene; Down, downregulated gene, NS, not significant
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1.2% agarose gel electrophoresis gel stained with ethidium bromide. Lane 1, Wild type mice; Lane 2,  
Transgnice mice; Lane 3, Transgnice mice; Lane 4, Transgnice mice; Lane 5, Transgnice mice; Lane 6,  
Wild type mice; Lane 7, Transgnice mice; Lane 8, Wild type mice. 
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APPENDIX 2.2 The female raw data at 7day. 
    wt wt C0d C3d C7d     mg/g of muscle     Adj. Vol CNT*mm2  confirm 
No wean 3d 5d 7d 10d 14d GAS Sol Plan E D L RNA DNA Ratio %Gas %pl %sol %EDL 4EBP1 p70S6k CL Geno 
689 12.1 14.1 14.7 16.2 16.2 16.2 0.0717 0.0036 0.0079 0.0056 1.2311 1.1674 1.0546 0.4426 0.0488 0.0222 0.0346 1976.3 2074.6 con Wild 
690 12.1 14.6 15.6 17.2 17.2 17.2 0.0730 0.0035 0.0080 0.0061 1.3281 1.2306 1.0792 0.4244 0.0465 0.0203 0.0352 1901.5 1929.5 con Wild 
691 13.2 15.4 16.4 19.4 19.2 19.6 0.0968 0.0030 0.0093 0.0065 1.3657 1.2125 1.1263 0.4939 0.0474 0.0153 0.0329 2016.5 2031.7 con Wild 
708 14.9 17.4 18.5 19.4 19.3 19.4 0.1067 0.0054 0.0127 0.0085 1.3283 1.1923 1.114 0.5500 0.0655 0.0278 0.0436 2032.3 2087.1 con Wild 
716 18.7 19.4 20 21.3 21.3 21.6 0.1108 0.0068 0.0132 0.0115 1.162 1.1658 0.9967 0.5130 0.0611 0.0315 0.0532 2047.7 1924.8 con Wild 
728 13.8 13.9 14.3 16.3 16.4 17.1 0.0694 0.0036 0.0077 0.0046 1.3512 1.1998 1.1262 0.4058 0.0450 0.0211 0.0269 2006.9 -  con Wild 
756 12.6 15.2 15.8 16.3 16.8 17.6 0.0846 0.0051 0.0095 0.0060 1.3354 1.2632 1.0571 0.4807 0.0540 0.0290 0.0338 2019.4 2058.4 con Wild 
787 13.4 15.4 16 16.6 17 17.7 0.0826 0.0038 0.0089 0.0063 1.4308 1.2703 1.1263 0.4667 0.0503 0.0215 0.0356 2095.4 1909.2 con Wild 
782 15.9 17.3 17.6 18.5 17.6 19.3 0.0858 0.0026 0.0100 0.0075 1.1294 1.2095 0.9338 0.4446 0.0518 0.0135 0.0386 2041.9 2021.2 con Wild 
797 15.7 16.4 16.6 17 18.4 18.1 0.0901 0.0024 0.0088 0.0061 1.0342 1.2569 0.8228 0.4978 0.0486 0.0133 0.0337 -  2339.9 con Wild 
798 15.8 16.4 17 17.2 18.6 19.9 0.091 0.0054 0.011 0.0062 1.0117 1.2335 0.8202 0.4573 0.0553 0.0271 0.0309 - 2144.1 con Wild 
801 15.5 16.5 16.6 16.6 17 17.7 0.0885 0.0046 0.0104 0.0075 1.0053 1.1918 0.8435 0.5000 0.0588 0.0260 0.0424 -  2012.2 con Wild 
698 18.1 19.6 20.5 21.4 21.5 22.2 0.1339 0.0056 0.0142 0.0097 1.3418 1.1753  1.1417 0.6032 0.0640 0.0252 0.0435 2877.4 3986.3 con Trans 
699 18.2 19 19.5 20.8 20.8 20.8 0.1076 0.0050 0.0117 0.0087 1.302 1.1601  1.1223 0.5173 0.0563 0.0240 0.0418 2855.1 3887.0 con Trans 
715 18.7 19.2 19.6 20 20.3 21.3 0.1278 0.0047 0.0129 0.0107 1.2766 1.1452  1.1148 0.6000 0.0606 0.0221 0.0502 2362.9 4002.9 con Trans 
709 14.9 17.1 18.1 19.2 19.8 20.3 0.1072 0.0052 0.0131 0.0102 1.2162 1.1021  1.1034 0.5281 0.0645 0.0256 0.0502 2870.5 4232.3 con Trans 
726 14.5 14.9 15.1 17.1 17.4 18.3 0.0998 0.0040 0.0111 0.0082 1.4473 1.2079  1.1982 0.5454 0.0607 0.0219 0.0448 2869.0 3906.6 con Trans 
727 16 15.9 16.3 18.6 19.2 19.4 0.1065 0.0050 0.0160 0.0094 1.4124 1.0492  1.3462 0.5490 0.0825 0.0258 0.0485 2888.5 4024.2 con Trans 
770 15.8 18.1 19.6 19.8 18.6 19.4 0.0860 0.0062 0.0104 0.0065 1.2456 1.1600  1.0738 0.4433 0.0536 0.0320 0.0332 2954.4 3937.8 con Trans 
786 14.5 16 17.1 17.8 17.8 19.5 0.1046 0.0043 0.0123 0.0093 1.2239 1.0875  1.1255 0.5364 0.0631 0.0221 0.0477 3742.8 4025.6 con Trans 
800 17.2 18.8 18.8 19.8 22 22.9 0.1359 0.0058 0.0145 0.0124 1.2161 1.1290  1.0772 0.5934 0.0633 0.0253 0.0541 3130.9 3990.8 con Trans 
818 13.3 15 15.5 16.1 17.3 18.2 0.1004 0.0034 0.0102 0.0086 1.3918 1.2095  1.1508 0.5516 0.0560 0.0187 0.0470 2968.8 3958.9 con Trans 
819 13.9 16.5 17.1 17.5 18 19.3 0.1197 0.0048 0.0125 0.0100 1.3462 1.0461  1.2869 0.6202 0.0648 0.0249 0.0516 - 4037.8 con Trans 
831 17 18 19.3 19.4 18.9 20.5 0.1202 0.006 0.0129 0.0096 1.2756 1.2022  1.0611 0.5863 0.0629 0.0293 0.0466 - 4087.4 con Trans 
832 12.4 13.4 14.8 14.7 14.6 16 0.0862 0.002 0.0118 0.0070 1.2633 1.2294  1.0276 0.5388 0.0738 0.0125 0.0438 -  4044.0 con Trans 
834 13.5 14.9 15.9 16.2 16.2 17.2 0.0941 0.0045 0.0103 0.0091 0.9843 1.1978  0.8218 0.5471 0.0599 0.0262 0.0526 -  4024.3 con Trans 
807 16.2 17.9 18.2 18.8 20.5 20.7 0.1323 0.0063 0.0148 0.0115 1.1366 1.1612  0.9788 0.6391 0.0715 0.0304 0.0553 -  -  con Trans 
692 12.8 16 17.1 18.9 19.5 19.8 0.1029 0.0081 0.0114 0.0101 1.2625 0.9252  1.3645 0.5197 0.0576 0.0409 0.0510 2744.5 3890.3 Clen Wild 
707 15.4 17 17.1 18.3 19.6 19.6 0.0945 0.0057 0.0114 0.0074 1.2085 1.1479  1.0528 0.4821 0.0582 0.0291 0.0378 2953.6 3814.6 Clen Wild 
761 13.2 14.8 15.2 16 16.2 18.6 0.0947 0.0051 0.0112 0.0064 1.3122 1.2158  1.0792 0.5091 0.0602 0.0274 0.0341 2216.3 3204.9 Clen Wild 
783 15.6 17.5 17.9 18.9 18.9 20.5 0.1085 0.0072 0.0118 0.0081 1.2246 1.1186  1.0947 0.5293 0.0576 0.0351 0.0395 2773.7 3439.6 Clen Wild 
788 15.2 16.4 17.5 18.3 17.7 19.6 0.1062 0.0067 0.0128 0.0082 1.2512 1.1315  1.1058 0.5418 0.0653 0.0342 0.0416 2555.5 3837.4 Clen Wild 
817 14.9 16.8 17.5 18.2 17.8 19.9 0.1042 0.0055 0.0121 0.0081 1.3173 1.2703  1.037 0.5236 0.0608 0.0276 0.0405 2870.3 3499.2 Clen Wild 
820 12.6 15 15.2 16.1 15.7 17.2 0.0801 0.0047 0.0095 0.0064 1.3354 1.1468  1.1645 0.4657 0.0552 0.0273 0.0369 3251.1 3246.3 Clen Wild 
833 15.8 17.1 17.5 16.4 16.4 18.4 0.0845 0.0065 0.0072 0.0067 1.2311 1.1674  1.0546 0.4592 0.0391 0.0353 0.0364 2588.8 3291.6 Clen Wild 
835 16.6 18 18.9 18.7 18.1 21.2 0.095 0.0056 0.0104 0.0072 0.9843 1.0839  0.9081 0.4481 0.0491 0.0264 0.0337 3097.4 3091.0 Clen Wild 
839 15.4 16.5 16.5 17.3 16.3 17.7 0.0789 0.0042 0.0063 0.0065 1.2582 1.2361  1.0179 0.4458 0.0356 0.0237 0.0364 2879.3 -  Clen Wild 
717 17.2 18.5 19.3 20.3 21.1 22 0.1527 0.0069 0.0166 0.0108 1.3237 1.0927  1.2114 0.6941 0.0755 0.0314 0.0491 4821.2 5590.8 Clen Trans 
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724 13.9 14.2 14.7 15.9 16.9 18.1 0.1122 0.0057 0.0159 0.0099 1.5591 1.0014 1.557 0.6199 0.0878 0.0315 0.0544 4992.7 5778.0 Clen Trans 
725 15.4 14.7 15.5 17.8 19.7 20.3 0.1311 0.0062 0.0161 0.0112 1.4064 1.1340 1.2402 0.6458 0.0793 0.0305 0.0552 4846.3 5575.7 Clen Trans 
758 16.7 17.8 19 19.1 20.7 22.6 0.1455 0.0062 0.0154 0.0097 1.6253 1.0723  1.5157 0.6438 0.0681 0.0274 0.0429 4861.6 5780.5 Clen Trans 
759 14.2 14.2 16.8 17.6 18.1 21 0.1335 0.0037 0.0166 0.0121 1.4124 1.0492  1.3462 0.6357 0.0790 0.0176 0.0576 5464.7 5792.0 Clen Trans 
769 15.3 16.9 18.6 19.1 20.4 23.2 0.1315 0.0091 0.0114 0.0109 1.3515 1.0596  1.2755 0.5668 0.0491 0.0392 0.0468 5594.6 5857.2 Clen Trans 
784 15.1 16.6 17.3 18.2 19.5 21.8 0.1463 0.0070 0.0187 0.0120 1.3244 1.0614  1.2478 0.6711 0.0858 0.0321 0.0548 4938.5 5444.1 Clen Trans 
785 16.2 17.1 18.6 19.7 19.6 22.5 0.1623 0.0070 0.0191 0.0127 1.3049 1.0791  1.2092 0.7213 0.0849 0.0311 0.0564 4597.6 5761.4 Clen Trans 
789 15.4 17.2 18.4 18.9 19.4 21.8 0.1264 0.0040 0.0154 0.0109 1.4718 1.0515  1.3997 0.5798 0.0706 0.0183 0.0500 4905.1 5324.0 Clen Trans 
790 17.3 18.9 19.5 20.1 21.3 23.2 0.1539 0.0054 0.0174 0.0119 1.2142 1.0406  1.1668 0.6634 0.0750 0.0233 0.0513 4870.7 5223.4 Clen Trans 
837 16.1 18.5 19.1 20.1 20 23.9 0.1382 0.0066 0.0186 0.0121 1.3221 1.1620  1.1378 0.5782 0.0778 0.0276 0.0504 4816.9 5954.1 Clen Trans 
838 16.9 18.4 19.7 20.9 20.1 23.9 0.1402 0.0076 0.0133 0.0117 1.297 1.1475  1.1303 0.5866 0.0556 0.0318 0.0490 4970.7 5881.3 Clen Trans 
840 14.9 16.6 17.2 18.1 17.7 21 0.126 0.0049 0.0134 0.0103 1.2162 1.0728  1.1336 0.6000 0.0638 0.0233 0.0488 0.0119 5757.4 Clen Trans 
757 13.2 14.4 15.7 16.3 18 20.2 0.1288 0.0066 0.0160 0.0105 1.3847 1.0152  1.364 0.6376 0.0792 0.0327 0.0517 0.0155 5854.4 Clen Trans 
836 15.6 17.8 18.7 18.7 18 21.4 0.1209 0.005 0.0149 0.0116 1.2356 1.1051  1.118 0.5650 0.0696 0.0234 0.0540 0.0125 -  Clen Trans 
Animals were weaned at 4 week. C0day, start of CL administration; C3day, 3day of CL administration; C7day, 7day of CL administrationl; Geno, Genotype; CL, 
Clenbuterol; Gas, Gastrocnemius; Pln, Plantaris; EDL, extensor digitorum longus; Sol, Soleus Con, control; Clen, Clenbuterol administration; Wild, wild type mice; 
Trans, Transgenic mice.  
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APPENDIX 2.3 The female raw data at 14 day. 
 wt wt wt wt 0day 3day 7day 10day 14day     mg/g of muscle     Adj. Vol CNT*mm2   
No wean 3day 5day 7day 10day 14day 18day 21day 25day GAS Sol Plan E D L RNA DNA Ratio %Gas %pl %sol %EDL 4EBP1 p70S6k CL Treat 
852 17.1 17.7 17.7 19 19.5 21 21.3 21.3 21.3 0.0906 0.0059 0.011 0.0070 1.096 1.119 0.980 0.4254 0.0516 0.0277 0.0329 2859.9 2840.8 con Wild 
853 15.8 17.6 17.9 18.5 19.4 19.8 20.1 20.3 20.8 0.0992 0.0063 0.0101 0.0071 1.244 0.934 1.333 0.4769 0.0486 0.0303 0.0339 2815.8 3162.1 con Wild 
854 13.8 15.1 15.2 16.3 17 18.4 19 19.3 19.3 0.0803 0.0031 0.0089 0.0062 1.029 0.935 1.101 0.4161 0.0461 0.0161 0.0321 2865.7 3162.1 con Wild 
949 12.7 14.6 16.1 16.6 17.1 17.3 17.9 18 18 0.0791 0.0042 0.0092 0.0060 1.033 1.081 0.956 0.4394 0.0511 0.0233 0.0333 2909.9 2910.9 con Wild 
950 13 13.9 15.5 15.6 16.2 16.7 16.9 17.5 18 0.0763 0.0038 0.0095 0.0059 1.009 1.046 0.965 0.4239 0.0528 0.0211 0.0328 2863.7 3087.8 con Wild 
951 11.4 12.7 14.1 14.4 15.9 16.4 17.1 17.1 17.3 0.0812 0.0037 0.0091 0.0061 1.108 0.928 1.194 0.4694 0.0526 0.0214 0.0353 2653.6 2937.6 con Wild 
961 14.7 16.0 16.5 17.6 18.1 18.2 18.6 18.6 19.4 0.0976 0.0049 0.0092 0.0068 1.150 0.915 1.257 0.5031 0.0474 0.0253 0.0348 2131.7 3842.8 con Wild 
962 12.8 14.2 15.0 15.7 16.6 17.2 18 18 18.1 0.0784 0.004 0.0077 0.0045 1.312 0.762 1.723 0.4331 0.0425 0.0221 0.0249 2682.7 2971.5 con Wild 
25 12.1 14.1 15.3 16.1 17.8 18.7 18.8 19.2 19.6 0.1016 0.004 0.012 0.0091 1.037 1.014 1.023 0.5184 0.0612 0.0204 0.0464 2078.8 2545.6 con Wild 
26 14.2 16.4 17.6 18.4 19.4 19.5 19.7 19.7 19.5 0.0797 0.0047 0.009 0.0051 1.294 0.941 1.375 0.4087 0.0462 0.0241 0.0259 2304.4 3354.2 con Wild 
30 11.3 14.2 15.8 16.4 18 18.3 18.3 18.4 18.9 0.0773 0.0035 0.0083 0.0067 1.232 0.770 1.600 0.4090 0.0439 0.0185 0.0354 - 3228.5 con Wild 
32 12.3 14.3 15.7 16.3 17.6 17.7 18.2 18.4 19 0.0775 0.0054 0.0104 0.0054 1.061 0.935 1.135 0.4079 0.0547 0.0284 0.0282 - 3045.4 con Wild 
865 12.4 13.9 15.3 17.2 18.9 20 20.5 21.2 22 0.1193 0.0043 0.0118 0.0091 1.329 0.914 1.454 0.5423 0.0536 0.0195 0.0414 2957.1 3463.5 con Trans 
960 15 16.5 17.2 17.4 18.2 18.4 19.1 20.7 20.9 0.1152 0.0055 0.0133 0.0094 1.085 0.911 1.191 0.5512 0.0636 0.0263 0.0447 3682.6 3356.5 con Trans 
948 12.3 13.2 14.6 14.8 17.2 19.4 20.1 20.1 21.4 0.1128 0.0053 0.0133 0.0095 1.191 0.937 1.271 0.5271 0.0621 0.0248 0.0444 3244.3 3743.2 con Trans 
17 11.4 13.1 14.2 15.2 17.2 17.8 19.1 19.6 20.1 0.1236 0.0054 0.0148 0.0098 1.121 0.906 1.238 0.6149 0.0736 0.0269 0.0488 3566.6 3743.2 con Trans 
20 14.1 16.9 18.7 18.9 20.1 20.8 21.6 21.5 22.1 0.12 0.0044 0.0145 0.0100 1.209 0.895 1.350 0.5430 0.0656 0.0199 0.0452 3578.1 3905.5 con Trans 
23 12.3 14.7 16.7 16.7 19.5 20.6 21.1 21.6 21.6 0.1252 0.0057 0.0134 0.0104 1.150 0.882 1.304 0.5796 0.0620 0.0264 0.0479 3594.7 3748.5 con Trans 
28 12.7 13.0 14.2 14.4 15.6 15.6 16.6 17.2 17.6 0.0868 0.0043 0.0125 0.0080 1.031 0.875 1.179 0.4932 0.0710 0.0244 0.0452 3929.5 3791.2 con Trans 
31 15.9 17.3 17.3 17.1 18.6 18.7 20.1 21 21 0.1162 0.0047 0.0135 0.0100 1.010 0.867 1.164 0.5533 0.0643 0.0224 0.0476 3924.3 3199.4 con Trans 
72 12.9 14.6 16.3 17.1 21.9 22.9 22.7 23.8 24.1 0.1328 0.006 0.0146 0.0095 1.186 0.898 1.321 0.5510 0.0606 0.0249 0.0392 3208.7 3658.4 con Trans 
85 17.9 19.9 20.4 20.9 21.4 22.4 23.2 24.1 25.3 0.1411 0.0049 0.0172 0.0108 1.198 0.729 1.644 0.5577 0.0680 0.0194 0.0427 3476.6 3926.9 con Trans 
29 12 14.0 15.2 16.6 18.7 19.4 19.6 20.8 21.1 0.1162 0.0059 0.0134 0.0095 1.120 0.655 1.711 0.5507 0.0635 0.0280 0.0450 - 3574.2 con Trans 
846 13.9 15.5 15.5 15.5 15.6 18.3 18.7 19.5 20.1 0.1008 0.0054 0.0097 0.0077 1.294 1.159 1.116 0.5015 0.0483 0.0269 0.0381 2894.9 3852.7 Clen Wild 
847 16.1 16.7 16.7 17.1 17.2 19.3 20 20.9 21.1 0.1071 0.006 0.0107 0.0071 1.282 1.056 1.213 0.5076 0.0507 0.0284 0.0334 2744.1 3872.5 Clen Wild 
848 15.1 16.8 16.6 17.4 17.6 20.2 20.7 21.8 22.3 0.1357 0.0076 0.017 0.0114 1.138 0.886 1.286 0.6085 0.0762 0.0341 0.0509 3200.0 3482.5 Clen Wild 
864 12 14 15 16.2 17.4 18.3 19.3 21.1 21.4 0.1076 0.0053 0.0132 0.0087 1.169 0.911 1.284 0.5028 0.0617 0.0248 0.0404 3678.9 3482.5 Clen Wild 
872 14 15.2 15.8 16.7 17.2 18.5 19.8 20.3 20.1 0.1046 0.007 0.0131 0.0074 1.173 0.797 1.472 0.5204 0.0652 0.0348 0.0368 3217.3 3763.4 Clen Wild 
873 12.2 14.2 15.0 15.6 17.3 17.9 19.2 20.3 19.1 0.106 0.0066 0.0136 0.0089 1.083 0.758 1.428 0.5550 0.0712 0.0346 0.0463 3575.0 3992.0 Clen Wild 
880 13.9 14.6 15.3 16.4 17.6 18.7 19.3 20.1 20.5 0.1047 0.0064 0.016 0.0087 1.037 0.863 1.203 0.5107 0.0780 0.0312 0.0424 3289.9 2626.9 Clen Wild 
882 13.4 13.9 14.8 15.8 16.8 18.4 18.7 19.2 19.7 0.0984 0.0058 0.0137 0.0078 1.120 0.896 1.250 0.4995 0.0695 0.0294 0.0396 2970.5 3706.3 Clen Wild 
886 13.6 15.5 16.3 16.8 18.7 19.9 20.7 21.4 21.1 0.1043 0.0058 0.0126 0.0084 1.096 0.853 1.285 0.4943 0.0597 0.0275 0.0398 2940.3 3775.4 Clen Wild 
893 15.1 14.9 15.9 17.1 18.3 19.8 20.1 21.2 20.7 0.104 0.0042 0.0141 0.0074 1.244 0.834 1.492 0.5024 0.0681 0.0203 0.0357 3047.2 3773.4 Clen Wild 
18 10.6 11.4 13.7 13.9 16.8 17.8 18.7 19.3 19.4 0.0962 0.0052 0.0116 0.0066 1.146 0.790 1.451 0.4959 0.0598 0.0268 0.0338 - 3969.5 Clen Wild 
19 13 14.8 16.2 16.3 18.7 19.3 18.7 19.2 20.1 0.1022 0.0067 0.0131 0.0073 1.030 0.797 1.293 0.5085 0.0652 0.0333 0.0363 - 3699.6 Clen Wild 
21 12 13.6 15.8 15.8 18.1 18.4 19.3 20 20.5 0.1111 0.0056 0.0132 0.0081 1.164 0.758 1.535 0.5420 0.0644 0.0273 0.0395 - 4491.7 Clen Wild 
24 14.4 15.8 17.1 17.5 19.6 19.8 20.5 21 21.6 0.1092 0.006 0.0137 0.0084 1.065 0.903 1.179 0.5056 0.0634 0.0278 0.0387 - - Clen Wild 
874 14.3 15.5 16.6 17 18.2 18.9 20.6 21 22.6 0.1472 0.0069 0.0183 0.0115 1.092 0.799 1.366 0.6513 0.0810 0.0305 0.0507 3481.9 3644.6 Clen Trans 
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883 14.4 16.0 16.6 17 17.8 18.7 19.6 22 23.3 0.1558 0.0082 0.0195 0.0131 1.115 0.822 1.356 0.6687 0.0837 0.0352 0.0560 3981.6 3634.7 Clen Trans 
884 14.7 16.9 18.0 18.4 20.5 21.5 22.9 24.2 24.4 0.1604 0.0072 0.0186 0.0130 1.133 0.807 1.405 0.6574 0.0762 0.0295 0.0531 3920.7 4273.4 Clen Trans 
885 10.8 12.0 13.3 14.9 15.6 17.4 19.3 19.8 19.8 0.1345 0.0049 0.0154 0.0114 1.120 0.787 1.423 0.6793 0.0778 0.0247 0.0573 4084.2 4273.4 Clen Trans 
891 15.8 17.9 18.9 20.4 20.2 21.5 22.4 22.9 22.9 0.1617 0.0074 0.0218 0.0124 1.075 0.823 1.306 0.7061 0.0952 0.0323 0.0541 3810.0 4222.3 Clen Trans 
892 16.3 16.3 17.3 18.7 18.5 19.7 20.9 23.3 23.3 0.1574 0.0075 0.018 0.0130 1.114 0.852 1.308 0.6755 0.0773 0.0322 0.0558 3847.0 4215.2 Clen Trans 
894 14.5 16.4 17.4 19.2 20.1 20.6 22.3 23.7 23.7 0.1653 0.0081 0.021 0.0118 1.055 0.807 1.307 0.6975 0.0886 0.0342 0.0496 4926.2 4414.0 Clen Trans 
881 15.3 16.5 17.5 18.9 18.9 20.1 21 22.9 22.5 0.1644 0.0078 0.0207 0.0116 1.142 0.785 1.455 0.7307 0.0920 0.0347 0.0516 3171.4 4486.5 Clen Trans 
896 13.9 15.2 16.2 18.4 19.8 21.5 22 22.4 23.4 0.1647 0.0071 0.019 0.0123 1.238 0.809 1.531 0.7038 0.0812 0.0303 0.0524 3840.1 5340.1 Clen Trans 
862 11.9 13.8 15.1 16.6 17.6 19.4 20.9 21.9 22.9 0.1492 0.0049 0.0171 0.0118 1.198 0.841 1.425 0.6515 0.0747 0.0214 0.0515 3854.5 4566.9 Clen Trans 
895 12.9 14.2 15.2 16.7 16.7 18.8 19.7 19.9 19.9 0.1109 0.0051 0.0114 0.0090 1.060 0.677 1.565 0.5573 0.0573 0.0256 0.0450 - 4507.1 Clen Trans 
40 10.1 12.0 13.6 15.8 18.3 19.4 22.5 22.7 24.3 0.1426 0.0082 0.0199 0.0112 1.219 0.805 1.515 0.5868 0.0819 0.0337 0.0459 - 4175.4 Clen Trans 
44 11.1 13.7 15.0 17.3 18.8 19 22.4 22.7 23.2 0.1442 0.0072 0.0198 0.0097 1.223 0.755 1.621 0.6216 0.0853 0.0310 0.0418 - 4375.2 Clen Trans 
22 14 16.1 16.9 16.9 19.4 19.4 22.4 22.9 23.2 0.1574 0.0069 0.021 0.0122 1.263 0.729 1.733 0.6784 0.0905 0.0297 0.0526 - - Clen Trans 
Animals were weaned at 4 week. C0day, start of CL administration; C3day, 3day of CL administration; C7day, 7day of CL administration; C10day, 10day of CL 
administration; C14day, 14day of CL administration; Geno, Genotype; CL, Clenbuterol; Gas, Gastrocnemius; Pln, Plantaris; EDL, extensor digitorum longus; Sol, 

















1.2% agarose gel electrophoresis gel stained with ethidium bromide. Lane 1, Wild type mice; Lane 2, 
Transgnice mice; Lane 3, Transgnice mice; Lane 4, Transgnice mice; Lane 5, Transgnice mice; Lane 6, 
Wild type mice; Lane 7, Transgnice mice; Lane 8, Wild type mice. 
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Appendix 3.2 The male raw data at 3day. 
  wt wt C0d C3d     mg/g of muscle     Adj. Vol CNT*mm2    
No wean 3d 5d 7d 10d GAS Sol Plan E D L RNA DNA Ratio %Gas %pl %sol %EDL Akt 4EBP1 p70S6k CL Geno  
721 15.4 16.5 15.6 17.9 18.7 0.0800 0.0054 0.0094 0.0066 0.985 1.379 0.714 0.4278 0.0503 0.0289 0.0350 2483.9 2116.2 2978.5 con Wild * 
667 14.8 15.9 15.6 16.0 16.9 0.0629 0.0038 0.0088 0.0054    0.3722 0.0521 0.0225 0.0320 2703.8 3015.6 2537.9 con Wild * 
702 17.2 18.3 18.9 19.6 20.0 0.1100 0.0067 0.0126 0.0083    0.5500 0.0630 0.0335 0.0413 2297.1 2581.6 2189.2 con Wild  
773 19.7 20.8 22.3 22.3 23.0 0.1193 0.0067 0.0153 0.0079 0.935 1.178 0.794 0.5187 0.0665 0.0291 0.0343 2432.3 2027.3 2038.8 con Wild  
774 15.7 16.8 17.7 18.6 19.1 0.0845 0.0041 0.0109 0.0069 1.282 1.196 1.072 0.4424 0.0571 0.0215 0.0361 2418.5 3569.0 2066.9 con Wild * 
776 17.4 18.5 20.5 21.4 21.8 0.1229 0.0056 0.0152 0.0091 1.011 1.108 0.912 0.5638 0.0697 0.0257 0.0417 1841.4 3290.9 3285.4 con Wild * 
779 17.5 18.6 19.9 20.1 20.2 0.1044 0.0048 0.0126 0.0084 0.992 1.152 0.861 0.5168 0.0624 0.0238 0.0416 1827.9 3047.1 2714.4 con Wild  
781 16.3 17.4 18.5 19.5 20.6 0.0976 0.0059 0.0115 0.0070    0.4738 0.0558 0.0286 0.0340 2269.7 2371.3 2367.7 con Wild  
821 16.1 17.2 18.8 19.7 19.3 0.0892 0.0045 0.0092 0.0067 1.102 1.262 0.873 0.4622 0.0477 0.0233 0.0347 1429.7 2492.9 2232.0 con Wild * 
822 18.2 19.3 23 23.7 23.4 0.1285 0.0076 0.0130 0.0089 1.137 1.464 0.777 0.5491 0.0556 0.0325 0.0378 2354.7 2646.7 1853.2 con Wild * 
825 15 16.1 18.9 19.7 19.4 0.0899 0.0042 0.0079 0.0065 1.262 1.275 0.990 0.4634 0.0407 0.0216 0.0335 2061.9 2158.8 2217.2 con Wild  
673 23.7 24.8 24.3 24.8 24.8 0.1822 0.0044 0.0213 0.0127    0.7347 0.0859 0.0177 0.0510 - - - con Trans * 
703 19.4 20.5 20.6 22.3 22.6 0.1491 0.0061 0.0168 0.0112 0.841 1.157 0.727 0.6597 0.0743 0.0270 0.0496 3781.8 2474.4 3531.5 con Trans  
720 20.0 21.1 20.1 22.7 24.0 0.1446 0.0065 0.0154 0.0100 1.079 1.164 0.927 0.6025 0.0642 0.0271 0.0417 2718.6 2047.0 2821.7 con Trans * 
704 18.2 19.3 20.8 19.0 20.9 0.1248 0.0062 0.0156 0.0103 1.262 1.029 1.227 0.5971 0.0746 0.0297 0.0493 2443.7 3866.3 2386.9 con Trans * 
823 17 18.1 21 22.9 22.3 0.1262 0.0036 0.0144 0.0096    0.5659 0.0646 0.0161 0.0428 - - - con Trans * 
829 14.2 15.3 18.8 20.4 20 0.1163 0.0050 0.0151 0.0107 1.176 1.144 1.028 0.5815 0.0755 0.0250 0.0535 3221.3 3806.0 2819.1 con Trans * 
830 16.8 17.9 21.2 23.3 22.9 0.1394 0.0054 0.0154 0.0102 1.358 1.055 1.287 0.6087 0.0672 0.0236 0.0443 2976.7 2615.6 3070.5 con Trans * 
772 14.5 15.6 17.0 18.9 20.9 0.1291 0.0050 0.0153 0.0105 1.163 1.155 1.007 0.6177 0.0732 0.0239 0.0502 3432.7 3117.4 4887.5 con Trans  
824 20 21.1 23.7 25.1 24.6 0.1575 0.0079 0.0172 0.0116 1.110 1.158 0.958 0.6402 0.0699 0.0321 0.0472 3286.7 4098.9 4792.6 con Trans  
826 15.9 17.0 17.2 18.6 18.7 0.1031 0.0024 0.0127 0.0088 1.161 1.042 1.114 0.5513 0.0679 0.0128 0.0471 2560.7 3803.9 3745.3 con Trans  
2 13.9 15.0 18.9 20 21.7 0.1104 0.0046 0.0118 0.0094    0.5088 0.0544 0.0212 0.0433 2834.4 3246.6 3526.0 con Trans  
11 16.4 17.5 21.8 23.5 25.2 0.1190 0.0052 0.0153 0.0105 1.074 1.236 0.870 0.4722 0.0607 0.0206 0.0415 2268.3 3064.4 3118.5 con Trans  
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13 14 15.1 20.8 22.4 24.9 0.1455 0.0073 0.0169 0.0109 1.033 1.045 0.988 0.5843 0.0679 0.0293 0.0438 2806.0 3265.6 3650.2 con Trans  
15 14 15.1 17.9 19.4 21.3 0.1092 0.0056 0.0127 0.0094 1.192 1.180 1.010 0.5127 0.0596 0.0263 0.0439 2640.0 4101.4 3979.9 con Trans  
16 14.4 15.5 18.9 20.4 22.7 0.1150 0.0045 0.0110 0.0094    0.5066 0.0485 0.0198 0.0412 2006.6 2336.0 3299.4 con Trans  
710 16.8 17.9 18.5 18.8 20.4 0.1193 0.0061 0.0139 0.0081 1.537 1.173 1.311 0.5848 0.0681 0.0299 0.0397 4040.4 3172.3 3247.2 Clen Wild  
711 20.9 22.0 19.1 20.7 21.4 0.1246 0.0095 0.0141 0.0097 1.367 1.151 1.188 0.5822 0.0659 0.0444 0.0451 3111.6 2650.8 3706.4 Clen Wild  
792 20.7 21.8 23.0 23.8 25.4 0.1416 0.0069 0.0182 0.0112 1.410 1.137 1.239 0.5575 0.0717 0.0272 0.0441 2665.7 3952.9 2681.9 Clen Wild  
794 20.0 21.1 21.6 22.3 23.9 0.1337 - 0.0147 0.0120 1.212 1.042 1.163 0.5594 0.0615 - 0.0500 - - - Clen Wild  
795 16.9 18.0 18.9 19.6 21.4 0.1172 0.0059 0.0146 0.0113 1.474 1.161 1.269 0.5477 0.0682 0.0276 0.0528 3506.1 4134.8 3112.6 Clen Wild  
804 17 18.1 19.3 20 21.6 0.1151 0.0057 0.0121 0.0087 1.271 1.091 1.166 0.5329 0.0560 0.0264 0.0400 3323.8 3133.0 2942.1 Clen Wild * 
805 17.3 18.4 20.3 21.4 24 0.1460 0.0060 0.0178 0.0119 1.065 1.165 0.914 0.6083 0.0742 0.0250 0.0496 3436.8 3782.2 4738.7 Clen Wild * 
806 17.1 18.2 17.6 18 19.1 0.1005 0.0043 0.0124 0.0078 1.224 0.808 1.516 0.5262 0.0649 0.0225 0.0408 2819.3 4027.7 5303.2 Clen Wild * 
812 15.3 16.4 21.3 22.7 22.6 0.1402 0.0052 0.0183 0.0126 1.630 1.117 1.460 0.6204 0.0810 0.0230 0.0558 3702.7 4220.2 3517.0 Clen Wild * 
813 16.8 17.9 20.8 21.5 21.8 0.1212 0.0042 0.0141 0.0089 1.669 1.160 1.439 0.5560 0.0647 0.0193 0.0406 4189.3 3582.7 2942.3 Clen Wild * 
816 14.6 15.7 19.9 20.5 21.3 0.1029 0.0062 0.0126 0.0096 1.294 1.189 1.088 0.4831 0.0592 0.0291 0.0448 1817.2 3118.3 3481.8 Clen Wild  
869 14.4 15.5 16.7 17.6 19.6 0.0816 0.0043 0.0106 0.0073 1.064 1.040 1.023 0.4163 0.0541 0.0219 0.0372 2566.2 3252.7 3234.2 Clen Wild  
887 12.5 13.6 15.8 18.4 20 0.0950 0.0050 0.0119 0.0085 1.129 1.150 0.982 0.4750 0.0595 0.0250 0.0423 2713.3 4299.7 4343.5 Clen Wild * 
889 15.5 16.6 18.2 19.8 21.2 0.1048 0.0056 0.0128 0.0087 0.963 1.091 0.883 0.4943 0.0604 0.0264 0.0410 2700.6 2506.0 3395.2 Clen Wild * 
890 17.3 18.4 20.8 21.5 23 0.1262 0.0076 0.0174 0.0102 0.864 1.023 0.844 0.5487 0.0757 0.0330 0.0443 - - - Clen Wild * 
986 15.3 16.4 19.5 21.5 24.4 0.1372 0.0060 0.0198 0.0126 1.016 1.067 0.952 0.5623 0.0811 0.0246 0.0514 - - - Clen Wild * 
994 17.2 18.3 21.2 22 22.9 0.1105 0.0068 0.0125 0.0084 1.018 1.049 0.970 0.4825 0.0546 0.0297 0.0365 - - - Clen Wild * 
402 17 18.1 20.7 20.9 23 0.1025 0.0063 0.0132 0.0092 0.999 1.052 0.950 0.4457 0.0574 0.0274 0.0400 - - - Clen Wild * 
403 16.7 17.8 20 20.7 21.5 0.1018 0.0072 0.0186 0.0082 0.922 0.710 1.299 0.4735 0.0865 0.0335 0.0379 - - - Clen Wild * 
404 14.6 15.7 20.4 20.7 22.9 0.1064 0.0063 0.0171 0.0085 1.033 1.030 1.003 0.4646 0.0747 0.0275 0.0371 - - - Clen Wild * 
405 15.6 16.7 19.2 19.7 21.2 0.1037 0.0065 0.0164 0.0098 1.052 1.040 1.011 0.4892 0.0774 0.0307 0.0460 - - - Clen Wild * 
406 17.3 18.4 19.8 19.3 20.7 0.1019 0.0061 0.0124 0.0085 1.003 1.099 0.913 0.4923 0.0599 0.0295 0.0411 - - - Clen Wild * 
413 18.2 19.3 21.4 21.7 22.4 0.1047 0.0059 0.0130 0.0087 0.865 1.023 0.846 0.4674 0.0580 0.0263 0.0386 - - - Clen Wild * 
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414 15 16.1 17.4 19.6 20.6 0.1053 0.0055 0.0136 0.0090 0.789 1.100 0.718 0.5112 0.0660 0.0267 0.0437 - - - Clen Wild * 
415 15.8 16.9 19.2 22.9 23.6 0.1448 0.0071 0.0202 0.0127 0.940 1.149 0.818 0.6136 0.0856 0.0301 0.0538 - - - Clen Wild  
672 21.8  22.9 23.6 24.1  25.9  0.1963 0.0090 0.0273 0.0163    0.7579  0.1054 0.0347 0.0647       Clen Trans * 
705 18.6  19.7 20.4 22.4  24.2  0.1817 0.0085 0.0254 0.0118    0.7508  0.1050 0.0351 0.0508       Clen Trans   
706 19.9  21.0 21.1 23.3  24.8  0.1836 0.0064 0.0281 0.0121 1.228 1.018 1.206 0.7403  0.1133 0.0258 0.0508 5181.0 4741.2 5233.9 Clen Trans   
791 16.5  17.6 19.7 21.0  22.6  0.1417 0.0065 0.0177 0.0133 1.307 0.980 1.334 0.6270  0.0783 0.0288 0.0586 4762.2 4078.9 5401.4 Clen Trans * 
793 17.0  18.1 19.8 20.5  22.9  0.1549 0.0061 0.0181 0.0141 1.256 0.934 1.345 0.6764  0.0790 0.0266 0.0616 4391.3 6488.0 4163.8 Clen Trans * 
802 17 18.1 21.4 22.3 23.6 0.1408 0.0068 0.0174 0.0122 1.310 0.912 1.437 0.5966  0.0737 0.0288 0.0536 4223.7 5307.4 6051.3 Clen Trans * 
811 18.3 19.4 22 23.2 25.6 0.1881 0.0087 0.0247 0.0138 1.637 1.052 1.557 0.7348  0.0965 0.0340 0.0559 4942.5 4889.9 4352.8 Clen Trans * 
844 19.2 20.3 21.8 22.5  24.1 0.1426 0.0036 0.0174 0.0125 1.224 0.950 1.288 0.5917  0.0722 0.0149 0.0560 4262.4 5777.9 6707.4 Clen Trans   
803 14.2 15.3 18.5 19.9 21.7 0.1454 0.007 0.017 0.0112 1.461 0.925 1.579 0.6700  0.0783 0.0323 0.0537 5100.5 6017.8 6839.1 Clen Trans * 
814 13.9 15.0 18.7 20.7 20.6 0.1379 0.0062 0.0172 0.0102 1.384 0.980 1.411 0.6694  0.0835 0.0301 0.0568 4275.4 5689.7 5624.3 Clen Trans * 
842 19.1 20.2 20.5 20.8  22.4 0.1548 0.0073 0.0178 0.0117 1.364 0.971 1.406 0.6911  0.0795 0.0326 0.0520 4898.7 4995.6 5190.9 Clen Trans * 
843 20.5 21.6 24.7 25.2  27.7 0.1989 0.0078 0.0279 0.0144 1.272 0.870 1.462 0.7181  0.1007 0.0282 0.0518 5429.3 5289.6 5337.4 Clen Trans   
888 17.3 18.4 20.4 22.4 23.3 0.1782 0.0065 0.021 0.0127 1.115 0.951 1.172 0.7648  0.0901 0.0279 0.0567 4173.5 5528.3 5357.8 Clen Trans * 
868 16.8 17.9 21.2 22.4 23.7 0.1621 0.0056 0.0193 0.0133 1.359 0.960 1.415 0.6840  0.0814 0.0236 0.0603 4809.0 6123.2 5686.6 Clen Trans * 
871 14.8 15.9 18.4 19.8 21.9 0.1429 0.0055 0.0182 0.0110 1.377 0.947 1.454 0.6525  0.0831 0.0251 0.0525 4827.0 4565.2 6535.3 Clen Trans * 
878 16 17.1 19.4 19.3 21.7 0.1244 0.0033 0.0172 0.0100 1.261 0.966 1.305 0.5733  0.0793 0.0152 0.0461      Clen Trans * 
47 15.8 16.9 22.7 23.3 24.5 0.1571 0.0064 0.0175 0.0118 1.285 0.996 1.291 0.6412  0.0714 0.0261 0.0480      Clen Trans * 
55 13.7  14.8 19.4 20.4  22.7  0.1410 0.0039 0.0169 0.0132 1.403 0.870 1.613 0.6211  0.0744 0.0172 0.0601      Clen Trans * 
64 13.1 14.2 18.2 21 22.7 0.1444 0.0057 0.017 0.0110 1.007 0.926 1.087 0.6361  0.0749 0.0251 0.0507      Clen Trans * 
Animals were weaned at 4 week. C0day, start of CL administration; C3day, 3day of CL administration; Geno, Genotype; CL, Clenbuterol; Gas, Gastrocnemius; Pln, Plantaris; EDL, extensor 
digitorum longus; Sol, Soleus Con, control; Clen, Clenbuterol administration; Wild, wild type mice; Trans, Transgenic mice; * indicates animals that were not used for microarray. 
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Appendix 3.3 The male raw data at 14 day.  
  wt wt C0d C3d C7d C10d C14d     mg/g of muscle     Adj. Vol CNT*mm2   
No wean 3d 5d 7d 10d 14d 17d 21d GAS Sol Plan E D L RNA DNA Ratio %Gas %pl %sol %EDL Akt 4EBP1 p70S6k CL Geno 
855 13.6 15.1 16.5 17.6 17.8  18.9  20.8 21.2 0.1132 0.0035 0.0110 0.0095 1.128 0.862 1.308 0.5340 0.0519 0.0165 0.0446 2639.8 1346.3 3099.5 con Wild 
857 12.6 14.8 17.2 19.4 20.3  21.4  23.2 24.2 0.1157 0.0056 0.0123 0.0080 1.183 0.792 1.493 0.4781 0.0508 0.0231 0.0329 1823.9 2441.3 2787.9 con Wild 
858 13.7 16.0 17.4 19.4 20.0  21.3  21.8 22.2 0.1183 0.0057 0.0128 0.0092 1.052 0.940 1.118 0.5329 0.0577 0.0257 0.0414 1189.3 2265.7 4036.1 con Wild 
860 12.4 14.0 16.4 18.0 19.3  20.2  20.9 22.8 0.1078 0.0049 0.0101 0.0066 1.139 1.281 0.889 0.4728 0.0443 0.0215 0.0287 1887.0 2690.8 2655.6 con Wild 
870 15.9 17.9 18.7 18.9 19.8  19.8  20.4 21.3 0.1022 0.0046 0.0111 0.0068 1.620 1.013 1.600 0.4798 0.0521 0.0216 0.0317 2147.0 1714.9 2613.9 con Wild 
875 15.4 17.4 18.8 19.5 20.4  21.4  22.4 22.9 0.1228 0.0048 0.0136 0.0091 1.313 1.081 1.214 0.5362 0.0594 0.0210 0.0397 1945.9 2146.5 2702.5 con Wild 
876 17.2 19.2 20.0 20.3 20.9  21.3  22.1 22.4 0.1039 0.0052 0.0151 0.0078 1.245 1.061 1.173 0.4638 0.0674 0.0232 0.0348 1804.1 2747.3 3366.4 con Wild 
879 15.5 17.5 19.1 20.6 21.6  22.4  23.3 23.3 0.1253 0.0057 0.0135 0.0099 1.303 1.029 1.265 0.5378 0.0579 0.0245 0.0423 2414.4 2713.0 1741.0 con Wild 
145 17.4 20.1 22.6 22.6 24.1  23.8  24.5 24.9 0.1317 0.0081 0.0157 0.0088 1.204 1.084 1.110 0.5289 0.0631 0.0325 0.0351 2405.5 4012.6 2753.3 con Wild 
146 17.0 19.6 21.3 20.7 21.9  22.7  23.4 24.1 0.1181 0.0064 0.0138 0.0079 1.170 1.057 1.107 0.4900 0.0573 0.0266 0.0328 2378.3 2557.1 2344.8 con Wild 
438 16.7 19.3 22.1 22.8 22.3  23.7  25.2 24.6 0.1280 0.0051 0.0155 0.0082 1.192 1.064 1.119 0.5203 0.0630 0.0207 0.0333 2250.4 2156.6 1770.1 con Wild 
441 19.4 21.0 22.5 22.3 24.5  25.3  27.8 27.2 0.1774 0.0053 0.0193 0.0139 1.223 0.848 1.441 0.6522 0.0710 0.0195 0.0509 - 2037.9 2557.4 con Wild 
444 19.4 19.0 18.7 19.0 18.9  19.2  20.6 20.7 0.1134 0.0037 0.0121 0.0081 - - - 0.5478 0.0585 0.0179 0.0389 - 2239.7 2440.2 con Wild 
856 15.7 16.9 18.5 19.5 20.7  24.1  25.3 26.3 0.1782 0.0055 0.0199 0.0142 1.263 0.791 1.596 0.6776 0.0757 0.0209 0.0540 3007.4 2092.0 4181.4 con Trans 
859 14.7 16.0 17.9 19.5 20.5  22.7  24.1 25.1 0.1865 0.0070 0.0202 0.0135 1.395 0.847 1.646 0.7430 0.0805 0.0279 0.0538 2941.6 2623.4 3297.4 con Trans 
861 13.5 15.5 18.3 19.5 21.7  22.5  23.8 24.3 0.1672 0.0064 0.0186 0.0119 1.153 0.838 1.376 0.6881 0.0765 0.0263 0.0488 3173.5 3206.4 3540.1 con Trans 
953 14.3 16.9 17.7 18.9 20.3  21.1  22.4 22.6 0.1436 0.0057 0.0159 0.0103 1.219 0.764 1.595 0.6354 0.0704 0.0252 0.0456 2720.9 3341.8 3695.2 con Trans 
75 17.7 18.9 22.0 22.5 24.2  26.2  27.2 27.5 0.1702 0.0072 0.0214 0.0132 1.276 0.739 1.725 0.6189 0.0778 0.0262 0.0480 3599.5 2500.3 2809.0 con Trans 
77 15.3 17.4 18.8 19.6 21.3  23.3  24.4 26.1 0.1581 0.0072 0.0176 0.0130 1.178 0.737 1.597 0.6057 0.0674 0.0276 0.0498 3059.4 3317.9 2974.2 con Trans 
84 17.5 19.0 22.6 23.5 23.9  25.6  26.8 27.2 0.1733 0.0059 0.0186 0.0125 1.144 0.687 1.663 0.6371 0.0684 0.0217 0.0458 1985.2 3349.0 3534.1 con Trans 
144 18.8 20.9 23.2 23.4 24.8  27.1  28.3 29.6 0.1958 0.0075 0.0217 0.0141 1.209 0.906 1.334 0.6615 0.0733 0.0253 0.0476 2787.6 4169.3 4775.2 con Trans 
155 19.4 21.3 22.8 22.9 23.8  24.5  25.8 26.5 0.1395 0.0074 0.0152 0.0092 1.338 0.873 1.533 0.5264 0.0574 0.0279 0.0347 2817.9 2715.7 3462.9 con Trans 
171 19.6 - - 21.1 24.3  25.9  27.1 28.0 0.1940 0.0054 0.0274 0.0128 1.332 0.981 1.357 0.6929 0.0979 0.0193 0.0457 2951.4 2965.7 2816.2 con Trans 
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424 18.9 21.4 23.5 23.8 25.8  27.2  28.7 29.2 0.1912 0.0068 0.0225 0.0129 1.263 0.976 1.293 0.6548 0.0771 0.0233 0.0440 2262.4 4182.0 2299.9 con Trans 
440 21.5 23.4 25.2 25.1 27.5  28.1  28.1 28.1 0.1993 0.0065 0.0236 0.0142 1.055 0.951 1.109 0.7093 0.0840 0.0231 0.0504 - 2958.3 3158.8 con Trans 
442 19.5 21.4 23.6 24.0 25.9  26.7  27.6 28.2 0.1871 0.0075 0.0217 0.0142 1.202 0.964 1.245 0.6635 0.0770 0.0266 0.0502 - 3009.4 3915.6 con Trans 
944 15.1 17.2 19.0 19.8 20.7  22.9  24.5 25.7 0.1438 0.0073 0.0185 0.0118 1.148 0.952 1.206 0.5595 0.0720 0.0284 0.0457 2267.7 2005.1 3031.1  Clen Wild 
947 12.4 15.0 16.1 17.5 19.4  21.3  22.7 22.8 0.1191 0.0058 0.0175 0.0097 1.213 0.914 1.326 0.5224 0.0768 0.0254 0.0423 2659.2 2461.1 3227.2  Clen Wild 
956 14.2 16.7 17.9 18.9 19.3  21.2  22.4 22.7 0.1230 0.0080 0.0157 0.0108 1.142 0.937 1.218 0.5419 0.0692 0.0352 0.0474 3204.7 2708.8 3044.7  Clen Wild 
958 15.6 18.2 18.5 19.3 20.1  22.3  23.8 24.4 0.1430 0.0077 0.0168 0.0109 1.239 0.948 1.306 0.5861 0.0689 0.0316 0.0447 3059.8 3098.4 2909.3  Clen Wild 
3 12.5 14.6 16.9 18.1 19.1  21.4  22.1 21.9 0.1210 0.0065 0.0136 0.0084 1.276 0.981 1.300 0.5525 0.0621 0.0297 0.0381 3014.8 2260.8 3069.4  Clen Wild 
7 12.0 15.1 18.2 19.2 22.6  24.3  24.9 25.3 0.1341 0.0071 0.0176 0.0105 1.289 0.925 1.392 0.5300 0.0696 0.0281 0.0415 2664.8 2893.3 2916.4  Clen Wild 
8 17.2 19.6 21.4 22.0 22.8  25.1  25.0 24.8 0.1304 0.0070 0.0192 0.0084 1.033 0.896 1.153 0.5258 0.0774 0.0282 0.0339 3155.9 2986.6 3250.9  Clen Wild 
10 17.2 20.2 21.9 22.7 22.9  24.8  25.3 25.5 0.1481 0.0088 0.0184 0.0088 1.219 0.915 1.333 0.5808 0.0722 0.0345 0.0343 2740.5 3353.3 3871.3  Clen Wild 
12 13.2 15.9 18.8 20.3 22.5  24.4  25.4 26.6 0.1452 0.0075 0.0185 0.0116 1.287 0.941 1.367 0.5459 0.0695 0.0282 0.0434 3616.3 3928.0 3932.6  Clen Wild 
153 16.8 17.4 19.1 19.4 20.3  22.5  23.3 25.3 0.1309 0.0081 0.0158 0.0090 1.256 0.887 1.415 0.5174 0.0625 0.0320 0.0354 2553.9 2841.8 2976.2  Clen Wild 
154 19.0 18.4 19.1 18.6 20.3  22.7  24.1 25.5 0.1335 0.0091 0.0177 0.0092 1.108 0.955 1.160 0.5235 0.0694 0.0357 0.0359 2181.3 2831.1 2917.2  Clen Wild 
164 20.9 22.3 - 21.7 22.2  24.7  26.3 27.4 0.1477 0.0091 0.0126 0.0129 1.319 0.930 1.416 0.5391 0.0460 0.0332 0.0469 - 2859.5 3095.1  Clen Wild 
165 19.3 18.0 - 18.8 21.5  24.5  25.3 25.9 0.1422 0.0077 0.0116 0.0124 1.175 0.942 1.247 0.5490 0.0448 0.0297 0.0479 - 2878.8 3104.1  Clen Wild 
172 17.8 - - 20.4 21.6  24.0  25.7 26.3 0.1434 0.0109 0.0186 0.0129 1.353 0.953 1.420 0.5452 0.0707 0.0414 0.0490 - - - Clen Wild 
173 18.2 - - 20.3 20.4  23.6  24.5 26.2 0.1401 0.0085 0.0197 0.0128 1.246 0.848 1.469 0.5347 0.0752 0.0324 0.0487 - - - Clen Wild 
425 15.2 17.9 20.0 22.7 24.6  26.8  28.1 28.3 0.1465 0.0095 0.0140 0.0126 1.273 1.062 1.199 0.5177 0.0495 0.0336 0.0445 - - - Clen Wild 
427 18.3 19.4 21.6 21.4 22.1  24.6  25.0 25.4 0.1455 0.0081 0.0195 0.0090 1.237 0.905 1.367 0.5728 0.0768 0.0319 0.0352 - - - Clen Wild 
429 16.9 19.0 21.5 21.8 25.7  27.6  29.0 29.8 0.1489 0.0082 0.0221 0.0139 1.304 1.025 1.272 0.4997 0.0742 0.0275 0.0465 - - - Clen Wild 
943 15.7 18.5 20.4 21.2 22.7  25.1  25.8 27.8 0.1938 0.0079 0.0237 0.0156 1.358 0.744 1.823 0.6971 0.0853 0.0284 0.0559 3479.1 2835.8 4676.9 Clen Trans 
946 15.1 17.9 19.3 20.6 22.1  25.2  25.5 26.4 0.1866 0.0096 0.0258 0.0143 1.307 0.891 1.467 0.7068 0.0977 0.0364 0.0542 3579.0 3631.9 3360.8 Clen Trans 
952 14.4 17.3 19.0 20.2 21.8  25.7  25.6 26.0 0.1855 0.0082 0.0202 0.0146 1.332 0.664 2.005 0.7135 0.0777 0.0315 0.0562 3980.8 3430.5 2853.1 Clen Trans 
957 17.2 20.0 20.3 20.9 23.2  25.0  25.2 26.3 0.1858 0.0053 0.0227 0.0149 1.349 0.832 1.622 0.7065 0.0863 0.0202 0.0565 3778.0 3812.9 4054.1 Clen Trans 
959 14.2 16.2 17.0 18.2 20.2  25.2  25.6 26.1 0.1740 0.0074 0.0213 0.0134 1.147 0.803 1.428 0.6667 0.0816 0.0284 0.0513 3751.4 2785.9 3729.6 Clen Trans 
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4 15.9 18.8 21.3 21.3 23.9  27.3  28.3 27.9 0.1966 0.0100 0.0208 0.0136 1.083 0.750 1.443 0.7047 0.0746 0.0358 0.0487 4728.0 3791.6 3321.9 Clen Trans 
5 16.2 18.8 21.1 22.1 24.9  27.7  28.5 27.4 0.1939 0.0097 0.0249 0.0145 1.151 0.820 1.403 0.7077 0.0909 0.0354 0.0527 4245.2 2828.2 3195.0 Clen Trans 
6 15.0 16.8 19.2 20.4 22.3  25.8  26.0 27.9 0.1942 0.0058 0.0262 0.0153 1.334 0.874 1.526 0.6961 0.0939 0.0208 0.0548 4208.3 4156.7 4221.1 Clen Trans 
14 12.4 15.5 18.5 20.9 23.0  25.9  26.9 26.8 0.1946 0.0091 0.0239 0.0130 1.275 0.797 1.597 0.7261 0.0892 0.0340 0.0485 4370.0 4146.1 4267.7 Clen Trans 
174 18.2 - - 20.4 22.3  26.7  27.6 28.0 0.1882 0.0064 0.0243 0.0146 1.197 0.837 1.430 0.6721 0.0868 0.0229 0.0520 3059.4 3016.0 4380.5 Clen Trans 
984 16.5 18.9 23.0 23.9 26.9  28.4  31.5 31.1 0.2009 0.0078 0.0273 0.0158 1.313 0.827 1.587 0.6460 0.0878 0.0251 0.0506 3147.4 5066.7 4402.2 Clen Trans 
995 22.9 26.8 27.4 26.6 30.8  33.2  35.9 35.8 0.2566 0.0105 0.0364 0.0194 1.154 0.869 1.327 0.7168 0.1017 0.0293 0.0541 - 5411.3 4445.4 Clen Trans 
996 20.2 24.5 25.3 24.8 27.0  31.4  31.4 31.9 0.2448 0.0087 0.0298 0.0138 1.201 0.814 1.474 0.7674 0.0934 0.0273 0.0433 - 3410.6 5649.5 Clen Trans 
401 19.6 22.4 24.7 24.9 28.2  30.2  31.1 32.9 0.2022 0.0107 0.0322 0.0185 1.214 0.751 1.614 0.6146 0.0979 0.0325 0.0562 - - - Clen Trans 
Animals were weaned at 4 week. C0day, start of CL administration; C3day, 3day of CL administration; C7day, 7day of CL administration; C10day, 10day of CL administration; C14day, 14day of CL 
administration; Geno, Genotype; CL, Clenbuterol; Gas, Gastrocnemius; Pln, Plantaris; EDL, extensor digitorum longus; Sol, Soleus Con, control; Clen, Clenbuterol administration; Wild, wild type mice; 
Trans, Transgenic mice
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Appendix 3.4 The raw data of RT-PCR. 
W VS M W VS CLW M VS CLM CLW VS CLM 
Gene Ct Gene Ct Gene Ct Gene Ct Gene Ct Gene Ct Gene Ct Gene Ct 
A1 23 D1 24.8 G1 24.7 J1 26.6 M1 N/A P1 20.9 S1 22 V1 20.3
A2 27.2 D2 21.3 G2 26.8 J2 22 M2 26.2 P2 21.9 S2 22.1 V2 21.2
A3 28.5 D3 22.9 G3 26.8 J3 23 M3 26.4 P3 21.6 S3 21.7 V3 21 
A4 26 D4 22.8 G4 26.6 J4 24.2 M4 26.9 P4 21.9 S4 22.3 V4 21.3
A5 28.7 D5 21.2 G5 26.1 J5 22.8 M5 26.6 P5 21.1 S5 21.9 V5 21.1
A6 28.6 D6 21 G6 26.3 J6 23.9 M6 26.7 P6 21.4 S6 22.8 V6 22 
A7 29.7 D7 22.9 G7 30.2 J7 24.6 M7 27.4 P7 21.5 S7 23.3 V7 25 
A8 N/A D8 24.6 G8 27.5 J8 22.6 M8 N/A P8 21.2 S8 23.3 V8 32.1
A9 24.1 D9 23.7 G9 26.4 J9 22.5 M9 31.6 P9 21 S9 23.8 V9 20.3
A10 23.4 D10 22 G10 26.9 J10 22.5 M10 29.1 P10 21.6 S10 22.3 V10 20.2
A11 24 D11 21.7 G11 26.9 J11 21.1 M11 26.1 P11 21.2 S11 22.8 V11 22.4
A12 24.9 D12 24 G12 28.6 J12 23.3 M12 25.6 P12 21 S12 21.4 V12 21.1
A13 31.1 D13 23.1 G13 28.1 J13 22.2 M13 26.2 P13 21 S13 22 V13 24.8
A14 28.4 D14 35 G14 29.5 J14 26.5 M14 25.6 P14 21.2 S14 22.3 V14 23.7
A15 44.8 D15 23.9 G15 28.9 J15 25.2 M15 26.5 P15 20.7 S15 21.1 V15 32.2
A16 29.4 D16 26.3 G16 29.8 J16 29.6 M16 28.9 P16 20.4 S16 23.2 V16 25.1
A17 33.1 D17 20.7 G17 22.6 J17 21.8 M17 29.8 P17 22.7 S17 21.5 V17 26.8
A18 26.7 - - G18 29.8 J18 29.1 M18 28.8 P18 23 S18 22.5 V18 22.6
A19 N/A D19 13.2 G19 15.9 J19 15.6 M19 17.3 P19 17.6 S19 19.2 V19 18.3
A20 N/A D20 15.8 G20 14.1 J20 18.8 M20 13 P20 14 S20 18.5 V20 18 
A21 19.5 D21 16.2 G21 15.2 J21 18.6 M21 15 P21 15 S21 20.4 V21 18.8
A22 18.8 D22 17.5 G22 16.8 J22 16.1 M22 13.6 P22 13.7 S22 19.7 V22 18.6
A23 18.5 D23 17.2 G23 15.2 J23 15.2 M23 12.3 P23 12.6 S23 20.6 V23 18.6
A24 18.4 D24 15.4 G24 14.1 J24 14.6 M24 13.6 P24 14.6 S24 20.5 V24 18.1
A25 17.8 D25 13.7 G25 14.7 J25 15 M25 13.2 P25 17.2 S25 20.2 V25 17.7
A26 19.2 D26 13.6 G26 13.7 J26 15.2 M26 16.1 P26 17.3 S26 19.4 V26 17.2
A27 19.9 D27 15.1 G27 16.4 J27 17.8 M27 13.6 P27 15.9 S27 19.7 V27 18.1
A28 N/A D28 14.7 G28 14.3 J28 18.7 M28 14.6 P28 14.8 S28 19.5 V28 17 
A29 19.5 D29 18.9 G29 16 J29 18.7 M29 13.2 P29 16.5 S29 18.6 V29 17.5
A30 18.4 D30 16.2 G30 15 J30 18.9 M30 13 P30 16 S30 18.1 V30 18.2
A31 19.8 D31 15.3 G31 14.9 J31 15.2 - - - - - - - - 
A32 18.9 D32 16 G32 14 J32 17.6 - - - - - - - - 
A33 18.7 D33 13.6 G33 14.8 J33 18.2 - - - - - - - - 
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A34 18.2 D34 14.8 G34 14.3 J34 18.1 - - - - - - - - 
A35 19 D35 16.7 G35 14.9 J35 18.7 - - - - - - - - 
A36 N/A D36 16.3 G36 13.2 J36 18.9 - - - - - - - - 
B1 22.6 E1 21.9 H1 20.7 K1 N/A N1 18 Q1 22 T1 20.9 W1 23.7
B2 22.6 E2 21.6 H2 20.6 K2 22.5 N2 20.2 Q2 21.1 T2 21.9 W2 25 
B3 22.8 E3 21.2 H3 19.7 K3 22 N3 19.2 Q3 21.7 T3 21.6 W3 23.2
B4 23.7 E4 21.4 H4 19.1 K4 21 N4 20.3 Q4 21.3 T4 21.9 W4 25.4
B5 23.1 E5 21.6 H5 20.2 K5 21.7 N5 20.8 Q1 21.9 T5 21.1 W5 24.1
B6 21.4 E6 23.9 H6 19.6 K6 23.5 N6 19 Q2 21.8 T6 21.4 W6 23.2
B7 21 E7 23.7 H7 22.4 K7 25.8 N7 18.7 Q3 23.3 T7 21.5 W7 24.9
B8 22.8 E8 21.1 H8 19.3 K8 N/A N8 17.5 Q4 23.3 T8 21.2 W8 26 
B9 23.3 E9 21.4 H9 21.5 K9 N/A N9 20.1 Q1 23.8 T9 21 W9 25 
B10 23.7 E10 21.1 H10 21.2 K10 21.6 N10 20.6 Q2 21.3 T10 21.6 W10 26.2
B11 23.2 E11 20.5 H11 19.4 K11 21.3 N11 19.7 Q3 22.8 T11 21.2 W11 26.6
B12 22.3 E12 23 H12 21.3 K12 22.7 N12 19 Q4 20.4 T12 21 W12 25.4
B13 23.2 E13 26.6 H13 20.8 K13 22 N13 17.5 Q1 22 T13 21 W13 25.9
B14 22.4 E14 25 H14 23.5 K14 26.3 N14 18.9 Q2 22.3 T14 21.2 W14 25.9
B15 33 E15 29.8 H15 23.8 K15 24.8 N15 19.6 Q3 21.1 T15 20.7 W15 25.8
B16 22.9 E16 21.1 H16 28.4 K16 26 N16 18.8 Q4 23.2 T16 20.4 W16 27.3
B17 25.3 E17 28.3 H17 21.6 K17 24 N17 19.9 Q1 21.5 T17 22.7 W17 27.1
B18 22.1 E18 23.8 H18 N/A K18 27.6 N18 21.6 Q2 22.5 T18 23 W18 27.9
B19 16.6 E19 18.9 H19 12.3 K19 19.1 N1 14.8 Q19 19.2 T19 17.6 W19 20.6
B20 17.7 E20 N/A H20 15.2 K20 19.8 N2 11.4 Q20 18.5 T20 17 W20 21.7
B21 17.8 E21 19.6 H21 14.9 K21 19.7 N3 12.7 Q21 20.4 T21 17 W21 21.3
B22 17.4 E22 18.5 H22 12.8 K22 19.8 N4 11.5 Q22 19.7 T22 17.7 W22 22.7
B23 18.4 E23 N/A H23 12.2 K23 19.4 N5 11.4 Q23 20.6 T23 16.6 W23 22.9
B24 16.6 E24 18.8 H24 11.9 K24 20.3 N6 11.6 Q24 20.5 T24 16.6 W24 22.1
B25 15.1 E25 18.7 H25 12.4 K25 18.9 N7 11 Q25 20.2 T25 17.2 W25 22.2
B26 17.5 E26 18.3 H26 11.7 K26 19.4 N8 13 Q26 19.4 T26 17.3 W26 22.9
B27 16.9 E27 19.2 H27 15.2 K27 19 N9 11.3 Q27 19.7 T27 15.9 W27 22.4
B28 17.6 E28 19.9 H28 13.6 K28 19.7 N10 11.7 Q28 19.5 T28 14.8 W28 22.7
B29 16.8 E29 18.6 H29 13.7 K29 19.2 N11 14.6 Q29 18.6 T29 16.5 W29 22.8
B30 15.7 E30 18.4 H30 15 K30 20.1 N12 14.1 Q30 18.1 T30 16 W30 21.9
B31 15.8 E31 18.6 H31 15.8 K31 20.2 - - - - - - - - 
B32 16 E32 N/A H32 16 K32 N/A - - - - - - - - 
B33 17.6 E33 18 H33 15.2 K33 20.4 - - - - - - - - 
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B34 14.6 E34 19.7 H34 14.1 K34 20.1 - - - - - - - - 
B35 18.3 E35 19.8 H35 14.9 K35 19.9 - - - - - - - - 
B36 17.7 E36 N/A H36 15.2 K36 20.4 - - - - - - - - 
C1 20.3 F1 9.2 I1 22.9 L1 8.9 O1 22.7 R1 9.7 U1 20 X1 10.2
C2 21.2 F2 10 I2 24 L2 9.7 O2 23 R2 8.8 U2 20.2 X2 9.3 
C3 21 F3 9.4 I3 23.1 L3 9.3 O3 23.2 R3 8.8 U3 19.2 X3 9.3 
C4 21.3 F4 10.1 I4 23.6 L4 9.9 O4 24.4 R4 9.3 U4 20.3 X4 9.8 
C5 21.1 F5 9.2 I5 22.1 L5 9.5 O5 24.1 R5 8.9 U5 20.8 X5 9.4 
C6 22 F6 10.4 I6 23 L6 10.6 O6 23.2 R6 8.9 U6 19 X6 9.4 
C7 25 F7 8.4 I7 28.4 L7 11.7 O7 21.9 R7 8.9 U7 18.7 X7 9.4 
C8 32.1 F8 10.1 I8 23.8 L8 10.1 O8 22 R8 9 U8 20.5 X8 9.5 
C9 20.3 F9 9.2 I9 23.8 L9 9 O9 25 R9 8.8 U9 20.1 X9 9.3 
C10 20.2 F10 9.5 I10 23.7 L10 9.9 O10 26.2 R10 8.9 U10 20.6 X10 9.4 
C11 22.4 F11 9.2 I11 24.2 L11 8.9 O11 26.6 R11 9.2 U11 19.7 X11 9.7 
C12 21.1 F12 10.6 I12 27.7 L12 10.6 O12 23.4 R12 9 U12 19 X12 9.5 
C13 24.8 F13 N/A I13 27.5 L13 10.7 O13 21.9 R13 9 U13 20.5 X13 9.5 
C14 23.7 F14 13 I14 27.7 L14 13.6 O14 23.9 R14 9.1 U14 20.9 X14 9.6 
C15 32.2 F15 N/A I15 26.9 L15 12.7 O15 23.8 R15 9.3 U15 19.6 X15 9.8 
C16 25.1 F16 N/A I16 28.1 L16 12.9 O16 22.3 R16 9.4 U16 20.8 X16 9.9 
C17 26.8 F17 9.3 I17 21.3 L17 13.1 O17 27.1 R17 9 U17 19.9 X17 9.5 
C18 22.6 F18 10.6 I18 27.5 L18 12.1 O18 27.9 R18 8.9 U18 21.6 X18 9.4 
C19 17.6 F19 9.3 I19 18.3 L19 8.8 O19 19.6 R19 9.7 U19 15.8 X19 9.2 
C20 21.9 F20 9.1 I20 18 L20 9.2 O20 17.7 R20 9.3 U20 17.4 X20 9.8 
C21 18.5 F21 9.2 I21 18.8 L21 9.9 O21 17.3 R21 9.5 U21 15.7 X21 9 
C22 14.1 F22 9.6 I22 18.6 L22 9.8 O22 16.7 R22 9.3 U22 17.5 X22 9.8 
C23 18.1 F23 9.7 I23 18.6 L23 9.5 O23 15.9 R23 9.5 U23 17.4 X23 9 
C24 17.6 F24 9.6 I24 18.1 L24 10 O24 16.1 R24 9.4 U24 17.6 X24 9.9 
C25 17.7 F25 9.5 I25 17.7 L25 8.6 O25 16.2 R25 9.7 U25 17 X25 9.2 
C26 17.5 F26 9.6 I26 17.2 L26 9.6 O26 17.9 R26 9.9 U26 17 X26 9.4 
C27 17.6 F27 9.6 I27 18.1 L27 9 O27 15.4 R27 10.5 U27 17.3 X27 11 
C28 18.8 F28 9.7 I28 17 L28 9.6 O28 16.7 R28 9 U28 17.7 X28 9.5 
C29 18.6 F29 9.8 I29 17.5 L29 10.1 O29 18.8 R29 9.8 U29 17.6 X29 9.3 
C30 18.9 F30 9.4 I30 18.2 L30 10.4 O30 14.9 R30 9.6 U30 17.1 X30 9.1 
C31 17.1 F31 9 I31 17.4 L31 13 - - - - - - - - 
C32 17.6 F32 9.7 I32 15.1 L32 N/A - - - - - - - - 
C33 17.6 F33 9.2 I33 18.9 L33 11.4 - - - - - - - - 
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C34 15.9 F34 11 I34 18.2 L34 11.2 - - - - - - - - 
C35 18.1 F35 10.2 I35 17.7 L35 12 - - - - - - - - 
C36 18.7 F36 11.7 I36 17.5 L36 14.4 - - - - - - - - 
A, MT3; B, S100a4; C, Tnnt2; D, Ctss; E, Cgref1; F, Gapdh; G, Krt8; H, Rrad; I, Gdf5; J. Myog; K, Myo10; L, Gaphd; M, Krt8; N, Runx1; 
O, Orm2; P, Myog; Q, Tubb2; R, Gapdh; S, Tubb2a; T, Myof; U, Atf3; V, Palm2; W, Cgref1; X, Gapdh.. Ct, Threshold cycle; W, wild type 
mice M, Mstn-pro mice; CLW, clenbuterol treated wild type mice; CLM, clenbuterol treated Mstn-pro mice.
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Appendix 3.5 Differential gene expression profiles as affected by the effect of genotype at 1.5 fold 
change (W vs M). 
Probe Set ID 
Fold 
change 
Gene Symbol Gene Title 
1420575_at 5.75 Mt3 metallothionein 3 
1420884_at 4.37 Sln sarcolipin 
1426808_at 4.36 Lgals3 lectin, galactose binding, soluble 3 
1427076_at 3.94 Mpeg1 macrophage expressed gene 1 
1418726_a_at 3.54 Tnnt2 troponin T2, cardiaca 
1416431_at 3.49 Tubb6 tubulin, beta 6a 
1459860_x_at 3.18 Trim2 tripartite motif-containing 2 
1427201_at 3.13 Mustn1 musculoskeletal, embryonic nuclear protein 1 
1416318_at 2.94 Serpinb1a serine (or cysteine) peptidase inhibitor, clade B, member 1aa 
1439426_x_at 2.92 Lyz1 lysozyme 1a 
1424542_at 2.90 S100a4 S100 calcium binding protein A4 
1443783_x_at 2.83 H2-Aa histocompatibility 2, class II antigen A, alphab 
1436905_x_at 2.68 Laptm5 lysosomal-associated protein transmembrane 5 
1419378_a_at 2.64 Fxyd2 FXYD domain-containing ion transport regulator 2 
1423569_at 2.58 Gatm glycine amidinotransferase  
1423547_at 2.47 Lyz2 lysozyme 2 
1425519_a_at 2.34 Cd74 CD74 antigen  
1448591_at 2.30 Ctss cathepsin S 
1448303_at 2.29 Gpnmb glycoprotein (transmembrane) nmb 
1436778_at 2.29 Cybb cytochrome b-245, beta polypeptide 
1448617_at 2.27 Cd53 CD53 antigen 
1451105_at 2.27 Vash2 vasohibin 2 
1449164_at 2.24 Cd68 CD68 antigen 
1432059_x_at 2.21 5031425E22Rik RIKEN cDNA 5031425E22 gene 
1455266_at 2.19 Kif5c kinesin family member 5C 
1422864_at 2.17 Runx1 runt related transcription factor 1a 
1448883_at 2.15 Lgmn legumain 
1425477_x_at 2.13 H2-Ab1 histocompatibility 2, class II antigen A, beta 1a 
1438988_x_at 2.12 Hn1 hematological and neurological expressed sequence 1a 
1419599_s_at 2.09 Ms4a6d membrane-spanning 4-domains, subfamily A, member 6D 
1451987_at 2.06 Arrb2 arrestin, beta 2 
1448152_at 2.05 Igf2 insulin-like growth factor 2 
1448226_at 2.04 Rrm2 ribonucleotide reductase M2a 
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1419280_at 2.03 Pip4k2a phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 
1437224_at 2.00 Rtn4 reticulon 4 
1437467_at 1.97 Alcam activated leukocyte cell adhesion molecule 
1436520_at 1.95 Ahnak2 AHNAK nucleoprotein 2 
1418196_at 1.95 Tep1 telomerase associated protein 1 
1450792_at 1.94 Tyrobp TYRO protein tyrosine kinase binding protein 
1444432_at 1.94 D330040H18Rik RIKEN cDNA D330040H18 gene 
1435477_s_at 1.93 Fcgr2b Fc receptor, IgG, low affinity Iiba 
1452016_at 1.92 Alox5ap arachidonate 5-lipoxygenase activating protein 
1451289_at 1.91 Dclk1 doublecortin-like kinase 1 
1452717_at 1.91 Slc25a24 solute carrier family 25, member 24 
1433893_s_at 1.90 Spag5 sperm associated antigen 5 
1418852_at 1.90 Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1  
1451064_a_at 1.87 Psat1 phosphoserine aminotransferase 1a 
1427347_s_at 1.87 Tubb2a tubulin, beta 2A 
1429954_at 1.85 Clec4a3 C-type lectin domain family 4, member a3 
1451201_s_at 1.84 Rnh1 ribonuclease/angiogenin inhibitor 1 
1428420_a_at 1.83 1200009I06Rik RIKEN cDNA 1200009I06 gene 
1422124_a_at 1.79 Ptprc protein tyrosine phosphatase, receptor type, C 
1421698_a_at 1.78 Col19a1 collagen, type XIX, alpha 1 
1450070_s_at 1.77 Pak1 p21 protein (Cdc42/Rac)-activated kinase 1a 
1424987_at 1.76 5430435G22Rik RIKEN cDNA 5430435G22 gene 
1421525_a_at 1.76 Naip5 NLR family, apoptosis inhibitory protein 5 
1417936_at 1.76 Ccl9 chemokine (C-C motif) ligand 9 
1438948_x_at 1.73 Tspo translocator proteina 
1451161_a_at 1.73 Emr1 EGF-like module containing, hormone receptor-like sequence 1 
1456014_s_at 1.73 Fermt3 fermitin family homolog 3 (Drosophila) 
1448239_at 1.73 Hmox1 heme oxygenase (decycling) 1 
1450234_at 1.72 Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 
1424529_s_at 1.69 Cgref1 cell growth regulator with EF hand domain 1 
1426755_at 1.68 Ckap4 cytoskeleton-associated protein 4 
1438596_at 1.68 1500017E21Rik RIKEN cDNA 1500017E21 gene 
1460555_at 1.64 Fam65b family with sequence similarity 65, member B 
1436188_a_at 1.64 Ndrg4 N-myc downstream regulated gene 4 
1416698_a_at 1.63 Cks1b CDC28 protein kinase 1b 
1437771_at 1.63 Lrrn4cl LRRN4 C-terminal like 
1424176_a_at 1.63 Anxa4 annexin A4 
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1435122_x_at 1.62 Dnmt1 DNA methyltransferase (cytosine-5) 1 
1455679_at 1.62 Obfc2a oligonucleotide/oligosaccharide-binding fold containing 2A 
1416844_at 1.61 Prmt2 protein arginine N-methyltransferase 2 
1427275_at 1.61 Smc4 structural maintenance of chromosomes 4 
1451780_at 1.60 Blnk B-cell linker 
1422186_s_at 1.60 Cyb5r3 cytochrome b5 reductase 3a 
1423423_at 1.60 Pdia3 protein disulfide isomerase associated 3 
1436566_at 1.60 Rab40b Rab40b, member RAS oncogene family 
1426215_at 1.60 Ddc dopa decarboxylase 
1417597_at 1.60 Cd28 CD28 antigen 
1438629_x_at 1.59 Grn granulin 
1419873_s_at 1.59 Csf1r colony stimulating factor 1 receptora 
1456377_x_at 1.59 Limd2 LIM domain containing 2 
1441259_s_at 1.57 Ift122 intraflagellar transport 122 homolog (Chlamydomonas) 
1434442_at 1.56 Stbd1 starch binding domain 1 
1426615_s_at 1.55 Ndrg4 N-myc downstream regulated gene 4 
1456783_at 1.55 Zdbf2 zinc finger, DBF-type containing 2 
1417647_at 1.54 Snx5 sorting nexin 5 
1436833_x_at 1.54 Ttll1 tubulin tyrosine ligase-like 1 
1439610_at 1.53 Rab27b RAB27b, member RAS oncogene family 
1449258_at 1.52 D11Wsu99e DNA segment, Chr 11, Wayne State University 99, expressed 
1417868_a_at 1.51 Ctsz cathepsin Z 
1452554_at 2.29 Gm8479 thiopurine S-methyltransferase pseudogene 
1437906_x_at 2.28 Txnl1 thioredoxin-like 1 
1431491_at 2.11 9430087N24Rik RIKEN cDNA 9430087N24 gene 
1460388_at 1.83 Acot6 acyl-CoA thioesterase 6 
1447567_at 1.83 D130007H15Rik RIKEN cDNA D130007H15 gene 
1438544_at 1.79 1700001G11Rik RIKEN cDNA 1700001G11 gene 
1440820_x_at 1.78 Tmco2 transmembrane and coiled-coil domains 2 
1453026_at 1.67 Fam166a family with sequence similarity 166, member A 
1417275_at 1.54 Mal myelin and lymphocyte protein, T-cell differentiation protein 
1440335_at 1.53 LOC100046468 hypothetical protein LOC100046468 
1440343_at 1.51 Rps6ka5 ribosomal protein S6 kinase, polypeptide 5 
1447868_x_at 1.51 Glrx3 glutaredoxin 3 
1426690_a_at 1.51 Srebf1 sterol regulatory element binding transcription factor 1 
A total 108 gene identified from 134 Affymetrix probe sets after a 1.5 fold change cut off. 92 genes were overexpressed, and 16 genes were 
underexpressed (grey box). a This gene appears two times; b This gene appears three times; W, wild type mice; M, Mstn-pro mice. 
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Appendix 3.6 Differential gene expression profiles as affected by the effect of genotype under CL 
administration at 1.5 fold change (CLW vs CLM). 
Probe Set ID 
Fold 
change 
Gene Symbol Gene Title 
1427838_at 4.38 Tubb2a tubulin, beta 2A 
1451054_at 3.75 Orm1 orosomucoid 1 
1449700_at 3.01 Igbp1 Immunoglobulin (CD79A) binding protein 1 
1430932_at 2.48 Slc9a8 solute carrier family 9, member 8 
1444565_at 2.46 BB166591 expressed sequence BB166591 
1455599_at 2.46 Gfod1 glucose-fructose oxidoreductase domain containing 1 
1423887_a_at 2.37 Telo2 TEL2, telomere maintenance 2, homolog (S. cerevisiae) 
1453673_at 2.29 LOC100046982 hypothetical protein LOC100046982 
1452679_at 2.21 Tubb2b tubulin, beta 2B 
1452455_at 2.15 Myof myoferlin 
1449363_at 2.13 Atf3 activating transcription factor 3 
1427205_x_at 2.08 Ccdc46 coiled-coil domain containing 46 
1437544_at 2.07 Fubp1 far upstream element (FUSE) binding protein 1 
1458385_at 2.01 Hspa4l heat shock protein 4 like 
1434204_x_at 1.91 Shmt2 serine hydroxymethyltransferase 2 (mitochondrial) 
1440999_at 1.90 Zfp697 zinc finger protein 697 
1456976_at 1.89 Wnt5a wingless-related MMTV integration site 5A 
1425362_at 1.87 Agfg2 ArfGAP with FG repeats 2 
1417103_at 1.85 Ddt D-dopachrome tautomerase 
1457823_at 1.82 Cyr61 cysteine rich protein 61 
1416396_at 1.75 Snx4 sorting nexin 4 
1417428_at 1.75 Gng3 guanine nucleotide binding protein (G protein), gamma 3 
1448885_at 1.74 Rap2b RAP2B, member of RAS oncogene family 
1454639_x_at 1.73 Rpl41 ribosomal protein L41 
1445886_at 1.72 Elk3 ELK3, member of ETS oncogene family 
1418908_at 1.70 Pam peptidylglycine alpha-amidating monooxygenase 
1444712_at 1.70 Hsf5 heat shock transcription factor family member 5 
1431838_at 1.70 1700128E19Rik RIKEN cDNA 1700128E19 gene 
1441055_at 1.66 Palm2 paralemmin 2 
1449590_a_at 1.64 Mras muscle and microspikes RAS 
1417758_at 1.61 Itga2b integrin alpha 2b 
1429509_at 1.60 Lsm12 LSM12 homolog (S. cerevisiae) 
1417595_at 1.59 Meox1 mesenchyme homeobox 1 
 207
1454674_at 1.59 Fez1 fasciculation and elongation protein zeta 1 (zygin I) 
1426275_a_at 1.57 Uxs1 UDP-glucuronate decarboxylase 1 
1430469_at 1.55 Ttll5 tubulin tyrosine ligase-like family, member 5 
1421354_at 1.54 Prkg2 protein kinase, cGMP-dependent, type II 
1453854_at 1.53 Ptar1 protein prenyltransferase alpha subunit repeat containing 1 
1434402_at 1.52 Samd8 sterile alpha motif domain containing 8 
1447924_at 1.51 Nucks1 nuclear casein kinase and cyclin-dependent kinase substrate 1 
1451505_at 1.51 Chchd5 coiled-coil-helix-coiled-coil-helix domain containing 5 
1435561_at 1.50 Erf Ets2 repressor factor 
1424529_s_at 1.50 Cgref1 cell growth regulator with EF hand domain 1 
1437915_at 3.35 Tom1l2 target of myb1-like 2 (chicken) 
1426340_at 3.23 Slc1a3 solute carrier family 1, member 3 
1436359_at 2.58 Ret ret proto-oncogene 
1427053_at 2.50 Abi3bp ABI gene family, member 3 (NESH) binding protein 
1436644_x_at 2.21 Tmem25 transmembrane protein 25 
1430700_a_at 2.11 Pla2g7 phospholipase A2, group  
1432001_at 2.10 Zmynd17 zinc finger, MYND domain containing 17 
1422414_a_at 2.06 Calm2 calmodulin 2 
1456312_x_at 2.03 Gsn gelsolin 
1434424_at 1.97 Mfsd7b major facilitator superfamily domain containing 7B 
1451047_at 1.94 Itm2a integral membrane protein 2A 
1426950_at 1.90 Parp16 poly (ADP-ribose) polymerase family, member 16 
1448735_at 1.89 Cp ceruloplasmin 
1433511_at 1.84 Gtf2a1 general transcription factor II A, 1 
1426109_a_at 1.81 Slc14a2 solute carrier family 14 (urea transporter), member 2 
1429728_at 1.80 Zh2c2 zinc finger, H2C2 domain containing 
1434093_at 1.77 Lysmd4 LysM, putative peptidoglycan-binding, domain containing 4 
1428145_at 1.75 Acaa2 acetyl-Coenzyme A acyltransferase 2  
1417625_s_at 1.75 Cxcr7 chemokine (C-X-C motif) receptor 7 
1417673_at 1.73 Grb14 growth factor receptor bound protein 14 
1451683_x_at 1.73 H2-D1 histocompatibility 2, D region locus 1 
1435828_at 1.70 Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog 
1423885_at 1.70 Lamc1 laminin, gamma 1 
1419693_at 1.69 Colec12 collectin sub-family member 12 
1434592_at 1.69 Slc16a10 solute carrier family 16, member 10 
1455468_at 1.69 Dpy19l3 dpy-19-like 3 (C. elegans) 
1448734_at 1.69 Cp ceruloplasmin 
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1444504_at 1.68 Dhrs7c dehydrogenase/reductase (SDR family) member 7C 
1454806_at 1.66 Fam49a family with sequence similarity 49, member A 
1428107_at 1.65 Sh3bgrl SH3-binding domain glutamic acid-rich protein like 
1428187_at 1.65 Cd47 CD47 antigen  
1415996_at 1.65 Txnip thioredoxin interacting protein 
1451718_at 1.64 Plp1 proteolipid protein (myelin) 1 
1416072_at 1.62 Cd34 CD34 antigen 
1452190_at 1.62 Prcp prolylcarboxypeptidase (angiotensinase C) 
1437313_x_at 1.62 Hmgb2 high mobility group box 2 
1417042_at 1.60 Slc37a4 solute carrier family 37, member 4 
1419442_at 1.60 Matn2 matrilin 2 
1416968_a_at 1.59 Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 
1437868_at 1.58 Fam46a family with sequence similarity 46, member A 
1416225_at 1.58 Adh1 alcohol dehydrogenase 1 (class I) 
1456956_at 1.58 Ikzf2 IKAROS family zinc finger 2 
1433907_at 1.57 Pknox2 Pbx/knotted 1 homeobox 2 
1425164_a_at 1.57 Phkg1 phosphorylase kinase gamma 1 
1458087_at 1.56 Stac3 SH3 and cysteine rich domain 3 
1451221_at 1.56 BC018507 cDNA sequence BC018507 
1419922_s_at 1.56 Atrnl1 attractin like 1 
1433842_at 1.55 Lrrfip1 leucine rich repeat (in FLII) interacting protein 1 
1455739_at 1.54 Gm4980 predicted gene 4980 
1455179_at 1.54 Mpp7 membrane protein, palmitoylated  
1437041_at 1.53 Sfrs18 splicing factor, arginine/serine-rich 18 
1416108_a_at 1.52 Tmed3 transmembrane emp24 domain containing 3 
1417408_at 1.51 F3 coagulation factor III 
1448421_s_at 1.51 Aspn asporin 
A total 97 gene identified from 302 Affymetrix probe sets after a 1.5 fold change cut off. 43 genes were overexpressed, and 54 genes were 
underexpressed (grey box). CLW, clenbuterol treated wild type mice; CLM, clenbuterol treated Mstn-pro mice. 
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Appendix 3.7 Differential gene expression profiles as affected by the effect of CL at 1.5 fold change 
(W vs CLW). 
Probe Set ID 
Fold 
change 
Gene Symbol Gene Title 
1423691_x_at 390.33  Krt8 keratin 8 b    
1448169_at 187.70  Krt18 keratin 18 
1440878_at 65.37  Runx1 runt related transcription factor 1 b 
1422562_at 54.82  Rrad Ras-related associated with diabetes 
1435053_s_at 52.42  Plekh pleckstrin homology domain H  b 
1419139_at 50.83  Gdf5 growth differentiation factor 5 
1434709_at 30.46  Nrcam neuron-glia-CAM-related cell adhesion molecule a 
1420991_at 23.76  Ankrd1 ankyrin repeat domain 1 (cardiac muscle) a 
1455271_at 23.06  Gm13889 predicted gene 13889 
1424831_at 23.02  Cpne2 copine II 
1448975_s_at 21.68  Ren1 renin 1 structural 
1454632_at 21.58  6330442E10Rik RIKEN cDNA 6330442E10 gene a 
1426808_at 16.80  Lgals3 lectin, galactose binding, soluble 3 
1424245_at 16.56  Ces2 carboxylesterase 2 
1458813_at 16.54  Scn5a sodium channel, voltage-gated, type V, alpha 
1418852_at 15.79  Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 
1428640_at 14.23  Hsf2bp heat shock transcription factor 2 binding protein 
1430086_at 13.92  Chrna9 cholinergic receptor, nicotinic, alpha polypeptide 9 
1449519_at 13.70  Gadd45a growth arrest and DNA-damage-inducible 45 alpha 
1427655_a_at 10.35  A630038E17Rik RIKEN cDNA A630038E17 gene 
1421698_a_at 9.43  Col19a1 collagen, type XIX, alpha 1 a 
1418460_at 9.23  Sh3 SH3 domain proteinb 
1440085_at 9.14  Eda2r ectodysplasin A2 isoform receptor 
1435176_a_at 8.97  Id2 inhibitor of DNA binding 2 a 
1451287_s_at 8.93  Aif1l allograft inflammatory factor 1-like a 
1419391_at 8.63  Myog Myogenin 
1420884_at 8.55  Sln Sarcolipin 
1422580_at 8.43  Myl4 myosin, light polypeptide 4 
1455649_at 7.72  Ttc9 tetratricopeptide repeat domain 9 
1421852_at 7.71  Kcnk5 potassium channel, subfamily K, member 5 
1419394_s_at 7.71  S100a8 S100 calcium binding protein A8 (calgranulin A) 
1455342_at 7.59  Prune2 prune homolog 2 (Drosophila) a 
1421269_at 7.41  Ugcg UDP-glucose ceramide glucosyltransferase b 
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1453125_at 7.12  Sox11 SRY-box containing gene 11 b 
1423186_at 6.99  Tiam2 T-cell lymphoma invasion and metastasis 2 a 
1427910_at 6.94  Cst6 cystatin E/M 
1418571_at 6.86  Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a a 
1438988_x_at 6.59  Hn1 hematological and neurological expressed sequence 1 b 
1420444_at 6.56  Slc22a3 solute carrier family 22 (organic cation transporter), member 3 
1416431_at 6.53  Tubb6 tubulin, beta 6 
1422629_s_at 6.38  Shroom3 shroom family member 3 
1423719_at 6.28  LOC632073 similar to long palate, lung and nasal epithelium carcinoma associated 1 isoform 2 
1434513_at 5.92  Atp13a3 ATPase type 13A3 a 
1460290_at 5.82  Lpin2 lipin 2 b 
1420938_at 5.80  Hs6st2 Heparan sulfate 6-O-sulfotransferase 2 a 
1455771_at 5.47  Bzrap1 benzodiazapine receptor associated protein 1 
1448660_at 5.38  Arhgdig Rho GDP dissociation inhibitor (GDI) gamma 
1421679_a_at 5.19  Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) a 
1450013_at 5.16  2900073G15Rik RIKEN cDNA 2900073G15 gene a 
1426650_at 5.02  Myh8 myosin, heavy polypeptide 8, skeletal muscle, perinatal 
1451036_at 4.80  Spg21 spastic paraplegia 21 homolog (human) 
1420438_at 4.72  Orm2 orosomucoid 2 
1418158_at 4.50  Trp63 transformation related protein 63 a 
1442590_at 4.49  Tnfrsf22 tumor necrosis factor receptor superfamily, member 22 a 
1437224_at 4.36  Rtn4 reticulon 4 
1449533_at 4.36  Tmem100 transmembrane protein 100 
1425543_s_at 4.34  Plekha5 pleckstrin homology domain containing, family A member 5 
1422573_at 4.33  Ampd3 adenosine monophosphate deaminase 3 
1434754_at 4.30  Garnl4 GTPase activating RANGAP domain-like 4 
1452232_at 4.23  Galnt7 UDP-N-acetyl-alpha-D-galactosamine 
1458245_at 4.17  Gm12528 predicted gene 12528 
1428834_at 4.15  Dusp4 dual specificity phosphatase 4 
1421499_a_at 4.10  Ptpn14 protein tyrosine phosphatase, non-receptor type 14 
1448605_at 4.06  Rhoc ras homolog gene family, member C a 
1426337_a_at 3.99  Tead4 TEA domain family member 4 
1454674_at 3.96  Fez1 fasciculation and elongation protein zeta 1 (zygin I) 
1422929_s_at 3.91  Atoh7 atonal homolog 7 (Drosophila) 
1430062_at 3.89  Hhipl1 hedgehog interacting protein-like 1 
1451160_s_at 3.88  Pvr poliovirus receptor c 
1449852_a_at 3.86  Ehd4 EH-domain containing 4 
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1424613_at 3.83  Gprc5b G protein-coupled receptor, family C, group 5, member B a 
1442827_at 3.83  Tlr4 Toll-like receptor 4 b 
1457779_at 3.81  1110046J04Rik RIKEN cDNA 1110046J04 gene 
1421175_at 3.78  Myt1l myelin transcription factor 1-like 
1420682_at 3.70  Chrnb1 cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) 
1422286_a_at 3.60  Tgif1 TGFB-induced factor homeobox 1 
1451105_at 3.59  Vash2 vasohibin 2 
1427347_s_at 3.57  Tubb2a tubulin, beta 2A 
1452799_at 3.55  Fggy FGGY carbohydrate kinase domain containing 
1429786_a_at 3.52  Zwint ZW10 interactor c 
1460521_a_at 3.51  Obfc2a oligonucleotide/oligosaccharide-binding fold containing 2A d 
1416401_at 3.51  Cd82 CD82 antigen 
1417014_at 3.49  Hspb8 heat shock protein 8 a 
1421042_at 3.46  Arhgef2 rho/rac guanine nucleotide exchange factor (GEF) 2 a 
1436507_at 3.35  Irak2 interleukin-1 receptor-associated kinase 2 
1450650_at 3.34  Myo10 myosin X b 
1428803_at 3.32  Acot6 acyl-CoA thioesterase 6 
1427005_at 3.29  Plk2 polo-like kinase 2 (Drosophila) 
1424354_at 3.25  Tmem140 transmembrane protein 140 
1451680_at 3.24  Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) b 
1435184_at 3.21  Npr3 natriuretic peptide receptor 3 a 
1426471_at 3.15  Zfp52 zinc finger protein 52 a 
1450241_a_at 3.13  Evi2a ecotropic viral integration site 2a 
1432075_a_at 3.12  Tekt1 tektin 1 
1424507_at 3.12  Rin1 Ras and Rab interactor 1 
1418649_at 3.11  Egln3 EGL nine homolog 3 (C. elegans) a 
1433571_at 3.10  Serinc5 serine incorporator 5 
1427483_at 3.10  Slc25a24 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 24 a 
1435948_at 3.09  Tmem181a transmembrane protein 181A 
1434526_at 3.09  Ephx4 epoxide hydrolase 4 
1416231_at 3.09  Vac14 Vac14 homolog (S. cerevisiae) 
1438596_at 3.07  1500017E21Rik RIKEN cDNA 1500017E21 gene 
1423596_at 3.06  Nek6 NIMA (never in mitosis gene a)-related expressed kinase 6 a 
1420895_at 3.02  Tgfbr1 transforming growth factor, beta receptor I 
1439618_at 2.99  Pde10a phosphodiesterase 10A 
1457296_at 2.98  Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 
1416065_a_at 2.97  Ankrd10 ankyrin repeat domain 10 b 
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1440008_at 2.95  2310043L19Rik RIKEN cDNA 2310043L19 gene 
1451814_a_at 2.93  Htatip2 HIV-1 tat interactive protein 2, homolog (human) 
1460062_at 2.93  Plekhh2 pleckstrin homology domain containing, family H member 2 
1434241_at 2.92  Wdr67 WD repeat domain 67 
1449164_at 2.89  Cd68 CD68 antigen 
1422101_at 2.87  Tnfrsf23 tumor necrosis factor receptor superfamily, member 23 
1416379_at 2.84  Panx1 pannexin 1 
1450437_a_at 2.83  Ncam1 neural cell adhesion molecule 1 a 
1425329_a_at 2.83  Cyb5r3 cytochrome b5 reductase 3 b 
1417856_at 2.81  Relb avian reticuloendotheliosis viral (v-rel) oncogene related B 
1453323_at 2.79  2900079G21Rik RIKEN cDNA 2900079G21 gene 
1460718_s_at 2.78  Mtch1 mitochondrial carrier homolog 1 (C. elegans) 
1434382_at 2.76  Serinc2 serine incorporator 2 
1424176_a_at 2.74  Anxa4 annexin A4 b 
1418420_at 2.73  Myod1 myogenic differentiation 1 
1423082_at 2.73  Derl1 Der1-like domain family, member 1 b 
1420832_at 2.69  Qsox1 quiescin Q6 sulfhydryl oxidase 1 
1417356_at 2.69  Peg3 paternally expressed 3 
1425347_a_at 2.68  Zfp318 zinc finger protein 318 c 
1428739_at 2.68  Enho energy homeostasis associated a 
1426576_at 2.64  Sgms1 sphingomyelin synthase 1 b 
1424517_at 2.64  Ccdc12 coiled-coil domain containing 12 a 
1417128_at 2.64  Plekho1 pleckstrin homology domain containing, family O member 1 
1460392_a_at 2.63  Eny2 enhancer of yellow 2 homolog (Drosophila) a 
1451064_a_at 2.63  Psat1 phosphoserine aminotransferase 1 a 
1446342_at 2.61  2310001H17Rik RIKEN cDNA 2310001H17 gene a 
1449839_at 2.60  Casp3 caspase 3 a 
1434442_at 2.57  Stbd1 starch binding domain 1 
1434927_at 2.56  Hspb7 heat shock protein family, member 7 (cardiovascular) a 
1438948_x_at 2.55  Tspo translocator protein b 
1449036_at 2.55  Rnf128 ring finger protein 128 a 
1452242_at 2.55  Cep55 centrosomal protein 55 
1436520_at 2.55  Ahnak2 AHNAK nucleoprotein 2 
1436237_at 2.54  Ttc9 tetratricopeptide repeat domain 9 
1436042_at 2.51  Tln1 talin 1 
1421052_a_at 2.51  Sms spermine synthase b 
1455203_at 2.50  A930003A15Rik RIKEN cDNA A930003A15 gene 
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1421654_a_at 2.49  Lmna lamin A 
1435981_at 2.47  Nav2 neuron navigator 2 
1417850_at 2.47  Rb1 retinoblastoma 1 
1425238_at 2.47  Gm6607 40S ribosomal protein S20 pseudogene 
1451227_a_at 2.46  Slc10a3 solute carrier family 10 (sodium/bile acid cotransporter family), member 3 
1450511_at 2.46  Musk muscle, skeletal, receptor tyrosine kinase 
1444786_at 2.46  Nol3 nucleolar protein 3 (apoptosis repressor with CARD domain) 
1438133_a_at 2.45  Cyr61 cysteine rich protein 61 a 
1436758_at 2.44  Hdac4 histone deacetylase 4 a 
1431281_at 2.44  Dysfip1 dysferlin interacting protein 1 
1417398_at 2.43  Rras2 related RAS viral (r-ras) oncogene homolog 2 a 
1416251_at 2.43  Mcm6 minichromosome maintenance deficient 6 (S. cerevisiae) 
1419028_at 2.42  Arpp21 cyclic AMP-regulated phosphoprotein, 21 a 
1422776_at 2.42  Serpinb8 serine (or cysteine) peptidase inhibitor, clade B, member 8 
1417005_at 2.41  Klc1 kinesin light chain 1 
1434364_at 2.41  Map3k14 mitogen-activated protein kinase kinase kinase 14 
1438429_at 2.40  2610319H10Rik RIKEN cDNA 2610319H10 gene 
1437669_x_at 2.40  Ccrl1 Chemokine (C-C motif) receptor-like 1 a 
1436204_at 2.40  1110059G02Rik RIKEN cDNA 1110059G02 gene a 
1449323_a_at 2.39  Rpl3 ribosomal protein L3 
1455350_at 2.39  Tmem62 transmembrane protein 62 
1435039_a_at 2.37  Pip5k1a phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha a 
1425964_x_at 2.35  Hspb1 heat shock protein 1 a 
1429618_at 2.35  Cyld cylindromatosis (turban tumor syndrome) a 
1450959_at 2.35  D930014E17Rik RIKEN cDNA D930014E17 gene 
1423606_at 2.35  Postn periostin, osteoblast specific factor 
1424489_a_at 2.34  Trit1 tRNA isopentenyltransferase 1 
1440999_at 2.34  Zfp697 zinc finger protein 697 
1423774_a_at 2.33  Prc1 protein regulator of cytokinesis 1 
1460302_at 2.32  Thbs1 thrombospondin 1 b 
1419150_at 2.29  Myf6 myogenic factor 6 
1448744_at 2.27  Galns galactosamine (N-acetyl)-6-sulfate sulfatase 
1421346_a_at 2.26  Slc6a6 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 a 
1454962_at 2.26  Spire1 spire homolog 1 (Drosophila) a 
1450062_a_at 2.26  Maged1 melanoma antigen, family D, 1 
1415899_at 2.26  Junb Jun-B oncogene 
1441055_at 2.24  Palm2 paralemmin 2 
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1453238_s_at 2.23  1200016E24Rik RIKEN cDNA 1200016E24 gene 
1417375_at 2.23  Tuba4a tubulin, alpha 4A a 
1424292_at 2.21  Depdc1a DEP domain containing 1a 
1424875_at 2.21  Spg20 spastic paraplegia 20, spartin (Troyer syndrome) homolog (human) 
1450686_at 2.21  Pon2 paraoxonase 2 a 
1449968_s_at 2.20  Acot10 acyl-CoA thioesterase 10 
1435137_s_at 2.19  1200015M12Rik RIKEN cDNA 1200015M12 gene 
1433928_a_at 2.19  Rpl13a ribosomal protein L13A 
1434369_a_at 2.19  Cryab crystallin, alpha B a 
1452478_at 2.18  Alpk2 alpha-kinase 2 
1422620_s_at 2.17  Ppap2a phosphatidic acid phosphatase type 2A a 
1416606_s_at 2.17  Nhp2 NHP2 ribonucleoprotein homolog (yeast) a 
1418498_at 2.17  Fgf13 fibroblast growth factor 13 a 
1452719_at 2.16  Zdhhc24 zinc finger, DHHC domain containing 24 a 
1423662_at 2.16  Atp6ap2 ATPase, H+ transporting, lysosomal accessory protein 2 a 
1416192_at 2.16  Napa N-ethylmaleimide sensitive fusion protein attachment protein alpha a 
1441071_at 2.16  Kcnq5 potassium voltage-gated channel, subfamily Q, member 5 
1419184_a_at 2.15  Fhl2 four and a half LIM domains 2 
1448883_at 2.15  Lgmn legumain 
1423264_at 2.15  Bop1 block of proliferation 1 
1450070_s_at 2.14  Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 b 
1423745_at 2.13  Snap47 synaptosomal-associated protein, 47 a 
1416749_at 2.13  Htra1 HtrA serine peptidase 1 
1451809_s_at 2.13  Rwdd3 RWD domain containing 3 
1422660_at 2.13  Rbm3 RNA binding motif protein 3 
1416034_at 2.12  Cd24a CD24a antigen b 
1418448_at 2.12  Rras Harvey rat sarcoma oncogene, subgroup R 
1448124_at 2.12  Gusb glucuronidase, beta 
1436305_at 2.11  Rnf217 ring finger protein 217 a  
1424378_at 2.10  Ldlrap1 low density lipoprotein receptor adaptor protein 1 
1434891_at 2.10  Ptgfrn prostaglandin F2 receptor negative regulator 
1419398_a_at 2.10  Reep5 receptor accessory protein 5 a 
1434748_at 2.09  Ckap2 cytoskeleton associated protein 2 
1426465_at 2.09  Dlgap4 discs, large homolog-associated protein 4 (Drosophila) a 
1456291_x_at 2.08  Scx scleraxis a 
1436833_x_at 2.08  Ttll1 tubulin tyrosine ligase-like 1 a 
1460235_at 2.08  Scarb2 scavenger receptor class B, member 2 
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1423122_at 2.07  Avpi1 arginine vasopressin-induced 1 
1417654_at 2.07  Sdc4 syndecan 4 a 
1432393_a_at 2.07  Thg1l tRNA-histidine guanylyltransferase 1-like (S. cerevisiae) 
1424529_s_at 2.06  Cgref1 cell growth regulator with EF hand domain 1 
1418428_at 2.06  Kif5b kinesin family member 5B c 
1427932_s_at 2.05  1200003I10Rik RIKEN cDNA 1200003I10 gene 
1436684_a_at 2.05  Riok2 RIO kinase 2 (yeast) a 
1451201_s_at 2.05  Rnh1 ribonuclease/angiogenin inhibitor 1 
1417032_at 2.05  Ube2g2 ubiquitin-conjugating enzyme E2G 2 a 
1424719_a_at 2.04  Mapt microtubule-associated protein tau 
1452761_a_at 2.04  8430436O14Rik RIKEN cDNA 8430436O14 gene 
1424538_at 2.04  Ubl4 ubiquitin-like 4 
1416119_at 2.03  Txn1 thioredoxin 1 
1435432_at 2.03  Agap1 ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 
1437828_s_at 2.03  Wdr46 WD repeat domain 46 
1418073_at 2.02  Acot9 acyl-CoA thioesterase 9 
1416138_at 2.01  Anxa7 annexin A7 
1448968_at 2.01  Ubfd1 ubiquitin family domain containing 1 
1452679_at 2.01  Tubb2b tubulin, beta 2B 
1434080_at 2.00  Aebp2 AE binding protein 2 b 
1423607_at 2.00  Lum lumican 
1422615_at 2.00  Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 
1422650_a_at 1.99  Riok3 RIO kinase 3 (yeast) a 
1416911_a_at 1.99  Akirin1 akirin 1 a 
1452787_a_at 1.99  Prmt1 protein arginine N-methyltransferase 1 
1423642_at 1.99  Tubb2c tubulin, beta 2C 
1426534_a_at 1.98  Arfgap3 ADP-ribosylation factor GTPase activating protein 3 
1427364_a_at 1.98  Odc1 ornithine decarboxylase, structural 1 b 
1426329_s_at 1.98  Baalc brain and acute leukemia, cytoplasmic 
1436710_at 1.97  Zswim4 zinc finger, SWIM domain containing 4 
1433555_at 1.97  Eaf1 ELL associated factor 1 
1449645_s_at 1.97  Cct3 chaperonin containing Tcp1, subunit 3 (gamma) a 
1422155_at 1.97  Hist2h3c2 histone cluster 2, H3c2 
1451480_at 1.97  E2f4 E2F transcription factor 4 
1448271_a_at 1.96  Ddx21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 
1449258_at 1.96  D11Wsu99e DNA segment, Chr 11, Wayne State University 99, expressed 
1450198_at 1.96  Dusp13 dual specificity phosphatase 13 
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1427186_a_at 1.95  Mef2a myocyte enhancer factor 2A b 
1451208_at 1.95  Etf1 eukaryotic translation termination factor 1 
1423239_at 1.95  Impdh1 inosine 5'-phosphate dehydrogenase 1 
1417455_at 1.95  Tgfb3 transforming growth factor, beta 3 
1418186_at 1.95  Gstt1 glutathione S-transferase, theta 1 
1423551_at 1.95  Cdh13 cadherin 13 a 
1449073_at 1.94  Flnc filamin C, gamma a 
1451325_at 1.93  Fyttd1 forty-two-three domain containing 1 
1426215_at 1.93  Ddc dopa decarboxylase 
1433599_at 1.93  Baz1a bromodomain adjacent to zinc finger domain 1A 
1419287_at 1.92  Tmem208 transmembrane protein 208 
1451269_at 1.92  Pdzd11 PDZ domain containing 11 
1426722_at 1.92  Slc38a2 solute carrier family 38, member 2 
1418726_a_at 1.92  Tnnt2 troponin T2, cardiac a 
1449275_at 1.92  Fam119a family with sequence similarity 119, member A 
1439708_at 1.92  Myom3 myomesin family, member 3 
1450846_at 1.92  Bzw1 basic leucine zipper and W2 domains 1 b 
1453137_at 1.92  Fbxo30 F-box protein 30 
1428420_a_at 1.91  1200009I06Rik RIKEN cDNA 1200009I06 gene 
1437109_s_at 1.91  Lsm6 LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
1424289_at 1.91  Osgin2 oxidative stress induced growth inhibitor family member 2 
1434923_at 1.91  Cox19 COX19 cytochrome c oxidase assembly homolog (S. cerevisiae) 
1448239_at 1.91  Hmox1 heme oxygenase (decycling) 1 
1419058_at 1.90  Polr1e polymerase (RNA) I polypeptide E 
1427771_x_at 1.90  Itgb1 integrin beta 1 (fibronectin receptor beta) b 
1455627_at 1.90  Col8a1 collagen, type VIII, alpha 1 
1426485_at 1.90  Ubxn4 UBX domain protein 4 b 
1423296_at 1.90  Psmd8 proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 
1424942_a_at 1.90  Myc myelocytomatosis oncogene 
1427239_at 1.90  Ift122 intraflagellar transport 122 homolog (Chlamydomonas) a 
1423158_at 1.89  Gnpnat1 glucosamine-phosphate N-acetyltransferase 1 
1416213_x_at 1.89  Surf4 surfeit gene 4 a 
1426403_at 1.89  Actr1b ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 
1426600_at 1.89  Slc2a1 solute carrier family 2 (facilitated glucose transporter), member 1 a 
1428847_a_at 1.89  Macf1 microtubule-actin crosslinking factor 1 
1422789_at 1.89  Aldh1a2 aldehyde dehydrogenase family 1, subfamily A2 
1416708_a_at 1.89  Gramd1a GRAM domain containing 1A 
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1419524_at 1.89  Tph1 tryptophan hydroxylase 1 
1423388_at 1.88  Ap1g1 adaptor protein complex AP-1, gamma 1 subunit 
1420984_at 1.88  Pctp phosphatidylcholine transfer protein 
1419254_at 1.88  Mthfd2 methylenetetrahydrofolate dehydrogenase (NAD+ dependent) 
1433972_at 1.88  Camta1 calmodulin binding transcription activator 1 a 
1455405_at 1.88  Pstpip2 proline-serine-threonine phosphatase-interacting protein 2 b 
1429307_s_at 1.87  Lzic leucine zipper and CTNNBIP1 domain containing 
1423810_at 1.87  Ppme1 protein phosphatase methylesterase 1 
1418822_a_at 1.87  Arf6 ADP-ribosylation factor 6 a 
1452011_a_at 1.87  Uxs1 UDP-glucuronate decarboxylase 1 
1421824_at 1.87  Bace1 beta-site APP cleaving enzyme 1 a 
1451257_at 1.86  Acsl6 acyl-CoA synthetase long-chain family member 6 
1418454_at 1.86  Mfap5 microfibrillar associated protein 5 a 
1450909_at 1.86  Eif4e eukaryotic translation initiation factor 4E 
1434985_a_at 1.86  Eif4a1 eukaryotic translation initiation factor 4A1 
1430724_at 1.86  Ephx3 epoxide hydrolase 3 
1417806_at 1.85  Popdc2 popeye domain containing 2 
1416608_a_at 1.85  BC004004 cDNA sequence BC004004 
1451891_a_at 1.85  Dysf dysferlin 
1431645_a_at 1.85  Gdi2 guanosine diphosphate (GDP) dissociation inhibitor 2 a 
1436234_at 1.85  4732471D19Rik RIKEN cDNA 4732471D19 gene 
1460345_at 1.85  Aida axin interactor, dorsalization associated 
1425550_a_at 1.85  Prkar1a protein kinase, cAMP dependent regulatory, type I, alpha 
1423223_a_at 1.84  Prdx6 peroxiredoxin 6 
1419568_at 1.84  Mapk1 mitogen-activated protein kinase 1 
1423358_at 1.84  Ece2 endothelin converting enzyme 2 
1452954_at 1.84  Ube2c ubiquitin-conjugating enzyme E2C 
1437524_x_at 1.84  Coro7 coronin 7 
1423923_a_at 1.84  Wdr8 WD repeat domain 8 
1425534_at 1.84  Stau2 staufen (RNA binding protein) homolog 2 (Drosophila) 
1450065_at 1.84  Adcy7 adenylate cyclase 7 
1417647_at 1.83  Snx5 sorting nexin 5 
1416974_at 1.83  Stam2 signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 
1426645_at 1.83  Hsp90aa1 heat shock protein 90, alpha (cytosolic), class A member 1 b 
1426931_s_at 1.83  D19Bwg1357e DNA segment, Chr 19, Brigham & Women's Genetics 1357 expressed 
1423865_at 1.83  Slc44a1 solute carrier family 44, member 1 
1450138_a_at 1.82  Serpinb6a serine (or cysteine) peptidase inhibitor, clade B, member 6a 
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1455210_at 1.82  Zhx2 zinc fingers and homeoboxes 2 
1428754_at 1.82  Trmt6 tRNA methyltransferase 6 homolog (S. cerevisiae) 
1448557_at 1.82  Fam13c family with sequence similarity 13, member C a 
1450423_s_at 1.81  Bxdc1 brix domain containing 1 a 
1448824_at 1.81  Ube2j1 ubiquitin-conjugating enzyme E2, J1 
1435034_at 1.81  Rpap2 RNA polymerase II associated protein 2 
1418364_a_at 1.81  Ftl1 ferritin light chain 1 
1421947_at 1.81  Gng12 guanine nucleotide binding protein (G protein), gamma 12 
1424926_at 1.81  Sec63 SEC63-like (S. cerevisiae) a 
1422859_a_at 1.81  Rpl23 ribosomal protein L23 
1422508_at 1.80  Atp6v1a ATPase, H+ transporting, lysosomal V1 subunit A a 
1428386_at 1.80  Acsl3 acyl-CoA synthetase long-chain family member 3 
1440822_x_at 1.80  Reps1 RalBP1 associated Eps domain containing protein 
1417103_at 1.80  Ddt D-dopachrome tautomerase 
1422506_a_at 1.80  Cstb cystatin B a 
1426266_s_at 1.80  Zbtb8os zinc finger and BTB domain containing 8 opposite strand 
1455798_at 1.79  Galk2 galactokinase 2 
1436828_a_at 1.79  Tpd52l2 tumor protein D52-like 2 a 
1449037_at 1.79  Crem cAMP responsive element modulator 
1420745_a_at 1.79  Ccndbp1 cyclin D-type binding-protein 1 
1451290_at 1.79  Map1lc3a microtubule-associated protein 1 light chain 3 alpha a 
1416038_at 1.79  Snd1 staphylococcal nuclease and tudor domain containing 1 
1424620_at 1.79  Nop16 NOP16 nucleolar protein homolog (yeast) 
1419446_at 1.79  Tbc1d1 TBC1 domain family, member 1 
1423465_at 1.79  Frrs1 ferric-chelate reductase 1 
1417143_at 1.78  Lpar1 lysophosphatidic acid receptor 1 
1422906_at 1.78  Abcg2 ATP-binding cassette, sub-family G (WHITE), member 2 
1451026_at 1.78  Ftsj3 FtsJ homolog 3 (E. coli) 
1423735_a_at 1.78  Wdr36 WD repeat domain 36 
1423706_a_at 1.78  Pgd phosphogluconate dehydrogenase 
1416748_a_at 1.78  Mre11a meiotic recombination 11 homolog A (S. cerevisiae) 
1423053_at 1.78  Arf4 ADP-ribosylation factor 4 
1421529_a_at 1.78  Txnrd1 thioredoxin reductase 1 
1425551_at 1.77  Hip1r huntingtin interacting protein 1 related 
1425027_s_at 1.77  Sft2d2 SFT2 domain containing 2 
1422844_a_at 1.77  Wdr77 WD repeat domain 77 
1419838_s_at 1.77  Plk4 polo-like kinase 4 (Drosophila) 
 219
1427578_a_at 1.77  Eif6 eukaryotic translation initiation factor 6 
1433548_at 1.76  Mare alpha globin regulatory element containing gene 
1439040_at 1.76  Cenpe centromere protein E 
1419573_a_at 1.76  Lgals1 lectin, galactose binding, soluble 1 a 
1455726_at 1.76  Gm71 predicted gene 71 
1446750_at 1.76  Impact imprinted and ancient a 
1429588_at 1.76  2810474O19Rik RIKEN cDNA 2810474O19 gene 
1424819_a_at 1.76  Ric8 resistance to inhibitors of cholinesterase 8 homolog (C. elegans) 
1427375_at 1.75  Rg9mtd2 RNA (guanine-9-) methyltransferase domain containing 2 
1416178_a_at 1.75  Plekhb1 pleckstrin homology domain containing, family B (evectins) member 1 
1419619_at 1.75  Krt80 keratin 80 
1423621_a_at 1.74  Slc33a1 solute carrier family 33 (acetyl-CoA transporter), member 1 
1417453_at 1.74  Cul4b cullin 4B 
1422813_at 1.74  Cacng1 calcium channel, voltage-dependent, gamma subunit 1 
1417088_at 1.74  Zfp346 zinc finger protein 346 
1423452_at 1.74  Stk17b serine/threonine kinase 17b (apoptosis-inducing) 
1416013_at 1.74  Pld3 phospholipase D family, member 3 
1429370_a_at 1.74  Psmd11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 
1448618_at 1.74  Mvp major vault protein a 
1415803_at 1.73  Cx3cl1 chemokine (C-X3-C motif) ligand 1 
1453228_at 1.73  Stx11 syntaxin 11 
1429088_at 1.73  Lbh limb-bud and heart 
1420886_a_at 1.73  Xbp1 X-box binding protein 1 
1452066_a_at 1.73  Ndfip2 Nedd4 family interacting protein 2 
1455390_at 1.73  Alkbh6 alkB, alkylation repair homolog 6 (E. coli) 
1460198_a_at 1.73  Psmb3 proteasome (prosome, macropain) subunit, beta type 3 a 
1421746_a_at 1.73  Fbxo17 F-box protein 17 
1423846_x_at 1.73  Tuba1b tubulin, alpha 1B 
1416309_at 1.72  Nusap1 nucleolar and spindle associated protein 1 
1431339_a_at 1.72  Efhd2 EF hand domain containing 2 
1422389_at 1.72  Tas2r105 taste receptor, type 2, member 105 
1451453_at 1.72  Dapk2 death-associated protein kinase 2 
1455792_x_at 1.72  Ndn necdin c 
1459890_s_at 1.72  1110008P14Rik RIKEN cDNA 1110008P14 gene 
1455043_at 1.72  Tnpo1 transportin 1 
1435537_at 1.72  Ptprd protein tyrosine phosphatase, receptor type, D b 
1434402_at 1.72  Samd8 sterile alpha motif domain containing 8 
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1416129_at 1.71  Errfi1 ERBB receptor feedback inhibitor 1 
1426626_at 1.71  Gtf2f2 general transcription factor IIF, polypeptide 2 
1435402_at 1.71  Gramd1b GRAM domain containing 1B 
1423605_a_at 1.71  Mdm2 transformed mouse 3T3 cell double minute 2 
1435091_at 1.71  Zfp568 zinc finger protein 568 
1417684_at 1.71  Thumpd3 THUMP domain containing 3 
1434173_s_at 1.71  D19Bwg1357e DNA segment, Chr 19, Brigham & Women's Genetics 1357 expressed 
1436047_at 1.71  Gm672 predicted gene 672 
1448279_at 1.71  Arpc3 actin related protein 2/3 complex, subunit 3 
1435803_a_at 1.71  Eif4e2 eukaryotic translation initiation factor 4E member 2 a 
1437993_x_at 1.71  Qdpr quinoid dihydropteridine reductase a 
1423423_at 1.70  Pdia3 protein disulfide isomerase associated 3 
1415941_s_at 1.70  Zfand2a zinc finger, AN1-type domain 2A a 
1435472_at 1.70  Kremen1 kringle containing transmembrane protein 1 
1426577_a_at 1.70  Lin37 lin-37 homolog (C. elegans) 
1447662_x_at 1.70  D18Ertd653e DNA segment, Chr 18, ERATO Doi 653, expressed 
1455266_at 1.70  Kif5c kinesin family member 5C 
1448694_at 1.69  Jun Jun oncogene 
1428512_at 1.69  Bhlhb9 basic helix-loop-helix domain containing, class B9 
1423234_at 1.69  Psmd5 proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 
1448595_a_at 1.69  Bex1 brain expressed gene 1 
1429384_at 1.69  Csnk1g3 casein kinase 1, gamma 3 
1448268_at 1.69  Tmed9 transmembrane emp24 protein transport domain containing 9 
1454221_a_at 1.69  Kif2c kinesin family member 2C 
1418093_a_at 1.69  Egf epidermal growth factor 
1426333_a_at 1.68  Ikbkb inhibitor of kappaB kinase beta 
1451780_at 1.68  Blnk B-cell linker 
1448571_a_at 1.68  Gmfb glia maturation factor, beta 
1423552_at 1.68  Leprotl1 leptin receptor overlapping transcript-like 1 
1424861_at 1.68  D930016D06Rik RIKEN cDNA D930016D06 gene 
1438480_a_at 1.68  Thyn1 thymocyte nuclear protein 1 a 
1453833_a_at 1.68  Rnaseh1 ribonuclease H1 
1423800_at 1.68  Dars aspartyl-tRNA synthetase 
1448730_at 1.68  Cpa3 carboxypeptidase A3, mast cell 
1429712_at 1.68  Gm14288 predicted gene 14288 
1416352_s_at 1.67  Tecr trans-2,3-enoyl-CoA reductase 
1428261_at 1.67  Ccdc134 coiled-coil domain containing 134 
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1451741_a_at 1.67  Cdk7 cyclin-dependent kinase 7 (homolog of Xenopus MO15 cdk-activating kinase) 
1435306_a_at 1.67  Kif11 kinesin family member 11 
1452170_at 1.67  Chpf2 chondroitin polymerizing factor 2 
1416655_at 1.67  C1galt1c1 C1GALT1-specific chaperone 1 
1448438_at 1.67  Derl2 Der1-like domain family, member 2 
1416426_at 1.66  Rab5a RAB5A, member RAS oncogene family 
1420654_a_at 1.66  Gbe1 glucan (1,4-alpha-), branching enzyme 1 
1456747_x_at 1.66  Cd99l2 CD99 antigen-like 2 
1444451_at 1.66  Pappa2 pappalysin 2 
1439610_at 1.66  Rab27b RAB27b, member RAS oncogene family 
1458716_at 1.66  Dusp27 dual specificity phosphatase 27 (putative) 
1418621_at 1.66  Rab2a RAB2A, member RAS oncogene family 
1448736_a_at 1.66  Hprt1 hypoxanthine guanine phosphoribosyl transferase 1 
1424110_a_at 1.65  LOC100046344 similar to Nucleoside diphosphate kinase A (NDK A)  
1425348_a_at 1.65  Srprb signal recognition particle receptor, B subunit 
1433682_at 1.65  Arhgef17 Rho guanine nucleotide exchange factor (GEF) 17 
1425933_a_at 1.65  Nt5c2 5'-nucleotidase, cytosolic II 
1415735_at 1.65  Ddb1 damage specific DNA binding protein 1 
1417473_a_at 1.65  Ppcs phosphopantothenoylcysteine synthetase 
1450731_s_at 1.65  Tnfrsf21 tumor necrosis factor receptor superfamily, member 21 
1434585_at 1.64  Tulp4 Tubby like protein 4 
1454120_a_at 1.64  Pcgf6 polycomb group ring finger 6 
1430700_a_at 1.64  Pla2g7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
1433482_a_at 1.64  Fubp1 far upstream element (FUSE) binding protein 1 
1460583_at 1.64  Golt1b golgi transport 1 homolog B (S. cerevisiae) 
1438094_x_at 1.64  Ola1 Obg-like ATPase 1 a 
1424216_a_at 1.64  Papola poly (A) polymerase alpha 
1448947_at 1.64  Setd6 SET domain containing 6 
1455725_a_at 1.64  H3f3b H3 histone, family 3B 
1433656_a_at 1.64  Gnl3 guanine nucleotide binding protein-like 3 (nucleolar) 
1437861_s_at 1.64  Prkce protein kinase C, epsilon 
1424343_a_at 1.64  Eif1a eukaryotic translation initiation factor 1A 
1429776_a_at 1.63  Dnajb6 DnaJ (Hsp40) homolog, subfamily B, member 6 a 
1428315_at 1.63  Ebna1bp2 EBNA1 binding protein 2 
1418300_a_at 1.63  Mknk2 MAP kinase-interacting serine/threonine kinase 2 
1424635_at 1.63  Eef1a1 eukaryotic translation elongation factor 1 alpha 1 
1424210_at 1.63  Erlin1 ER lipid raft associated 1 
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1422516_a_at 1.63  Fibp fibroblast growth factor (acidic) intracellular binding protein 
1423648_at 1.63  Pdia6 protein disulfide isomerase associated 6 
1428910_at 1.63  2310022B05Rik RIKEN cDNA 2310022B05 gene 
1415676_a_at 1.63  Psmb5 proteasome (prosome, macropain) subunit, beta type 5 
1419648_at 1.63  Myo1c myosin IC 
1451120_at 1.63  Polr1d polymerase (RNA) I polypeptide D b 
1449002_at 1.63  Phlda3 pleckstrin homology-like domain, family A, member 3 
1422567_at 1.63  Fam129a family with sequence similarity 129, member A 
1452707_at 1.63  Klhl30 kelch-like 30 (Drosophila) 
1423920_at 1.62  Ncaph non-SMC condensin I complex, subunit H 
1434059_at 1.62  B230312A22Rik RIKEN cDNA B230312A22 gene 
1423299_at 1.62  Txnl1 thioredoxin-like 1 a 
1423569_at 1.62  Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
1450720_at 1.62  Acp1 acid phosphatase 1, soluble 
1416925_at 1.62  Kpnb1 karyopherin (importin) beta 1 
1419169_at 1.62  Mapk6 mitogen-activated protein kinase 6 
1449821_a_at 1.62  Memo1 mediator of cell motility 1 
1449930_a_at 1.62  Ssr2 signal sequence receptor, beta 
1450087_a_at 1.62  Nolc1 nucleolar and coiled-body phosphoprotein 1 
1428011_a_at 1.62  Erbb2ip Erbb2 interacting protein 
1416291_at 1.61  Psmc4 proteasome (prosome, macropain) 26S subunit, ATPase, 4 
1428335_a_at 1.61  Scfd1 Sec1 family domain containing 1 
1435705_at 1.61  Zscan18 zinc finger and SCAN domain containing 18 
1416537_at 1.61  Creld1 cysteine-rich with EGF-like domains 1 
1421751_a_at 1.61  Psmd14 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 
1416146_at 1.61  Hspa4 heat shock protein 4 
1451233_at 1.61  Traf2 TNF receptor-associated factor 2 
1419548_at 1.60  Kpna1 karyopherin (importin) alpha 1 a 
1416473_a_at 1.60  Igdcc4 immunoglobulin superfamily, DCC subclass, member 4 a 
1436202_at 1.60  Malat1 metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) 
1425780_a_at 1.60  Tmem167 transmembrane protein 167 
1452251_at 1.60  Nbea neurobeachin 
1451968_at 1.60  Xrcc5 X-ray repair complementing defective repair in Chinese hamster cells 5 
1427885_at 1.60  Pold4 polymerase (DNA-directed), delta 4 
1417817_a_at 1.60  Wwtr1 WW domain containing transcription regulator 1 
1416657_at 1.59  Akt1 thymoma viral proto-oncogene 1 
1415828_a_at 1.59  Serp1 stress-associated endoplasmic reticulum protein 1 
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1423784_at 1.59  Gars glycyl-tRNA synthetase 
1423453_at 1.59  Nol12 nucleolar protein 12 
1452182_at 1.59  Galnt2 UDP-N-acetyl-alpha-D-galactosamine 
1437495_at 1.59  Mbtps2 membrane-bound transcription factor peptidase, site 2 
1423850_at 1.59  Nsun2 NOL1/NOP2/Sun domain family member 2 
1419108_at 1.59  Ophn1 oligophrenin 1 
1417408_at 1.59  F3 coagulation factor III 
1423247_at 1.59  Erp44 endoplasmic reticulum protein 44 
1428587_at 1.59  Tmem41b transmembrane protein 41B 
1418602_at 1.58  Cdh15 cadherin 15 
1419029_at 1.58  Ero1l ERO1-like (S. cerevisiae) 
1418371_at 1.58  Dynll2 dynein light chain LC8-type 2 
1426441_at 1.58  Slc11a2 solute carrier family 11, member 2 
1424047_at 1.58  Dera 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) 
1435444_at 1.58  Atf6 activating transcription factor 6 
1428635_at 1.58  Comtd1 catechol-O-methyltransferase domain containing 1 
1416130_at 1.58  Prnp prion protein 
1436026_at 1.58  Zfp703 zinc finger protein 703 
1449304_at 1.58  2310061J03Rik RIKEN cDNA 2310061J03 gene 
1420340_at 1.58  Cspp1 centrosome and spindle pole associated protein 1 
1434303_at 1.58  Raph1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 
1454004_at 1.58  5033414K04Rik RIKEN cDNA 5033414K04 gene 
1422609_at 1.58  Arpp19 cAMP-regulated phosphoprotein 19 a 
1428534_at 1.57  Nr2c2ap nuclear receptor 2C2-associated protein 
1433766_at 1.57  C330023M02Rik RIKEN cDNA C330023M02 gene 
1416638_at 1.57  Sall2 sal-like 2 (Drosophila) 
1455643_s_at 1.57  Tsr1 TSR1, 20S rRNA accumulation, homolog (yeast) a 
1448472_at 1.57  Vars valyl-tRNA synthetase 
1424214_at 1.57  9130213B05Rik RIKEN cDNA 9130213B05 gene a 
1449111_a_at 1.57  Grb2 growth factor receptor bound protein 2 
1416979_at 1.57  Pomp proteasome maturation protein 
1426873_s_at 1.57  Jup junction plakoglobin 
1417657_s_at 1.57  Dnajc2 DnaJ (Hsp40) homolog, subfamily C, member 2 
1417057_a_at 1.56  Lamp3 lysosomal-associated membrane protein 3 
1427108_at 1.56  9530068E07Rik RIKEN cDNA 9530068E07 gene 
1423142_a_at 1.56  Gtpbp4 GTP binding protein 4 b 
1427035_at 1.56  Slc39a14 solute carrier family 39 (zinc transporter), member 14 
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1416529_at 1.56  Emp1 epithelial membrane protein 1 
1451908_a_at 1.56  Sec14l1 SEC14-like 1 (S. cerevisiae) 
1418102_at 1.56  Hes1 hairy and enhancer of split 1 (Drosophila) 
1450722_at 1.56  Nup50 nucleoporin 50 
1434543_a_at 1.56  Bola2 bolA-like 2 (E. coli) 
1456139_at 1.56  Airn antisense Igf2r RNA 
1455605_at 1.56  Rufy3 RUN and FYVE domain containing 3 
1425134_a_at 1.56  Pigx phosphatidylinositol glycan anchor biosynthesis, class X 
1434436_at 1.56  Morc4 microrchidia 4 
1451207_at 1.55  Cbara1 calcium binding atopy-related autoantigen 1 
1415892_at 1.55  Sgpl1 sphingosine phosphate lyase 1 
1448715_x_at 1.55  Sgip1 SH3-domain GRB2-like (endophilin) interacting protein 1 
1424894_at 1.55  Rab13 RAB13, member RAS oncogene family 
1425389_a_at 1.55  Runx2 runt related transcription factor 2 
1427934_at 1.55  Lyrm2 LYR motif containing 2 
1420540_a_at 1.55  Rit1 Ras-like without CAAX 1 
1433908_a_at 1.55  Cttn cortactin 
1432367_a_at 1.55  Ufd1l ubiquitin fusion degradation 1 like 
1423167_at 1.55  Mobkl3 MOB1, Mps One Binder kinase activator-like 3 (yeast) 
1417252_at 1.55  Nt5c 5',3'-nucleotidase, cytosolic 
1451223_a_at 1.55  Btf3l4 basic transcription factor 3-like 4 
1452843_at 1.55  Il6st interleukin 6 signal transducer 
1445568_at 1.55  Inca1 Inhibitor of CDK, cyclin A1 interacting protein 1 
1416563_at 1.55  Ctps cytidine 5'-triphosphate synthase 
1418937_at 1.55  Dio2 deiodinase, iodothyronine, type II 
1437500_at 1.54  Noc3l nucleolar complex associated 3 homolog (S. cerevisiae) 
1451068_s_at 1.54  Rps25 ribosomal protein S25 
1429328_at 1.54  Nsfl1c NSFL1 (p97) cofactor (p47) 
1455870_at 1.54  Akap2 A kinase (PRKA) anchor protein 2 
1460344_at 1.54  Pbxip1 pre-B-cell leukemia transcription factor interacting protein 1 
1427032_at 1.54  Herc4 hect domain and RLD 4 
1453075_at 1.54  1600012P17Rik RIKEN cDNA 1600012P17 gene 
1427739_a_at 1.54  Trp53 transformation related protein 53 
1422576_at 1.54  Atxn10 ataxin 10 a 
1415780_a_at 1.54  Armcx2 armadillo repeat containing, X-linked 2 
1451136_a_at 1.54  Eif2b2 eukaryotic translation initiation factor 2B, subunit 2 beta 
1449674_s_at 1.54  Pdcd6ip programmed cell death 6 interacting protein 
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1416861_at 1.54  Stam signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 
1418825_at 1.53  Irgm1 immunity-related GTPase family M member 1 
1460556_at 1.53  Micall1 microtubule associated monoxygenase 
1418387_at 1.53  Mphosph8 M-phase phosphoprotein 8 
1425299_s_at 1.53  Trmt112 tRNA methyltransferase 11-2 homolog (S. cerevisiae) 
1418794_at 1.53  Cds2 CDP-diacylglycerol synthase 2 a 
1454901_at 1.53  Ypel2 yippee-like 2 (Drosophila) 
1426956_a_at 1.53  Trp53bp1 transformation related protein 53 binding protein 1 
1429400_at 1.53  Clcn5 chloride channel 5 
1448480_at 1.53  Nip7 nuclear import 7 homolog (S. cerevisiae) 
1416985_at 1.53  Sirpa signal-regulatory protein alpha 
1434809_at 1.53  Arhgap28 Rho GTPase activating protein 28 
1455462_at 1.53  Adcy2 adenylate cyclase 2 
1433982_at 1.53  Usp28 ubiquitin specific peptidase 28 
1415683_at 1.53  Nmt1 N-myristoyltransferase 1 
1416208_at 1.52  Usp14 ubiquitin specific peptidase 14 
1425215_at 1.52  Ffar2 free fatty acid receptor 2 
1422768_at 1.52  Syncrip synaptotagmin binding, cytoplasmic RNA interacting protein 
1453129_a_at 1.52  Rgs12 regulator of G-protein signaling 12 
1438928_x_at 1.52  Ninj1 ninjurin 1 
1456085_x_at 1.52  Cd151 CD151 antigen a 
1450890_a_at 1.52  Abi1 abl-interactor 1 
1455493_at 1.52  Syne1 synaptic nuclear envelope 1 
1417235_at 1.52  Ehd3 EH-domain containing 3 
1437242_at 1.52  Ttll12 tubulin tyrosine ligase-like family, member 12 
1451113_a_at 1.52  Ik IK cytokine 
1454897_at 1.52  6330509M05Rik RIKEN cDNA 6330509M05 gene 
1419003_at 1.52  Bves blood vessel epicardial substance 
1455994_x_at 1.52  Elovl1 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 1 
1424634_at 1.52  Tceal1 transcription elongation factor A (SII)-like 1 
1424222_s_at 1.52  Rad23b RAD23b homolog (S. cerevisiae) 
1434558_at 1.52  Wdr47 WD repeat domain 47 
1417125_at 1.52  Ahcy S-adenosylhomocysteine hydrolase 
1460317_s_at 1.52  Gna13 guanine nucleotide binding protein, alpha 13 a 
1423126_at 1.51  Atp1b3 ATPase, Na+/K+ transporting, beta 3 polypeptide 
1460479_at 1.51  A330094K24Rik RIKEN cDNA A330094K24 gene 
1437033_a_at 1.51  Skp2 S-phase kinase-associated protein 2 (p45) 
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1434153_at 1.51  Shb src homology 2 domain-containing transforming protein B 
1422980_a_at 1.51  Bet1l blocked early in transport 1 homolog (S. cerevisiae)-like 
1454963_at 1.51  E430028B21Rik RIKEN cDNA E430028B21 gene 
1452196_a_at 1.51  Nckap1 NCK-associated protein 1 
1449799_s_at 1.51  Pkp2 plakophilin 2 
1449841_at 1.51  Kif3a kinesin family member 3A 
1435775_at 1.51  Clock circadian locomoter output cycles kaput 
1453796_a_at 1.51  Ergic2 ERGIC and golgi 2 
1435822_at 1.51  D830012I24Rik RIKEN cDNA D830012I24 gene 
1436138_at 1.50  Ttc19 tetratricopeptide repeat domain 19 
1455316_x_at 1.50  BC094435 cDNA sequence BC094435 
1419428_a_at 1.50  Gaa glucosidase, alpha, acid 
1415670_at 1.50  Copg coatomer protein complex, subunit gamma 
1449507_a_at 1.50  Cd47 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) 
1430999_a_at 1.50  Scoc short coiled-coil protein 
1424749_at 1.50  Wdfy1 WD repeat and FYVE domain containing 1 
1435417_at 1.50  AI464131 expressed sequence AI464131 
1450388_s_at 1.50  Twsg1 twisted gastrulation homolog 1 (Drosophila) 
1450841_at 1.50  Stt3a STT3, subunit of the oligosaccharyltransferase complex, homolog A  
1417825_at 1.50  Esd esterase D/formylglutathione hydrolase 
1423519_at 1.50  Fam108c family with sequence similarity 108, member C 
1426187_a_at 1.50  Hax1 HCLS1 associated X-1 
1433611_s_at 1.50  Bud31 BUD31 homolog (yeast) 
1448533_at 1.50  Tbcb tubulin folding cofactor B 
1448232_x_at 1.50  Tuba1a tubulin, alpha 1A 
1417481_at 6.03  Ramp1 receptor (calcitonin) activity modifying protein 1 
1451382_at 4.67  Chac1 ChaC, cation transport regulator-like 1 (E. coli) 
1437250_at 4.23  Mreg melanoregulin 
1449876_at 3.92  Prkg1 protein kinase, cGMP-dependent, type I a 
1428025_s_at 3.68  Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1 e 
1434499_a_at 3.65  Ldhb lactate dehydrogenase B c 
1449422_at 3.55  Cdh4 cadherin 4 a 
1458635_at 3.54  4832428D23Rik RIKEN cDNA 4832428D23 gene 
1439143_at 3.42  A930018M24Rik RIKEN cDNA A930018M24 gene 
1422798_at 3.40  Cntnap2 contactin associated protein-like 2 
1427329_a_at 3.35  Igh-6 immunoglobulin heavy chain 6 (heavy chain of IgM) 
1450048_a_at 3.33  Idh2 isocitrate dehydrogenase 2 (NADP+), mitochondrial 
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1424393_s_at 3.28  Adhfe1 alcohol dehydrogenase, iron containing, 1 a 
1435370_a_at 3.18  Ces3 carboxylesterase 3 a 
1434645_at 3.17  C530008M17Rik RIKEN cDNA C530008M17 gene 
1416023_at 3.12  Fabp3 fatty acid binding protein 3, muscle and heart 
1448300_at 3.12  Mgst3 microsomal glutathione S-transferase 3 
1440335_at 3.11  LOC100046468 hypothetical protein LOC100046468 
1423454_a_at 3.10  Sema6c sema domain, transmembrane domain (TM), (semaphorin) 6C 
1444504_at 3.02  Dhrs7c dehydrogenase/reductase (SDR family) member 7C 
1436736_x_at 2.96  D0H4S114 DNA segment, human D4S114 a 
1438263_at 2.91  9430020K01Rik RIKEN cDNA 9430020K01 gene a 
1418421_at 2.88  Bcl6b B-cell CLL/lymphoma 6, member B 
1422153_a_at 2.84  Asb11 ankyrin repeat and SOCS box-containing 11 
1451553_at 2.81  Art5 ADP-ribosyltransferase 5 
1435605_at 2.81  Actr3b ARP3 actin-related protein 3 homolog B (yeast) 
1416835_s_at 2.80  Amd1 S-adenosylmethionine decarboxylase 1 a 
1454867_at 2.78  Mn1 meningioma 1 
1416468_at 2.78  Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 
1441581_at 2.77  Asb10 ankyrin repeat and SOCS box-containing 10 a 
1423405_at 2.76  Timp4 tissue inhibitor of metalloproteinase 4 
1417877_at 2.76  Eepd1 endonuclease/exonuclease/phosphatase family domain containing 1 
1418589_a_at 2.76  Mlf1 myeloid leukemia factor 1 
1439491_at 2.73  Lrrc38 leucine rich repeat containing 38 
1419145_at 2.73  Smtnl1 smoothelin-like 1 
1439821_at 2.73  Lrp2bp Lrp2 binding protein 
1417061_at 2.72  Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 b 
1424105_a_at 2.70  Pttg1 pituitary tumor-transforming gene 1 a 
1418057_at 2.70  Tiam1 T-cell lymphoma invasion and metastasis 1 
1416617_at 2.69  Acss1 acyl-CoA synthetase short-chain family member 1 
1437273_at 2.69  Htra4 HtrA serine peptidase 4 
1453904_at 2.69  Ccdc146 coiled-coil domain containing 146 
1453851_a_at 2.68  Gadd45g growth arrest and DNA-damage-inducible 45 gamma 
1439087_a_at 2.67  Pik3ip1 phosphoinositide-3-kinase interacting protein 1 a 
1455622_at 2.60  Podxl2 podocalyxin-like 2 
1423062_at 2.59  Igfbp3 insulin-like growth factor binding protein 3 a 
1452766_at 2.59  Tppp tubulin polymerization promoting protein 
1424937_at 2.57  Plin5 perilipin 5 a 
1457999_at 2.54  Fam82b family with sequence similarity 82, member B b 
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1429144_at 2.51  Prei4 preimplantation protein 4 a 
1455506_at 2.50  Slc25a34 solute carrier family 25, member 34 
1422678_at 2.50  Dgat2 diacylglycerol O-acyltransferase 2 a 
1453084_s_at 2.49  Col22a1 collagen, type XXII, alpha 1 a 
1451716_at 2.48  Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) 
1418181_at 2.46  Ptp4a3 protein tyrosine phosphatase 4a3 
1452474_a_at 2.45  Art3 ADP-ribosyltransferase 3 
1449834_at 2.43  Magix MAGI family member, X-linked 
1422811_at 2.40  Slc27a1 solute carrier family 27 (fatty acid transporter), member 1 a 
1417163_at 2.40  Dusp10 dual specificity phosphatase 10 
1417283_at 2.39  Lynx1 Ly6/neurotoxin 1 a 
1430522_a_at 2.39  Vamp5 vesicle-associated membrane protein 5 
1419140_at 2.38  Acvr2b activin receptor IIB 
1420346_at 2.38  Asb12 ankyrin repeat and SOCS box-containing 12 
1427482_a_at 2.38  Car8 carbonic anhydrase 8 
1430969_at 2.38  Mtch2 mitochondrial carrier homolog 2 (C. elegans) 
1457721_at 2.38  PPAR-γ peroxisome proliferative activated receptor-γ 
1426450_at 2.38  Plcl2 phospholipase C-like 2 
1418507_s_at 2.38  Socs2 suppressor of cytokine signaling 2 a 
1423422_at 2.37  Asb4 ankyrin repeat and SOCS box-containing 4 
1451313_a_at 2.36  1110067D22Rik RIKEN cDNA 1110067D22 gene a 
1450971_at 2.35  Gadd45b growth arrest and DNA-damage-inducible 45 beta a 
1435292_at 2.34  Tbc1d4 TBC1 domain family, member 4 
1449290_at 2.34  Dpysl5 dihydropyrimidinase-like 5 
1449547_at 2.33  Asb14 ankyrin repeat and SOCS box-containing 14 
1425089_at 2.33  Kcnc4 potassium voltage gated channel, Shaw-related subfamily, member 4 
1416203_at 2.32  Aqp1 aquaporin 1 
1417645_at 2.31  Sspn sarcospan a 
1451322_at 2.31  Cmbl carboxymethylenebutenolidase-like (Pseudomonas) 
1422605_at 2.31  Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A 
1452962_at 2.28  Tmem25 transmembrane protein 25 a 
1433532_a_at 2.25  Mbp myelin basic protein a 
1426729_at 2.24  Fam131a family with sequence similarity 131, member A 
1435745_at 2.24  5031439G07Rik RIKEN cDNA 5031439G07 gene 
1427213_at 2.24  Pfkfb1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 
1427100_at 2.24  Metrn meteorin, glial cell differentiation regulator 
1436361_at 2.24  Vgll2 vestigial like 2 homolog (Drosophila) 
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1453552_at 2.23  2310014F07Rik RIKEN cDNA 2310014F07 gene 
1454749_at 2.23  Pcnt pericentrin (kendrin) a 
1450490_at 2.23  Kcna7 potassium voltage-gated channel, shaker-related subfamily, member 7 
1429071_at 2.22  Me3 malic enzyme 3, NADP(+)-dependent, mitochondrial 
1455220_at 2.22  Frat2 frequently rearranged in advanced T-cell lymphomas 2 
1426719_at 2.21  Apbb2 amyloid beta (A4) precursor protein-binding, family B, member 2 a 
1434386_at 2.20  Atp2c1 ATPase, Ca++-sequestering 
1428140_at 2.20  Oxct1 3-oxoacid CoA transferase 1 b 
1434210_s_at 2.20  Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 a 
1432062_at 2.20  Mdga1 MAM domain containing glycosylphosphatidylinositol anchor 1 
1420712_a_at 2.19  Hpn hepsin 
1455031_at 2.19  Cdc2l6 cell division cycle 2-like 6 (CDK8-like) 
1454822_x_at 2.18  Apcdd1 adenomatosis polyposis coli down-regulated 1 
1440343_at 2.18  Rps6ka5 ribosomal protein S6 kinase, polypeptide 5 a 
1440435_at 2.18  Ky kyphoscoliosis peptidase 
1430176_at 2.18  5430433E21Rik RIKEN cDNA 5430433E21 gene 
1457311_at 2.18  Camk2a calcium/calmodulin-dependent protein kinase II alpha a 
1436763_a_at 2.18  Klf9 Kruppel-like factor 9 c 
1440443_at 2.17  E030016H06Rik RIKEN cDNA E030016H06 gene 
1428864_at 2.17  5530400B01Rik RIKEN cDNA 5530400B01 gene 
1417590_at 2.17  Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 
1450251_a_at 2.16  Lnx1 ligand of numb-protein X 1 
1428991_at 2.16  Hrasls HRAS-like suppressor a 
1449334_at 2.15  Timp3 tissue inhibitor of metalloproteinase 3 b 
1430462_at 2.15  2310002L09Rik RIKEN cDNA 2310002L09 gene 
1417067_s_at 2.15  Cabc1 chaperone, ABC1 activity of bc1 complex like (S. pombe) 
1429598_at 2.15  2310042D19Rik RIKEN cDNA 2310042D19 gene 
1432107_at 2.15  2310010M20Rik RIKEN cDNA 2310010M20 gene 
1438031_at 2.15  Rasgrp3 RAS, guanyl releasing protein 3 a 
1444178_at 2.14  Gm9895 predicted gene 9895 
1417542_at 2.14  Rps6ka2 ribosomal protein S6 kinase, polypeptide 2 
1457881_at 2.13  Osbpl6 oxysterol binding protein-like 6 a 
1429264_at 2.13  C030044B11Rik RIKEN cDNA C030044B11 gene 
1421425_a_at 2.13  Rcan2 regulator of calcineurin 2 
1456812_at 2.13  Abcd2 ATP-binding cassette, sub-family D (ALD), member 2 a 
1435733_x_at 2.12  Rnaseh2c ribonuclease H2, subunit C 
1419301_at 2.12  Fzd4 frizzled homolog 4 (Drosophila) 
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1437197_at 2.12  Sorbs2 sorbin and SH3 domain containing 2 
1439096_at 2.12  Ddo D-aspartate oxidase a 
1435917_at 2.12  Ociad2 OCIA domain containing 2 
1437473_at 2.11  Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog c 
1416564_at 2.11  Sox7 SRY-box containing gene 7 
1434354_at 2.09  Maob monoamine oxidase B 
1417680_at 2.09  Kcna5 potassium voltage-gated channel, shaker-related subfamily, member 5 
1438201_at 2.09  Pdp1 pyruvate dehyrogenase phosphatase catalytic subunit 1 a 
1449581_at 2.08  Emid1 EMI domain containing 1 
1436440_at 2.08  Slc25a12 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 
1429796_at 2.07  Kalrn kalirin, RhoGEF kinase 
1428536_at 2.07  Kcng4 potassium voltage-gated channel, subfamily G, member 4 
1456755_at 2.07  Trak1 trafficking protein, kinesin binding 1 
1447934_at 2.07  9630033F20Rik RIKEN cDNA 9630033F20 gene b 
1419137_at 2.07  Shank3 SH3/ankyrin domain gene 3 
1421961_a_at 2.06  Dnajb5 DnaJ (Hsp40) homolog, subfamily B, member 5 a 
1416775_at 2.06  Atp5sl ATP5S-like 
1438012_at 2.05  Ppm1l protein phosphatase 1 (formerly 2C)-like 
1434454_at 2.05  Adcy9 adenylate cyclase 9 c 
1446619_at 2.04  A130038J17Rik RIKEN cDNA A130038J17 gene 
1423104_at 2.04  Irs1 insulin receptor substrate 1 
1429267_at 2.04  Acot11 acyl-CoA thioesterase 11 
1424737_at 2.03  Thrsp thyroid hormone responsive SPOT14 homolog (Rattus) a 
1441727_s_at 2.03  Zfp467 zinc finger protein 467 a 
1440007_at 2.03  D930003E18Rik RIKEN cDNA D930003E18 gene 
1455712_at 2.03  Hist3h2a histone cluster 3, H2a 
1452942_at 2.02  Tmem65 transmembrane protein 65 
1448900_at 2.02  D16H22S680E DNA segment, Chr 16, human D22S680E, expressed 
1429918_at 2.02  Arhgap20 Rho GTPase activating protein 20 a 
1453418_at 2.01  Col24a1 collagen, type XXIV, alpha 1 
1418370_at 2.01  Tnnc1 troponin C, cardiac/slow skeletal 
1456574_at 2.01  Zfp800 zinc finger protein 800 
1416105_at 2.01  Nnt nicotinamide nucleotide transhydrogenase a 
1421498_a_at 2.01  2010204K13Rik RIKEN cDNA 2010204K13 gene 
1438294_at 1.99  Atxn1 ataxin 1 
1424182_at 1.99  Acat1 acetyl-Coenzyme A acetyltransferase 1 
1453094_at 1.99  Foxo forkhead box b 
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1416666_at 1.99  Serpine2 serine (or cysteine) peptidase inhibitor, clade E, member 2 
1436756_x_at 1.98  Hadh hydroxyacyl-Coenzyme A dehydrogenase b 
1430653_at 1.98  A930026B05Rik RIKEN cDNA A930026B05 gene 
1425344_at 1.98  Narf nuclear prelamin A recognition factor a 
1418328_at 1.98  Chkb-cpt1b choline kinase beta, carnitine palmitoyltransferase 1b, muscle transcription unit 
1456640_at 1.98  Sh3rf2 SH3 domain containing ring finger 2 
1460652_at 1.98  Esrra estrogen related receptor, alpha 
1429012_at 1.98  Arhgef6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
1422852_at 1.98  Cib2 calcium and integrin binding family member 2 
1431714_at 1.97  2310015D24Rik RIKEN cDNA 2310015D24 gene 
1424563_at 1.97  Slc25a4 solute carrier family 25, member 4 
1448636_at 1.97  Myoz1 myozenin 1 
1426043_a_at 1.96  Capn3 calpain 3 a 
1419042_at 1.96  Iigp1 interferon inducible GTPase 1 
1426850_a_at 1.96  Map2k6 mitogen-activated protein kinase kinase 6 
1450637_a_at 1.96  Aebp1 AE binding protein 1 a 
1448667_x_at 1.96  Tob2 transducer of ERBB2, 2 b 
1450044_at 1.96  Fzd7 frizzled homolog 7 (Drosophila) 
1441636_at 1.96  Sec14l5 SEC14-like 5 (S. cerevisiae) 
1427416_x_at 1.95  Dusp7 dual specificity phosphatase 7 
1452985_at 1.95  Uaca uveal autoantigen with coiled-coil domains and ankyrin repeats 
1435464_at 1.95  1110003E01Rik RIKEN cDNA 1110003E01 gene 
1426027_a_at 1.95  Arhgap10 Rho GTPase activating protein 10 
1418951_at 1.95  Txlnb taxilin beta a 
1440346_at 1.95  Kdm6b KDM1 lysine (K)-specific demethylase 6B 
1437797_at 1.95  Atp2a2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
1424367_a_at 1.94  Homer2 homer homolog 2 (Drosophila) 
1452973_at 1.94  Ppm1k protein phosphatase 1K (PP2C domain containing) 
1441531_at 1.94  Plcb4 phospholipase C, beta 4 a 
1436387_at 1.94  C330006P03Rik RIKEN cDNA C330006P03 gene 
1415904_at 1.94  Lpl lipoprotein lipase a 
1418091_at 1.93  Tcfcp2l1 transcription factor CP2-like 1 
1428444_at 1.93  Asb2 ankyrin repeat and SOCS box-containing 2 
1456909_at 1.93  LOC676974 similar to Glucose-6-phosphate isomerase  
1443923_at 1.93  Akap13 A kinase (PRKA) anchor protein 13 
1457102_at 1.93  A030001D16Rik RIKEN cDNA A030001D16 gene 
1456069_at 1.93  Dtna dystrobrevin alpha 
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1433453_a_at 1.92  Abtb2 ankyrin repeat and BTB (POZ) domain containing 2 
1454397_at 1.92  4632418H02Rik RIKEN cDNA 4632418H02 gene 
1423785_at 1.92  Egln1 EGL nine homolog 1 (C. elegans) a 
1452299_at 1.92  Wwp1 WW domain containing E3 ubiquitin protein ligase 1 a 
1438292_x_at 1.92  Adk adenosine kinase a 
1442243_at 1.91  Per3 period homolog 3 (Drosophila) 
1428301_at 1.91  100041874 predicted gene, 100041874 a 
1445843_at 1.91  Chd2 chromodomain helicase DNA binding protein 2 a 
1440635_at 1.91  Palld palladin, cytoskeletal associated protein a 
1416008_at 1.90  Satb1 special AT-rich sequence binding protein 1 b 
1444612_at 1.90  Ppp2r3a protein phosphatase 2, regulatory subunit B'', alpha 
1449964_a_at 1.90  Mlycd malonyl-CoA decarboxylase 
1433628_at 1.90  Coq10a coenzyme Q10 homolog A (yeast) 
1454873_at 1.90  Zfp775 zinc finger protein 775 
1448927_at 1.89  Kcnn2 potassium intermediate/small conductance calcium-activated channel 2 
1455475_at 1.89  3110057O12Rik RIKEN cDNA 3110057O12 gene a 
1449078_at 1.89  St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
1449405_at 1.88  Tns1 tensin 1 b 
1435357_at 1.88  D4Wsu53e DNA segment, Chr 4, Wayne State University 53, expressed a 
1448607_at 1.88  Nampt nicotinamide phosphoribosyltransferase a 
1448949_at 1.88  Car4 carbonic anhydrase 4 
1428146_s_at 1.87  Acaa2 acetyl-Coenzyme A acyltransferase 2 b 
1455698_at 1.87  Sec62 SEC62 homolog (S. cerevisiae) 
1449818_at 1.87  Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 
1424504_at 1.86  Rab22a RAB22A, member RAS oncogene family 
1424531_a_at 1.86  Tcea3 transcription elongation factor A (SII), 3 
1457304_at 1.85  D13Ertd787e DNA segment, Chr 13, ERATO Doi 787, expressed 
1426959_at 1.85  Bdh1 3-hydroxybutyrate dehydrogenase, type 1 a 
1449398_at 1.85  Rpl3l ribosomal protein L3-like 
1448876_at 1.85  Evc Ellis van Creveld gene homolog (human) 
1423835_at 1.85  Zfp503 zinc finger protein 503 
1417673_at 1.85  Grb14 growth factor receptor bound protein 14 
1425425_a_at 1.85  Wif1 Wnt inhibitory factor 1 
1450884_at 1.84  Cd36 CD36 antigen a 
1417841_at 1.84  Pxmp2 peroxisomal membrane protein 2 
1450700_at 1.83  Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3 a 
1417702_a_at 1.83  Hnmt histamine N-methyltransferase 
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1431199_at 1.83  Ggnbp1 gametogenetin binding protein 1 
1427045_at 1.83  Synpo synaptopodin 
1422323_a_at 1.82  Lbx1 ladybird homeobox homolog 1 (Drosophila) 
1453657_at 1.82  2310065F04Rik RIKEN cDNA 2310065F04 gene 
1434008_at 1.82  Scn4b sodium channel, type IV, beta 
1451740_at 1.82  Paip1 polyadenylate binding protein-interacting protein 1 
1420098_s_at 1.82  D13Ertd787e DNA segment, Chr 13, ERATO Doi 787, expressed 
1445632_at 1.82  Ogdh oxoglutarate dehydrogenase (lipoamide) 
1456629_at 1.81  Kank3 KN motif and ankyrin repeat domains 3 
1428432_at 1.81  Zcchc24 zinc finger, CCHC domain containing 24 
1444982_at 1.81  C230007H23Rik RIKEN cDNA C230007H23 gene 
1434480_at 1.81  4930402E16Rik RIKEN cDNA 4930402E16 gene 
1435591_at 1.81  AI426330 expressed sequence AI426330 
1435471_at 1.81  Zfp708 zinc finger protein 708 
1417050_at 1.80  C1qtnf4 C1q and tumor necrosis factor related protein 4 
1433762_at 1.80  C630043F03Rik RIKEN cDNA C630043F03 gene 
1415743_at 1.80  Hdac5 histone deacetylase 5 
1454976_at 1.80  Sod2 superoxide dismutase 2, mitochondrial 
1424553_at 1.80  Hhatl hedgehog acyltransferase-like 
1432562_at 1.79  1110006G14Rik RIKEN cDNA 1110006G14 gene 
1436538_at 1.79  Ankrd37 ankyrin repeat domain 37 
1428016_a_at 1.79  Rasip1 Ras interacting protein 1 
1416424_at 1.79  Plin3 perilipin 3 
1424362_at 1.78  Ppapdc3 phosphatidic acid phosphatase type 2 domain containing 3 
1415984_at 1.78  Acadm acyl-Coenzyme A dehydrogenase, medium chain 
1448394_at 1.78  Myl2 myosin, light polypeptide 2, regulatory, cardiac, slow 
1429097_at 1.78  C030044C12Rik RIKEN cDNA C030044C12 gene 
1451932_a_at 1.78  Adamtsl4 ADAMTS-like 4 
1448104_at 1.78  Aldh6a1 aldehyde dehydrogenase family 6, subfamily A1 
1434647_at 1.78  Egflam EGF-like, fibronectin type III and laminin G domains 
1427436_at 1.77  Six2 sine oculis-related homeobox 2 homolog (Drosophila) 
1454840_at 1.77  Mccc2 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 
1425678_a_at 1.77  Snrk SNF related kinase a 
1452841_at 1.77  Pgm2l1 phosphoglucomutase 2-like 1 a 
1425920_at 1.77  Cuedc1 CUE domain containing 1 
1449062_at 1.76  Khk ketohexokinase 
1434671_at 1.76  B230337E12Rik RIKEN cDNA B230337E12 gene 
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1449576_at 1.76  Eif1ay eukaryotic translation initiation factor 1A, Y-linked 
1448530_at 1.76  Gmpr guanosine monophosphate reductase 
1425891_a_at 1.76  Grtp1 GH regulated TBC protein 1 
1422927_at 1.76  Yipf7 Yip1 domain family, member 7 
1434717_at 1.76  Cul3 cullin 3 c 
1424777_at 1.76  Dcaf4 DDB1 and CUL4 associated factor 4 
1437869_at 1.76  Ppp2r3a protein phosphatase 2, regulatory subunit B'', alpha 
1455087_at 1.76  D7Ertd715e DNA segment, Chr 7, ERATO Doi 715, expressed 
1453135_at 1.76  Fndc5 fibronectin type III domain containing 5 a 
1451803_a_at 1.76  Vegfb vascular endothelial growth factor B 
1453141_at 1.75  0610009L18Rik RIKEN cDNA 0610009L18 gene 
1456903_at 1.75  Ptx3 pentraxin related gene 
1422445_at 1.75  Itga6 integrin alpha 6 a 
1454984_at 1.75  Lifr leukemia inhibitory factor receptor 
1449544_a_at 1.75  Kcnh2 potassium voltage-gated channel, subfamily H (eag-related), member 2 
1417580_s_at 1.75  Selenbp1 selenium binding protein 1 
1426951_at 1.75  Crim1 cysteine rich transmembrane BMP regulator 1 (chordin like) 
1427982_s_at 1.74  Syne2 synaptic nuclear envelope 2 
1435171_at 1.74  2810416G20Rik RIKEN cDNA 2810416G20 gene 
1452005_at 1.74  Dlat dihydrolipoamide S-acetyltransferase 
1435344_at 1.74  Tfdp2 transcription factor Dp 2 
1437689_x_at 1.74  Clu clusterin b 
1422589_at 1.74  Rab3a RAB3A, member RAS oncogene family 
1435553_at 1.74  Pdzd2 PDZ domain containing 2 
1439565_at 1.74  Fam123b family with sequence similarity 123, member B 
1435549_at 1.74  Trpm4 transient receptor potential cation channel, subfamily M, member 4 
1429178_at 1.73  Odz3 odd Oz/ten-m homolog 3 (Drosophila) a 
1456981_at 1.73  Tmc7 transmembrane channel-like gene family 7 
1454850_at 1.73  Tbc1d10c TBC1 domain family, member 10c 
1460591_at 1.73  Esr1 estrogen receptor 1 (alpha) a 
1435881_at 1.73  Pcbp2 poly(rC) binding protein 2 
1422910_s_at 1.73  Smc6 structural maintenance of chromosomes 6 
1433907_at 1.73  Pknox2 Pbx/knotted 1 homeobox 2 
1448825_at 1.73  Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2 
1429108_at 1.72  Msl2 male-specific lethal 2 homolog (Drosophila) 
1434537_at 1.72  Slco3a1 solute carrier organic anion transporter family, member 3a1 
1422622_at 1.72  Nos3 nitric oxide synthase 3, endothelial cell 
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1426858_at 1.72  Inhbb inhibin beta-B 
1425753_a_at 1.72  Ung uracil DNA glycosylase 
1435787_at 1.72  Ppm1l protein phosphatase 1 (formerly 2C)-like 
1415698_at 1.72  Golm1 golgi membrane protein 1 
1417846_at 1.71  Ulk2 Unc-51 like kinase 2 (C. elegans) a 
1459903_at 1.71  Sema7a sema domain, immunoglobulin domain (Ig), and GPI membrane anchor 7A 
1418592_at 1.71  Dnaja4 DnaJ (Hsp40) homolog, subfamily A, member 4 c 
1428081_at 1.71  Klhl21 kelch-like 21 (Drosophila) 
1429768_at 1.71  Dtna dystrobrevin alpha 
1452227_at 1.70  2310045A20Rik RIKEN cDNA 2310045A20 gene 
1454720_at 1.70  Apba3 amyloid beta (A4) precursor protein-binding, family A, member 3 
1434380_at 1.70  Gbp6 guanylate binding protein 6 
1415959_at 1.70  Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 a 
1428704_at 1.70  Zfp661 zinc finger protein 661 
1416846_a_at 1.70  Pdzrn3 PDZ domain containing RING finger 3 
1424790_at 1.70  Slc25a42 solute carrier family 25, member 42 
1453103_at 1.70  Ablim1 actin-binding LIM protein 1 
1417056_at 1.70  Psme1 proteasome (prosome, macropain) 28 subunit, alpha 
1431328_at 1.70  Ppp1cb protein phosphatase 1, catalytic subunit, beta isoform 
1457671_at 1.70  9330120H11Rik RIKEN cDNA 9330120H11 gene 
1425362_at 1.70  Agfg2 ArfGAP with FG repeats 2 
1434815_a_at 1.70  Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 
1423072_at 1.69  6720475J19Rik RIKEN cDNA 6720475J19 gene 
1429552_at 1.69  Wdr16 WD repeat domain 16 
1448297_a_at 1.69  Tnk2 tyrosine kinase, non-receptor, 2 
1422478_a_at 1.69  Acss2 acyl-CoA synthetase short-chain family member 2 
1434099_at 1.69  Ppargc1a peroxisome proliferative activated receptor, gamma, coactivator 1 alpha a 
1426894_s_at 1.69  Fam102a family with sequence similarity 102, member A 
1451304_at 1.69  Tmem143 transmembrane protein 143 
1451718_at 1.69  Plp1 proteolipid protein (myelin) 1 
1434204_x_at 1.69  Shmt2 serine hydroxymethyltransferase 2 (mitochondrial) 
1443078_at 1.69  6030439D06Rik RIKEN cDNA 6030439D06 gene 
1435207_at 1.69  Dixdc1 DIX domain containing 1 
1449536_at 1.68  Kcnn1 potassium intermediate/small conductance calcium-activated channel, member 1
1439196_at 1.68  Hook3 hook homolog 3 (Drosophila) 
1455091_at 1.68  Ppp2r3a protein phosphatase 2, regulatory subunit B'', alpha 
1427556_at 1.68  Mylk2 myosin, light polypeptide kinase 2, skeletal muscle 
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1453384_at 1.68  Dennd1b DENN/MADD domain containing 1B 
1428930_at 1.67  Tmem29 transmembrane protein 29 
1417661_at 1.67  Rdm1 RAD52 motif 1 
1449553_at 1.67  Nkain1 Na+/K+ transporting ATPase interacting 1 a 
1455155_at 1.67  Lsm14b LSM14 homolog B (SCD6, S. cerevisiae) 
1427151_at 1.67  Qser1 glutamine and serine rich 1 
1438483_at 1.67  Nos1 nitric oxide synthase 1, neuronal a 
1418888_a_at 1.67  Sepx1 selenoprotein X 1 
1452332_at 1.67  Ccdc85a coiled-coil domain containing 85A 
1418170_a_at 1.67  Zcchc14 zinc finger, CCHC domain containing 14 
1428467_at 1.67  Tardbp TAR DNA binding protein 
1428926_at 1.67  1110003O08Rik RIKEN cDNA 1110003O08 gene 
1423994_at 1.67  Kif1b kinesin family member 1B c 
1436219_at 1.67  4933403F05Rik RIKEN cDNA 4933403F05 gene 
1451372_a_at 1.67  Art1 ADP-ribosyltransferase 1 a 
1426345_at 1.67  Prepl prolyl endopeptidase-like 
1420930_s_at 1.66  Ctnnal1 catenin (cadherin associated protein), alpha-like 1 
1439283_at 1.66  Osbpl9 Oxysterol binding protein-like 9 
1451523_a_at 1.66  Mif4gd MIF4G domain containing 
1418715_at 1.66  Pank1 pantothenate kinase 1 
1420950_at 1.66  Znrf1 zinc and ring finger 1 
1433725_at 1.66  Acvr1b activin A receptor, type 1B 
1423076_at 1.66  Snx9 sorting nexin 9 
1451357_at 1.66  Mpnd MPN domain containing 
1425512_at 1.66  Map2k7 mitogen-activated protein kinase kinase 7 
1424632_a_at 1.66  Rev3l REV3-like, catalytic subunit of DNA polymerase zeta RAD54 like 
1458364_s_at 1.65  Tor1aip1 torsin A interacting protein 1 
1430253_at 1.65  2900006B11Rik RIKEN cDNA 2900006B11 gene 
1418714_at 1.65  Dusp8 dual specificity phosphatase 8 
1443835_x_at 1.65  Fam100b family with sequence similarity 100, member B a 
1418595_at 1.65  Plin4 perilipin 4 
1427258_at 1.65  Trim24 tripartite motif-containing 24 
1440187_at 1.65  Taf3 TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor 
1438317_a_at 1.65  Endog endonuclease G 
1434441_at 1.65  1110018J18Rik RIKEN cDNA 1110018J18 gene 
1438241_at 1.65  Rgma RGM domain family, member A 
1439036_a_at 1.65  Atp1b1 ATPase, Na+/K+ transporting, beta 1 polypeptide 
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1435117_a_at 1.65  Dnajc27 DnaJ (Hsp40) homolog, subfamily C, member 27 
1450449_a_at 1.65  Rilpl1 Rab interacting lysosomal protein-like 1 a 
1428614_at 1.65  Ldhd lactate dehydrogenase D 
1460056_at 1.65  1700109F18Rik RIKEN cDNA 1700109F18 gene 
1449530_at 1.65  Trps1 trichorhinophalangeal syndrome I (human) 
1460324_at 1.65  Dnmt3a DNA methyltransferase 3A 
1433512_at 1.64  Fli1 Friend leukemia integration 1 
1417793_at 1.64  Irgm2 immunity-related GTPase family M member 2 
1426516_a_at 1.64  Lpin1 lipin 1 a 
1456087_at 1.64  Nfia nuclear factor I/A 
1450376_at 1.64  Mxi1 Max interacting protein 1 
1435203_at 1.64  Man2a2 mannosidase 2, alpha 2 
1429084_at 1.64  Vezf1 vascular endothelial zinc finger 1 
1443904_at 1.64  Fads6 fatty acid desaturase domain family, member 6 
1417985_at 1.64  Nrarp Notch-regulated ankyrin repeat protein 
1424045_at 1.64  5730437N04Rik RIKEN cDNA 5730437N04 gene 
1429083_at 1.63  Agl amylo-1,6-glucosidase, 4-alpha-glucanotransferase 
1448130_at 1.63  Fdft1 farnesyl diphosphate farnesyl transferase 1 
1422771_at 1.63  Smad6 MAD homolog 6 (Drosophila) 
1416858_a_at 1.63  Fkbp3 FK506 binding protein 3 
1439500_at 1.63  Scrn1 secernin 1 
1418746_at 1.63  Pnkd paroxysmal nonkinesiogenic dyskinesia 
1427345_a_at 1.63  Sult1a1 sulfotransferase family 1A, phenol-preferring, member 1 
1428160_at 1.63  Ndufab1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 
1449019_at 1.63  Akap1 A kinase (PRKA) anchor protein 1 a 
1449121_at 1.63  Fusip1 FUS interacting protein (serine-arginine rich) 1 
1425537_at 1.63  Ppm1a protein phosphatase 1A, magnesium dependent, alpha isoform 
1422493_at 1.63  Cpox coproporphyrinogen oxidase a 
1454801_at 1.62  Ankrd28 ankyrin repeat domain 28 
1454838_s_at 1.62  Pkdcc protein kinase domain containing, cytoplasmic a 
1439505_at 1.62  Clic5 chloride intracellular channel 5 b 
1417264_at 1.62  Coq5 coenzyme Q5 homolog, methyltransferase (yeast) 
1420859_at 1.62  Pkia protein kinase inhibitor, alpha 
1434128_a_at 1.62  Zfp574 zinc finger protein 574 
1453421_at 1.62  Srr serine racemase 
1448499_a_at 1.62  Ephx2 epoxide hydrolase 2, cytoplasmic 
1457568_at 1.62  Hnrnpd heterogeneous nuclear ribonucleoprotein D 
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1454637_at 1.62  Klhl8 kelch-like 8 (Drosophila) 
1452294_at 1.62  Pcdh1 protocadherin 1 
1423101_at 1.62  Paqr4 progestin and adipoQ receptor family member IV 
1455680_at 1.62  9630025H16Rik RIKEN cDNA 9630025H16 gene 
1439066_at 1.62  Angpt1 angiopoietin 1 
1415964_at 1.62  Scd1 stearoyl-Coenzyme A desaturase 1 
1418716_at 1.61  Mrps25 mitochondrial ribosomal protein S25 
1427992_a_at 1.61  Rab12 RAB12, member RAS oncogene family 
1451364_at 1.61  Polr3gl polymerase (RNA) III (DNA directed) polypeptide G like 
1434633_at 1.61  Crebbp CREB binding protein 
1418780_at 1.61  Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 
1446288_at 1.61  C78692 expressed sequence C78692 
1424671_at 1.61  Plekhf1 pleckstrin homology domain containing, family F member 1 
1428394_at 1.61  Lrrc8a leucine rich repeat containing 8A 
1446244_at 1.61  Zyg11b zyg-ll homolog B (C. elegans) 
1421340_at 1.61  Map3k5 mitogen-activated protein kinase kinase kinase 5 
1434977_at 1.61  4933403F05Rik RIKEN cDNA 4933403F05 gene 
1435836_at 1.60  Pdk1 pyruvate dehydrogenase kinase, isoenzyme 1 
1433832_at 1.60  Unc84b unc-84 homolog B (C. elegans) 
1435004_at 1.60  Pank4 pantothenate kinase 4 
1448943_at 1.60  Nrp1 neuropilin 1 a 
1454747_a_at 1.60  Klhdc3 kelch domain containing 3 a 
1433827_at 1.60  Atp8a1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 a 
1452789_at 1.60  Snn stannin 
1435672_at 1.60  3830612M24 hypothetical protein 3830612M24 
1416505_at 1.60  Nr4a1 nuclear receptor subfamily 4, group A, member 1 
1416362_a_at 1.60  Fkbp4 FK506 binding protein 4 
1444550_at 1.60  1110021J02Rik RIKEN cDNA 1110021J02 gene 
1417892_a_at 1.60  Sirt3 sirtuin 3 (silent mating type information regulation 2, homolog) 3 (S. cerevisiae)
1422501_s_at 1.60  Idh3a isocitrate dehydrogenase 3 (NAD+) alpha a 
1433657_at 1.60  Fam78a family with sequence similarity 78, member A 
1449108_at 1.60  Fdx1 ferredoxin 1 
1428637_at 1.60  Dyrk2 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 
1426857_a_at 1.60  Hsdl2 hydroxysteroid dehydrogenase like 2 a 
1435396_at 1.60  Stxbp6 syntaxin binding protein 6 (amisyn) 
1437309_a_at 1.60  Rpa1 replication protein A1 
1417116_at 1.60  Slc6a8 solute carrier family 6 (neurotransmitter transporter, creatine), member 8 
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1418117_at 1.60  Ndufs4 NADH dehydrogenase (ubiquinone) Fe-S protein 4 
1440926_at 1.60  Flt1 FMS-like tyrosine kinase 1 
1437939_s_at 1.59  Ctsc cathepsin C 
1422698_s_at 1.59  Jarid2 jumonji, AT rich interactive domain 2 a 
1453739_at 1.59  Tmem126b transmembrane protein 126B 
1418332_a_at 1.59  Agtpbp1 ATP/GTP binding protein 1 
1420484_a_at 1.59  Vtn vitronectin 
1435384_at 1.59  Ube2n ubiquitin-conjugating enzyme E2N 
1425848_a_at 1.59  Dusp26 dual specificity phosphatase 26 (putative) 
1417393_a_at 1.59  Fam132a family with sequence similarity 132, member A 
1417042_at 1.59  Slc37a4 solute carrier family 37 (glucose-6-phosphate transporter), member 4 
1438562_a_at 1.59  Ptpn2 protein tyrosine phosphatase, non-receptor type 2 
1424716_at 1.59  Retsat retinol saturase (all trans retinol 13,14 reductase) 
1452922_at 1.59  Ppp1r3d protein phosphatase 1, regulatory subunit 3D 
1434756_at 1.58  5430421B17 hypothetical protein 5430421B17 
1456046_at 1.58  Cd93 CD93 antigen 
1429146_at 1.58  Svip small VCP/p97-interacting protein 
1422692_at 1.58  Sub1 SUB1 homolog (S. cerevisiae) 
1442033_at 1.58  C1qtnf9 C1q and tumor necrosis factor related protein 9 
1455071_at 1.58  Zbtb7b zinc finger and BTB domain containing 7B 
1441444_at 1.58  Nbeal1 Neurobeachin like 1 
1428014_at 1.58  Hist1h4h histone cluster 1, H4h 
1452207_at 1.58  Cited2 Cbp/p300-interacting transactivator domain 2 
1433931_at 1.58  C030046I01Rik RIKEN cDNA C030046I01 gene 
1424359_at 1.58  Oplah 5-oxoprolinase (ATP-hydrolysing) 
1418886_s_at 1.58  Idh3b isocitrate dehydrogenase 3 (NAD+) beta 
1429438_at 1.58  Bcor BCL6 interacting corepressor 
1452358_at 1.57  Rai2 retinoic acid induced 2 
1434133_s_at 1.57  Dcaf8 DDB1 and CUL4 associated factor 8 
1441987_at 1.57  Mbd5 methyl-CpG binding domain protein 5 
1441047_at 1.57  Slc45a4 solute carrier family 45, member 4 
1420909_at 1.57  Vegfa vascular endothelial growth factor A 
1420374_at 1.57  Foxj2 forkhead box J2 
1455975_x_at 1.57  Rnf114 ring finger protein 114 
1446560_at 1.57  Prss23 protease, serine, 23 
1429433_at 1.57  Bat2d BAT2 domain containing 1 
1416737_at 1.57  Gys1 glycogen synthase 1, muscle 
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1452868_at 1.56  Usp24 ubiquitin specific peptidase 24 
1437067_at 1.56  Phtf2 putative homeodomain transcription factor 2 a 
1453022_at 1.56  Gpihbp1 GPI-anchored HDL-binding protein 1 
1449180_at 1.56  Kcmf1 potassium channel modulatory factor 1 
1428651_at 1.56  Klhl24 kelch-like 24 (Drosophila) 
1435716_x_at 1.56  Snrpn small nuclear ribonucleoprotein N 
1435551_at 1.56  Fhod3 formin homology 2 domain containing 3 
1452198_at 1.56  Kdm2b lysine (K)-specific demethylase 2B 
1430392_at 1.56  9530086O07Rik RIKEN cDNA 9530086O07 gene 
1418068_at 1.56  Ndufa10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10 
1438641_x_at 1.56  Fam57b family with sequence similarity 57, member B a 
1460241_a_at 1.56  St3gal5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 
1456611_at 1.56  Fam13a family with sequence similarity 13, member A 
1431083_a_at 1.55  1810014B01Rik RIKEN cDNA 1810014B01 gene 
1436913_at 1.55  Cdc14a CDC14 cell division cycle 14 homolog A (S. cerevisiae) 
1455323_at 1.55  Rbak RB-associated KRAB repressor 
1459843_s_at 1.55  Smad1 MAD homolog 1 (Drosophila) 
1427922_at 1.55  2310061C15Rik RIKEN cDNA 2310061C15 gene 
1451577_at 1.55  Zbtb20 zinc finger and BTB domain containing 20 
1416275_at 1.55  Slc26a6 solute carrier family 26, member 6 
1417175_at 1.55  Csnk1e casein kinase 1, epsilon 
1428342_at 1.55  Rcor3 REST corepressor 3 
1438477_a_at 1.55  Mcee methylmalonyl CoA epimerase 
1420019_at 1.55  Tspan8 Tetraspanin 8 
1433486_at 1.54  Clcn3 chloride channel 3 
1418321_at 1.54  Dci dodecenoyl-Coenzyme A delta isomerase  
1455059_at 1.54  Helz helicase with zinc finger domain 
1451148_at 1.54  Pten PTEN 
1443905_at 1.54  Hpvc-ps Human papillomavirus 18 E5 central sequence motif, pseudogene 
1424223_at 1.54  1700020C11Rik RIKEN cDNA 1700020C11 gene 
1454670_at 1.54  Rere arginine glutamic acid dipeptide (RE) repeats a 
1420483_at 1.54  Cnnm3 cyclin M3 
1450643_s_at 1.54  Acsl1 acyl-CoA synthetase long-chain family member 1 
1423202_a_at 1.54  Ncor1 nuclear receptor co-repressor 1 a 
1424746_at 1.54  Kif1c kinesin family member 1C b 
1421066_at 1.53  Jak2 Janus kinase 2 
1426689_s_at 1.53  Sdha succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 
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1436189_at 1.53  Nqo2 NAD(P)H dehydrogenase, quinone 2 
1437474_at 1.53  Gatad2b GATA zinc finger domain containing 2B 
1429515_at 1.53  Ubr2 ubiquitin protein ligase E3 component n-recognin 2 
1426822_at 1.53  Rhot2 ras homolog gene family, member T2 
1448743_at 1.53  Ssx2ip synovial sarcoma, X breakpoint 2 interacting protein 
1453065_at 1.53  Aldh5a1 aldhehyde dehydrogenase family 5, subfamily A1 
1445841_at 1.53  Lrrc39 leucine rich repeat containing 39 
1436555_at 1.53  Slc7a2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 
1447923_at 1.53  1810026B05Rik RIKEN cDNA 1810026B05 gene 
1416513_at 1.53  Lamb2 laminin, beta 2 
1424166_at 1.53  Msh3 mutS homolog 3 (E. coli) 
1437552_at 1.52  2410127L17Rik RIKEN cDNA 2410127L17 gene 
1428295_at 1.52  Synpo2l synaptopodin 2-like 
1423831_at 1.52  Prkag2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 
1417371_at 1.52  Peli1 pellino 1 
1417480_at 1.52  Fbxo9 f-box protein 9 
1428929_s_at 1.52  Slc25a26 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 26 
1440884_s_at 1.52  A530047J11Rik RIKEN cDNA A530047J11 gene 
1431335_a_at 1.52  Wfdc1 WAP four-disulfide core domain 1 
1416647_at 1.52  Bckdha branched chain ketoacid dehydrogenase E1, alpha polypeptide 
1420059_at 1.52  Fam54b Family with sequence similarity 54, member B 
1436919_at 1.52  Trp53i11 transformation related protein 53 inducible protein 11 
1426094_at 1.52  Rhbdl1 rhomboid, veinlet-like 1 (Drosophila) 
1421878_at 1.52  Mapk9 mitogen-activated protein kinase 9 
1438658_a_at 1.52  S1pr3 sphingosine-1-phosphate receptor 3 
1415998_at 1.52  Vdac1 voltage-dependent anion channel 1 
1419369_at 1.52  Rnf138 ring finger protein 138 
1435645_at 1.52  Mmd monocyte to macrophage differentiation-associated 
1425164_a_at 1.52  Phkg1 phosphorylase kinase gamma 1 a 
1443932_at 1.52  Klhdc1 kelch domain containing 1 
1419171_at 1.51  Fam174a family with sequence similarity 174, member A 
1455777_x_at 1.51  Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 
1454858_x_at 1.51  Mettl7a1 methyltransferase like 7A1 
1448288_at 1.51  Nfib nuclear factor I/B 
1451669_at 1.51  Ppm1b protein phosphatase 1B, magnesium dependent, beta isoform 
1456048_at 1.51  Cpeb3 cytoplasmic polyadenylation element binding protein 3 
1428519_at 1.51  2610528E23Rik RIKEN cDNA 2610528E23 gene 
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1452821_at 1.51  Tial1 Tia1 cytotoxic granule-associated RNA binding protein-like 1 
1448717_at 1.51  Gcdh glutaryl-Coenzyme A dehydrogenase 
1434551_at 1.51  Hnrnpul2 heterogeneous nuclear ribonucleoprotein U-like 2 
1437287_at 1.51  1110020G09Rik RIKEN cDNA 1110020G09 gene 
1433503_at 1.51  Ptgr2 prostaglandin reductase 2 
1451575_a_at 1.51  Nudt3 nudix (nucleotide diphosphate linked moiety X)-type motif 3 
1444085_at 1.51  Pdss2 prenyl (solanesyl) diphosphate synthase, subunit 2 
1427591_at 1.51  Clcn1 chloride channel 1 
1416367_at 1.51  Fmc1 formation of mitochondrial complexes 1 homolog (S. cerevisiae) 
1454773_at 1.51  Rxra retinoid X receptor alpha 
1415897_a_at 1.50  Mgst1 microsomal glutathione S-transferase 1 
1437992_x_at 1.50  Gja1 gap junction protein, alpha 1 
1417203_at 1.50  Ethe1 ethylmalonic encephalopathy 1 
1416778_at 1.50  Sdpr serum deprivation response 
1424797_a_at 1.50  Pitx2 paired-like homeodomain transcription factor 2 
1417585_at 1.50  Nup210 nucleoporin 210 
1422025_at 1.50  Mitf microphthalmia-associated transcription factor 
1436358_at 1.50  Atpaf1 ATP synthase mitochondrial F1 complex assembly factor 1 
1415949_at 1.50  Cpe carboxypeptidase E 
1421046_a_at 1.50  Pabpc4 poly(A) binding protein, cytoplasmic 4 
1435391_at 1.50  Prr8 proline rich 8 
1425403_at 1.50  Dnm3 dynamin 3 
1427072_at 1.50  Stard8 START domain containing 8 
1427191_at 1.50  Npr2 natriuretic peptide receptor 2 
A total 1242 gene identified from 1652 Affymetrix probe sets after a 1.5 fold change cut off. 649 genes were overexpressed, and 593 genes 
were underexpressed (grey box). a This gene appears two times; b This gene appears three times; c This gene appears four times; d This gene 
appears five times; e This gene appears six times. W, wild type mice; CLW, clenbuterol treated wild type mice. 
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Appendix 3.8 Differential gene expression profiles as affected by the effect of CL under Mstn-pro at 
1.5 fold change (M vs CLM). 
Probe Set ID 
Fold 
change 
Gene Symbol Gene Title 
1423691_x_at 413.40  Krt8 keratin 8 b 
1448169_at 144.41  Krt18 keratin 18 
1419139_at 77.47  Gdf5 growth differentiation factor 5 
1440878_at 41.09  Runx1 runt related transcription factor 1 c 
1422562_at 38.79  Rrad Ras-related associated with diabetes 
1424245_at 32.27  Ces2 carboxylesterase 2 
1458813_at 31.87  Scn5a sodium channel, voltage-gated, type V, alpha 
1420992_at 21.26  Ankrd1 ankyrin repeat domain 1 (cardiac muscle) a 
1420438_at 20.69  Orm2 orosomucoid 2 
1423933_a_at 19.24  1600029D21Rik RIKEN cDNA 1600029D21 gene 
1434709_at 18.91  Nrcam neuron-glia-CAM-related cell adhesion molecule a 
1435053_s_at 16.27  Plekhh1 pleckstrin homology domain containing, family H a 
1455271_at 14.23  Gm13889 predicted gene 13889 
1454632_at 12.56  6330442E10Rik RIKEN cDNA 6330442E10 gene 
1419394_s_at 12.54  S100a8 S100 calcium binding protein A8 (calgranulin A) 
1435176_a_at 12.29  Id2 inhibitor of DNA binding 2 
1421852_at 12.14  Kcnk5 potassium channel, subfamily K, member 5 
1451054_at 11.27  Orm1 orosomucoid 1 
1449519_at 10.97  Gadd45a growth arrest and DNA-damage-inducible 45 alpha 
1448975_s_at 10.72  Ren1 renin 1 structural 
1418852_at 9.72  Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 
1458245_at 9.60  Gm12528 predicted gene 12528 
1420444_at 9.18  Slc22a3 solute carrier family 22 (organic cation transporter), member 3 
1451287_s_at 9.15  Aif1l allograft inflammatory factor 1-like a 
1421269_at 9.04  Ugcg UDP-glucose ceramide glucosyltransferase b  
1419391_at 8.47  Myog myogenin 
1428640_at 7.96  Hsf2bp heat shock transcription factor 2 binding protein 
1456953_at 6.78  Col19a1 collagen, type XIX, alpha 1 a 
1430062_at 6.74  Hhipl1 hedgehog interacting protein-like 1 
1424638_at 6.72 Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) a 
1442145_at 6.72  Atp13a3 ATPase type 13A3 a 
1449084_s_at 6.72  Sh3d19 SH3 domain protein D19 c 
1450013_at 6.67  2900073G15Rik RIKEN cDNA 2900073G15 gene a 
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1440085_at 6.65  Eda2r ectodysplasin A2 isoform receptor 
1426808_at 6.63  Lgals3 lectin, galactose binding, soluble 3 
1427910_at 6.58  Cst6 cystatin E/M 
1437669_x_at 6.52  Ccrl1 Chemokine (C-C motif) receptor-like 1 a 
1423186_at 6.50  Tiam2 T-cell lymphoma invasion and metastasis 2 
1424831_at 6.29  Cpne2 copine II 
1436790_a_at 6.17  Sox11 SRY-box containing gene 11c 
1456393_at 6.16  2310002J21Rik RIKEN cDNA 2310002J21 gene 
1437460_x_at 5.99  Rin1 Ras and Rab interactor 1 a 
1434754_at 5.84  Garnl4 GTPase activating RANGAP domain-like 4 
1455649_at 5.70  Ttc9 tetratricopeptide repeat domain 9 
1455771_at 5.58  Bzrap1 benzodiazapine receptor associated protein 1 
1422629_s_at 5.58  Shroom3 shroom family member 3 
1421499_a_at 5.14  Ptpn14 protein tyrosine phosphatase, non-receptor type 14 a 
1423719_at 5.02  LOC632073 similar to long palate, lung and nasal epithelium carcinoma associated 1 isoform 2 
1422573_at 4.95  Ampd3 adenosine monophosphate deaminase 3 
1427838_at 4.77  Tubb2a tubulin, beta 2A a  
1418572_x_at 4.77  Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a 
1455342_at 4.76  Prune2 prune homolog 2 (Drosophila) a 
1454674_at 4.69  Fez1 fasciculation and elongation protein zeta 1 (zygin I) 
1457254_x_at 4.55  6330442E10Rik RIKEN cDNA 6330442E10 gene 
1442827_at 4.54  Tlr4 Toll-like receptor 4 b  
1424354_at 4.46  Tmem140 transmembrane protein 140 
1428834_at 4.46  Dusp4 dual specificity phosphatase 4 
1440999_at 4.34  Zfp697 zinc finger protein 697 
1452836_at 4.33  Lpin2 lipin 2 a 
1435062_at 4.29  1500001A10Rik RIKEN cDNA 1500001A10 gene 
1426337_a_at 4.24  Tead4 TEA domain family member 4 
1437062_s_at 4.15  Phyhipl phytanoyl-CoA hydroxylase interacting protein-like 
1430086_at 4.14  Chrna9 cholinergic receptor, nicotinic, alpha polypeptide 9 
1416028_a_at 4.06  Hn1 hematological and neurological expressed sequence 1 b 
1424517_at 3.97  Ccdc12 coiled-coil domain containing 12 a 
1435184_at 3.95  Npr3 natriuretic peptide receptor 3 
1451006_at 3.95  Xdh xanthine dehydrogenase 
1457157_at 3.94  Plch1 phospholipase C, eta 1 
1419621_at 3.92  Ankrd2 ankyrin repeat domain 2 (stretch responsive muscle) 
1428803_at 3.91  Acot6 acyl-CoA thioesterase 6 a 
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1451411_at 3.89  Gprc5b G protein-coupled receptor, family C, group 5, member B a 
1441055_at 3.89  Palm2 paralemmin 2 
1449852_a_at 3.89  Ehd4 EH-domain containing 4 
1452799_at 3.80  Fggy FGGY carbohydrate kinase domain containing 
1419184_a_at 3.77  Fhl four and a half LIM domains 
1433731_at 3.70  Igf2bp3 insulin-like growth factor 2 mRNA binding protein 3 
1450047_at 3.70  Hs6st2 heparan sulfate 6-O-sulfotransferase 2 
1455149_at 3.64  Sh3rf1 SH3 domain containing ring finger 1 a 
1437224_at 3.55  Rtn4 reticulon 4 a 
1429086_at 3.45  Grhl2 grainyhead-like 2 (Drosophila) 
1418840_at 3.43  Pdcd4 programmed cell death 4 
1438795_x_at 3.38  Fkbp1 fk506 binding protein 12-rapamycin associated protein 1 
1460392_a_at 3.38  Eny2 enhancer of yellow 2 homolog (Drosophila) a 
1417103_at 3.37  Ddt D-dopachrome tautomerase 
1431281_at 3.37  Dysfip1 dysferlin interacting protein 1 
1416065_a_at 3.36  Ankrd10 ankyrin repeat domain 10 b 
1436362_x_at 3.34  Ccrn4l CCR4 carbon catabolite repression 4-like (S. cerevisiae) 
1418158_at 3.32  Trp63 transformation related protein 63 a 
1420884_at 3.32  Sln sarcolipin 
1452232_at 3.29  Galnt7 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 7 
1456291_x_at 3.29  Scx scleraxis a 
1451757_at 3.27  BC003883 cDNA sequence BC003883 
1448660_at 3.25  Arhgdig Rho GDP dissociation inhibitor (GDI) gamma 
1418853_at 3.22  Apon apolipoprotein N 
1425964_x_at 3.21  Hspb1 heat shock protein 1 a 
1425543_s_at 3.14  Plekha5 pleckstrin homology domain containing, family A member 5 
1420895_at 3.13  Tgfbr1 transforming growth factor, beta receptor I a 
1448793_a_at 3.10  Sdc4 syndecan 4 a 
1435394_s_at 3.10  Rhoc ras homolog gene family, member C 
1426329_s_at 3.09  Baalc brain and acute leukemia, cytoplasmic 
1418648_at 3.08  Egln3 EGL nine homolog 3 (C. elegans) a 
1443667_at 3.07  C79407 expressed sequence C79407 
1458067_at 3.06  Fam179b Family with sequence similarity 179, member B 
1433972_at 3.02  Camta1 calmodulin binding transcription activator 1 a 
1422286_a_at 3.02  Tgif1 TGFB-induced factor homeobox 1 
1421479_at 3.02  Zfp318 zinc finger protein 318 c 
1416401_at 3.01  Cd82 CD82 antigen 
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1421407_at 2.99  F2rl2 coagulation factor II (thrombin) receptor-like 2 
1438621_x_at 2.98  Axl AXL receptor tyrosine kinase 
1425238_at 2.98  Gm6607 40S ribosomal protein S20 pseudogene 
1428427_at 2.97  Fbxl2 F-box and leucine-rich repeat protein 2 
1428294_at 2.97  Zfp259 zinc finger protein 259 
1416379_at 2.95  Panx1 pannexin 1 
1442340_x_at 2.94  Cyr61 cysteine rich protein 61 b 
1444786_at 2.93  Nol3 nucleolar protein 3 (apoptosis repressor with CARD domain) 
1420832_at 2.92  Qsox1 quiescin Q6 sulfhydryl oxidase 1 
1436042_at 2.91  Tln1 talin 1 
1421943_at 2.91  Tgfa transforming growth factor alpha 
1447662_x_at 2.89  D18Ertd653e DNA segment, Chr 18, ERATO Doi 653, expressed 
1444451_at 2.88  Pappa2 pappalysin 2 
1426471_at 2.88  Zfp52 zinc finger protein 52 a 
1426095_a_at 2.87  Tnfrsf22 tumor necrosis factor receptor superfamily, member 22 a 
1449533_at 2.86  Tmem100 transmembrane protein 100 
1434927_at 2.85  Hspb7 heat shock protein family, member 7 (cardiovascular) 
1426288_at 2.83  Lrp4 low density lipoprotein receptor-related protein 4 
1437109_s_at 2.83  Lsm6 LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
1454731_at 2.82  Myo10 myosin X a 
1451160_s_at 2.82  Pvr poliovirus receptor a 
1423172_at 2.81  Napb N-ethylmaleimide sensitive fusion protein attachment protein beta a 
1438701_at 2.81  Bicd1 bicaudal D homolog 1 (Drosophila) 
1430929_at 2.80  9430082L08Rik RIKEN cDNA 9430082L08 gene 
1455573_at 2.79  Krt14 keratin 14 
1417013_at 2.79  Hspb8 heat shock protein 8 
1439708_at 2.75  Myom3 myomesin family, member 3 
1422101_at 2.75  Tnfrsf23 tumor necrosis factor receptor superfamily, member 23 
1439049_at 2.74  Dph5 DPH5 homolog (S. cerevisiae) a 
1453323_at 2.74  2900079G21Rik RIKEN cDNA 2900079G21 gene 
1455605_at 2.74  Rufy3 RUN and FYVE domain containing 3 
1450320_at 2.72  4931432E15Rik RIKEN cDNA 4931432E15 gene 
1421043_s_at 2.72  Arhgef2 rho/rac guanine nucleotide exchange factor (GEF) 2 a 
1451889_at 2.71  Notch2 Notch gene homolog 2 (Drosophila) 
1433360_at 2.71  1700023B13Rik RIKEN cDNA 1700023B13 gene 
1445439_at 2.68  Epb4.9 erythrocyte protein band 4.9 
1421947_at 2.68  Gng12 guanine nucleotide binding protein (G protein), gamma 12 
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1441101_at 2.66  Hecw1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 
1429618_at 2.65  Cyld cylindromatosis (turban tumor syndrome) a 
1435402_at 2.65  Gramd1b GRAM domain containing 1B 
1450541_at 2.64  Pvt1 plasmacytoma variant translocation 1 
1434985_a_at 2.64  Eif4a1 eukaryotic translation initiation factor 4A1 
1420769_at 2.63  Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58 
1424489_a_at 2.62  Trit1 tRNA isopentenyltransferase 1 
1445709_at 2.61  Mdm1 transformed mouse 3T3 cell double minute 1 
1438001_x_at 2.61  Reep5 receptor accessory protein 5 
1445553_at 2.60  Ric3 resistance to inhibitors of cholinesterase 3 homolog (C. elegans) 
1432570_at 2.60  6030458E02Rik RIKEN cDNA 6030458E02 gene 
1440008_at 2.59  2310043L19Rik RIKEN cDNA 2310043L19 gene 
1438824_at 2.58  Slc20a1 solute carrier family 20, member 1 a 
1445568_at 2.58  Inca1 Inhibitor of CDK, cyclin A1 interacting protein 1 a 
1436938_at 2.57  Rbms3 RNA binding motif, single stranded interacting protein 
1433571_at 2.57  Serinc5 serine incorporator 5 
1444089_at 2.57  Spnb2 spectrin beta 2 
1431869_at 2.56  5730419F03Rik RIKEN cDNA 5730419F03 gene 
1427539_a_at 2.54  Zwint ZW10 interactor b 
1451453_at 2.54  Dapk2 death-associated protein kinase 2 
1456387_at 2.54  Nol4 nucleolar protein 4 
1452719_at 2.54  Zdhhc24 zinc finger, DHHC domain containing 24 a 
1418186_at 2.53  Gstt1 glutathione S-transferase, theta 1 
1436235_x_at 2.53  4732471D19Rik RIKEN cDNA 4732471D19 gene a 
1439166_at 2.52  Nol11 nucleolar protein 11 
1446470_at 2.51  Gm9799 predicted gene 9799 
1450511_at 2.50  Musk muscle, skeletal, receptor tyrosine kinase 
1420377_at 2.50  St8sia2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 
1422316_at 2.50  Gp1ba glycoprotein 1b, alpha polypeptide 
1454693_at 2.50  Hdac4 histone deacetylase 4 a 
1457587_at 2.49  Kcnq5 potassium voltage-gated channel, subfamily Q, member 5 
1438354_x_at 2.49  Cnn3 Calponin 3, acidic 
1436305_at 2.49  Rnf217 ring finger protein 217 a 
1441144_at 2.48  Arr3 arrestin 3, retinal 
1448694_at 2.47  Jun Jun oncogene 
1454133_s_at 2.46  4930523O13Rik RIKEN cDNA 4930523O13 gene 
1449363_at 2.45  Atf3 activating transcription factor 3 
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1439483_at 2.44  AI506816 expressed sequence AI506816 
1442957_at 2.44  G730013B05Rik RIKEN cDNA G730013B05 gene 
1449907_at 2.44  Bcmo1 beta-carotene 15,15'-monooxygenase 
1449691_at 2.41  Zfp644 Zinc finger protein 644 
1419916_at 2.41  Rnf20 Ring finger protein 20 
1436499_at 2.40  Sgms1 sphingomyelin synthase 1 a 
1428739_at 2.39  Enho energy homeostasis associated 
1434080_at 2.38  Aebp2 AE binding protein 2 a 
1455577_at 2.38  Ccl28 chemokine (C-C motif) ligand 28 
1420539_a_at 2.38  Chrdl2 chordin-like 2 
1423596_at 2.38  Nek6 NIMA (never in mitosis gene a)-related expressed kinase 6 a 
1422608_at 2.38  Arpp19 cAMP-regulated phosphoprotein 19 
1418938_at 2.36  Dio2 deiodinase, iodothyronine, type II 
1455493_at 2.35  Syne1 synaptic nuclear envelope 1 
1433990_at 2.34  Lhfpl3 lipoma HMGIC fusion partner-like 3 
1435987_x_at 2.34  1110059G02Rik RIKEN cDNA 1110059G02 gene 
1438307_at 2.34  Hmgb2 high mobility group box 2 
1434402_at 2.33  Samd8 sterile alpha motif domain containing 8 
1416119_at 2.33  Txn1 thioredoxin 1 
1458504_at 2.32  Zc3h12d zinc finger CCCH type containing 12D 
1415803_at 2.32  Cx3cl1 chemokine (C-X3-C motif) ligand 1 
1448744_at 2.32  Galns galactosamine (N-acetyl)-6-sulfate sulfatase 
1419305_a_at 2.31  Fbxo36 F-box protein 36 
1426875_s_at 2.31  Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) b 
1438429_at 2.30  2610319H10Rik RIKEN cDNA 2610319H10 gene 
1437722_x_at 2.30  Pcbp3 Poly(rC) binding protein 3 
1430724_at 2.30  Ephx3 epoxide hydrolase 3 
1452909_at 2.29  Klhdc10 kelch domain containing 10 
1439805_at 2.29  Nfat5 Nuclear factor of activated T-cells 5 
1452478_at 2.29  Alpk2 alpha-kinase 2 
1440688_at 2.28  Arhgap26 Rho GTPase activating protein 26 
1426486_at 2.28  Ubxn4 UBX domain protein 4 
1416431_at 2.28  Tubb6 tubulin, beta 6 
1415862_at 2.27  Tyrp1 tyrosinase-related protein 1 
1420682_at 2.27  Chrnb1 cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) 
1447507_at 2.27  C80406 expressed sequence C80406 
1417128_at 2.26  Plekho1 pleckstrin homology domain containing, family O member 1 
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1449839_at 2.26  Casp3 caspase 3 
1451814_a_at 2.25  Htatip2 HIV-1 tat interactive protein 2, homolog (human) 
1421928_at 2.25  Epha4 Eph receptor A4 a 
1432171_at 2.25  4933409F18Rik RIKEN cDNA 4933409F18 gene 
1419344_at 2.25  Tcte1 t-complex-associated testis expressed 1 
1455350_at 2.25  Tmem62 transmembrane protein 62 
1432129_a_at 2.25  Prrx1 paired related homeobox 1 
1419446_at 2.24  Tbc1d1 TBC1 domain family, member 1 
1456251_x_at 2.24  Tspo translocator protein a 
1454520_at 2.23  5830415B17Rik RIKEN cDNA 5830415B17 gene 
1457296_at 2.23  Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 
1421746_a_at 2.23  Fbxo17 F-box protein 17 
1416606_s_at 2.22  Nhp2 NHP2 ribonucleoprotein homolog (yeast) a 
1439396_x_at 2.22  Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble) 
1435936_at 2.22  Slc13a5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 
1432949_at 2.20  5330421F21Rik RIKEN cDNA 5330421F21 gene 
1448715_x_at 2.20  Sgip1 SH3-domain GRB2-like (endophilin) interacting protein 1 
1453228_at 2.20  Stx11 syntaxin 11 
1416911_a_at 2.20  Akirin1 akirin 1 a 
1435303_at 2.20  Taf4b TAF4B RNA polymerase II, TATA box binding protein (TBP)-associated factor 
1427938_at 2.19  Mycbp c-myc binding protein 
1422301_at 2.19  Ftl1 ferritin light chain 1 
1416708_a_at 2.19  Gramd1a GRAM domain containing 1A 
1438288_x_at 2.18  1110059G02Rik RIKEN cDNA 1110059G02 gene 
1454489_at 2.18  4930513L20Rik RIKEN cDNA 4930513L20 gene 
1438059_at 2.18  Ctxn3 cortexin 3 
1425389_a_at 2.17  Runx2 runt related transcription factor 2 
1434241_at 2.17  Wdr67 WD repeat domain 67 
1418470_at 2.17  Yes1 Yamaguchi sarcoma viral (v-yes) oncogene homolog 1 
1417236_at 2.17  Ehd3 EH-domain containing 3 
1422363_at 2.17  Olfr65 olfactory receptor 65 
1416916_at 2.17  Elf3 E74-like factor 3 
1416231_at 2.16  Vac14 Vac14 homolog (S. cerevisiae) 
1448571_a_at 2.16  Gmfb glia maturation factor, beta 
1445691_at 2.15  Chn1 chimerin (chimaerin) 1 
1426159_x_at 2.15  Tcrb-J T-cell receptor beta, joining region 
1455284_x_at 2.14  Pigx phosphatidylinositol glycan anchor biosynthesis, class X 
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1420096_at 2.14  Zscan21 Zinc finger and SCAN domain containing 21 
1449304_at 2.14  2310061J03Rik RIKEN cDNA 2310061J03 gene 
1434153_at 2.14  Shb src homology 2 domain-containing transforming protein B 
1435981_at 2.14  Nav2 neuron navigator 2 a 
1442637_at 2.13  Itsn1 Intersectin 1 (SH3 domain protein 1A) 
1419557_a_at 2.13  Tmem9 transmembrane protein 9 
1454354_at 2.13  8030476L19Rik RIKEN cDNA 8030476L19 gene 
1418908_at 2.13  Pam peptidylglycine alpha-amidating monooxygenase 
1457208_at 2.13  Nfxl1 nuclear transcription factor, X-box binding-like 1 
1459003_at 2.13  Fhl1 four and a half LIM domains 1 
1418318_at 2.12  Rnf128 ring finger protein 128 a 
1450260_at 2.12  Grpr gastrin releasing peptide receptor 
1438021_at 2.12  Rbm47 RNA binding motif protein 47 
1435049_s_at 2.12  AI854703 expressed sequence AI854703 
1457775_at 2.12  Sacs sacsin a 
1423810_at 2.12  Ppme1 protein phosphatase methylesterase 1 
1423923_a_at 2.11  Wdr8 WD repeat domain 8 
1429990_at 2.11  Hyal4 hyaluronoglucosaminidase 4 
1440522_at 2.11  Gm10454 predicted gene 10454 
1424171_a_at 2.11  Hagh hydroxyacyl glutathione hydrolase a 
1426054_at 2.11  Npy1r neuropeptide Y receptor Y1 
1450959_at 2.11  D930014E17Rik RIKEN cDNA D930014E17 gene 
1446183_at 2.11  Als2 Amyotrophic lateral sclerosis 2 (juvenile) homolog (human) 
1430294_at 2.11  Ssbp1 single-stranded DNA binding protein 1 
1436761_s_at 2.11  Fam13c family with sequence similarity 13, member C 
1453414_at 2.10  Ypel2 yippee-like 2 (Drosophila) 
1447819_x_at 2.10  Col8a1 collagen, type VIII, alpha 1 
1428833_at 2.10  4930406D14Rik RIKEN cDNA 4930406D14 gene 
1451227_a_at 2.08  Slc10a3 solute carrier family 10 (sodium/bile acid cotransporter family), member 3 
1436026_at 2.08  Zfp703 zinc finger protein 703 
1436887_x_at 2.08  Grwd1 glutamate-rich WD repeat containing 1 a 
1418497_at 2.08  Fgf13 fibroblast growth factor 13 
1433211_at 2.08  Rptn repetin 
1448689_at 2.08  Rras2 related RAS viral (r-ras) oncogene homolog 2 
1442858_at 2.08  Mycbp2 MYC binding protein 2 
1455316_x_at 2.07  BC094435 cDNA sequence BC094435 
1420626_at 2.07  Gtf3c6 general transcription factor IIIC, polypeptide 6, alpha 
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1433110_at 2.06  5830474E16Rik RIKEN cDNA 5830474E16 gene 
1424378_at 2.06  Ldlrap1 low density lipoprotein receptor adaptor protein 1 
1434382_at 2.05  Serinc2 serine incorporator 2 
1426873_s_at 2.05  Jup junction plakoglobin 
1444712_at 2.05  Hsf5 heat shock transcription factor family member 5 
1432494_a_at 2.04  1700019E19Rik RIKEN cDNA 1700019E19 gene 
1441881_x_at 2.04  Fam101a family with sequence similarity 101, member A 
1427434_at 2.04  Birc1f baculoviral IAP repeat-containing 1f 
1424886_at 2.04  Ptprd protein tyrosine phosphatase, receptor type, D a 
1457681_at 2.04  2610301F02Rik RIKEN cDNA 2610301F02 gene 
1437058_at 2.04  Megf6 multiple EGF-like-domains 6 
1424530_at 2.03  Sec14l2 SEC14-like 2 (S. cerevisiae) 
1455661_at 2.03  Gm9958 predicted gene 9958 
1433182_at 2.03  4930431N21Rik RIKEN cDNA 4930431N21 gene 
1437502_x_at 2.03  Cd24a CD24a antigen a 
1446344_at 2.03  Nyx nyctalopin 
1422218_at 2.02  P2rx7 purinergic receptor P2X, ligand-gated ion channel, 7 
1455064_at 2.02  Rab36 RAB36, member RAS oncogene family 
1423239_at 2.02  Impdh1 inosine 5'-phosphate dehydrogenase 1 
1456586_x_at 2.02  Mvp major vault protein a 
1415993_at 2.02  Sqle squalene epoxidase 
1416350_at 2.01  Klf16 Kruppel-like factor 16 
1445901_at 2.01  Lrp2 low density lipoprotein receptor-related protein 2 
1425858_at 2.01  Ube2m ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) 
1426403_at 2.01  Actr1b ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 
1426722_at 2.01  Slc38a2 solute carrier family 38, member 2 
1438176_x_at 2.00  Snap47 synaptosomal-associated protein, 47 
1458385_at 2.00  Hspa4l heat shock protein 4 like 
1436710_at 2.00  Zswim4 zinc finger, SWIM domain containing 4 
1447865_x_at 2.00  Pdzd11 PDZ domain containing 11 
1453585_at 2.00  1600010M07Rik RIKEN cDNA 1600010M07 gene 
1453358_s_at 2.00  Amn1 antagonist of mitotic exit network 1 homolog (S. cerevisiae) 
1436978_at 2.00  Wnt9a wingless-type MMTV integration site 9A 
1439556_at 1.99  Ncam1 neural cell adhesion molecule 1 
1433367_at 1.99  8430401P03Rik RIKEN cDNA 8430401P03 gene 
1449323_a_at 1.99  Rpl3 ribosomal protein L3 
1450686_at 1.99  Pon2 paraoxonase 2 a 
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1455203_at 1.99  A930003A15Rik RIKEN cDNA A930003A15 gene 
1446871_at 1.99  D7Ertd481e DNA segment, Chr 7, ERATO Doi 481, expressed 
1418448_at 1.99  Rras Harvey rat sarcoma oncogene, subgroup R 
1434724_at 1.99  Usp31 ubiquitin specific peptidase 31 
1453854_at 1.98  Ptar1 protein prenyltransferase alpha subunit repeat containing 1 
1442838_at 1.98  Gm11691 predicted gene 11691 
1423850_at 1.98  Nsun2 NOL1/NOP2/Sun domain family member 2 
1458370_at 1.97  Bmp2k BMP2 inducible kinase 
1423082_at 1.97  Derl1 Der1-like domain family, member 1 
1450198_at 1.97  Dusp13 dual specificity phosphatase 13 
1459914_at 1.97  Mcart6 mitochondrial carrier triple repeat 6 
1437614_x_at 1.97  Zdhhc14 zinc finger, DHHC domain containing 14 a 
1447868_x_at 1.96  Glrx3 glutaredoxin 3 
1415676_a_at 1.96  Psmb5 proteasome (prosome, macropain) subunit, beta type 5 
1422646_at 1.96  Mga MAX gene associated 
1419116_at 1.96  Alg14 asparagine-linked glycosylation 14 homolog (yeast) 
1423846_x_at 1.95  Tuba1b tubulin, alpha 1B 
1449902_at 1.95  Lce1a2 late cornified envelope 1A2 
1424860_at 1.95  D930016D06Rik RIKEN cDNA D930016D06 gene a 
1430429_at 1.94  Pgs1 phosphatidylglycerophosphate synthase 1 
1446731_at 1.94  Fancf Fanconi anemia, complementation group F 
1424344_s_at 1.94  Eif1a eukaryotic translation initiation factor 1A 
1440941_at 1.93  LOC552912 hypothetical LOC552912 
1441190_at 1.93  Arpc5l actin related protein 2/3 complex, subunit 5-like 
1416192_at 1.93  Napa N-ethylmaleimide sensitive fusion protein attachment protein alpha 
1455689_at 1.93  Fzd10 frizzled homolog 10 (Drosophila) 
1440916_at 1.93  2510049J12Rik RIKEN cDNA 2510049J12 gene 
1418227_at 1.93  Orc2l origin recognition complex, subunit 2-like (S. cerevisiae) 
1441503_at 1.93  Dcdc2a doublecortin domain containing 2a 
1434585_at 1.93  Tulp4 Tubby like protein 4 
1439060_s_at 1.93  Wipi1 WD repeat domain, phosphoinositide interacting 1 
1430171_at 1.93  Fibp fibroblast growth factor (acidic) intracellular binding protein 
1417850_at 1.92  Rb1 retinoblastoma 1 
1432418_a_at 1.92  Ckmt1 creatine kinase, mitochondrial 1, ubiquitous 
1434891_at 1.92  Ptgfrn prostaglandin F2 receptor negative regulator 
1417453_at 1.92  Cul4b cullin 4B 
1455994_x_at 1.92  Elovl1 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 1 a 
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1426465_at 1.91  Dlgap4 discs, large homolog-associated protein 4 (Drosophila) 
1448345_at 1.91  Tomm34 translocase of outer mitochondrial membrane 34 
1459230_at 1.91  B430319G15Rik RIKEN cDNA B430319G15 gene 
1439091_at 1.91  Fancd2 Fanconi anemia, complementation group D2 
1455738_at 1.91  Ccdc55 coiled-coil domain containing 55 
1420150_at 1.91  Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 
1455643_s_at 1.91  Tsr1 TSR1, 20S rRNA accumulation, homolog (yeast) a 
1432569_at 1.90  Cby3 chibby homolog 3 (Drosophila) 
1451862_a_at 1.90  Prf1 perforin 1 (pore forming protein) 
1417428_at 1.90  Gng3 guanine nucleotide binding protein (G protein), gamma 3 
1440990_at 1.90  Kif26b kinesin family member 26B 
1426577_a_at 1.90  Lin37 lin-37 homolog (C. elegans) 
1442454_at 1.90  Top2a topoisomerase (DNA) II alpha 
1424718_at 1.90  Mapt microtubule-associated protein tau 
1452222_at 1.90  Utrn utrophin 
1434660_at 1.89  Alkbh1 alkB, alkylation repair homolog 1 (E. coli) 
1447577_x_at 1.89  Pcca propionyl-Coenzyme A carboxylase, alpha polypeptide 
1432156_a_at 1.89  Rnf32 ring finger protein 32 
1426426_at 1.89  Mak16 MAK16 homolog (S. cerevisiae) 
1426275_a_at 1.88  Uxs1 UDP-glucuronate decarboxylase 1 a 
1448271_a_at 1.88  Ddx21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 
1452759_s_at 1.88  Ppfibp1 PTPRF interacting protein, binding protein 1 (liprin beta 1) 
1453129_a_at 1.88  Rgs12 regulator of G-protein signaling 12 
1427186_a_at 1.88  Mef2a myocyte enhancer factor 2A b 
1427364_a_at 1.88  Odc1 ornithine decarboxylase, structural 1 a 
1433656_a_at 1.88  Gnl3 guanine nucleotide binding protein-like 3 (nucleolar) 
1439399_a_at 1.87  Snhg1 small nucleolar RNA host gene (non-protein coding) 1 
1433719_at 1.87  Slc9a9 solute carrier family 9 (sodium/hydrogen exchanger), member 9 
1434963_at 1.87  Supt3h suppressor of Ty 3 homolog (S. cerevisiae) 
1427028_at 1.87  Lgr6 leucine-rich repeat-containing G protein-coupled receptor 6 
1417005_at 1.87  Klc1 kinesin light chain 1 a 
1421354_at 1.86  Prkg2 protein kinase, cGMP-dependent, type II 
1431838_at 1.86  1700128E19Rik RIKEN cDNA 1700128E19 gene 
1450852_s_at 1.86  F2r coagulation factor II (thrombin) receptor a 
1422929_s_at 1.86  Atoh7 atonal homolog 7 (Drosophila) 
1419150_at 1.86  Myf6 myogenic factor 6 
1415941_s_at 1.86  Zfand2a zinc finger, AN1-type domain 2A 
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1433849_at 1.85  Cdc27 cell division cycle 27 homolog (S. cerevisiae) a 
1428847_a_at 1.85  Macf1 microtubule-actin crosslinking factor 1 
1424469_a_at 1.85  Cpsf4 cleavage and polyadenylation specific factor 4 
1437688_x_at 1.85  Atp6ap2 ATPase, H+ transporting, lysosomal accessory protein 2 
1425253_a_at 1.85  Madcam1 mucosal vascular addressin cell adhesion molecule 1 
1429049_at 1.84  Nuak2 NUAK family, SNF1-like kinase, 2 
1427980_at 1.84  4933407C03Rik RIKEN cDNA 4933407C03 gene a 
1418429_at 1.84  Kif5b kinesin family member 5B 
1443008_at 1.84  Msi2 Musashi homolog 2 (Drosophila) a 
1451233_at 1.84  Traf2 TNF receptor-associated factor 2 
1455442_at 1.84  Slc6a19 solute carrier family 6 (neurotransmitter transporter), member 19 
1441911_x_at 1.84  Gart phosphoribosylglycinamide formyltransferase 
1430978_at 1.84  Rps25 ribosomal protein S25 
1448968_at 1.83  Ubfd1 ubiquitin family domain containing 1 
1423605_a_at 1.83  Mdm2 transformed mouse 3T3 cell double minute 2 
1436060_at 1.83  Ralyl RALY RNA binding protein-like 
1420048_at 1.83  C78859 expressed sequence C78859 
1417817_a_at 1.83  Wwtr1 WW domain containing transcription regulator 1 
1451257_at 1.83  Acsl6 acyl-CoA synthetase long-chain family member 6 
1438699_at 1.83  Srd5a1 steroid 5 alpha-reductase 1 
1441464_at 1.82  A630035D09Rik RIKEN cDNA A630035D09 gene 
1453233_s_at 1.82  Calr3 calreticulin 3 
1424529_s_at 1.82  Cgref1 cell growth regulator with EF hand domain 1 
1432665_at 1.82  2210416J07Rik RIKEN cDNA 2210416J07 gene 
1459764_x_at 1.82  Snx10 Sorting nexin 10 
1433379_at 1.82  9430019H13Rik RIKEN cDNA 9430019H13 gene 
1437166_at 1.82  Tinf2 Terf1 (TRF1)-interacting nuclear factor 2 
1440620_at 1.82  Rab8a RAB8A, member RAS oncogene family 
1453571_at 1.82  Depdc6 DEP domain containing 6 
1444242_at 1.81  Slco2a1 Solute carrier organic anion transporter family, member 2a1 
1438704_at 1.81  Trim63 tripartite motif-containing 63 
1443787_x_at 1.81  Casp14 caspase 14 
1460421_at 1.80  Zfp133 zinc finger protein 133 
1425969_a_at 1.80  Htt huntingtin a 
1435775_at 1.80  Clock circadian locomoter output cycles kaput 
1457638_x_at 1.80  Rfc2 replication factor C (activator 1) 2 
1438544_at 1.80  1700001G11Rik RIKEN cDNA 1700001G11 gene 
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1448435_at 1.80  Med15 mediator complex subunit 15 
1422567_at 1.80  Fam129a family with sequence similarity 129, member A 
1424985_a_at 1.79  Sox10 SRY-box containing gene 10 
1419819_s_at 1.79  Sec63 SEC63-like (S. cerevisiae) 
1454391_at 1.79  6030442K20Rik RIKEN cDNA 6030442K20 gene 
1416030_a_at 1.79  Mcm7 minichromosome maintenance deficient 7 (S. cerevisiae) 
1416029_at 1.79  Klf10 Kruppel-like factor 10 
1427880_at 1.79  Uqcrq ubiquinol-cytochrome c reductase, complex III subunit VII 
1420570_x_at 1.79  Tcl1b3 T-cell leukemia/lymphoma 1B, 3 
1443746_x_at 1.79  Dmp1 dentin matrix protein 1 
1452964_at 1.79  Ttll11 tubulin tyrosine ligase-like family, member 11 
1429976_at 1.78  Clasp2 CLIP associating protein 2 
1459696_at 1.78  Fry Furry homolog (Drosophila) 
1443159_at 1.78  9130221J17Rik RIKEN cDNA 9130221J17 gene 
1424087_at 1.77  Psmg3 proteasome (prosome, macropain) assembly chaperone 3 
1431566_at 1.77  9030622O22Rik RIKEN cDNA 9030622O22 gene 
1457628_at 1.77  Ccdc53 coiled-coil domain containing 53 
1417843_s_at 1.77  Eps8l2 EPS8-like 2 
1436180_at 1.77  Dnajc5 DnaJ (Hsp40) homolog, subfamily C, member 5 
1449027_at 1.77  Rhou ras homolog gene family, member U 
1430680_a_at 1.77  Gon4l gon-4-like (C.elegans) 
1448450_at 1.77  Ak2 adenylate kinase 2 
1416974_at 1.77  Stam2 signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 
1417499_at 1.76  Timm10 translocase of inner mitochondrial membrane 10 homolog (yeast) 
1428635_at 1.76  Comtd1 catechol-O-methyltransferase domain containing 1 
1453324_at 1.76  6330509M23Rik RIKEN cDNA 6330509M23 gene 
1453451_at 1.75  6820402I19Rik RIKEN cDNA 6820402I19 gene 
1423567_a_at 1.75  Psma7 proteasome (prosome, macropain) subunit, alpha type 7 
1435035_at 1.75  Rg9mtd2 RNA (guanine-9-) methyltransferase domain containing 2 
1451809_s_at 1.75  Rwdd3 RWD domain containing 3 
1440152_x_at 1.75  Edf1 endothelial differentiation-related factor 1 
1425780_a_at 1.75  Tmem167 transmembrane protein 167 
1439552_at 1.75  Trio triple functional domain (PTPRF interacting) 
1433555_at 1.75  Eaf1 ELL associated factor 1 
1434532_at 1.75  Csrnp2 cysteine-serine-rich nuclear protein 2 
1416419_s_at 1.75  Gabarapl1 gamma-aminobutyric acid (GABA) A receptor-associated protein-like 1 
1450377_at 1.74  Thbs1 thrombospondin 1 
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1456470_x_at 1.74  Tubb2c tubulin, beta 2C 
1435444_at 1.74  Atf6 activating transcription factor 6 
1422906_at 1.74  Abcg2 ATP-binding cassette, sub-family G (WHITE), member 2 
1435431_at 1.74  Psmg4 proteasome (prosome, macropain) assembly chaperone 4 
1446145_at 1.74  Eif4g3 eukaryotic translation initiation factor 4 gamma, 3 
1426362_at 1.74  Tmem144 transmembrane protein 144 a 
1443919_at 1.74  Prrt3 proline-rich transmembrane protein 3 
1421052_a_at 1.73  Sms spermine synthase 
1422508_at 1.73  Atp6v1a ATPase, H+ transporting, lysosomal V1 subunit A 
1416748_a_at 1.73  Mre11a meiotic recombination 11 homolog A (S. cerevisiae) 
1460260_s_at 1.73  Kpna1 karyopherin (importin) alpha 1 a 
1438769_a_at 1.73  Thyn1 thymocyte nuclear protein 1 a 
1428874_at 1.73  Fam96b family with sequence similarity 96, member B 
1451290_at 1.73  Map1lc3a microtubule-associated protein 1 light chain 3 alpha 
1439447_x_at 1.73  Rpl37a ribosomal protein L37a 
1422650_a_at 1.73  Riok3 RIO kinase 3 (yeast) 
1426600_at 1.72  Slc2a1 solute carrier family 2 (facilitated glucose transporter), member 1 
1426591_at 1.72  Gfm2 G elongation factor, mitochondrial 2 
1424538_at 1.72  Ubl4 ubiquitin-like 4 
1449841_at 1.72  Kif3a kinesin family member 3A 
1416146_at 1.72  Hspa4 heat shock protein 4 
1435926_at 1.72  Chml choroideremia-like 
1455210_at 1.71  Zhx2 zinc fingers and homeoboxes 2 
1436573_at 1.71  Scrn3 secernin 3 a 
1419029_at 1.71  Ero1l ERO1-like (S. cerevisiae) 
1456738_s_at 1.71  Brp16 brain protein 16 
1450319_at 1.71  Gabrb2 gamma-aminobutyric acid (GABA) A receptor, subunit beta 2 
1416014_at 1.71  Abce1 ATP-binding cassette, sub-family E (OABP), member 1 
1434258_s_at 1.71  Phactr4 phosphatase and actin regulator 4 
1438497_at 1.70  Mfsd8 major facilitator superfamily domain containing 8 a 
1423453_at 1.70  Nol12 nucleolar protein 12 
1458431_at 1.70  Eif4g2 eukaryotic translation initiation factor 4, gamma 2 b 
1426806_at 1.70  Obfc2a oligonucleotide/oligosaccharide-binding fold containing 2A b 
1416171_at 1.70  2310037I24Rik RIKEN cDNA 2310037I24 gene 
1434059_at 1.70  B230312A22Rik RIKEN cDNA B230312A22 gene 
1422706_at 1.70  Pmepa1 prostate transmembrane protein, androgen induced 1 
1417375_at 1.69  Tuba4a tubulin, alpha 4A 
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1419999_at 1.69  Igbp1 immunoglobulin (CD79A) binding protein 1 
1436797_a_at 1.69  Surf4 surfeit gene 4 
1436202_at 1.69  Malat1 metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) a 
1448480_at 1.69  Nip7 nuclear import 7 homolog (S. cerevisiae) 
1456761_at 1.68  D630030B22Rik RIKEN cDNA D630030B22 gene 
1428522_at 1.68  Ttf2 transcription termination factor, RNA polymerase II 
1439270_x_at 1.68  Ran RAN, member RAS oncogene family 
1432984_at 1.68  1700026H06Rik RIKEN cDNA 1700026H06 gene 
1446096_at 1.68  2310001H17Rik RIKEN cDNA 2310001H17 gene 
1451505_at 1.68  Chchd5 coiled-coil-helix-coiled-coil-helix domain containing 5 
1440715_s_at 1.68  Cdkn2aipnl CDKN2A interacting protein N-terminal like a 
1448736_a_at 1.68  Hprt1 hypoxanthine guanine phosphoribosyl transferase 1 
1456422_at 1.68  Dennd5b DENN/MADD domain containing 5B 
1449037_at 1.68  Crem cAMP responsive element modulator 
1437080_s_at 1.68  Psmd11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 
1450745_at 1.68  C1galt1 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 
1435372_a_at 1.68  Pa2g4 proliferation-associated 2G4 
1419562_at 1.67  Birc6 baculoviral IAP repeat-containing 6 
1418999_at 1.67  2310033P09Rik RIKEN cDNA 2310033P09 gene 
1424047_at 1.67  Dera 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) 
1429307_s_at 1.67  Lzic leucine zipper and CTNNBIP1 domain containing 
1416429_a_at 1.67  Cat catalase 
1419495_at 1.67  Immp2l IMP2 inner mitochondrial membrane peptidase-like (S. cerevisiae) 
1423358_at 1.67  Ece2 endothelin converting enzyme 2 
1426266_s_at 1.67  Zbtb8os zinc finger and BTB domain containing 8 opposite strand 
1426931_s_at 1.67  D19Bwg1357e DNA segment, Chr 19, Brigham & Women's Genetics 1357 expressed 
1427190_at 1.66  Appl1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1
1441018_at 1.66  Usp24 ubiquitin specific peptidase 24 
1416396_at 1.66  Snx4 sorting nexin 4 
1460583_at 1.66  Golt1b golgi transport 1 homolog B (S. cerevisiae) 
1420630_at 1.66  8430419L09Rik RIKEN cDNA 8430419L09 gene 
1425649_at 1.66  Slc39a14 solute carrier family 39 (zinc transporter), member 14 
1422216_at 1.65  Mid2 midline 2 
1454346_at 1.65  4930540E01Rik RIKEN cDNA 4930540E01 gene 
1429109_at 1.65  Msl2 male-specific lethal 2 homolog (Drosophila) 
1436947_a_at 1.65  Txnl1 thioredoxin-like 1 
1434016_at 1.65  Znrf2 zinc and ring finger 2 
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1418794_at 1.65  Cds2 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 
1435803_a_at 1.65  Eif4e eukaryotic translation initiation factor 4E  
1417684_at 1.65  Thumpd3 THUMP domain containing 3 
1438514_at 1.65  Npc1l1 NPC1-like 1 
1427678_at 1.65  Zim3 zinc finger, imprinted 3 
1437238_x_at 1.65  Nmd3 NMD3 homolog (S. cerevisiae) 
1435057_x_at 1.65  Polr1e polymerase (RNA) I polypeptide E 
1438726_at 1.65  Mical2 microtubule associated monoxygenase, calponin and LIM domain containing 2 
1438566_at 1.64  St8sia6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 
1452838_at 1.64  Ddx10 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 
1430042_at 1.64  A930012M21Rik RIKEN cDNA A930012M21 gene 
1430725_at 1.64  4933432I09Rik RIKEN cDNA 4933432I09 gene 
1425534_at 1.64  Stau2 staufen (RNA binding protein) homolog 2 (Drosophila) 
1456339_at 1.64  2810410D24Rik RIKEN cDNA 2810410D24 gene 
1422813_at 1.64  Cacng1 calcium channel, voltage-dependent, gamma subunit 1 
1423552_at 1.64  Leprotl1 leptin receptor overlapping transcript-like 1 
1460053_at 1.64  Smyd4 SET and MYND domain containing 4 
1434115_at 1.63  Cdh13 cadherin 13 
1416920_at 1.63  Rbm4 RNA binding motif protein 4 
1415911_at 1.63  Impact imprinted and ancient 
1455462_at 1.63  Adcy2 adenylate cyclase 2 
1459756_at 1.63  Cnot10 CCR4-NOT transcription complex, subunit 10 
1441976_at 1.63  5430434G16Rik RIKEN cDNA 5430434G16 gene 
1448836_s_at 1.62  Gpn2 GPN-loop GTPase 2 
1452012_a_at 1.62  Exosc1 exosome component 1 
1418305_s_at 1.62  Gar1 GAR1 ribonucleoprotein homolog (yeast) 
1428197_at 1.62  Tspan9 tetraspanin 9 
1432321_at 1.62  Zcchc13 zinc finger, CCHC domain containing 13 
1418616_at 1.62  Mafk v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K (avian) 
1419287_at 1.62  Tmem208 transmembrane protein 208 
1454784_at 1.61  Hs3st2 heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
1433928_a_at 1.61  Rpl13a ribosomal protein L13A 
1438501_at 1.61  Gm2614 predicted gene 2614 
1452594_at 1.61  Dusp11 dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) 
1427885_at 1.61  Pold4 polymerase (DNA-directed), delta 4 
1434442_at 1.61  Stbd1 starch binding domain 1 
1450729_at 1.61  Hs2st1 heparan sulfate 2-O-sulfotransferase 1 
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1443681_at 1.61  Fbll1 Fibrillarin-like 1 
1424174_at 1.61  Shkbp1 Sh3kbp1 binding protein 1 
1419253_at 1.61  Mthfd2 methylenetetrahydrofolate dehydrogenase, methenyltetrahydrofolate cyclohydrolase 
1452118_at 1.61  Rrp1b ribosomal RNA processing 1 homolog B (S. cerevisiae) 
1450375_at 1.60  Pspn persephin 
1458164_at 1.60  LOC552913 hypothetical LOC552913 
1416925_at 1.60  Kpnb1 karyopherin (importin) beta 1 
1423865_at 1.60  Slc44a1 solute carrier family 44, member 1 
1437828_s_at 1.60  Wdr46 WD repeat domain 46 
1433599_at 1.59  Baz1a bromodomain adjacent to zinc finger domain 1A 
1434524_at 1.59  Eif2b3 eukaryotic translation initiation factor 2B, subunit 3 
1433766_at 1.59  C330023M02Rik RIKEN cDNA C330023M02 gene 
1423784_at 1.59  Gars glycyl-tRNA synthetase 
1434035_at 1.59  Dnajb6 DnaJ (Hsp40) homolog, subfamily B, member 6 
1429087_at 1.59  1110054O05Rik RIKEN cDNA 1110054O05 gene 
1436849_x_at 1.59  Gaa glucosidase, alpha, acid 
1430158_at 1.58  3110021A11Rik RIKEN cDNA 3110021A11 gene 
1418388_s_at 1.58  Mphosph8 M-phase phosphoprotein 8 a 
1416540_at 1.58  Hgs HGF-regulated tyrosine kinase substrate 
1458466_at 1.58  Ctsa cathepsin A a 
1456072_at 1.58  Ppp1r9a protein phosphatase 1, regulatory (inhibitor) subunit 9A 
1437225_x_at 1.58  Gnai3 guanine nucleotide binding protein (G protein), alpha inhibiting 3 
1438596_at 1.57  1500017E21Rik RIKEN cDNA 1500017E21 gene 
1435055_a_at 1.57  Tom1 target of myb1 homolog (chicken) 
1428390_at 1.57  Wdr43 WD repeat domain 43 
1415903_at 1.57  Slc38a1 solute carrier family 38, member 1 
1424257_at 1.57  Cdk7 cyclin-dependent kinase 7 (homolog of Xenopus MO15 cdk-activating kinase) 
1435705_at 1.57  Zscan18 zinc finger and SCAN domain containing 18 
1444436_at 1.56  Hsf2 heat shock factor 2 
1423563_at 1.56  Prrt1 proline-rich transmembrane protein 1 
1424753_at 1.56  Nudt14 nudix (nucleoside diphosphate linked moiety X)-type motif 14 
1415735_at 1.56  Ddb1 damage specific DNA binding protein 1 
1419035_s_at 1.56  Csnk2a1 casein kinase 2, alpha 1 polypeptide 
1428835_at 1.56  Myh14 myosin, heavy polypeptide 14 
1455887_at 1.56  Alg8 asparagine-linked glycosylation 8 homolog (yeast, alpha-1,3-glucosyltransferase) 
1437303_at 1.56  Il6st interleukin 6 signal transducer 
1451095_at 1.56  Asns asparagine synthetase 
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1435528_at 1.56  Dnlz DNL-type zinc finger 
1416328_a_at 1.56  Atp6v0e ATPase, H+ transporting, lysosomal V0 subunit E 
1441814_s_at 1.56  Rpain RPA interacting protein 
1415683_at 1.55  Nmt1 N-myristoyltransferase 1 
1438312_s_at 1.55  Ltbp3 latent transforming growth factor beta binding protein 3 
1434753_at 1.55  Nfrkb nuclear factor related to kappa B binding protein 
1428374_at 1.55  Glce glucuronyl C5-epimerase 
1416216_at 1.55  Reps1 RalBP1 associated Eps domain containing protein a 
1427199_at 1.55  Fryl furry homolog-like (Drosophila) 
1434619_at 1.55  Rptor regulatory associated protein of MTOR, complex 1 
1428011_a_at 1.55  Erbb2ip Erbb2 interacting protein 
1426480_at 1.55  Sbds Shwachman-Bodian-Diamond syndrome homolog (human) 
1435160_at 1.55  Ahsa2 AHA1, activator of heat shock protein ATPase homolog 2 (yeast) 
1416483_at 1.54  Ttc3 tetratricopeptide repeat domain 3 
1456854_at 1.54  Neurl1a neuralized homolog 1A (Drosophila) 
1426749_at 1.54  Prmt3 protein arginine N-methyltransferase 3 
1459857_at 1.54  Usp32 ubiquitin specific peptidase 32 
1424788_at 1.54  Kri1 KRI1 homolog (S. cerevisiae) 
1438226_at 1.54  AU022252 expressed sequence AU022252 
1423465_at 1.54  Frrs1 ferric-chelate reductase 1 
1419217_at 1.54  Sergef secretion regulating guanine nucleotide exchange factor 
1440356_at 1.54  Ciapin1 cytokine induced apoptosis inhibitor 1 
1456482_at 1.54  Pik3r3 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) 
1442252_at 1.54  Kif13a kinesin family member 13A 
1455904_at 1.54  Gas5 growth arrest specific 5 
1456466_x_at 1.54  Atxn10 ataxin 10 
1423274_at 1.53  Ints6 integrator complex subunit 6 
1460357_at 1.53  Ythdf2 YTH domain family 2 
1427077_a_at 1.53  Ap2b1 adaptor-related protein complex 2, beta 1 subunit 
1459992_x_at 1.53  Cln8 ceroid-lipofuscinosis, neuronal 8 
1458930_at 1.53  A4gnt alpha-1,4-N-acetylglucosaminyltransferase 
1424193_at 1.52  Pwp2 PWP2 periodic tryptophan protein homolog (yeast) 
1455787_x_at 1.52  Minpp1 multiple inositol polyphosphate histidine phosphatase 1 
1436828_a_at 1.52  Tpd52l2 tumor protein D52-like 2 
1452209_at 1.52  Pkp4 plakophilin 4 
1423808_at 1.52  Wrap53 WD repeat containing, antisense to TP53 
1416426_at 1.52  Rab5a RAB5A, member RAS oncogene family 
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1449072_a_at 1.52  N6amt2 N-6 adenine-specific DNA methyltransferase 2 (putative) 
1438180_x_at 1.52  Hax1 HCLS1 associated X-1 
1416861_at 1.52  Stam signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 
1437735_at 1.52  Ppp1r12a protein phosphatase 1, regulatory (inhibitor) subunit 12A 
1436897_at 1.52  Mfhas1 malignant fibrous histiocytoma amplified sequence 1 
1448564_at 1.51  Cib1 calcium and integrin binding 1 (calmyrin) 
1433548_at 1.51  Mare alpha globin regulatory element containing gene 
1423457_at 1.51  Slc35a5 solute carrier family 35, member A5 
1448824_at 1.51  Ube2j1 ubiquitin-conjugating enzyme E2, J1 a 
1438853_x_at 1.51  Ddx54 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 
1436360_at 1.51  Zscan22 zinc finger and SCAN domain containing 22 
1429508_at 1.51  2310057M21Rik RIKEN cDNA 2310057M21 gene 
1452384_at 1.51  Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 
1437394_at 1.51  Agap1 ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 
1453166_at 1.50  Ccdc109a coiled-coil domain containing 109A 
1415742_at 1.50  Aup1 ancient ubiquitous protein 1 
1437465_a_at 1.50  P4hb prolyl 4-hydroxylase, beta polypeptide 
1424216_a_at 1.50  Papola poly (A) polymerase alpha 
1440799_s_at 1.50  Farp2 FERM, RhoGEF and pleckstrin domain protein 2 
1448657_a_at 1.50  Dnajb2 DnaJ (Hsp40) homolog, subfamily B, member 2 
1425546_a_at 5.88  Trf transferrin 
1458635_at 5.71  4832428D23Rik RIKEN cDNA 4832428D23 gene 
1444504_at 5.42  Dhrs7c dehydrogenase/reductase (SDR family) member 7C 
1425089_at 5.42  Kcnc4 potassium voltage gated channel, Shaw-related subfamily, member 4 a 
1436644_x_at 5.27  Tmem25 transmembrane protein 25 a 
1421979_at 5.03  Phex phosphate regulating gene with homologies to endopeptidases on the X chromosome 
1437273_at 4.95  Htra4 HtrA serine peptidase 4 
1436986_at 4.89  Sntb2 syntrophin, basic 2 
1417481_at 4.68  Ramp1 receptor (calcitonin) activity modifying protein 1 
1439821_at 4.57  Lrp2bp Lrp2 binding protein 
1453904_at 4.52  Ccdc146 coiled-coil domain containing 146 
1439491_at 4.41  Lrrc38 leucine rich repeat containing 38 
1427919_at 4.34  Srpx2 sushi-repeat-containing protein, X-linked 2 
1439426_x_at 4.33  Lyz1 lysozyme 1 a 
1442251_at 4.19  Vcpip1 valosin containing protein (p97)/p47 complex interacting protein 1 
1451715_at 4.18  Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) a 
1432107_at 4.18  2310010M20Rik RIKEN cDNA 2310010M20 gene 
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1427329_a_at 4.12  Igh-6 immunoglobulin heavy chain 6 (heavy chain of IgM) 
1435370_a_at 4.10  Ces3 carboxylesterase 3 
1436359_at 4.10  Ret ret proto-oncogene 
1434911_s_at 4.07  Arhgap19 Rho GTPase activating protein 19 
1416863_at 4.04  Abhd8 abhydrolase domain containing 8 
1439311_at 3.97  B830012L14Rik RIKEN cDNA B830012L14 gene 
1427076_at 3.95  Mpeg1 macrophage expressed gene 1 
1451305_at 3.92  Cby1 chibby homolog 1 (Drosophila) 
1442739_at 3.92  BC031441 cDNA sequence BC031441 
1440435_at 3.92  Ky kyphoscoliosis peptidase 
1434210_s_at 3.90  Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 a 
1450243_a_at 3.81  Rcan2 regulator of calcineurin 2 a 
1419456_at 3.78  Dcxr dicarbonyl L-xylulose reductase 
1429012_at 3.77  Arhgef6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
1450048_a_at 3.76  Idh2 isocitrate dehydrogenase 2 (NADP+), mitochondrial 
1448300_at 3.75  Mgst3 microsomal glutathione S-transferase 3 
1418589_a_at 3.74  Mlf1 myeloid leukemia factor 1 
1455224_at 3.68  Angptl1 angiopoietin-like 1 
1438431_at 3.63  Abcd2 ATP-binding cassette, sub-family D (ALD), member 2 
1453851_a_at 3.63  Gadd45g growth arrest and DNA-damage-inducible 45 gamma 
1424393_s_at 3.49  Adhfe1 alcohol dehydrogenase, iron containing, 1 a 
1455220_at 3.45  Frat2 frequently rearranged in advanced T-cell lymphomas 2 
1420346_at 3.42  Asb12 ankyrin repeat and SOCS box-containing 12 
1416318_at 3.42  Serpinb1a serine (or cysteine) peptidase inhibitor, clade B, member 1a a 
1456397_at 3.38  Cdh4 cadherin 4 a 
1437915_at 3.36  Tom1l2 target of myb1-like 2 (chicken) 
1438396_at 3.35  Ocrl oculocerebrorenal syndrome of Lowe 
1451989_a_at 3.35  Mapre2 microtubule-associated protein, RP/EB family, member 2 
1451322_at 3.35  Cmbl carboxymethylenebutenolidase-like (Pseudomonas) 
1451500_at 3.34  Ushbp1 Usher syndrome 1C binding protein 1 
1426981_at 3.29  Pcsk6 proprotein convertase subtilisin/kexin type 6 
1428025_s_at 3.26  Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1 b 
1429474_at 3.23  Ptgr2 prostaglandin reductase 2 a 
1421878_at 3.21  Mapk9 mitogen-activated protein kinase 9 
1452766_at 3.17  Tppp tubulin polymerization promoting protein 
1452474_a_at 3.16  Art3 ADP-ribosyltransferase 3 
1436763_a_at 3.16  Klf9 Kruppel-like factor 9 a 
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1422605_at 3.14  Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A 
1439836_at 3.13  Asb15 ankyrin repeat and SOCS box-containing 15 
1427053_at 3.11  Abi3bp ABI gene family, member 3 (NESH) binding protein 
1449547_at 3.09  Asb14 ankyrin repeat and SOCS box-containing 14 
1449078_at 3.08  St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
1422798_at 3.06  Cntnap2 contactin associated protein-like 2 
1426208_x_at 3.06  Plagl1 pleiomorphic adenoma gene-like 1 
1451991_at 3.00  Epha7 Eph receptor A7 
1450839_at 2.97  D0H4S114 DNA segment, human D4S114 a 
1425621_at 2.95  Trim35 tripartite motif-containing 35 a 
1435917_at 2.93  Ociad2 OCIA domain containing 2 a 
1451063_at 2.93  Stxbp4 syntaxin binding protein 4 
1437874_s_at 2.90  Hexb hexosaminidase B 
1450699_at 2.87  Selenbp1 selenium binding protein 1 a 
1424362_at 2.86  Ppapdc3 phosphatidic acid phosphatase type 2 domain containing 3 
1441636_at 2.85  Sec14l5 SEC14-like 5 (S. cerevisiae) 
1439087_a_at 2.85  Pik3ip1 phosphoinositide-3-kinase interacting protein 1 a 
1454867_at 2.85  Mn1 meningioma 1 
1457881_at 2.84  Osbpl6 oxysterol binding protein-like 6 a 
1429144_at 2.84  Prei4 preimplantation protein 4 a 
1422153_a_at 2.82  Asb11 ankyrin repeat and SOCS box-containing 11 
1454840_at 2.82  Mccc2 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) a 
1416023_at 2.82  Fabp3 fatty acid binding protein 3, muscle and heart 
1428750_at 2.80  Cdc42ep2 CDC42 effector protein (Rho GTPase binding) 2 
1434424_at 2.78  Mfsd7b major facilitator superfamily domain containing 7B 
1424737_at 2.78  Thrsp thyroid hormone responsive SPOT14 homolog (Rattus) a 
1426043_a_at 2.78  Capn3 calpain 3 a 
1438030_at 2.77  Rasgrp3 RAS, guanyl releasing protein 3 
1437250_at 2.77  Mreg melanoregulin 
1417644_at 2.77  Sspn sarcospan 
1431057_a_at 2.77  Prss23 protease, serine, 23 b 
1456069_at 2.76  Dtna dystrobrevin alpha a 
1437939_s_at 2.75  Ctsc cathepsin C a 
1433827_at 2.75  Atp8a1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 a 
1434572_at 2.75  Hdac9 histone deacetylase 9 
1426340_at 2.74  Slc1a3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 
1439422_a_at 2.74  Fam132a family with sequence similarity 132, member A a 
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1440884_s_at 2.74  A530047J11Rik RIKEN cDNA A530047J11 gene 
1418666_at 2.71  Ptx3 pentraxin related gene a 
1450675_at 2.71  Smap2 stromal membrane-associated GTPase-activating protein 2 
1450971_at 2.69  Gadd45b growth arrest and DNA-damage-inducible 45 beta 
1427982_s_at 2.69  Syne2 synaptic nuclear envelope 2 
1432062_at 2.68  Mdga1 MAM domain containing glycosylphosphatidylinositol anchor 1 
1417625_s_at 2.67  Cxcr7 chemokine (C-X-C motif) receptor 7 
1454699_at 2.67  Sesn1 sestrin 1 b 
1455235_x_at 2.67  Ldhb lactate dehydrogenase B c 
1418328_at 2.65  Chkb-cpt1b choline kinase beta, carnitine palmitoyltransferase 1b, muscle transcription unit 
1448561_at 2.64  Ncf2 neutrophil cytosolic factor 2 
1435292_at 2.64  Tbc1d4 TBC1 domain family, member 4 
1433907_at 2.64  Pknox2 Pbx/knotted 1 homeobox 2 
1415864_at 2.64  Bpgm 2,3-bisphosphoglycerate mutase b 
1416666_at 2.64  Serpine2 serine (or cysteine) peptidase inhibitor, clade E, member 2 
1422324_a_at 2.63  Pthlh parathyroid hormone-like peptide 
1449834_at 2.62  Magix MAGI family member, X-linked 
1426319_at 2.62  Pdgfd platelet-derived growth factor, D polypeptide 
1435828_at 2.62  Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog c 
1415871_at 2.62  Tgfbi transforming growth factor, beta induced 
1419652_s_at 2.61  Nkain1 Na+/K+ transporting ATPase interacting 1 a 
1423547_at 2.60  Lyz2 lysozyme 2 
1439096_at 2.58  Ddo D-aspartate oxidase 
1421466_at 2.58  Asb10 ankyrin repeat and SOCS box-containing 10 
1427157_at 2.56  Ccdc85a coiled-coil domain containing 85A 
1416225_at 2.55  Adh1 alcohol dehydrogenase 1 (class I) 
1436918_at 2.55  LOC100044376 similar to Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 
1429084_at 2.55  Vezf1 vascular endothelial zinc finger 1 
1424553_at 2.55  Hhatl hedgehog acyltransferase-like 
1434079_s_at 2.54  Mcm2 minichromosome maintenance deficient 2 mitotin (S. cerevisiae) a 
1436566_at 2.53  Rab40b Rab40b, member RAS oncogene family 
1424933_at 2.53  Myo5c myosin VC 
1417963_at 2.52  Pltp phospholipid transfer protein 
1427410_at 2.52  Dleu2 deleted in lymphocytic leukemia, 2 
1438858_x_at 2.52  H2-Aa histocompatibility 2, class II antigen A, alpha 
1437030_at 2.51  Plcd4 phospholipase C, delta 4 
1416203_at 2.51  Aqp1 aquaporin 1 
 265
1428145_at 2.51  Acaa2 acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) a 
1418181_at 2.50  Ptp4a3 protein tyrosine phosphatase 4a3 
1417542_at 2.50  Rps6ka2 ribosomal protein S6 kinase, polypeptide 2 
1423104_at 2.49  Irs1 insulin receptor substrate 1 
1427098_at 2.48  Wwp1 WW domain containing E3 ubiquitin protein ligase 1 a 
1416617_at 2.47  Acss1 acyl-CoA synthetase short-chain family member 1 
1453578_at 2.47  Pter phosphotriesterase related 
1435745_at 2.47  5031439G07Rik RIKEN cDNA 5031439G07 gene 
1439143_at 2.46  A930018M24Rik RIKEN cDNA A930018M24 gene 
1434647_at 2.46  Egflam EGF-like, fibronectin type III and laminin G domains 
1444550_at 2.46  1110021J02Rik RIKEN cDNA 1110021J02 gene 
1424531_a_at 2.46  Tcea3 transcription elongation factor A (SII), 3 
1453084_s_at 2.45  Col22a1 collagen, type XXII, alpha 1 a 
1417042_at 2.45  Slc37a4 solute carrier family 37 (glucose-6-phosphate transporter), member 4 
1438292_x_at 2.45  Adk adenosine kinase a 
1425394_at 2.43  BC023105 cDNA sequence BC023105 
1434866_x_at 2.42  Cpt1a carnitine palmitoyltransferase 1a, liver 
1426850_a_at 2.42  Map2k6 mitogen-activated protein kinase kinase 6 
1426450_at 2.42  Plcl2 phospholipase C-like 2 
1448721_at 2.42  D1Ertd622e DNA segment, Chr 1, ERATO Doi 622, expressed a 
1448104_at 2.42  Aldh6a1 aldehyde dehydrogenase family 6, subfamily A1 
1419279_at 2.40  Pip4k2a phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 
1417056_at 2.40  Psme1 proteasome (prosome, macropain) 28 subunit, alpha 
1451313_a_at 2.39  1110067D22Rik RIKEN cDNA 1110067D22 gene a 
1424716_at 2.39  Retsat retinol saturase (all trans retinol 13,14 reductase) 
1423835_at 2.39  Zfp503 zinc finger protein 503 
1416846_a_at 2.39  Pdzrn3 PDZ domain containing RING finger 3 
1426950_at 2.39  Parp16 poly (ADP-ribose) polymerase family, member 16 
1450883_a_at 2.38  Cd36 CD36 antigen a 
1418509_at 2.38  Cbr2 carbonyl reductase 2 
1417673_at 2.38  Grb14 growth factor receptor bound protein 14 
1455031_at 2.37  Cdc2l6 cell division cycle 2-like 6 (CDK8-like) 
1419140_at 2.35  Acvr2b activin receptor IIB 
1425164_a_at 2.35  Phkg1 phosphorylase kinase gamma 1 a 
1438012_at 2.35  Ppm1l protein phosphatase 1 (formerly 2C)-like a 
1429071_at 2.34  Me3 malic enzyme 3, NADP(+)-dependent, mitochondrial 
1422558_at 2.34  Gamt guanidinoacetate methyltransferase 
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1426272_at 2.34  Lmbr1 limb region 1 a 
1434354_at 2.34  Maob monoamine oxidase B 
1416452_at 2.34  Oat ornithine aminotransferase 
1419145_at 2.34  Smtnl1 smoothelin-like 1 
1434454_at 2.33  Adcy9 adenylate cyclase 9 c 
1419382_a_at 2.32  Dhrs4 dehydrogenase/reductase (SDR family) member 4 a 
1419565_a_at 2.32  Zfx zinc finger protein X-linked 
1417680_at 2.32  Kcna5 potassium voltage-gated channel, shaker-related subfamily, member 5 
1417590_at 2.32  Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 
1417061_at 2.32  Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 
1438201_at 2.31  Pdp1 pyruvate dehyrogenase phosphatase catalytic subunit 1 a 
1457424_at 2.31  Eya1 eyes absent 1 homolog (Drosophila) 
1426345_at 2.30  Prepl prolyl endopeptidase-like 
1431936_a_at 2.30  Neu2 neuraminidase 2 
1419292_at 2.30  Htra3 HtrA serine peptidase 3 
1424807_at 2.30  Lama4 laminin, alpha 4 
1427258_at 2.29  Trim24 tripartite motif-containing 24 
1448530_at 2.29  Gmpr guanosine monophosphate reductase 
1416592_at 2.28  Glrx glutaredoxin 
1422414_a_at 2.28  Calm2 calmodulin 2 a 
1425719_a_at 2.28  Nmi N-myc (and STAT) interactor 
1425519_a_at 2.28  Cd74 CD74 antigen  
1449398_at 2.28  Rpl3l ribosomal protein L3-like 
1457999_at 2.28  Fam82b family with sequence similarity 82, member B a 
1418595_at 2.27  Plin4 perilipin 4 
1433453_a_at 2.27  Abtb2 ankyrin repeat and BTB (POZ) domain containing 2 
1437724_x_at 2.27  Pitpnm1 phosphatidylinositol transfer protein, membrane-associated 1 
1423885_at 2.27  Lamc1 laminin, gamma 1 
1437868_at 2.27  Fam46a family with sequence similarity 46, member A 
1441937_s_at 2.27  PTEN PTEN a 
1455007_s_at 2.26  Gpt2 glutamic pyruvate transaminase (alanine aminotransferase) 2 a 
1426719_at 2.26  Apbb2 amyloid beta (A4) precursor protein-binding, family B, member 2 
1425407_s_at 2.26  Clec4a2 C-type lectin domain family 4, member a2 
1422852_at 2.26  Cib2 calcium and integrin binding family member 2 
1451932_a_at 2.25  Adamtsl4 ADAMTS-like 4 
1436440_at 2.25  Slc25a12 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 a 
1417283_at 2.25  Lynx1 Ly6/neurotoxin 1 
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1429598_at 2.25  2310042D19Rik RIKEN cDNA 2310042D19 gene 
1425179_at 2.25  Shmt1 serine hydroxymethyltransferase 1 (soluble) 
1418888_a_at 2.24  Sepx1 selenoprotein X 1 
1451707_s_at 2.24  Slc41a3 solute carrier family 41, member 3 b 
1417847_at 2.24  Ulk2 Unc-51 like kinase 2 (C. elegans) a 
1437197_at 2.24  Sorbs2 sorbin and SH3 domain containing 2 
1430738_at 2.24  Myoz3 myozenin 3 
1454873_at 2.23  Zfp775 zinc finger protein 775 
1437689_x_at 2.23  Clu clusterin b 
1424062_at 2.23  Ube2d1 ubiquitin-conjugating enzyme E2D 1, UBC4/5 homolog (yeast) 
1435591_at 2.23  AI426330 expressed sequence AI426330 
1416799_at 2.23  Trpm7 transient receptor potential cation channel, subfamily M, member 7 a 
1427556_at 2.22  Mylk2 myosin, light polypeptide kinase 2, skeletal muscle 
1450414_at 2.21  Pdgfb platelet derived growth factor, B polypeptide 
1433508_at 2.21  Klf6 Kruppel-like factor 6 a 
1422927_at 2.21  Yipf7 Yip1 domain family, member 7 
1417050_at 2.21  C1qtnf4 C1q and tumor necrosis factor related protein 4 
1420664_s_at 2.20  Procr protein C receptor, endothelial 
1426852_x_at 2.20  Nov nephroblastoma overexpressed gene 
1456312_x_at 2.20  Gsn gelsolin b 
1455091_at 2.19  Ppp2r3a protein phosphatase 2, regulatory subunit B'', alpha a 
1453836_a_at 2.19  Mgll monoglyceride lipase 
1418370_at 2.19  Tnnc1 troponin C, cardiac/slow skeletal 
1450044_at 2.19  Fzd7 frizzled homolog 7 (Drosophila) 
1448382_at 2.19  Ehhadh enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase 
1449335_at 2.19  Timp3 tissue inhibitor of metalloproteinase 3 a 
1416968_a_at 2.19  Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 
1436778_at 2.19  Cybb cytochrome b-245, beta polypeptide 
1448666_s_at 2.18  Tob2 transducer of ERBB2, 2 b 
1448839_at 2.18  Kank3 KN motif and ankyrin repeat domains 3 a 
1416321_s_at 2.18  Prelp proline arginine-rich end leucine-rich repeat 
1435272_at 2.18  Itpkb inositol 1,4,5-trisphosphate 3-kinase B 
1431335_a_at 2.18  Wfdc1 WAP four-disulfide core domain 1 
1452469_a_at 2.18  Smtn smoothelin 
1457227_at 2.18  AI843755 expressed sequence AI843755 
1448484_at 2.18  Amd1 S-adenosylmethionine decarboxylase 1 
1456944_at 2.17  Kcnc1 potassium voltage gated channel, Shaw-related subfamily, member 1 
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1416412_at 2.17  Nsmaf neutral sphingomyelinase (N-SMase) activation associated factor 
1417701_at 2.17  Ppp1r14c protein phosphatase 1, regulatory (inhibitor) subunit 14c 
1416007_at 2.17  Satb1 special AT-rich sequence binding protein 1 a 
1428140_at 2.17  Oxct1 3-oxoacid CoA transferase 1 b 
1415994_at 2.17  Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 
1422919_at 2.16  Hrasls HRAS-like suppressor a 
1423422_at 2.15  Asb4 ankyrin repeat and SOCS box-containing 4 
1455087_at 2.15  D7Ertd715e DNA segment, Chr 7, ERATO Doi 715, expressed 
1418525_at 2.15  Pcm1 pericentriolar material 1 
1433873_s_at 2.15  Pcnt pericentrin (kendrin) 
1450429_at 2.14  Capn6 calpain 6 
1416737_at 2.14  Gys1 glycogen synthase 1, muscle 
1423447_at 2.14  Clpx caseinolytic peptidase X (E.coli) 
1434900_at 2.14  Mkl1 MKL (megakaryoblastic leukemia)/myocardin-like 1 
1425156_at 2.14  Gbp6 guanylate binding protein 6 a 
1436405_at 2.14  Dock4 dedicator of cytokinesis 4 
1433842_at 2.14  Lrrfip1 leucine rich repeat (in FLII) interacting protein 1 a 
1428444_at 2.14  Asb2 ankyrin repeat and SOCS box-containing 2 
1455698_at 2.13  Sec62 SEC62 homolog (S. cerevisiae) 
1417500_a_at 2.13  Tgm2 transglutaminase 2, C polypeptide b 
1457568_at 2.13  Hnrnpd heterogeneous nuclear ribonucleoprotein D 
1425678_a_at 2.12  Snrk SNF related kinase a 
1437287_at 2.12  1110020G09Rik RIKEN cDNA 1110020G09 gene 
1454637_at 2.12  Klhl8 kelch-like 8 (Drosophila) 
1433628_at 2.12  Coq10a coenzyme Q10 homolog A (yeast) 
1426857_a_at 2.12  Hsdl2 hydroxysteroid dehydrogenase like 2 a 
1454758_a_at 2.12  Tsc TSC domain family a 
1433725_at 2.12  Acvr1b activin A receptor, type 1B 
1427043_s_at 2.12  Enox2 ecto-NOX disulfide-thiol exchanger 2 
1448460_at 2.12  Acvr1 activin A receptor, type 1 
1435929_at 2.11  9630033F20Rik RIKEN cDNA 9630033F20 gene 
1448636_at 2.11  Myoz1 myozenin 1 
1434671_at 2.11  B230337E12Rik RIKEN cDNA B230337E12 gene 
1444232_at 2.11  Prkg1 protein kinase, cGMP-dependent, type I 
1434592_at 2.11  Slc16a10 solute carrier family 16 (monocarboxylic acid transporters), member 10 
1448569_at 2.10  Mlec malectin 
1437637_at 2.10  Phtf2 putative homeodomain transcription factor 2 b 
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1416424_at 2.10  Plin3 perilipin 3 
1428535_at 2.10  9430020K01Rik RIKEN cDNA 9430020K01 gene 
1427567_a_at 2.10  Tpm3 tropomyosin 3, gamma 
1430462_at 2.10  2310002L09Rik RIKEN cDNA 2310002L09 gene 
1423489_at 2.10  Mmd monocyte to macrophage differentiation-associated 
1429918_at 2.10  Arhgap20 Rho GTPase activating protein 20 a 
1431056_a_at 2.10  Lpl lipoprotein lipase 
1420619_a_at 2.10  Aes amino-terminal enhancer of split 
1456573_x_at 2.10  Nnt nicotinamide nucleotide transhydrogenase a 
1449405_at 2.10  Tns1 tensin 1 a 
1427213_at 2.10  Pfkfb1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 
1436501_at 2.10  Mtus1 mitochondrial tumor suppressor 1 a 
1439505_at 2.09  Clic5 chloride intracellular channel 5 b 
1441384_at 2.09  Gadl1 glutamate decarboxylase-like 1 
1448609_at 2.09  Tst thiosulfate sulfurtransferase, mitochondrial 
1457676_at 2.09  Tirap toll-interleukin 1 receptor (TIR) domain-containing adaptor protein 
1415984_at 2.08  Acadm acyl-Coenzyme A dehydrogenase, medium chain 
1443315_at 2.08  Dmd dystrophin, muscular dystrophy 
1435343_at 2.08  Dock10 dedicator of cytokinesis 10 
1417190_at 2.08  Nampt nicotinamide phosphoribosyltransferase 
1425419_a_at 2.08  Raf1 v-raf-leukemia viral oncogene 1 a 
1437041_at 2.08  Sfrs18 splicing factor, arginine/serine-rich 18 
1436555_at 2.08  Slc7a2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 a 
1428467_at 2.07  Tardbp TAR DNA binding protein 
1455842_x_at 2.07  Usp15 ubiquitin specific peptidase 15 
1422012_at 2.07  Crhr2 corticotropin releasing hormone receptor 2 
1449576_at 2.07  Eif1ay eukaryotic translation initiation factor 1A, Y-linked 
1436189_at 2.07  Nqo2 NAD(P)H dehydrogenase, quinone 2 
1416775_at 2.07  Atp5sl ATP5S-like 
1452889_at 2.07  2310007H09Rik RIKEN cDNA 2310007H09 gene 
1436185_at 2.07  AI314180 expressed sequence AI314180 
1452942_at 2.06  Tmem65 transmembrane protein 65 
1440635_at 2.06  Palld palladin, cytoskeletal associated protein b 
1422445_at 2.05  Itga6 integrin alpha 6 
1460411_s_at 2.05  Pkdcc protein kinase domain containing, cytoplasmic a 
1451221_at 2.05  BC018507 cDNA sequence BC018507 a 
1443078_at 2.05  6030439D06Rik RIKEN cDNA 6030439D06 gene 
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1451047_at 2.05  Itm2a integral membrane protein 2A a 
1430308_at 2.05  5730409N16Rik RIKEN cDNA 5730409N16 gene 
1417877_at 2.04  Eepd1 endonuclease/exonuclease/phosphatase family domain containing 1 
1452789_at 2.04  Snn stannin 
1458268_s_at 2.04  Igfbp3 insulin-like growth factor binding protein 3 
1434815_a_at 2.04  Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 
1455544_at 2.04  Zranb3 zinc finger, RAN-binding domain containing 3 
1420484_a_at 2.04  Vtn vitronectin 
1443932_at 2.04  Klhdc1 kelch domain containing 1 
1439675_at 2.03  Ppara peroxisome proliferator activated receptor alpha 
1439256_x_at 2.03  Gpr137b-ps G protein-coupled receptor 137B, pseudogene 
1418561_at 2.03  Sf3b1 splicing factor 3b, subunit 1 
1451683_x_at 2.03  H2-D1 histocompatibility 2, D region locus 1 
1416513_at 2.03  Lamb2 laminin, beta 2 
1453343_s_at 2.03  Vrk2 vaccinia related kinase 2 
1422323_a_at 2.03  Lbx1 ladybird homeobox homolog 1 (Drosophila) a 
1424194_at 2.02  Rcsd1 RCSD domain containing 1 
1426482_at 2.02  Prkrir protein-kinase, interferon-inducible double stranded RNA dependent inhibitor 
1423063_at 2.02  Dnmt3a DNA methyltransferase 3A a 
1456483_at 2.02  Zfp9 zinc finger protein 9 
1436689_a_at 2.02  Aldh9a1 aldehyde dehydrogenase 9, subfamily A1 
1451212_at 2.02  Ccdc21 coiled-coil domain containing 21 
1418951_at 2.01  Txlnb taxilin beta a 
1420859_at 2.01  Pkia protein kinase inhibitor, alpha 
1427100_at 2.01  Metrn meteorin, glial cell differentiation regulator 
1436913_at 2.00  Cdc14a CDC14 cell division cycle 14 homolog A (S. cerevisiae) 
1422624_at 2.00  Rev1 REV1 homolog (S. cerevisiae) 
1451140_s_at 2.00  Prkag2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 
1418990_at 1.99  Ms4a4d membrane-spanning 4-domains, subfamily A, member 4D 
1449944_a_at 1.99  Sec61a2 Sec61, alpha subunit 2 (S. cerevisiae) 
1428323_at 1.99  Gpd2 glycerol phosphate dehydrogenase 2, mitochondrial 
1452331_s_at 1.99  Qser1 glutamine and serine rich 1 
1421065_at 1.99  Jak2 Janus kinase 2 
1420387_at 1.98  Mpv17 Mpv17 transgene, kidney disease mutant 
1423994_at 1.98  Kif1b kinesin family member 1B b 
1422642_at 1.98  Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3 a 
1429300_at 1.98  Ankrd9 ankyrin repeat domain 9 
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1444178_at 1.98  Gm9895 predicted gene 9895 
1423600_a_at 1.98  Tcof1 Treacher Collins Franceschetti syndrome 1, homolog 
1423282_at 1.96  Pitpna phosphatidylinositol transfer protein, alpha 
1422603_at 1.96  Rnase4 ribonuclease, RNase A family 4 
1454834_at 1.96  Nfib nuclear factor I/B b 
1417841_at 1.96  Pxmp2 peroxisomal membrane protein 2 
1451718_at 1.95  Plp1 proteolipid protein (myelin) 1 
1436387_at 1.95  C330006P03Rik RIKEN cDNA C330006P03 gene 
1422011_s_at 1.95  Xlr X-linked lymphocyte-regulated complex 
1417960_at 1.94  Cpeb1 cytoplasmic polyadenylation element binding protein 1 
1433695_at 1.94  Cnrip1 cannabinoid receptor interacting protein 1 
1422807_at 1.94  Arf5 ADP-ribosylation factor 5 
1451523_a_at 1.94  Mif4gd MIF4G domain containing 
1422501_s_at 1.94  Idh3a isocitrate dehydrogenase 3 (NAD+) alpha a 
1433868_at 1.94  Btbd3 BTB (POZ) domain containing 3 
1429234_s_at 1.94  11-Sep septin 11 
1435464_at 1.93  1110003E01Rik RIKEN cDNA 1110003E01 gene 
1434100_x_at 1.93  PPAR-γ peroxisome proliferative activated receptor-γ b 
1429111_at 1.93  Tln2 talin 2 a 
1457035_at 1.93  AI607873 expressed sequence AI607873 
1428016_a_at 1.93  Rasip1 Ras interacting protein 1 
1434133_s_at 1.93  Dcaf8 DDB1 and CUL4 associated factor 8 
1448316_at 1.93  Cmtm3 CKLF-like MARVEL transmembrane domain containing 3 
1435836_at 1.92  Pdk1 pyruvate dehydrogenase kinase, isoenzyme 1 
1452767_at 1.92  Rrbp1 ribosome binding protein 1 
1454951_at 1.92  Zfp606 zinc finger protein 606 
1433639_at 1.92  Fam117a family with sequence similarity 117, memberA 
1457031_at 1.92  Fsd2 fibronectin type III and SPRY domain containing 2 
1440007_at 1.92  D930003E18Rik RIKEN cDNA D930003E18 gene 
1451357_at 1.92  Mpnd MPN domain containing 
1422678_at 1.91  Dgat2 diacylglycerol O-acyltransferase 2 
1456388_at 1.91  Atp11a ATPase, class VI, type 11A 
1435339_at 1.91  Kctd15 potassium channel tetramerisation domain containing 15 
1419270_a_at 1.91  Dut deoxyuridine triphosphatase 
1458456_x_at 1.91  6430571L13Rik RIKEN cDNA 6430571L13 gene a 
1449106_at 1.90  Gpx3 glutathione peroxidase 3 
1460591_at 1.90  Esr1 estrogen receptor 1 (alpha) a 
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1429083_at 1.90  Agl amylo-1,6-glucosidase, 4-alpha-glucanotransferase 
1417290_at 1.90  Lrg1 leucine-rich alpha-2-glycoprotein 1 
1427014_at 1.90  Dennd4b DENN/MADD domain containing 4B 
1423785_at 1.90  Egln1 EGL nine homolog 1 (C. elegans) 
1423305_at 1.90  Extl1 exostoses (multiple)-like 1 
1434956_at 1.90  Rnf170 ring finger protein 170 
1436714_at 1.90  Lpp LIM domain containing preferred translocation partner in lipoma 
1433623_at 1.90  Zfp367 zinc finger protein 367 
1451229_at 1.89  Hdac11 histone deacetylase 11 
1454801_at 1.89  Ankrd28 ankyrin repeat domain 28 
1448825_at 1.89  Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2 
1427149_at 1.89  Plekha6 pleckstrin homology domain containing, family A member 6 
1452841_at 1.89  Pgm2l1 phosphoglucomutase 2-like 1 
1424130_a_at 1.89  Ptrf polymerase I and transcript release factor 
1435551_at 1.89  Fhod3 formin homology 2 domain containing 3 
1425646_at 1.89  BC016495 cDNA sequence BC016495 
1428691_at 1.88  Chd2 chromodomain helicase DNA binding protein 2 
1433512_at 1.88  Fli1 Friend leukemia integration 1 
1447977_x_at 1.88  3100002L24Rik RIKEN cDNA 3100002L24 gene 
1456909_at 1.88  LOC676974 similar to Glucose-6-phosphate isomerase (GPI)  
1424367_a_at 1.88  Homer2 homer homolog 2 (Drosophila) 
1452005_at 1.88  Dlat dihydrolipoamide S-acetyltransferase  
1417492_at 1.88  Ctsb cathepsin B a 
1426094_at 1.88  Rhbdl1 rhomboid, veinlet-like 1 (Drosophila) 
1428097_at 1.88  2510009E07Rik RIKEN cDNA 2510009E07 gene 
1438951_x_at 1.88  Nup54 nucleoporin 54 
1415949_at 1.88  Cpe carboxypeptidase E 
1422429_at 1.87  Rnf14 ring finger protein 14 
1428224_at 1.87  Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 
1456755_at 1.87  Trak1 trafficking protein, kinesin binding 1 
1436944_x_at 1.87  Pisd phosphatidylserine decarboxylase 
1430522_a_at 1.87  Vamp5 vesicle-associated membrane protein 5 
1453734_at 1.87  Atrx alpha thalassemia/mental retardation syndrome X-linked homolog (human) 
1455009_at 1.87  Cpd carboxypeptidase D 
1448376_at 1.87  Wrnip1 Werner helicase interacting protein 1 
1456640_at 1.86  Sh3rf2 SH3 domain containing ring finger 2 
1454984_at 1.86  Lifr leukemia inhibitory factor receptor 
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1417567_at 1.86  Ctnnbip1 catenin beta interacting protein 1 
1453657_at 1.86  2310065F04Rik RIKEN cDNA 2310065F04 gene 
1419554_at 1.86  Cd47 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) a 
1424649_a_at 1.86  Tspan8 tetraspanin 8 
1428725_at 1.85  Pias2 protein inhibitor of activated STAT 2 
1455372_at 1.85  Cpeb3 cytoplasmic polyadenylation element binding protein 3 a 
1429042_at 1.85  Tmem167b transmembrane protein 167B 
1451801_at 1.85  Trdn triadin 
1448297_a_at 1.85  Tnk2 tyrosine kinase, non-receptor, 2 
1427345_a_at 1.85  Sult1a1 sulfotransferase family 1A, phenol-preferring, member 1 
1434449_at 1.85  Aqp4 aquaporin 4 
1434611_at 1.85  Rnf123 ring finger protein 123 
1451811_at 1.85  Cacng6 calcium channel, voltage-dependent, gamma subunit 6 
1454795_at 1.85  Cobll1 Cobl-like 1 
1427467_a_at 1.84  Rpgr retinitis pigmentosa GTPase regulator 
1415996_at 1.84  Txnip thioredoxin interacting protein 
1458087_at 1.84  Stac3 SH3 and cysteine rich domain 3 
1425458_a_at 1.84  Grb10 growth factor receptor bound protein 10 
1434766_at 1.84  Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 
1452341_at 1.84  Echs1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 
1460004_x_at 1.84  Stx6 syntaxin 6 
1428679_s_at 1.84  0610010K14Rik RIKEN cDNA 0610010K14 gene 
1452016_at 1.84  Alox5ap arachidonate 5-lipoxygenase activating protein 
1449964_a_at 1.84  Mlycd malonyl-CoA decarboxylase 
1416536_at 1.83  Mum1 melanoma associated antigen (mutated) 1 
1428111_at 1.83  Slc38a4 solute carrier family 38, member 4 
1460565_at 1.83  Slc41a1 solute carrier family 41, member 1 
1427226_at 1.83  Epn2 epsin 2 
1416727_a_at 1.83  Cyb5 cytochrome b-5 
1426895_at 1.83  Zfp191 zinc finger protein 191 
1425075_at 1.83  Gatad2b GATA zinc finger domain containing 2B 
1453406_a_at 1.83  Rab28 RAB28, member RAS oncogene family a 
1419518_at 1.83  Tuba8 tubulin, alpha 8 
1423456_at 1.83  Bzw2 basic leucine zipper and W2 domains 2 
1419442_at 1.83  Matn2 matrilin 2 
1417892_a_at 1.83  Sirt3 sirtuin 3 (silent mating type information regulation 2, homolog) 3 (S. cerevisiae) 
1438022_at 1.83  Rab11fip3 RAB11 family interacting protein 3 (class II) 
 274
1460652_at 1.83  Esrra estrogen related receptor, alpha 
1415939_at 1.83  Fmod fibromodulin 
1451084_at 1.82  Etfdh electron transferring flavoprotein, dehydrogenase 
1439658_at 1.82  Lmod3 leiomodin 3 (fetal) 
1452985_at 1.82  Uaca uveal autoantigen with coiled-coil domains and ankyrin repeats 
1449109_at 1.82  Socs2 suppressor of cytokine signaling 2 a 
1454670_at 1.82  Rere arginine glutamic acid dipeptide (RE) repeats 
1426774_at 1.82  Parp12 poly (ADP-ribose) polymerase family, member 12 
1429223_a_at 1.82  Hfe2 hemochromatosis type 2 (juvenile) (human homolog) 
1416713_at 1.82  Tppp3 tubulin polymerization-promoting protein family member 3 
1450376_at 1.82  Mxi1 Max interacting protein 1 
1452346_at 1.81  B3gnt1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 
1426247_at 1.81  Stk24 serine/threonine kinase 24 (STE20 homolog, yeast) 
1417044_at 1.81  Lcmt1 leucine carboxyl methyltransferase 1 
1434002_at 1.81  Foxo forkhead box  
1417582_s_at 1.81  Dhodh dihydroorotate dehydrogenase a 
1422375_a_at 1.81  Art1 ADP-ribosyltransferase 1 a 
1435445_at 1.80  Ccnt2 cyclin T2 a 
1421899_a_at 1.80  Mr1 major histocompatibility complex, class I-related 
1436012_s_at 1.80  Scrn2 secernin 2 
1420909_at 1.80  Vegfa vascular endothelial growth factor A 
1457218_at 1.80  Strbp spermatid perinuclear RNA binding protein 
1449875_s_at 1.80  H2-T10 histocompatibility 2, T region locus 10 
1434537_at 1.80  Slco3a1 solute carrier organic anion transporter family, member 3a1 
1451782_a_at 1.80  Slc29a1 solute carrier family 29 (nucleoside transporters), member 1 
1417962_s_at 1.80  Ghr growth hormone receptor a 
1434717_at 1.80  Cul3 cullin 3 a 
1418187_at 1.80  Ramp2 receptor (calcitonin) activity modifying protein 2 
1422752_at 1.79  Polr3k polymerase (RNA) III (DNA directed) polypeptide K 
1435177_a_at 1.79  Anapc5 anaphase-promoting complex subunit 5 
1452615_s_at 1.79  Trpt1 tRNA phosphotransferase 1 
1424669_at 1.79  Zfyve21 zinc finger, FYVE domain containing 21 
1426822_at 1.79  Rhot2 ras homolog gene family, member T2 
1435553_at 1.79  Pdzd2 PDZ domain containing 2 
1428829_at 1.79  6820401H01Rik RIKEN cDNA 6820401H01 gene 
1437363_at 1.79  Homer1 homer homolog 1 (Drosophila) a 
1418057_at 1.79  Tiam1 T-cell lymphoma invasion and metastasis 1 
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1427041_at 1.79  BC013712 cDNA sequence BC013712 
1418341_at 1.78  Rab4a RAB4A, member RAS oncogene family 
1449406_at 1.78  Cyhr1 cysteine and histidine rich 1 a 
1428519_at 1.78  2610528E23Rik RIKEN cDNA 2610528E23 gene 
1453592_at 1.78  Lrrc39 leucine rich repeat containing 39 
1416454_s_at 1.78  Acta2 actin, alpha 2, smooth muscle, aorta 
1452670_at 1.78  Myl9 myosin, light polypeptide 9, regulatory 
1434758_at 1.78  Crispld2 cysteine-rich secretory protein LCCL domain containing 2 
1457672_at 1.78  Chd9 chromodomain helicase DNA binding protein 9 
1443992_at 1.78  Nipbl Nipped-B homolog (Drosophila) 
1460303_at 1.78  Nr3c1 nuclear receptor subfamily 3, group C, member 1 
1416072_at 1.78  Cd34 CD34 antigen 
1455071_at 1.77  Zbtb7b zinc finger and BTB domain containing 7B 
1433657_at 1.77  Fam78a family with sequence similarity 78, member A 
1438629_x_at 1.77  Grn granulin 
1452823_at 1.77  Gstk1 glutathione S-transferase kappa 1 
1423645_a_at 1.77  Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
1454730_at 1.77  Tapt1 transmembrane anterior posterior transformation 1 
1450409_a_at 1.77  Slc48a1 solute carrier family 48 (heme transporter), member 1 
1428479_at 1.77  Nfatc1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
1426819_at 1.76  Hipk3 homeodomain interacting protein kinase 3 
1448835_at 1.76  E2f6 E2F transcription factor 6 
1417327_at 1.76  Cav2 caveolin 2 
1452241_at 1.76  Topbp1 topoisomerase (DNA) II binding protein 1 
1434977_at 1.76  4933403F05Rik RIKEN cDNA 4933403F05 gene a 
1426440_at 1.76  Dhrs7 dehydrogenase/reductase (SDR family) member 7 
1436954_at 1.76  Wipf1 WAS/WASL interacting protein family, member 1 
1415743_at 1.76  Hdac5 histone deacetylase 5 
1448900_at 1.76  D16H22S680E DNA segment, Chr 16, human D22S680E, expressed 
1435081_at 1.76  Sypl synaptophysin-like protein 
1423789_at 1.76  BC005624 cDNA sequence BC005624 
1433655_at 1.76  Rnf141 ring finger protein 141 
1423364_a_at 1.75  Aktip thymoma viral proto-oncogene 1 interacting protein 
1435588_at 1.75  Wdfy1 WD repeat and FYVE domain containing 1 
1426459_s_at 1.75  AW549877 expressed sequence AW549877 
1420821_at 1.75  Sgpp1 sphingosine-1-phosphate phosphatase 1 
1436729_at 1.75  Afap1 actin filament associated protein 1 
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1437302_at 1.75  Adrb2 adrenergic receptor, beta 2 
1448897_at 1.75  Mkrn2 makorin, ring finger protein, 2 
1425580_a_at 1.75  Pik3c3 phosphoinositide-3-kinase, class 3 
1420950_at 1.74  Znrf1 zinc and ring finger 1 
1415897_a_at 1.74  Mgst1 microsomal glutathione S-transferase 1 
1438169_a_at 1.74  Frmd4b FERM domain containing 4B 
1453094_at 1.74  Foxn3 forkhead box N3 
1448623_at 1.74  Tmem123 transmembrane protein 123 
1424426_at 1.74  Mtap methylthioadenosine phosphorylase 
1425328_at 1.74  Fam76a family with sequence similarity 76, member A 
1420098_s_at 1.74  D13Ertd787e DNA segment, Chr 13, ERATO Doi 787, expressed 
1425537_at 1.74  Ppm1a protein phosphatase 1A, magnesium dependent, alpha isoform 
1458364_s_at 1.74  Tor1aip1 torsin A interacting protein 1 
1421046_a_at 1.74  Pabpc4 poly(A) binding protein, cytoplasmic 4 
1433591_at 1.74  Ppp3r1 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) 
1428630_x_at 1.74  Haghl hydroxyacylglutathione hydrolase-like 
1455700_at 1.74  Mterfd3 MTERF domain containing 3 
1456838_at 1.74  Lingo3 leucine rich repeat and Ig domain containing 3 
1449510_at 1.74  Zfp467 zinc finger protein 467 
1438647_x_at 1.74  Cetn2 centrin 2 
1441792_at 1.74  A630033E08Rik RIKEN cDNA A630033E08 gene 
1426124_a_at 1.74  Clk1 CDC-like kinase 1 
1418763_at 1.74  Nit2 nitrilase family, member 2 
1456413_at 1.73  Pde4dip phosphodiesterase 4D interacting protein (myomegalin) 
1438241_at 1.73  Rgma RGM domain family, member A 
1417001_a_at 1.73  D4Wsu53e DNA segment, Chr 4, Wayne State University 53, expressed 
1453552_at 1.73  2310014F07Rik RIKEN cDNA 2310014F07 gene 
1451931_x_at 1.73  H2-L histocompatibility 2, D region 
1456981_at 1.73  Tmc7 transmembrane channel-like gene family 7 
1423852_at 1.73  Shisa2 shisa homolog 2 (Xenopus laevis) 
1441352_at 1.73  9430034N14Rik RIKEN cDNA 9430034N14 gene 
1428295_at 1.73  Synpo2l synaptopodin 2-like 
1433545_s_at 1.73  Acad11 acyl-Coenzyme A dehydrogenase family, member 11 
1451219_at 1.72  Ormdl1 ORM1-like 1 (S. cerevisiae) 
1428326_s_at 1.72  Hrsp12 heat-responsive protein 12 
1451050_at 1.72  Nt5c3 5'-nucleotidase, cytosolic III 
1450394_at 1.71  Golph3 golgi phosphoprotein 3 
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1422982_at 1.71  Ar androgen receptor 
1427416_x_at 1.71  Dusp7 dual specificity phosphatase 7 
1426773_at 1.71  Mfn1 mitofusin 1 a 
1416108_a_at 1.71  Tmed3 transmembrane emp24 domain containing 3 
1437150_at 1.71  Fam110b family with sequence similarity 110, member B 
1417265_s_at 1.71  Coq5 coenzyme Q5 homolog, methyltransferase (yeast) 
1418483_a_at 1.71  Ggta1 glycoprotein galactosyltransferase alpha 1, 3 
1417067_s_at 1.71  Cabc1 chaperone, ABC1 activity of bc1 complex like (S. pombe) 
1449383_at 1.71  Adssl1 adenylosuccinate synthetase like 1 
1450380_at 1.71  Epdr1 ependymin related protein 1 (zebrafish) 
1418505_at 1.71  Nudt4 nudix (nucleoside diphosphate linked moiety X)-type motif 4 
1435026_at 1.71  Spock2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 
1448211_at 1.71  Atp6v0e2 ATPase, H+ transporting, lysosomal V0 subunit E2 
1423293_at 1.71  Rpa1 replication protein A1 
1419137_at 1.71  Shank3 SH3/ankyrin domain gene 3 
1428151_x_at 1.70  Ccbl1 cysteine conjugate-beta lyase 1 
1437498_at 1.70  Gm9971 predicted gene 9971 
1423732_at 1.70  Tram1 translocating chain-associating membrane protein 1 
1430526_a_at 1.70  Smarca2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, member 2 
1429382_at 1.70  Tomm40l translocase of outer mitochondrial membrane 40 homolog-like (yeast) 
1429122_a_at 1.70  1700040I03Rik RIKEN cDNA 1700040I03 gene 
1434325_x_at 1.70  Prkar1b protein kinase, cAMP dependent regulatory, type I beta 
1434401_at 1.70  Zcchc2 zinc finger, CCHC domain containing 2 
1435261_at 1.69  Tmtc1 transmembrane and tetratricopeptide repeat containing 1 
1455680_at 1.69  9630025H16Rik RIKEN cDNA 9630025H16 gene 
1439189_at 1.69  Fnip2 folliculin interacting protein 2 
1435754_at 1.69  0 zyg-ll homolog B (C. elegans) 
1425753_a_at 1.69  Ung uracil DNA glycosylase 
1428385_at 1.69  08-Mar membrane-associated ring finger (C3HC4) 8 
1460210_at 1.69  Pkd1 polycystic kidney disease 1 homolog 
1449145_a_at 1.69  Cav1 caveolin 1, caveolae protein 
1448890_at 1.68  Klf2 Kruppel-like factor 2 (lung) 
1435115_at 1.68  Fndc5 fibronectin type III domain containing 5 
1424183_at 1.68  Acat1 acetyl-Coenzyme A acetyltransferase 1 a 
1455777_x_at 1.68  Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 
1448131_at 1.68  Mfn2 mitofusin 2 
1436389_at 1.68  Atl3 Atlastin GTPase 3 
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1416923_a_at 1.67  Bnip3l BCL2/adenovirus E1B interacting protein 3-like 
1436161_at 1.67  Pds5b PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae) a 
1426382_at 1.67  Ppm1b protein phosphatase 1B, magnesium dependent, beta isoform 
1450490_at 1.67  Kcna7 potassium voltage-gated channel, shaker-related subfamily, member 7 
1454893_at 1.67  Fam189b family with sequence similarity 189, member B 
1422514_at 1.66  Aebp1 AE binding protein 1 
1435097_at 1.66  Mmab methylmalonic aciduria (cobalamin deficiency) type B homolog (human) 
1453127_at 1.66  Ppm1j protein phosphatase 1J 
1453200_at 1.66  Rai1 retinoic acid induced 1 
1454236_a_at 1.66  Fam118b family with sequence similarity 118, member B 
1434829_at 1.66  Cbl Casitas B-lineage lymphoma 
1416253_at 1.66  Cdkn2d cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
1449818_at 1.66  Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 a 
1457696_at 1.66  Rilp Rab interacting lysosomal protein 
1456039_at 1.66  Snx14 sorting nexin 14 
1449066_a_at 1.66  Arhgef7 Rho guanine nucleotide exchange factor (GEF7) 
1436495_s_at 1.66  Zfp260 zinc finger protein 260 
1418288_at 1.66  Lpin1 lipin 1 
1423266_at 1.66  2810405K02Rik RIKEN cDNA 2810405K02 gene 
1423707_at 1.66  Tmem50b transmembrane protein 50B 
1419023_x_at 1.66  Eno1 enolase 1, alpha non-neuron 
1448735_at 1.65  Cp ceruloplasmin 
1421923_at 1.65  Sh3bp5 SH3-domain binding protein 5 (BTK-associated) 
1428508_at 1.65  Tbc1d2b TBC1 domain family, member 2B 
1454959_s_at 1.65  Gnai1 guanine nucleotide binding protein (G protein), alpha inhibiting 1 
1427138_at 1.65  Ccdc88c coiled-coil domain containing 88C 
1415708_at 1.65  Tug1 taurine upregulated gene 1 
1436569_at 1.65  Prex2 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 
1456735_x_at 1.65  Acpl2 acid phosphatase-like 2 
1455404_at 1.65  Jph2 junctophilin 2 
1416653_at 1.65  Stxbp3a syntaxin binding protein 3A 
1449108_at 1.65  Fdx1 ferredoxin 1 
1430038_at 1.64  Gphn gephyrin 
1427050_at 1.64  Txndc16 thioredoxin domain containing 16 
1418232_s_at 1.64  Lims1 LIM and senescent cell antigen-like domains 1 
1431928_at 1.64  Ttn titin 
1429097_at 1.64  C030044C12Rik RIKEN cDNA C030044C12 gene 
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1453113_at 1.64  Wdsub1 WD repeat, SAM and U-box domain containing 1 
1416766_at 1.64  Mosc2 MOCO sulphurase C-terminal domain containing 2 
1435436_at 1.64  Epas1 endothelial PAS domain protein 1 
1453022_at 1.64  Gpihbp1 GPI-anchored HDL-binding protein 1 
1433816_at 1.64  Mcart1 mitochondrial carrier triple repeat 1 
1432136_s_at 1.64  Zdhhc4 zinc finger, DHHC domain containing 4 
1450327_at 1.64  P2rx6 purinergic receptor P2X, ligand-gated ion channel, 6 
1433581_at 1.64  1190002N15Rik RIKEN cDNA 1190002N15 gene 
1450706_a_at 1.64  Arl3 ADP-ribosylation factor-like 3 
1437193_s_at 1.64  Snrpb small nuclear ribonucleoprotein B a 
1419922_s_at 1.64  Atrnl1 attractin like 1 
1439234_a_at 1.64  Tm2d2 TM2 domain containing 2 a 
1454976_at 1.64  Sod2 superoxide dismutase 2, mitochondrial 
1451975_at 1.64  2810453I06Rik RIKEN cDNA 2810453I06 gene 
1422811_at 1.63  Slc27a1 solute carrier family 27 (fatty acid transporter), member 1 
1416273_at 1.63  Tnfaip2 tumor necrosis factor, alpha-induced protein 2 a 
1456888_at 1.63  Pfkfb4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 
1454753_at 1.63  Rnpepl1 arginyl aminopeptidase (aminopeptidase B)-like 1 
1416978_at 1.63  Fcgrt Fc receptor, IgG, alpha chain transporter 
1451474_a_at 1.63  Parp8 poly (ADP-ribose) polymerase family, member 8 
1453003_at 1.63  Sorl1 sortilin-related receptor, LDLR class A repeats-containing a 
1422566_at 1.63  Tcfeb transcription factor EB 
1437829_s_at 1.63  Eef2k eukaryotic elongation factor-2 kinase 
1438428_at 1.63  Jph1 junctophilin 1 
1434720_at 1.63  Zfp652 zinc finger protein 652 
1416858_a_at 1.63  Fkbp3 FK506 binding protein 3 
1415958_at 1.63  Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 
1427981_a_at 1.62  Csad cysteine sulfinic acid decarboxylase 
1437992_x_at 1.62  Gja1 gap junction protein, alpha 1 
1415814_at 1.62  Atp6v1b2 ATPase, H+ transporting, lysosomal V1 subunit B2 
1460464_at 1.62  2700089E24Rik RIKEN cDNA 2700089E24 gene 
1424124_at 1.62  Mospd2 motile sperm domain containing 2 
1435096_at 1.62  Ric8b resistance to inhibitors of cholinesterase 8 homolog B (C. elegans) 
1434205_at 1.62  Ppp2r5c protein phosphatase 2, regulatory subunit B (B56), gamma isoform 
1454397_at 1.62  4632418H02Rik RIKEN cDNA 4632418H02 gene 
1451413_at 1.62  Cast calpastatin 
1438199_at 1.62  AI316807 expressed sequence AI316807 
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1418330_at 1.62  Ctcf CCCTC-binding factor 
1422492_at 1.62  Cpox coproporphyrinogen oxidase 
1417208_at 1.62  Amacr alpha-methylacyl-CoA racemase 
1417474_at 1.62  1500035H01Rik RIKEN cDNA 1500035H01 gene 
1435171_at 1.62  2810416G20Rik RIKEN cDNA 2810416G20 gene 
1450938_at 1.61  Pnn pinin 
1436181_at 1.61  Ddef2 development and differentiation enhancing factor 2 
1448221_at 1.61  Bat1a HLA-B-associated transcript 1A 
1417480_at 1.61  Fbxo9 f-box protein 9 
1426734_at 1.61  Fam43a family with sequence similarity 43, member A 
1432158_a_at 1.61  Trappc2 trafficking protein particle complex 2 
1419499_at 1.61  Gpam glycerol-3-phosphate acyltransferase, mitochondrial 
1440353_at 1.61  Ntf5 neurotrophin 5 
1439713_at 1.60  Itga1 integrin alpha 1 
1427677_a_at 1.60  Sox6 SRY-box containing gene 6 
1429173_at 1.60  Dnase1l1 deoxyribonuclease 1-like 1 
1434738_at 1.60  Tarsl2 threonyl-tRNA synthetase-like 2 
1449297_at 1.60  Casp12 caspase 12 
1424632_a_at 1.60  Rev3l REV3-like, catalytic subunit of DNA polymerase zeta RAD54 like (S. cerevisiae) 
1425262_at 1.60  Cebpg CCAAT/enhancer binding protein (C/EBP), gamma 
1424223_at 1.60  1700020C11Rik RIKEN cDNA 1700020C11 gene 
1428293_at 1.60  Bod1 biorientation of chromosomes in cell division 1 
1434510_at 1.60  Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 
1433834_at 1.60  06-Mar membrane-associated ring finger (C3HC4) 6 
1428474_at 1.60  Ppp3cb protein phosphatase 3, catalytic subunit, beta isoform 
1429690_at 1.60  1300003B13Rik RIKEN cDNA 1300003B13 gene 
1456611_at 1.60  Fam13a family with sequence similarity 13, member A 
1433649_at 1.59  Aof1 amine oxidase, flavin containing 1 
1440397_at 1.59  Cacna2d1 calcium channel, voltage-dependent, alpha2/delta subunit 1 a 
1417724_at 1.59  Thoc4 THO complex 4 
1417827_at 1.59  Ngly1 N-glycanase 1 
1450859_s_at 1.59  Gm15361 ubiquitin-conjugating enzyme E2D 3 pseudogene 
1451190_a_at 1.59  Sbk1 SH3-binding kinase 1 a 
1426668_at 1.59  Slc30a9 solute carrier family 30 (zinc transporter), member 9 
1419259_at 1.59  Rsu1 Ras suppressor protein 1 
1423097_s_at 1.59  Capn7 calpain 7 
1456087_at 1.59  Nfia nuclear factor I/A 
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1419703_at 1.59  Col5a3 collagen, type V, alpha 3 
1419421_at 1.59  Ank1 ankyrin 1, erythroid 
1460121_at 1.58  9630010G10Rik RIKEN cDNA 9630010G10 gene 
1435554_at 1.58  Tmcc3 transmembrane and coiled coil domains 3 
1428432_at 1.58  Zcchc24 zinc finger, CCHC domain containing 24 
1429213_at 1.58  2310030N02Rik RIKEN cDNA 2310030N02 gene 
1434487_at 1.58  Mef2d myocyte enhancer factor 2D 
1429146_at 1.58  Svip small VCP/p97-interacting protein 
1425920_at 1.58  Cuedc1 CUE domain containing 1 
1460694_s_at 1.58  Svil supervillin 
1452202_at 1.58  Pde2a phosphodiesterase 2A, cGMP-stimulated 
1452281_at 1.58  Sos2 son of sevenless homolog 2 (Drosophila) 
1448130_at 1.58  Fdft1 farnesyl diphosphate farnesyl transferase 1 
1448753_at 1.58  Srp9 signal recognition particle 9 
1418413_at 1.58  Cav3 caveolin 3 
1426979_at 1.58  Mlxip MLX interacting protein 
1456041_at 1.58  Snx16 sorting nexin 16 
1434515_at 1.58  Ncoa1 nuclear receptor coactivator 1 
1449738_s_at 1.57  Fam48a family with sequence similarity 48, member A 
1448224_at 1.57  Tfam transcription factor A, mitochondrial 
1436841_at 1.57  B230380D07Rik RIKEN cDNA B230380D07 gene a 
1427070_at 1.57  Snx21 sorting nexin family member 21 
1426449_a_at 1.57  Pja1 praja1, RING-H2 motif containing a 
1425323_a_at 1.57  Fam173a family with sequence similarity 173, member A 
1450688_at 1.57  Rgl2 ral guanine nucleotide dissociation stimulator-like 2 
1417789_at 1.57  Ccl11 chemokine (C-C motif) ligand 11 
1447693_s_at 1.57  Neo1 neogenin 
1434551_at 1.57  Hnrnpul2 heterogeneous nuclear ribonucleoprotein U-like 2 
1429141_at 1.57  Neurl2 neuralized-like 2 (Drosophila) 
1416703_at 1.57  Mapk14 mitogen-activated protein kinase 14 
1427191_at 1.57  Npr2 natriuretic peptide receptor 2 
1416530_a_at 1.57  Pnp1 purine-nucleoside phosphorylase 1 
1450870_at 1.56  Rala v-ral simian leukemia viral oncogene homolog A (ras related) 
1437730_at 1.56  Ppp2r2a protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform 
1433782_at 1.56  Cldn12 claudin 12 
1460192_at 1.56  Osbpl1a oxysterol binding protein-like 1A 
1458126_at 1.56  D030041H20Rik RIKEN cDNA D030041H20 gene 
 282
1452660_s_at 1.56  Klhl7 kelch-like 7 (Drosophila) 
1452169_a_at 1.56  Dgkz diacylglycerol kinase zeta 
1450782_at 1.56  Wnt4 wingless-related MMTV integration site 4 
1415779_s_at 1.56  Actg1 actin, gamma, cytoplasmic 1 
1448513_a_at 1.56  Npc2 Niemann Pick type C2 a 
1425129_a_at 1.56  Taldo1 transaldolase 1 
1425149_a_at 1.56  Pdcl phosducin-like 
1436187_at 1.56  1110054M08Rik RIKEN cDNA 1110054M08 gene 
1425508_s_at 1.55  Arfrp1 ADP-ribosylation factor related protein 1 
1460167_at 1.55  Aldh7a1 aldehyde dehydrogenase family 7, member A1 
1422064_a_at 1.55  Zbtb20 zinc finger and BTB domain containing 20 
1422478_a_at 1.55  Acss2 acyl-CoA synthetase short-chain family member 2 
1454925_x_at 1.55  Mdh1 malate dehydrogenase 1, NAD (soluble) 
1417158_at 1.55  Zxdc ZXD family zinc finger C 
1433486_at 1.55  Clcn3 chloride channel 3 
1424790_at 1.55  Slc25a42 solute carrier family 25, member 42 
1416275_at 1.55  Slc26a6 solute carrier family 26, member 6 
1418372_at 1.55  Adsl adenylosuccinate lyase 
1427407_s_at 1.55  Trip11 thyroid hormone receptor interactor 11 
1416690_at 1.55  Gtpbp2 GTP binding protein 2 
1452769_at 1.55  Rnf145 ring finger protein 145 
1428651_at 1.55  Klhl24 kelch-like 24 (Drosophila) 
1426581_at 1.55  Ptpmt1 protein tyrosine phosphatase, mitochondrial 1 
1424033_at 1.54  Sfrs7 splicing factor, arginine/serine-rich 7 
1449686_s_at 1.54  Scp2 sterol carrier protein 2, liver 
1454919_at 1.54  Nmt2 N-myristoyltransferase 2 
1448429_at 1.54  Gyg glycogenin 
1448664_a_at 1.54  Speg SPEG complex locus 
1455014_at 1.54  Hint3 histidine triad nucleotide binding protein 3 
1426453_at 1.54  Pitrm1 pitrilysin metallepetidase 1 
1438035_at 1.54  Fam82a1 family with sequence similarity 82, member A1 
1434093_at 1.53  Lysmd4 LysM, putative peptidoglycan-binding, domain containing 4 
1434107_at 1.53  Spata2 spermatogenesis associated 2 
1451264_at 1.53  Frmd6 FERM domain containing 6 
1435086_s_at 1.53  Klhdc2 kelch domain containing 2 
1419401_at 1.53  Asb13 ankyrin repeat and SOCS box-containing 13 
1460194_at 1.53  Phyh phytanoyl-CoA hydroxylase 
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1426759_at 1.53  Map4k3 mitogen-activated protein kinase kinase kinase kinase 3 
1435547_at 1.53  Mkl2 MKL/myocardin-like 2 
1419821_s_at 1.53  Idh1 isocitrate dehydrogenase 1 (NADP+), soluble 
1456625_at 1.53  Aasdhppt aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase 
1437552_at 1.53  2410127L17Rik RIKEN cDNA 2410127L17 gene 
1448373_at 1.53  Mrpl18 mitochondrial ribosomal protein L18 
1421863_at 1.52  Vamp1 vesicle-associated membrane protein 1 
1423908_at 1.52  Ndufs8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 
1449038_at 1.52  Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 
1439549_at 1.52  Prrg3 proline rich Gla (G-carboxyglutamic acid) 3 (transmembrane) 
1423246_at 1.52  Erp44 endoplasmic reticulum protein 44 
1460434_at 1.52  Fundc2 FUN14 domain containing 2 
1428516_a_at 1.52  Alkbh7 alkB, alkylation repair homolog 7 (E. coli) 
1436531_at 1.52  Metap2 methionine aminopeptidase 2 
1424748_at 1.52  Galnt11 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 11
1460548_a_at 1.52  Eral1 Era (G-protein)-like 1 (E. coli) 
1420967_at 1.52  Slc25a15 solute carrier family 25 (mitochondrial carrier ornithine transporter), member 15 
1450034_at 1.52  Stat1 signal transducer and activator of transcription 1 
1451176_at 1.52  Mavs mitochondrial antiviral signaling protein 
1418886_s_at 1.52  Idh3b isocitrate dehydrogenase 3 (NAD+) beta 
1417565_at 1.51  Abhd5 abhydrolase domain containing 5 
1427177_at 1.51  Fyco1 FYVE and coiled-coil domain containing 1 
1452353_at 1.51  Gpr155 G protein-coupled receptor 155 
1418210_at 1.51  Pfn2 profilin 2 
1439389_s_at 1.51  Myadm myeloid-associated differentiation marker 
1423883_at 1.51  Acsl1 acyl-CoA synthetase long-chain family member 1 
1424433_at 1.51  Msrb2 methionine sulfoxide reductase B2 
1453766_a_at 1.51  Efcab6 EF-hand calcium binding domain 6 
1424166_at 1.51  Msh3 mutS homolog 3 (E. coli) 
1428755_at 1.51  Creb1 cAMP responsive element binding protein 1 
1438164_x_at 1.51  Flot2 flotillin 2 
1415961_at 1.51  Itm2c integral membrane protein 2C 
1418234_s_at 1.51  Bcas2 breast carcinoma amplified sequence 2 
1434348_at 1.51  Fez2 fasciculation and elongation protein zeta 2 (zygin II) 
1430786_at 1.50  1110002E22Rik RIKEN cDNA 1110002E22 gene 
1455610_at 1.50  Synm synemin, intermediate filament protein 
1455101_at 1.50  Phactr2 phosphatase and actin regulator 2 
 284
1452661_at 1.50  Tfrc transferrin receptor 
1421147_at 1.50  Terf2 telomeric repeat binding factor 2 
1423200_at 1.50  Ncor1 nuclear receptor co-repressor 1 
1417124_at 1.50  Dstn destrin 
1431885_a_at 1.50  Mus81 MUS81 endonuclease homolog (yeast) 
1433830_at 1.50  Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 
1434390_at 1.50  LOC100270747 hypothetical LOC100270747 
A total 1521 gene identified from 1907 Affymetrix probe sets after a 1.5 fold change cut off. 683 genes were overexpressed, and 838 genes 
were underexpressed (grey box).a This gene appears two times; b This gene appears three times; c This gene appears four times; d This gene 
appears five times. M, Mstn-pro mice; CLM, clenbuterol treated Mstn-pro mice.  
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Appendix 3.9 The expression of overlapping genes between the effects of CL (W vs CLW VS M vs 
CLM). 
Probe Set ID Gene Symbol Gene Title 
1422906_at Abcg2 ATP-binding cassette, sub-family G (WHITE), member 2 
1428803_at Acot6 acyl-CoA thioesterase 6 
1451257_at Acsl6 acyl-CoA synthetase long-chain family member 6 
1426403_at Actr1b ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 
1455462_at Adcy2 adenylate cyclase 2 
1434080_at Aebp2 AE binding protein 2 
1435432_at Agap1 ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 
1451287_s_at Aif1l allograft inflammatory factor 1-like 
1416911_a_at Akirin1 akirin 1 
1452478_at Alpk2 alpha-kinase 2 
1422573_at Ampd3 adenosine monophosphate deaminase 3 
1420992_at Ankrd1 ankyrin repeat domain 1 (cardiac muscle) 
1416065_a_at Ankrd10 ankyrin repeat domain 10 
1448660_at Arhgdig Rho GDP dissociation inhibitor (GDI) gamma 
1427646_a_at Arhgef2 rho/rac guanine nucleotide exchange factor (GEF) 2 
1422608_at Arpp19 cAMP-regulated phosphoprotein 19 
1435444_at Atf6 activating transcription factor 6 
1422929_s_at Atoh7 atonal homolog 7 (Drosophila) 
1442145_at Atp13a3 ATPase type 13A3 
1437688_x_at Atp6ap2 ATPase, H+ transporting, lysosomal accessory protein 2 
1422508_at Atp6v1a ATPase, H+ transporting, lysosomal V1 subunit A 
1456466_x_at Atxn10 ataxin 10 
1426329_s_at Baalc brain and acute leukemia, cytoplasmic 
1433599_at Baz1a bromodomain adjacent to zinc finger domain 1A 
1455316_x_at BC094435 cDNA sequence BC094435 
1455771_at Bzrap1 benzodiazapine receptor associated protein 1 
1422813_at Cacng1 calcium channel, voltage-dependent, gamma subunit 1 
1433972_at Camta1 calmodulin binding transcription activator 1 
1449839_at Casp3 caspase 3 
1424517_at Ccdc12 coiled-coil domain containing 12 
1437669_x_at Ccrl1 Chemokine (C-C motif) receptor-like 1 
1437502_x_at Cd24a CD24a antigen 
1416401_at Cd82 CD82 antigen 
1434115_at Cdh13 cadherin 13 
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1451741_a_at Cdk7 cyclin-dependent kinase 7  
1424638_at Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 
1418794_at Cds2 CDP-diacylglycerol synthase 2 
1424245_at Ces2 carboxylesterase 2 
1424529_s_at Cgref1 cell growth regulator with EF hand domain 1 
1418852_at Chrna1 cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 
1430086_at Chrna9 cholinergic receptor, nicotinic, alpha polypeptide 9 
1420682_at Chrnb1 cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) 
1457296_at Cilp cartilage intermediate layer protein 
1435775_at Clock circadian locomoter output cycles kaput 
1456953_at Col19a1 collagen, type XIX, alpha 1 
1455627_at Col8a1 collagen, type VIII, alpha 1 
1428635_at Comtd1 catechol-O-methyltransferase domain containing 1 
1424831_at Cpne2 copine II 
1449037_at Crem cAMP responsive element modulator 
1427910_at Cst6 cystatin E/M 
1417453_at Cul4b cullin 4B 
1415803_at Cx3cl1 chemokine (C-X3-C motif) ligand 1 
1429618_at Cyld cylindromatosis (turban tumor syndrome) 
1416039_x_at Cyr61 cysteine rich protein 61 
1451453_at Dapk2 death-associated protein kinase 2 
1415735_at Ddb1 damage specific DNA binding protein 1 
1417103_at Ddt D-dopachrome tautomerase 
1448271_a_at Ddx21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 
1424047_at Dera 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) 
1423082_at Derl1 Der1-like domain family, member 1 
1418937_at Dio2 deiodinase, iodothyronine, type II 
1426465_at Dlgap4 discs, large homolog-associated protein 4 (Drosophila) 
1434035_at Dnajb6 DnaJ (Hsp40) homolog, subfamily B, member 6 
1450198_at Dusp13 dual specificity phosphatase 13 
1428834_at Dusp4 dual specificity phosphatase 4 
1431281_at Dysfip1 dysferlin interacting protein 1 
1433555_at Eaf1 ELL associated factor 1 
1423358_at Ece2 endothelin converting enzyme 2 
1440085_at Eda2r ectodysplasin A2 isoform receptor 
1418648_at Egln3 EGL nine homolog 3 (C. elegans) 
1417235_at Ehd3 EH-domain containing 3 
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1449852_a_at Ehd4 EH-domain containing 4 
1424343_a_at Eif1a eukaryotic translation initiation factor 1A 
1434985_a_at Eif4a1 eukaryotic translation initiation factor 4A1 
1435803_a_at Eif4e2 eukaryotic translation initiation factor 4E member 2 
1455994_x_at Elovl1 elongation of very long chain fatty acids-like 1 
1428739_at Enho energy homeostasis associated 
1460392_a_at Eny2 enhancer of yellow 2 homolog (Drosophila) 
1430724_at Ephx3 epoxide hydrolase 3 
1428011_a_at Erbb2ip Erbb2 interacting protein 
1419029_at Ero1l ERO1-like (S. cerevisiae) 
1422567_at Fam129a family with sequence similarity 129, member A 
1436761_s_at Fam13c family with sequence similarity 13, member C 
1421746_a_at Fbxo17 F-box protein 17 
1454674_at Fez1 fasciculation and elongation protein zeta 1 (zygin I) 
1418497_at Fgf13 fibroblast growth factor 13 
1452799_at Fggy FGGY carbohydrate kinase domain containing 
1419184_a_at Fhl2 four and a half LIM domains 2 
1422516_a_at Fibp fibroblast growth factor (acidic) intracellular binding protein 
1423465_at Frrs1 ferric-chelate reductase 1 
1418364_a_at Ftl1 ferritin light chain 1 
1419428_a_at Gaa glucosidase, alpha, acid 
1449519_at Gadd45a growth arrest and DNA-damage-inducible 45 alpha 
1448744_at Galns galactosamine (N-acetyl)-6-sulfate sulfatase 
1452232_at Galnt7 UDP-N-acetyl-alpha-D-galactosamine 
1434754_at Garnl4 GTPase activating RANGAP domain-like 4 
1423784_at Gars glycyl-tRNA synthetase 
1419139_at Gdf5 growth differentiation factor 5 
1458245_at Gm12528 predicted gene 12528 
1455271_at Gm13889 predicted gene 13889 
1425238_at Gm6607 40S ribosomal protein S20 pseudogene 
1448571_a_at Gmfb glia maturation factor, beta 
1421947_at Gng12 guanine nucleotide binding protein (G protein), gamma 12 
1433656_a_at Gnl3 guanine nucleotide binding protein-like 3 (nucleolar) 
1460583_at Golt1b golgi transport 1 homolog B (S. cerevisiae) 
1451411_at Gprc5b G protein-coupled receptor, family C, group 5, member B 
1416708_a_at Gramd1a GRAM domain containing 1A 
1435402_at Gramd1b GRAM domain containing 1B 
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1418186_at Gstt1 glutathione S-transferase, theta 1 
1426187_a_at Hax1 HCLS1 associated X-1 
1454693_at Hdac4 histone deacetylase 4 
1430062_at Hhipl1 hedgehog interacting protein-like 1 
1438988_x_at Hn1 hematological and neurological expressed sequence 1 
1448736_a_at Hprt1 hypoxanthine guanine phosphoribosyl transferase 1 
1450047_at Hs6st2 heparan sulfate 6-O-sulfotransferase 2 
1428640_at Hsf2bp heat shock transcription factor 2 binding protein 
1416146_at Hspa4 heat shock protein 4 
1425964_x_at Hspb1 heat shock protein 1 
1434927_at Hspb7 heat shock protein family, member 7 (cardiovascular) 
1417013_at Hspb8 heat shock protein 8 
1451814_a_at Htatip2 HIV-1 tat interactive protein 2, homolog (human) 
1435176_a_at Id2 inhibitor of DNA binding 2 
1415911_at Impact imprinted and ancient 
1423239_at Impdh1 inosine 5'-phosphate dehydrogenase 1 
1445568_at Inca1 Inhibitor of CDK, cyclin A1 interacting protein 1 
1448694_at Jun Jun oncogene 
1426873_s_at Jup junction plakoglobin 
1421852_at Kcnk5 potassium channel, subfamily K, member 5 
1441071_at Kcnq5 potassium voltage-gated channel, subfamily Q, member 5 
1449841_at Kif3a kinesin family member 3A 
1418429_at Kif5b kinesin family member 5B 
1417005_at Klc1 kinesin light chain 1 
1460260_s_at Kpna1 karyopherin (importin) alpha 1 
1416925_at Kpnb1 karyopherin (importin) beta 1 
1448169_at Krt18 keratin 18 
1423691_x_at Krt8 keratin 8 
1424378_at Ldlrap1 low density lipoprotein receptor adaptor protein 1 
1423552_at Leprotl1 leptin receptor overlapping transcript-like 1 
1426808_at Lgals3 lectin, galactose binding, soluble 3 
1426577_a_at Lin37 lin-37 homolog (C. elegans) 
1423719_at LOC632073 lung and nasal epithelium carcinoma associated 1 isoform 2 
1452836_at Lpin2 lipin 2 
1437109_s_at Lsm6 LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
1429307_s_at Lzic leucine zipper and CTNNBIP1 domain containing 
1428847_a_at Macf1 microtubule-actin crosslinking factor 1 
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1436202_at Malat1 metastasis associated lung adenocarcinoma transcript  
1451290_at Map1lc3a microtubule-associated protein 1 light chain 3 alpha 
1424719_a_at Mapt microtubule-associated protein tau 
1433548_at Mare alpha globin regulatory element containing gene 
1423605_a_at Mdm2 transformed mouse 3T3 cell double minute 2 
1427186_a_at Mef2a myocyte enhancer factor 2A 
1418387_at Mphosph8 M-phase phosphoprotein 8 
1416748_a_at Mre11a meiotic recombination 11 homolog A (S. cerevisiae) 
1419254_at Mthfd2 methylenetetrahydrofolate dehydrogenase (NAD+ dependent) 
1450511_at Musk muscle, skeletal, receptor tyrosine kinase 
1456586_x_at Mvp major vault protein 
1419150_at Myf6 myogenic factor 6 
1454731_at Myo10 myosin X 
1419391_at Myog myogenin 
1439708_at Myom3 myomesin family, member 3 
1416192_at Napa N-ethylmaleimide sensitive fusion protein attachment protein alpha 
1435981_at Nav2 neuron navigator 2 
1439556_at Ncam1 neural cell adhesion molecule 1 
1423596_at Nek6 NIMA (never in mitosis gene a)-related expressed kinase 6 
1416606_s_at Nhp2 NHP2 ribonucleoprotein homolog (yeast) 
1448480_at Nip7 nuclear import 7 homolog (S. cerevisiae) 
1415683_at Nmt1 N-myristoyltransferase 1 
1423453_at Nol12 nucleolar protein 12 
1444786_at Nol3 nucleolar protein 3 (apoptosis repressor with CARD domain) 
1435184_at Npr3 natriuretic peptide receptor 3 
1434709_at Nrcam neuron-glia-CAM-related cell adhesion molecule 
1423850_at Nsun2 NOL1/NOP2/Sun domain family member 2 
1426806_at Obfc2a oligonucleotide/oligosaccharide-binding fold containing 2A 
1427364_a_at Odc1 ornithine decarboxylase, structural 1 
1420438_at Orm2 orosomucoid 2 
1441055_at Palm2 paralemmin 2 
1416379_at Panx1 pannexin 1 
1424216_a_at Papola poly (A) polymerase alpha 
1444451_at Pappa2 pappalysin 2 
1451269_at Pdzd11 PDZ domain containing 11 
1425134_a_at Pigx phosphatidylinositol glycan anchor biosynthesis, class X 
1425543_s_at Plekha5 pleckstrin homology domain containing, family A member 5 
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1435053_s_at Plekhh1 pleckstrin homology domain containing, family H member 1 
1417128_at Plekho1 pleckstrin homology domain containing, family O member 1 
1427885_at Pold4 polymerase (DNA-directed), delta 4 
1419058_at Polr1e polymerase (RNA) I polypeptide E 
1450686_at Pon2 paraoxonase 2 
1423810_at Ppme1 protein phosphatase methylesterase 1 
1455342_at Prune2 prune homolog 2 (Drosophila) 
1415676_a_at Psmb5 proteasome (prosome, macropain) subunit, beta type 5 
1429370_a_at Psmd11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 
1434891_at Ptgfrn prostaglandin F2 receptor negative regulator 
1421499_a_at Ptpn14 protein tyrosine phosphatase, non-receptor type 14 
1424886_at Ptprd protein tyrosine phosphatase, receptor type, D 
1451160_s_at Pvr poliovirus receptor 
1420832_at Qsox1 quiescin Q6 sulfhydryl oxidase 1 
1416426_at Rab5a RAB5A, member RAS oncogene family 
1417850_at Rb1 retinoblastoma 1 
1438001_x_at Reep5 receptor accessory protein 5 
1448975_s_at Ren1 renin 1 structural 
1440822_x_at Reps1 RalBP1 associated Eps domain containing protein 
1427375_at Rg9mtd2 RNA (guanine-9-) methyltransferase domain containing 2 
1453129_a_at Rgs12 regulator of G-protein signaling 12 
1435394_s_at Rhoc ras homolog gene family, member C 
1424507_at Rin1 Ras and Rab interactor 1 
1422650_a_at Riok3 RIO kinase 3 (yeast) 
1418318_at Rnf128 ring finger protein 128 
1436305_at Rnf217 ring finger protein 217 
1433928_a_at Rpl13a ribosomal protein L13A 
1449323_a_at Rpl3 ribosomal protein L3 
1451068_s_at Rps25 ribosomal protein S25 
1422562_at Rrad Ras-related associated with diabetes 
1418448_at Rras Harvey rat sarcoma oncogene, subgroup R 
1448689_at Rras2 related RAS viral (r-ras) oncogene homolog 2 
1437224_at Rtn4 reticulon 4 
1455605_at Rufy3 RUN and FYVE domain containing 3 
1440878_at Runx1 runt related transcription factor 1 
1425389_a_at Runx2 runt related transcription factor 2 
1451809_s_at Rwdd3 RWD domain containing 3 
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1419394_s_at S100a8 S100 calcium binding protein A8 (calgranulin A) 
1434402_at Samd8 sterile alpha motif domain containing 8 
1458813_at Scn5a sodium channel, voltage-gated, type V, alpha 
1456291_x_at Scx scleraxis 
1448793_a_at Sdc4 syndecan 4 
1419819_s_at Sec63 SEC63-like (S. cerevisiae) 
1434382_at Serinc2 serine incorporator 2 
1433571_at Serinc5 serine incorporator 5 
1448715_x_at Sgip1 SH3-domain GRB2-like (endophilin) interacting protein 1 
1436499_at Sgms1 sphingomyelin synthase 1 
1449084_s_at Sh3d19 SH3 domain protein D19 
1434153_at Shb src homology 2 domain-containing transforming protein B 
1422629_s_at Shroom3 shroom family member 3 
1451227_a_at Slc10a3 solute carrier family 10, member 3 
1420444_at Slc22a3 solute carrier family 22 (organic cation transporter), member 3 
1426600_at Slc2a1 solute carrier family 2 (facilitated glucose transporter), member 1 
1426722_at Slc38a2 solute carrier family 38, member 2 
1427035_at Slc39a14 solute carrier family 39 (zinc transporter), member 14 
1423865_at Slc44a1 solute carrier family 44, member 1 
1420884_at Sln sarcolipin 
1421052_a_at Sms spermine synthase 
1438176_x_at Snap47 synaptosomal-associated protein, 47 
1453125_at Sox11 SRY-box containing gene 11 
1420150_at Spsb1 splA/ryanodine receptor domain and SOCS box containing 1 
1451680_at Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 
1416861_at Stam signal transducing adaptor molecule 1 
1416974_at Stam2 signal transducing adaptor molecule 2 
1425534_at Stau2 staufen (RNA binding protein) homolog 2 (Drosophila) 
1434442_at Stbd1 starch binding domain 1 
1453228_at Stx11 syntaxin 11 
1436797_a_at Surf4 surfeit gene 4 
1455493_at Syne1 synaptic nuclear envelope 1 
1419446_at Tbc1d1 TBC1 domain family, member 1 
1426337_a_at Tead4 TEA domain family member 4 
1420895_at Tgfbr1 transforming growth factor, beta receptor I 
1422286_a_at Tgif1 TGFB-induced factor homeobox 1 
1450377_at Thbs1 thrombospondin 1 
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1417684_at Thumpd3 THUMP domain containing 3 
1438769_a_at Thyn1 thymocyte nuclear protein 1 
1423186_at Tiam2 T-cell lymphoma invasion and metastasis 2 
1436042_at Tln1 talin 1 
1442827_at Tlr4 Toll-like receptor 4 
1449533_at Tmem100 transmembrane protein 100 
1424354_at Tmem140 transmembrane protein 140 
1425780_a_at Tmem167 transmembrane protein 167 
1419287_at Tmem208 transmembrane protein 208 
1455350_at Tmem62 transmembrane protein 62 
1418572_x_at Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a 
1426095_a_at Tnfrsf22 tumor necrosis factor receptor superfamily, member 22 
1422101_at Tnfrsf23 tumor necrosis factor receptor superfamily, member 23 
1436828_a_at Tpd52l2 tumor protein D52-like 2 
1451233_at Traf2 TNF receptor-associated factor 2 
1424489_a_at Trit1 tRNA isopentenyltransferase 1 
1418158_at Trp63 transformation related protein 63 
1456251_x_at Tspo translocator protein 
1455643_s_at Tsr1 TSR1, 20S rRNA accumulation, homolog (yeast) 
1455649_at Ttc9 tetratricopeptide repeat domain 9 
1423846_x_at Tuba1b tubulin, alpha 1B 
1417375_at Tuba4a tubulin, alpha 4A 
1427347_s_at Tubb2a tubulin, beta 2A 
1423642_at Tubb2c tubulin, beta 2C 
1416431_at Tubb6 tubulin, beta 6 
1434585_at Tulp4 Tubby like protein 4 
1416119_at Txn1 thioredoxin 1 
1423299_at Txnl1 thioredoxin-like 1 
1448824_at Ube2j1 ubiquitin-conjugating enzyme E2, J1 
1448968_at Ubfd1 ubiquitin family domain containing 1 
1424538_at Ubl4 ubiquitin-like 4 
1426486_at Ubxn4 UBX domain protein 4 
1421269_at Ugcg UDP-glucose ceramide glucosyltransferase 
1452011_a_at Uxs1 UDP-glucuronate decarboxylase 1 
1416231_at Vac14 Vac14 homolog (S. cerevisiae) 
1437828_s_at Wdr46 WD repeat domain 46 
1434241_at Wdr67 WD repeat domain 67 
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1423923_a_at Wdr8 WD repeat domain 8 
1417817_a_at Wwtr1 WW domain containing transcription regulator 1 
1454901_at Ypel2 yippee-like 2 (Drosophila) 
1426266_s_at Zbtb8os zinc finger and BTB domain containing 8 opposite strand 
1452719_at Zdhhc24 zinc finger, DHHC domain containing 24 
1415940_at Zfand2a zinc finger, AN1-type domain 2A 
1421479_at Zfp318 zinc finger protein 318 
1426471_at Zfp52 zinc finger protein 52 
1440999_at Zfp697 zinc finger protein 697 
1436026_at Zfp703 zinc finger protein 703 
1455210_at Zhx2 zinc fingers and homeoboxes 2 
1435705_at Zscan18 zinc finger and SCAN domain containing 18 
1436710_at Zswim4 zinc finger, SWIM domain containing 4 
1423724_at Zwint ZW10 interactor 
1449507_a_at Cd47 CD47 antigen  
1423247_at Erp44 endoplasmic reticulum protein 44 
1424749_at Wdfy1 WD repeat and FYVE domain containing 1 
1429108_at Msl2 male-specific lethal 2 homolog (Drosophila) 
1452868_at Usp24 ubiquitin specific peptidase 24 
1449818_at Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 
1438431_at Abcd2 ATP-binding cassette, sub-family D (ALD), member 2 
1428145_at Acaa2 acetyl-Coenzyme A acyltransferase 2  
1415984_at Acadm acyl-Coenzyme A dehydrogenase, medium chain 
1424182_at Acat1 acetyl-Coenzyme A acetyltransferase 1 
1450643_s_at Acsl1 acyl-CoA synthetase long-chain family member 1 
1416617_at Acss1 acyl-CoA synthetase short-chain family member 1 
1422478_a_at Acss2 acyl-CoA synthetase short-chain family member 2 
1433725_at Acvr1b activin A receptor, type 1B 
1419140_at Acvr2b activin receptor IIB 
1451932_a_at Adamtsl4 ADAMTS-like 4 
1434454_at Adcy9 adenylate cyclase 9 
1424393_s_at Adhfe1 alcohol dehydrogenase, iron containing, 1 
1438292_x_at Adk adenosine kinase 
1422514_at Aebp1 AE binding protein 1 
1429083_at Agl amylo-1,6-glucosidase, 4-alpha-glucanotransferase 
1435591_at AI426330 expressed sequence AI426330 
1448104_at Aldh6a1 aldehyde dehydrogenase family 6, subfamily A1 
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1448484_at Amd1 S-adenosylmethionine decarboxylase 1 
1454801_at Ankrd28 ankyrin repeat domain 28 
1426719_at Apbb2 amyloid beta (A4) precursor protein-binding, family B, member 2 
1416203_at Aqp1 aquaporin 1 
1429918_at Arhgap20 Rho GTPase activating protein 20 
1429012_at Arhgef6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
1422375_a_at Art1 ADP-ribosyltransferase 1 
1452474_a_at Art3 ADP-ribosyltransferase 3 
1421466_at Asb10 ankyrin repeat and SOCS box-containing 10 
1422153_a_at Asb11 ankyrin repeat and SOCS box-containing 11 
1420346_at Asb12 ankyrin repeat and SOCS box-containing 12 
1449547_at Asb14 ankyrin repeat and SOCS box-containing 14 
1428444_at Asb2 ankyrin repeat and SOCS box-containing 2 
1423422_at Asb4 ankyrin repeat and SOCS box-containing 4 
1416775_at Atp5sl ATP5S-like 
1433827_at Atp8a1 ATPase, aminophospholipid transporter, class I, type 8A, member 1 
1417067_s_at Cabc1 chaperone, ABC1 activity of bc1 complex like (S. pombe) 
1426043_a_at Capn3 calpain 3 
1453904_at Ccdc146 coiled-coil domain containing 146 
1452332_at Ccdc85a coiled-coil domain containing 85A 
1450883_a_at Cd36 CD36 antigen 
1436913_at Cdc14a CDC14 cell division cycle 14 homolog A (S. cerevisiae) 
1455031_at Cdc2l6 cell division cycle 2-like 6 (CDK8-like) 
1422642_at Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3 
1449422_at Cdh4 cadherin 4 
1435370_a_at Ces3 carboxylesterase 3 
1452991_at Chd2 chromodomain helicase DNA binding protein 2 
1418328_at Chkb-cpt1b choline kinase beta, carnitine palmitoyltransferase 1b 
1422852_at Cib2 calcium and integrin binding family member 2 
1433486_at Clcn3 chloride channel 3 
1439505_at Clic5 chloride intracellular channel 5 
1437689_x_at Clu clusterin 
1451322_at Cmbl carboxymethylenebutenolidase-like (Pseudomonas) 
1422798_at Cntnap2 contactin associated protein-like 2 
1453084_s_at Col22a1 collagen, type XXII, alpha 1 
1433628_at Coq10a coenzyme Q10 homolog A (yeast) 
1417264_at Coq5 coenzyme Q5 homolog, methyltransferase (yeast) 
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1415949_at Cpe carboxypeptidase E 
1456048_at Cpeb3 cytoplasmic polyadenylation element binding protein 3 
1422492_at Cpox coproporphyrinogen oxidase 
1437939_s_at Ctsc cathepsin C 
1425920_at Cuedc1 CUE domain containing 1 
1434717_at Cul3 cullin 3 
1417590_at Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 
1434133_s_at Dcaf8 DDB1 and CUL4 associated factor 8 
1439096_at Ddo D-aspartate oxidase 
1422677_at Dgat2 diacylglycerol O-acyltransferase 2 
1444504_at Dhrs7c dehydrogenase/reductase (SDR family) member 7C 
1452005_at Dlat dihydrolipoamide S-acetyltransferase  
1460324_at Dnmt3a DNA methyltransferase 3A 
1456069_at Dtna dystrobrevin alpha 
1427416_x_at Dusp7 dual specificity phosphatase 7 
1417877_at Eepd1 endonuclease/exonuclease/phosphatase family domain containing 1 
1434647_at Egflam EGF-like, fibronectin type III and laminin G domains 
1423785_at Egln1 EGL nine homolog 1 (C. elegans) 
1449576_at Eif1ay eukaryotic translation initiation factor 1A, Y-linked 
1460591_at Esr1 estrogen receptor 1 (alpha) 
1460652_at Esrra estrogen related receptor, alpha 
1416023_at Fabp3 fatty acid binding protein 3, muscle and heart 
1417393_a_at Fam132a family with sequence similarity 132, member A 
1456611_at Fam13a family with sequence similarity 13, member A 
1433657_at Fam78a family with sequence similarity 78, member A 
1457999_at Fam82b family with sequence similarity 82, member B 
1417480_at Fbxo9 f-box protein 9 
1448130_at Fdft1 farnesyl diphosphate farnesyl transferase 1 
1449108_at Fdx1 ferredoxin 1 
1435551_at Fhod3 formin homology 2 domain containing 3 
1416858_a_at Fkbp3 FK506 binding protein 3 
1433512_at Fli1 Friend leukemia integration 1 
1453135_at Fndc5 fibronectin type III domain containing 5 
1434002_at Foxn3 forkhead box N3 
1455220_at Frat2 frequently rearranged in advanced T-cell lymphomas 2 
1450044_at Fzd7 frizzled homolog 7 (Drosophila) 
1450971_at Gadd45b growth arrest and DNA-damage-inducible 45 beta 
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1453851_a_at Gadd45g growth arrest and DNA-damage-inducible 45 gamma 
1437474_at Gatad2b GATA zinc finger domain containing 2B 
1434380_at Gbp6 guanylate binding protein 6 
1437992_x_at Gja1 gap junction protein, alpha 1 
1444178_at Gm9895 predicted gene 9895 
1448530_at Gmpr guanosine monophosphate reductase 
1453022_at Gpihbp1 GPI-anchored HDL-binding protein 1 
1417673_at Grb14 growth factor receptor bound protein 14 
1416737_at Gys1 glycogen synthase 1, muscle 
1436756_x_at Hadh hydroxyacyl-Coenzyme A dehydrogenase 
1415743_at Hdac5 histone deacetylase 5 
1424553_at Hhatl hedgehog acyltransferase-like 
1457568_at Hnrnpd heterogeneous nuclear ribonucleoprotein D 
1434551_at Hnrnpul2 heterogeneous nuclear ribonucleoprotein U-like 2 
1424367_a_at Homer2 homer homolog 2 (Drosophila) 
1422919_at Hrasls HRAS-like suppressor 
1455777_x_at Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 
1426857_a_at Hsdl2 hydroxysteroid dehydrogenase like 2 
1437273_at Htra4 HtrA serine peptidase 4 
1450048_a_at Idh2 isocitrate dehydrogenase 2 (NADP+), mitochondrial 
1422501_s_at Idh3a isocitrate dehydrogenase 3 (NAD+) alpha 
1418886_s_at Idh3b isocitrate dehydrogenase 3 (NAD+) beta 
1458268_s_at Igfbp3 insulin-like growth factor binding protein 3 
1427329_a_at Igh-6 immunoglobulin heavy chain 6 (heavy chain of IgM) 
1423104_at Irs1 insulin receptor substrate 1 
1422445_at Itga6 integrin alpha 6 
1421066_at Jak2 Janus kinase 2 
1456629_at Kank3 KN motif and ankyrin repeat domains 3 
1417680_at Kcna5 potassium voltage-gated channel, shaker-related subfamily, member 5 
1450490_at Kcna7 potassium voltage-gated channel, shaker-related subfamily, member 7 
1425089_at Kcnc4 potassium voltage gated channel, Shaw-related subfamily, member 4 
1423994_at Kif1b kinesin family member 1B 
1436763_a_at Klf9 Kruppel-like factor 9 
1443932_at Klhdc1 kelch domain containing 1 
1428651_at Klhl24 kelch-like 24 (Drosophila) 
1454637_at Klhl8 kelch-like 8 (Drosophila) 
1440435_at Ky kyphoscoliosis peptidase 
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1416513_at Lamb2 laminin, beta 2 
1422323_a_at Lbx1 ladybird homeobox homolog 1 (Drosophila) 
1455235_x_at Ldhb lactate dehydrogenase B 
1454984_at Lifr leukemia inhibitory factor receptor 
1456909_at LOC676974 similar to Glucose-6-phosphate isomerase (GPI)  
1418288_at Lpin1 lipin 1 
1431056_a_at Lpl lipoprotein lipase 
1434210_s_at Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 
1439821_at Lrp2bp Lrp2 binding protein 
1439491_at Lrrc38 leucine rich repeat containing 38 
1445841_at Lrrc39 leucine rich repeat containing 39 
1417283_at Lynx1 Ly6/neurotoxin 1 
1435828_at Maf avian musculoaponeurotic fibrosarcoma (v-maf) AS42  
1451716_at Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B  
1449834_at Magix MAGI family member, X-linked 
1434354_at Maob monoamine oxidase B 
1426850_a_at Map2k6 mitogen-activated protein kinase kinase 6 
1421878_at Mapk9 mitogen-activated protein kinase 9 
1434815_a_at Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 
1454840_at Mccc2 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 
1432062_at Mdga1 MAM domain containing glycosylphosphatidylinositol anchor 1 
1429071_at Me3 malic enzyme 3, NADP(+)-dependent, mitochondrial 
1427100_at Metrn meteorin, glial cell differentiation regulator 
1415897_a_at Mgst1 microsomal glutathione S-transferase 1 
1448300_at Mgst3 microsomal glutathione S-transferase 3 
1451523_a_at Mif4gd MIF4G domain containing 
1418589_a_at Mlf1 myeloid leukemia factor 1 
1449964_a_at Mlycd malonyl-CoA decarboxylase 
1435645_at Mmd monocyte to macrophage differentiation-associated 
1454867_at Mn1 meningioma 1 
1451357_at Mpnd MPN domain containing 
1437250_at Mreg melanoregulin 
1424166_at Msh3 mutS homolog 3 (E. coli) 
1450376_at Mxi1 Max interacting protein 1 
1427556_at Mylk2 myosin, light polypeptide kinase 2, skeletal muscle 
1448636_at Myoz1 myozenin 1 
1417190_at Nampt nicotinamide phosphoribosyltransferase 
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1423202_a_at Ncor1 nuclear receptor co-repressor 1 
1456087_at Nfia nuclear factor I/A 
1448288_at Nfib nuclear factor I/B 
1419652_s_at Nkain1 Na+/K+ transporting ATPase interacting 1 
1456573_x_at Nnt nicotinamide nucleotide transhydrogenase 
1427191_at Npr2 natriuretic peptide receptor 2 
1436189_at Nqo2 NAD(P)H dehydrogenase, quinone 2 
1435917_at Ociad2 OCIA domain containing 2 
1457881_at Osbpl6 oxysterol binding protein-like 6 
1428140_at Oxct1 3-oxoacid CoA transferase 1 
1421046_a_at Pabpc4 poly(A) binding protein, cytoplasmic 4 
1440635_at Palld palladin, cytoskeletal associated protein 
1433873_s_at Pcnt pericentrin (kendrin) 
1435836_at Pdk1 pyruvate dehydrogenase kinase, isoenzyme 1 
1448825_at Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2 
1438201_at Pdp1 pyruvate dehyrogenase phosphatase catalytic subunit 1 
1435553_at Pdzd2 PDZ domain containing 2 
1416846_a_at Pdzrn3 PDZ domain containing RING finger 3 
1427213_at Pfkfb1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 
1452841_at Pgm2l1 phosphoglucomutase 2-like 1 
1425164_a_at Phkg1 phosphorylase kinase gamma 1 
1437637_at Phtf2 putative homeodomain transcription factor 2 
1439087_a_at Pik3ip1 phosphoinositide-3-kinase interacting protein 1 
1451148_at Pink1 PTEN induced putative kinase 1 
1428025_s_at Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1 
1460411_s_at Pkdcc protein kinase domain containing, cytoplasmic 
1420859_at Pkia protein kinase inhibitor, alpha 
1433907_at Pknox2 Pbx/knotted 1 homeobox 2 
1437030_at Plcd4 phospholipase C, delta 4 
1426450_at Plcl2 phospholipase C-like 2 
1416424_at Plin3 perilipin 3 
1418595_at Plin4 perilipin 4 
1451718_at Plp1 proteolipid protein (myelin) 1 
1424362_at Ppapdc3 phosphatidic acid phosphatase type 2 domain containing 3 
1457721_at Ppara peroxisome proliferator activated receptor alpha 
1434100_x_at Ppargc1a peroxisome proliferative activated receptor, gamma 
1425537_at Ppm1a protein phosphatase 1A, magnesium dependent, alpha isoform 
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1451669_at Ppm1b protein phosphatase 1B, magnesium dependent, beta isoform 
1438012_at Ppm1l protein phosphatase 1 (formerly 2C)-like 
1422605_at Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A 
1455091_at Ppp2r3a protein phosphatase 2, regulatory subunit B'', alpha 
1429144_at Prei4 preimplantation protein 4 
1426345_at Prepl prolyl endopeptidase-like 
1423831_at Prkag2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 
1444232_at Prkg1 protein kinase, cGMP-dependent, type I 
1446560_at Prss23 protease, serine, 23 
1417056_at Psme1 proteasome (prosome, macropain) 28 subunit, alpha 
1433503_at Ptgr2 prostaglandin reductase 2 
1418181_at Ptp4a3 protein tyrosine phosphatase 4a3 
1456903_at Ptx3 pentraxin related gene 
1417841_at Pxmp2 peroxisomal membrane protein 2 
1427151_at Qser1 glutamine and serine rich 1 
1417481_at Ramp1 receptor (calcitonin) activity modifying protein 1 
1438030_at Rasgrp3 RAS, guanyl releasing protein 3 
1428016_a_at Rasip1 Ras interacting protein 1 
1421425_a_at Rcan2 regulator of calcineurin 2 
1454670_at Rere arginine glutamic acid dipeptide (RE) repeats 
1424716_at Retsat retinol saturase (all trans retinol 13,14 reductase) 
1424632_a_at Rev3l REV3-like, catalytic subunit of DNA polymerase zeta RAD54 like  
1438241_at Rgma RGM domain family, member A 
1426094_at Rhbdl1 rhomboid, veinlet-like 1 (Drosophila) 
1426822_at Rhot2 ras homolog gene family, member T2 
1437309_a_at Rpa1 replication protein A1 
1449398_at Rpl3l ribosomal protein L3-like 
1417542_at Rps6ka2 ribosomal protein S6 kinase, polypeptide 2 
1416007_at Satb1 special AT-rich sequence binding protein 1 
1441636_at Sec14l5 SEC14-like 5 (S. cerevisiae) 
1455698_at Sec62 SEC62 homolog (S. cerevisiae) 
1417580_s_at Selenbp1 selenium binding protein 1 
1418888_a_at Sepx1 selenoprotein X 1 
1416666_at Serpine2 serine (or cysteine) peptidase inhibitor, clade E, member 2 
1456640_at Sh3rf2 SH3 domain containing ring finger 2 
1419137_at Shank3 SH3/ankyrin domain gene 3 
1417892_a_at Sirt3 sirtuin 3 (silent mating type information regulation 2, homolog) 3  
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1436440_at Slc25a12 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 
1424790_at Slc25a42 solute carrier family 25, member 42 
1416275_at Slc26a6 solute carrier family 26, member 6 
1422811_at Slc27a1 solute carrier family 27 (fatty acid transporter), member 1 
1415958_at Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 
1417042_at Slc37a4 solute carrier family 37 (glucose-6-phosphate transporter), member 4 
1417061_at Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 
1460565_at Slc41a1 solute carrier family 41, member 1 
1436555_at Slc7a2 solute carrier family 7, member 2 
1434537_at Slco3a1 solute carrier organic anion transporter family, member 3a1 
1419145_at Smtnl1 smoothelin-like 1 
1452789_at Snn stannin 
1425678_a_at Snrk SNF related kinase 
1449109_at Socs2 suppressor of cytokine signaling 2 
1454976_at Sod2 superoxide dismutase 2, mitochondrial 
1437197_at Sorbs2 sorbin and SH3 domain containing 2 
1417644_at Sspn sarcospan 
1449078_at St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
1427345_a_at Sult1a1 sulfotransferase family 1A, phenol-preferring, member 1 
1429146_at Svip small VCP/p97-interacting protein 
1427982_s_at Syne2 synaptic nuclear envelope 2 
1428295_at Synpo2l synaptopodin 2-like 
1428467_at Tardbp TAR DNA binding protein 
1435292_at Tbc1d4 TBC1 domain family, member 4 
1424531_a_at Tcea3 transcription elongation factor A (SII), 3 
1424737_at Thrsp thyroid hormone responsive SPOT14 homolog (Rattus) 
1418057_at Tiam1 T-cell lymphoma invasion and metastasis 1 
1449335_at Timp3 tissue inhibitor of metalloproteinase 3 
1456981_at Tmc7 transmembrane channel-like gene family 7 
1452962_at Tmem25 transmembrane protein 25 
1452942_at Tmem65 transmembrane protein 65 
1448297_a_at Tnk2 tyrosine kinase, non-receptor, 2 
1418370_at Tnnc1 troponin C, cardiac/slow skeletal 
1449405_at Tns1 tensin 1 
1448667_x_at Tob2 transducer of ERBB2, 2 
1458364_s_at Tor1aip1 torsin A interacting protein 1 
1452766_at Tppp tubulin polymerization promoting protein 
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1456755_at Trak1 trafficking protein, kinesin binding 1 
1427258_at Trim24 tripartite motif-containing 24 
1420019_at Tspan8 Tetraspanin 8 
1418951_at Txlnb taxilin beta 
1452985_at Uaca uveal autoantigen with coiled-coil domains and ankyrin repeats 
1417847_at Ulk2 Unc-51 like kinase 2 (C. elegans) 
1425753_a_at Ung uracil DNA glycosylase 
1430522_a_at Vamp5 vesicle-associated membrane protein 5 
1420909_at Vegfa vascular endothelial growth factor A 
1429084_at Vezf1 vascular endothelial zinc finger 1 
1420484_a_at Vtn vitronectin 
1431335_a_at Wfdc1 WAP four-disulfide core domain 1 
1427098_at Wwp1 WW domain containing E3 ubiquitin protein ligase 1 
1422927_at Yipf7 Yip1 domain family, member 7 
1451577_at Zbtb20 zinc finger and BTB domain containing 20 
1455071_at Zbtb7b zinc finger and BTB domain containing 7B 
1428432_at Zcchc24 zinc finger, CCHC domain containing 24 
1449510_at Zfp467 zinc finger protein 467 
1423835_at Zfp503 zinc finger protein 503 
1454873_at Zfp775 zinc finger protein 775 
1420950_at Znrf1 zinc and ring finger 1 
1446244_at Zyg11b zyg-ll homolog B (C. elegans) 
A total 660 genes was identified between the effects of genotype and CL (327 overexpressed genes and 333 underexpressed genes). Among 
the 660 genes, 50 genes were ESTs resulting in 610 known gene identified (310 overexpressed genes and 300 underexpressed genes). W, 
wild type mice; M, Mstn-pro mice; CLW, clenbuterol treated wild type mice. Grey box is underexpressed genes.
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Appendix 3.10 The expression of overlapping genes between the effects of genotype and genotype in 
CL (W vs M VS CLW vs CLM). 
Probe Set ID Gene Symbol Gene Title 
1424529_s_at Cgref1 cell growth regulator with EF hand domain 1 
1427347_s_at Tubb2a tubulin, beta 2A 
A total 2 genes was identified between the effects of genotype and CL (2 overexpressed genes). W, wild type mice; M, Mstn-pro mice; CLW, 
clenbuterol treated wild mice; CLM, clenbuterol treated Mstn-pro.  
 
 
 
